<SEC-DOCUMENT>0001731122-21-001347.txt : 20210812
<SEC-HEADER>0001731122-21-001347.hdr.sgml : 20210812
<ACCEPTANCE-DATETIME>20210812171309
ACCESSION NUMBER:		0001731122-21-001347
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		40
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210812
DATE AS OF CHANGE:		20210812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		211168676

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>e3018_10-q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:avxl="http://anavex.com/20210630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2021_currency -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_avxl_anavex.com_20210630 -->
<!-- Field: Set; Name: xdx; ID: xdx_047_20201001_20210630 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001314052 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DDocumentFiscalYearFocus_2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DCurrentFiscalYearEndDate_09/30 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:EntityCentralIndexKey">0001314052</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2020-10-01to2021-06-30" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2020-10-01to2021-06-30" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate">09/30</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPusuantToExerciseOfWarrants" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2020-10-01to2021-06-30" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPusuantToExerciseOfWarrants" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2019-10-012020-06-30" id="xdx2ixbrl0441" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2019-10-012020-06-30" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="avxl-20210630.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2020-10-01to2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-25_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-25_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_ParkinsonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:ParkinsonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-012017-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2021-06-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-06</xbrli:startDate>
        <xbrli:endDate>2019-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_PurchaseWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_OptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:OptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_StockOptionPlan2015Member_custom_OptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:OptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 12pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 14pt Times New Roman, Times, Serif">UNITED
STATES&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 14pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_908_edei--DocumentType_c20201001__20210630_z2kmmpqt6Zqg"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">(Mark
One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 31.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b><span id="xdx_90E_edei--DocumentQuarterlyReport_c20201001__20210630_zZRqhVVdkNHd"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
the quarterly period ended: <b><span style="text-decoration: underline"><span id="xdx_901_edei--DocumentPeriodEndDate_c20201001__20210630_zHwfaRALdOZ5"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 30, 2021</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b><span id="xdx_907_edei--DocumentTransitionReport_c20201001__20210630_zblmKjdDq0Gb"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
the transition period from _____to _____</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Commission
File Number: <span style="text-decoration: underline"><span id="xdx_902_edei--EntityFileNumber_c20201001__20210630_zlJfcCvPfTw7"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:EntityFileNumber">001-37606</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 24pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_90E_edei--EntityRegistrantName_c20201001__20210630_zGXgIp3j1yt9"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:EntityRegistrantName">ANAVEX LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20201001__20210630_zIFatTerErge"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></b></span></td>
<td style="width: 50%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20201001__20210630_zu5f4KzdIDgk"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:EntityTaxIdentificationNumber">98-0608404</ix:nonNumeric></span></span></b></span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of</span></td>
<td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(IRS Employer</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">incorporation or organization)</span></td>
<td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Identification No.)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_904_edei--EntityAddressAddressLine1_c20201001__20210630_zsp7Bce6mBia"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:EntityAddressAddressLine1">51 West 52nd Street,</ix:nonNumeric> </span><span id="xdx_90E_edei--EntityAddressAddressLine2_c20201001__20210630_z3WMILFcwM28"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:EntityAddressAddressLine2">7th Floor,</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressCityOrTown_c20201001__20210630_zThw9GYQz4ua"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span></span></b></span><b><span style="text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif">,
<span id="xdx_908_edei--EntityAddressStateOrProvince_c20201001__20210630_zozaT8lcXmEj"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> USA</span></span></b><b><span style="text-decoration: underline"> <span id="xdx_90D_edei--EntityAddressPostalZipCode_c20201001__20210630_zzTMWN7yJp66" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:EntityAddressPostalZipCode">10019</ix:nonNumeric></span></span></b><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Address
of principal executive offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_90A_edei--CityAreaCode_c20201001__20210630_z9tXcwo2kjz9"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:CityAreaCode">1-844</ix:nonNumeric></span>-<span id="xdx_904_edei--LocalPhoneNumber_c20201001__20210630_zubcBWN8Z8Il"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:LocalPhoneNumber">689-3939</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration: underline">N/A</span></b><br />
(Former name, former address and former fiscal year, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Securities
Registered Pursuant to Section&#160;12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Title
of Each Class</span></td>
<td style="vertical-align: top; padding-bottom: 1pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Trading
Symbol</span></td>
<td style="vertical-align: top; padding-bottom: 1pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Name
of Each Exchange on Which Registered</span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="width: 32%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--Security12bTitle_c20201001__20210630_zcEBcITbXVU2"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:Security12bTitle">Common Stock Par Value $0.001</ix:nonNumeric></span></span></td>
<td style="width: 1%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 32%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--TradingSymbol_c20201001__20210630_zhrt4J8zi8ml"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:TradingSymbol">AVXL</ix:nonNumeric></span></span></td>
<td style="width: 1%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 34%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--SecurityExchangeName_c20201001__20210630_zB1bcXLBwZ38"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#9746;&#160;
<b><span id="xdx_905_edei--EntityCurrentReportingStatus_c20201001__20210630_zyy5Hr2ziY21"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#9744;&#160; No</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#9746;&#160;
<b><span id="xdx_90D_edei--EntityInteractiveDataCurrent_c20201001__20210630_zYTqhizMyeGa"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;&#9744;&#160; No</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 27%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Large accelerated filer</span></td>
<td style="width: 3%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;</span></td>
<td style="width: 41%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 26%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accelerated filer</span></td>
<td style="width: 3%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--EntityFilerCategory_c20201001__20210630_zLiqry7Ob4C9"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated Filer</ix:nonNumeric></span></span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9746;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Smaller reporting company</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--EntitySmallBusiness_c20201001__20210630_zTvukw9V7cQl"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Emerging growth company</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20201001__20210630_z0dFDXw9qRai"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><b>&#9744;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;&#9744;&#160; <b>Yes&#160;&#9746;&#160; <span id="xdx_90C_edei--EntityShellCompany_c20201001__20210630_ztwDBp0TMRf6"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate the number of shares outstanding of
each of the issuer&#8217;s classes of common stock, as of the latest practicable date: <span><span id="xdx_909_edei--EntityCommonStockSharesOutstanding_iI_c20210812_ze3MgfQrfCEe"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2021-08-12" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,707,382</ix:nonFraction></span></span>
<span style="color: black">shares of common stock outstanding as of August <span>12, </span>2021</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>TABLE OF CONTENTS </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160; </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 95%"><span style="font: 10pt Times New Roman, Times, Serif">PART I -<a href="#a_001"> FINANCIAL INFORMATION</a></span></td>
<td style="text-align: right; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif">3</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 1.<a href="#a_002"> FINANCIAL STATEMENTS</a></span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
  <td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 2.<a href="#a_003"> MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</a></span></td>
  <td style="text-align: right">&#160; <span style="font: 10pt Times New Roman, Times, Serif">16</span></td>
</tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 3.<a href="#a_004"> QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.</a></span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">30</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 4.<a href="#a_005"> CONTROLS AND PROCEDURES.</a></span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">30</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">PART II&#160;&#160;&#160;<a href="#a_006">OTHER INFORMATION</a></span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 1.<a href="#a_007"> LEGAL PROCEEDINGS.</a></span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 1A.<a href="#a_008"> RISK FACTORS</a></span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 2.<a href="#a_009"> UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">33</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 3.<a href="#a_010"> DEFAULTS UPON SENIOR SECURITIES.</a></span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">33</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 4.<a href="#a_011"> MINE SAFETY DISCLOSURES</a></span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">33</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 5.<a href="#a_012"> OTHER INFORMATION.</a></span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">33</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 6.<a href="#a_013"> EXHIBITS.</a></span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_014">SIGNATURES</a></span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">35</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span id="a_001"></span>PART I - FINANCIAL
INFORMATION</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span id="a_002"></span>Item 1. FINANCIAL
STATEMENTS</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 100%; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: center"><span style="color: black"><b>ANAVEX
    LIFE SCIENCES CORP.</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: center"><span style="color: black"><b>INTERIM
    CONDENSED CONSOLIDATED BALANCE SHEETS</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: center"><span style="color: black"><b>June
    30, 2021 and September 30, 2020</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_111_ziYc4RAgVLDd" summary="xdx: Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20210630" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20200930" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold">&#160;</td>
    <td colspan="3" style="color: black; font-weight: bold; text-align: center">June 30,</td><td style="color: black">&#160;</td>
    <td colspan="3" style="color: black; text-align: center">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2021</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold">&#160;</td>
    <td colspan="3" style="color: black; font-weight: bold; text-align: center">(Unaudited)</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsAbstract_iB_zEoVoXMX1rJb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrentAbstract_i01B_zw7a4YhI1c31" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzHib_zJy5pw45PM44" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; width: 56%; color: black; text-align: left; text-indent: -10pt">Cash and cash equivalents</td><td style="width: 8%; color: black; font-weight: bold">&#160;</td>
    <td style="width: 1%; color: black; font-weight: bold; text-align: left">$</td><td style="width: 12%; color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,560,045</ix:nonFraction></td><td style="width: 1%; color: black; font-weight: bold; text-align: left">&#160;</td><td style="width: 8%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 12%; color: black; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,249,018</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxesReceivable_i02I_maCzHib_zBHwfRwcueNb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-align: left; text-indent: -10pt">Incentive and tax receivables</td><td style="color: black; font-weight: bold">&#160;</td>
    <td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,601,258</ix:nonFraction></td><td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,849,340</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidExpenseCurrent_i02I_maCzHib_ztyohyU7jMvh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-align: left; text-indent: -10pt">Prepaid expenses and deposits</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">258,198</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,839</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Assets_i01TI_mtCzHib_zAHhHCLZanl7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Total Assets</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,419,501</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,542,197</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zTuv9BELlVS8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_zy7PdCc1QWZe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_i02I_maCzgvd_zBmVBypigeIb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-align: left; text-indent: -10pt">Accounts payable</td><td style="color: black; font-weight: bold">&#160;</td>
    <td style="color: black; font-weight: bold; text-align: left">$</td><td style="color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,176,707</ix:nonFraction></td><td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,989,054</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzgvd_zNLN9bGpHkTb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-align: left; text-indent: -10pt">Accrued liabilities</td><td style="color: black; font-weight: bold">&#160;</td>
    <td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,653,234</ix:nonFraction></td><td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,316,574</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredIncomeCurrent_i02I_d0_maCzgvd_zLSEW91bwrE5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-align: left; text-indent: -10pt">Deferred grant income</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,831</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2020-09-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Liabilities_i02TI_mtCzgvd_maCzgLy_zYFiSsjHAa19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Total Liabilities</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,273,772</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,305,628</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CommitmentsAndContingencies_i01I_zNuPJVeVvUxg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Commitments and Contingencies - Note 5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Capital stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Authorized:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-indent: -10pt"><span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_c20210630_pdd" title="Preferred stock, shares authorized"><span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_c20200930_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> preferred stock, par value $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_c20210630_pdd" title="Preferred stock, par value"><span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_c20200930_pdd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-indent: -10pt"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20210630_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></span>
    <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_c20200930_pdd" style="display: none"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span> common stock, par value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_c20210630_pdd" title="Common stock, par value"><span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20200930_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>
    per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Issued and outstanding:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-indent: -10pt"><span id="xdx_907_eus-gaap--CommonStockSharesIssued_c20210630_pdd" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20210630_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,149,833</ix:nonFraction></ix:nonFraction></span></span> common shares (September 30, 2020 - <span id="xdx_905_eus-gaap--CommonStockSharesIssued_c20200930_pdd" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_c20200930_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,045,198</ix:nonFraction></ix:nonFraction></span></span>)</td><td style="color: black; font-weight: bold">&#160;</td>
    <td style="color: black; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_ecustom--CapitalStockValue_iI_maCzgYE_c20210630_zuygN3pGVdah" title="Capital Stock" style="color: black; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:CapitalStockValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,151</ix:nonFraction></td><td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98B_ecustom--CapitalStockValue_iI_c20200930_zacZWYdnnzdc" style="color: black; text-align: right"><ix:nonFraction name="avxl:CapitalStockValue" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,047</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_maCzgYE_zkzCR0TUdOJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Additional paid-in capital</td><td style="color: black; font-weight: bold">&#160;</td>
    <td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">342,938,236</ix:nonFraction></td><td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,851,752</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maCzgYE_zFgfN0gfWZy8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Accumulated deficit</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">185,867,658</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">159,677,230</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquity_iTI_mtCzgYE_maCzgLy_zI7eJ9obni65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Total Stockholders&#8217; Equity</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,145,729</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,236,569</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzgLy_zWFqAhuL2zXd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">&#160;Total Liabilities and Stockholders&#8217; Equity</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,419,501</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,542,197</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See Accompanying Notes to Condensed Consolidated
Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 100%; padding-top: 0.65pt; padding-right: 0.65pt; padding-left: 0.65pt; text-align: center"><span style="color: black"><b>ANAVEX
    LIFE SCIENCES CORP.</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-top: 0.65pt; padding-right: 0.65pt; padding-left: 0.65pt; text-align: center"><span style="color: black"><b>INTERIM
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-top: 0.65pt; padding-right: 0.65pt; padding-left: 0.65pt; text-align: center"><span style="color: black"><b>For
    the three and nine months ended June 30, 2021 and 2020</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-top: 0.65pt; padding-right: 0.65pt; padding-left: 0.65pt; text-align: center"><span style="color: black"><b>(Unaudited)</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_113_zeMKB77QZJY4" summary="xdx: Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20210401_20210630" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20200401_20200630" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20201001_20210630" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20191001_20200630" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black">&#160;</td>
    <td colspan="7" style="color: black; text-align: center">Three months ended June 30,</td><td style="color: black">&#160;</td>
    <td colspan="7" style="color: black; text-align: center">Nine months ended June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2021</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2020</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2021</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2020</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingExpensesAbstract_iB_zKNjYJVSuVCg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzl27_zwHdx4MGCTrg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; color: black; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 3%; color: black; font-weight: bold">&#160;</td>
    <td style="width: 1%; color: black; font-weight: bold; text-align: left">$</td><td style="width: 10%; color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,434,127</ix:nonFraction></td><td style="width: 1%; color: black; font-weight: bold; text-align: left">&#160;</td><td style="width: 3%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 10%; color: black; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,381,477</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 3%; color: black; font-weight: bold">&#160;</td>
    <td style="width: 1%; color: black; font-weight: bold; text-align: left">$</td><td style="width: 10%; color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,138,528</ix:nonFraction></td><td style="width: 1%; color: black; font-weight: bold; text-align: left">&#160;</td><td style="width: 3%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 10%; color: black; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,453,654</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzl27_zY1WiMn3Ou2b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Research and development</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,964,528</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,725,002</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,610,888</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,126,717</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingExpenses_iNT_di_mtCzl27_msCzSTZ_zwImVsUGxyUg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Total operating expenses</td><td style="color: black; font-weight: bold">&#160;</td>
    <td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,398,655</ix:nonFraction></td><td style="color: black; font-weight: bold; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,106,479</ix:nonFraction></td><td style="color: black; text-align: left">)</td><td style="color: black; font-weight: bold">&#160;</td>
    <td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,749,416</ix:nonFraction></td><td style="color: black; font-weight: bold; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,580,371</ix:nonFraction></td><td style="color: black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zPey0hWyh5y7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Other income (expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--NonOperatingIncomeFromGrant_i01_d0_maCz13q_zXTDEgdl3fNh" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Grant income</td><td style="color: black; font-weight: bold">&#160;</td>
    <td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,280</ix:nonFraction></td><td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2020-04-012020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black; font-weight: bold">&#160;</td>
    <td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,100</ix:nonFraction></td><td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,888</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--ResearchAndDevelopmentIncentiveIncome_i01_maCz13q_zoqWDNZ3oh6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Research and development incentive income</td><td style="color: black; font-weight: bold">&#160;</td>
    <td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,363,661</ix:nonFraction></td><td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,319,913</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black; font-weight: bold">&#160;</td>
    <td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,593,856</ix:nonFraction></td><td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,980,456</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestIncomeExpenseNet_i01_maCz13q_zGOwtTUeBPkg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Interest income, net</td><td style="color: black; font-weight: bold">&#160;</td>
    <td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,453</ix:nonFraction></td><td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,096</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black; font-weight: bold">&#160;</td>
    <td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,110</ix:nonFraction></td><td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,996</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maCz13q_zXR07O8OpfN9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Foreign exchange gain (loss), net</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">160,880</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">248,665</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,191</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,182</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_iT_mtCz13q_maCzSTZ_zQagkkg7xBt6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Total other income, net</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,257,514</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,624,674</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,684,257</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,279,158</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzSTZ_maCz6oO_zsnPJcNOR2Rd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Net loss before provision for income taxes</td><td style="color: black; font-weight: bold">&#160;</td>
    <td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,141,141</ix:nonFraction></td><td style="color: black; font-weight: bold; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,481,805</ix:nonFraction></td><td style="color: black; text-align: left">)</td><td style="color: black; font-weight: bold">&#160;</td>
    <td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,065,159</ix:nonFraction></td><td style="color: black; font-weight: bold; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,301,213</ix:nonFraction></td><td style="color: black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentIncomeTaxExpenseBenefit_iN_di_msCz6oO_zKckUZ1d3gj4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Income tax expense, current</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,000</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,817</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,269</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,031</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_iT_mtCz6oO_zx4GZTh6OCil" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Net loss and comprehensive loss</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,180,141</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,486,622</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,190,428</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,315,244</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB_z26tudMnOPX7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Net Loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EarningsPerShareBasicAndDiluted_i01_zAacziQj0Lmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-align: left; text-indent: -10pt">Basic and diluted</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.14</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.11</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.39</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; font-weight: bold; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.35</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_zHBugeIx18Xc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Weighted average number of shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--WeightedAverageNumberOfSharesOutstanding_i01_zOI3DmlBEfJd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-align: left; text-indent: -10pt">Basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstanding" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,589,561</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstanding" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">59,105,399</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstanding" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,810,774</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstanding" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">57,401,387</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See Accompanying Notes to Condensed Consolidated
Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 100%; padding-top: 0.65pt; padding-right: 0.65pt; padding-left: 0.65pt; text-align: center"><span style="color: black"><b>ANAVEX
    LIFE SCIENCES CORP.</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-top: 0.65pt; padding-right: 0.65pt; padding-left: 0.65pt; text-align: center"><span style="color: black"><b>INTERIM
    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-top: 0.65pt; padding-right: 0.65pt; padding-left: 0.65pt; text-align: center"><span style="color: black"><b>For
    the nine months ended June 30, 2021 and 2020</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-top: 0.65pt; padding-right: 0.65pt; padding-left: 0.65pt; text-align: center"><span style="color: black"><b>(Unaudited)</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_112_zDHcIcbaoD28" summary="xdx: Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_494_20201001__20210630_zENn3yVcg7ge" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20191001__20200630_zRJ1DZBxTKu4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2021</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_zfiEMwT1Ilyk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Cash Flows used in Operating Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_i01_maCz1RA_z5ehQ2g48ia8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; color: black; text-align: left; text-indent: -10pt">Net loss</td><td style="width: 8%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,190,428</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,315,244</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zqOUxkK9ORXe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Adjustments to reconcile net loss to net cash used in operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i02_maCz1RA_zuCWLEqvKOg4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-align: left; text-indent: -10pt">Stock-based compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,079,395</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,216,306</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zDdbeeosf7Wh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Changes in non-cash working capital balances related to operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInIncomeTaxesReceivable_i02N_di_msCz1RA_zSUBxYN4ilSe" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-align: left; text-indent: -10pt">Incentive and tax receivables</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,751,918</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">905,227</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msCz1RA_zPG3WVza7Fii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-align: left; text-indent: -10pt">Prepaid expenses and deposits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">185,641</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">62,367</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCz1RA_zXMCroFSK4xh" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-align: left; text-indent: -10pt">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">187,653</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">456,872</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maCz1RA_zbLxiERntWll" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-align: left; text-indent: -10pt">Accrued liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,336,660</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,452,652</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInDeferredRevenue_i02_d0_maCz1RA_za1ZM8w9GDKf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-align: left; text-indent: -10pt">Deferred grant income</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,831</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2019-10-012020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCz1RA_maCzhdO_zpwUidizcfD4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Net cash used in operating activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,709,166</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,032,274</ix:nonFraction></td><td style="color: black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_zw3bMVUofCNj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Cash Flows provided by Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzxL4_zpl19ZTRgQN7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Issuance of common shares</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,218,758</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,490,297</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PaymentsOfFinancingCosts_i01N_di_msCzxL4_zlLYXFO89mGk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Share issue costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,533,473</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,508</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromWarrantExercises_i01_d0_maCzxL4_zARfFdjVDaka" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Proceeds from exercise of warrants</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,466,500</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2019-10-012020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromStockOptionsExercised_i01_d0_maCzxL4_zc0eqHh1toHi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Proceeds from exercise of stock options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,868,408</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2019-10-012020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCzxL4_maCzhdO_zJEkttdZZS91" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Net cash provided by financing activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,020,193</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,465,789</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_mtCzhdO_z7MSlb65OUAa" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Increase in cash and cash equivalents during the period</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,311,027</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,433,515</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_zu25sNhnmn5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Cash and cash equivalents, beginning of period</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,249,018</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,185,630</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_ziuZ6MlS4S1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Cash and cash equivalents, end of period</td><td style="color: black; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,560,045</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,619,145</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See Accompanying Notes to Condensed Consolidated
Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 100%; padding-top: 0.65pt; padding-right: 0.65pt; padding-left: 0.65pt; text-align: center"><span style="color: black"><b>ANAVEX
    LIFE SCIENCES CORP.</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-top: 0.65pt; padding-right: 0.65pt; padding-left: 0.65pt; text-align: center"><span style="color: black"><b>INTERIM
    CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-top: 0.65pt; padding-right: 0.65pt; padding-left: 0.65pt; text-align: center"><span style="color: black"><b>For
    the three months ended June 30, 2021 and 2020</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-top: 0.65pt; padding-right: 0.65pt; padding-left: 0.65pt; text-align: center"><span style="color: black"><b>(Unaudited)</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_309_114_zI1danZu0BKf" summary="xdx: Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#160;</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zVQMlPggMLDa" style="color: black; text-align: right">&#160;</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zN8By3k6c8Ah" style="color: black; text-align: right">&#160;</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zYbWf1YfyXcf" style="color: black; text-align: right">&#160;</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_4BA_zRIU2mpKN1q9" style="color: black; text-align: right">&#160;</td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; color: black; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="color: black">&#160;</td>
    <td colspan="3" style="color: black; text-align: center">Additional</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="color: black">&#160;</td>
    <td colspan="3" style="color: black; text-align: center">Paid-in</td><td style="color: black">&#160;</td>
    <td colspan="3" style="color: black; text-align: center">Accumulated</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Shares</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Par Value</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Capital</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Deficit</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20210401__20210630_eus-gaap--StockholdersEquity_iS_zD4eEnnitJUd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 35%; color: black; text-indent: -10pt">Balance, April 1, 2021</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMsECilnenKb" title="Balance beginning, shares" style="width: 9%; color: black; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,030,620</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 9%; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,032</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 9%; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,427,781</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 9%; color: black; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">175,687,517</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">)</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 9%; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,810,296</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueOther_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Shares issued under Sales Agreement, net of share issue costs</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBlfg5k7BMvc" title="Shares issued under 2019 purchase agreement Purchase shares, shares" style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,082,263</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,082</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,979,399</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,981,481</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts_zXb49LhdHmTl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Shares issued pursuant to registered direct offering, net of share issue costs</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_986_ecustom--SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmdwg3SVutAg" title="Shares issued pursuant to registered direct offering, net of share issue costs, Shares" style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,380,953</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,381</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,901,681</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,904,062</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_iP3custom--SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares_zg8bOZJOLMf4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Shares issued upon exercise of stock options</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98C_ecustom--SharesIssuedUponExerciseOfOptionsShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkji6yCzxCvh" title="Shares issued upon exercise of options, shares" style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedUponExerciseOfOptionsShares" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">305,997</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">306</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">869,300</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">869,606</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--SharesIssuedPusuantToExerciseOfWarrants_zGhID5wCqxh7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Shares issued pusuant to exercise of warrants</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_985_ecustom--SharesIssuedPusuantToExerciseOfWarrantsShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmUv5NbH6YD6" title="Shares issued pusuant to exercise of warrants, Shares" style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPusuantToExerciseOfWarrantsShares" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPusuantToExerciseOfWarrants" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">350</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPusuantToExerciseOfWarrants" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,466,150</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPusuantToExerciseOfWarrants" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,466,500</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_zDCOSXSa5lvl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Share based compensation</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#8212;</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,293,925</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,293,925</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProfitLoss_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Net loss</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8212;</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#8212;</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,180,141</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,180,141</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td></tr>
  <tr id="xdx_434_c20210401__20210630_eus-gaap--StockholdersEquity_iE_zentTYgElcXf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Balance, June 30, 2021</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjgQwMRpaFni" title="Balance ending, shares" style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,149,833</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,151</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">342,938,236</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">185,867,658</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,145,729</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_436_c20200401__20200630_eus-gaap--StockholdersEquity_iS_zxzSSJO9J8ie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Balance, April 1, 2020</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqkL0RzRp3ze" title="Balance beginning, shares" style="color: black; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,664,946</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,666</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,958,462</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">147,225,382</ix:nonFraction></td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,791,746</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Shares issued under 2019 purchase agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueNewIssues_iP3us-gaap--SharesOutstanding_zOf8WmiZntBi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; color: black; text-indent: -10pt">&#160;Purchase shares</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_iP3us-gaap--StockIssuedDuringPeriodValueNewIssues_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCJrYssUQXuj" title="Shares issued under 2019 purchase agreement Purchase shares, shares" style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,400,000</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,400</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,123,405</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,124,805</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_iP3us-gaap--StockIssuedDuringPeriodSharesNewIssues_zlOtyF6j6Q13" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; color: black; text-indent: -10pt">&#160;Commitment shares</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_984_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_iP3custom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfkhLBQnbdwb" title="Shares issued under 2019 purchase agreement Commitment shares, shares" style="color: black; text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,624</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(<ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16</ix:nonFraction></td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--SharesIssuedPursuantToCashlessExerciseOfOptions_iP3custom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_zD6lemPCX0d6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Shares issued pursuant to cashless exercise of options</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_981_ecustom--SharesIssuedPursuantToCashlessExerciseOfOptionsShares_iP3custom--SharesIssuedPursuantToCashlessExerciseOfOptions_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNiw2O0rOPNf" title="Shares issued pursuant to cashless exercise of options, Shares" style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsShares" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">721</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(<ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_iP3custom--SharesIssuedPursuantToCashlessExerciseOfOptionsShares_zf39ed25Ccoa" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Share based compensation</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#8212;</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0341">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,251,129</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,251,129</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProfitLoss_zOgFKbfpmpzl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Net loss</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8212;</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">&#8212;</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,486,622</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,486,622</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td></tr>
  <tr id="xdx_43E_c20200401__20200630_eus-gaap--StockholdersEquity_iE_z16txrMS7JO9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Balance, June 30, 2020</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdOIisEvoVeb" title="Balance ending, shares" style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,082,291</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,083</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,332,979</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">153,712,004</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,681,058</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See Accompanying Notes to Condensed Consolidated
Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 100%; padding-top: 0.65pt; padding-right: 0.65pt; padding-left: 0.65pt; text-align: center"><span style="color: black"><b>ANAVEX
    LIFE SCIENCES CORP.</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-top: 0.65pt; padding-right: 0.65pt; padding-left: 0.65pt; text-align: center"><span style="color: black"><b>INTERIM
    CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-top: 0.65pt; padding-right: 0.65pt; padding-left: 0.65pt; text-align: center"><span style="color: black"><b>For
    the nine months ended June 30, 2021 and 2020</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-top: 0.65pt; padding-right: 0.65pt; padding-left: 0.65pt; text-align: center"><span style="color: black"><b>(Unaudited)</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; color: black; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="color: black">&#160;</td>
    <td colspan="3" style="color: black; text-align: center">Additional</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="color: black">&#160;</td>
    <td colspan="3" style="color: black; text-align: center">Paid-in</td><td style="color: black">&#160;</td>
    <td colspan="3" style="color: black; text-align: center">Accumulated</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Shares</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Par Value</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Capital</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Deficit</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20201001__20210630_eus-gaap--StockholdersEquity_iS_zvmdViT4jZQ3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 35%; color: black; text-indent: -10pt">Balance, October 1, 2020</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20201001__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuuNBytcnlwe" title="Balance beginning, shares" style="width: 9%; color: black; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,045,198</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 9%; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,047</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 9%; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,851,752</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 9%; color: black; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">159,677,230</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">)</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 9%; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,236,569</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Shares issued under 2019 purchase agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zLg4LWJeVFHa" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-indent: -10pt">&#160;Purchase shares</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zorAQgrTiufc" title="Shares issued under 2019 purchase agreement Purchase shares, shares" style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,007,996</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,008</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,107,190</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,111,198</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_zC2rOgjHdR64" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-indent: -10pt">&#160;Commitment shares</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_981_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_c20201001__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztucYHgW5XPg" title="Shares issued under 2019 purchase agreement Commitment shares, shares" style="color: black; text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,213</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(<ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">78</ix:nonFraction></td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueOther_zzdELyKzvxp6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Shares issued under Sales Agreement, net of share issue costs</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98D_ecustom--SharesIssuedUnderSalesAgreementNetOfShareIssueCosts_c20201001__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcKH3JSh5Hli" title="Shares issued under Sales Agreement, net of share issue costs" style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,634,576</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,634</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,664,391</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,670,025</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts_z4B6VE6cUNia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Shares issued pursuant to registered direct offering, net of share issue costs</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_989_ecustom--SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares_c20201001__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrHSQ9odDbB" title="Shares issued pursuant to registered direct offering, net of share issue costs, Shares" style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,380,953</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,381</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,901,681</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,904,062</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zqizJngx3WMl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Shares issued upon exercise of stock options</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_987_ecustom--SharesIssuedPursuantToCashlessExerciseOfOptionsShares_c20201001__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyURZwJUX9n2" title="Shares issued upon exercise of options, shares" style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsShares" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">652,897</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">653</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,867,755</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,868,408</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--SharesIssuedPusuantToExerciseOfWarrants_z5zC4ODUaWn4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Shares issued pusuant to exercise of warrants</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharesIssuedPusuantToExerciseOfWarrantsShares_c20201001__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBsEb74FbAI1" title="Shares issued pusuant to exercise of warrants, Shares" style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPusuantToExerciseOfWarrantsShares" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPusuantToExerciseOfWarrants" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">350</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPusuantToExerciseOfWarrants" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,466,150</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPusuantToExerciseOfWarrants" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,466,500</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_zia42ndYmL4b" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Share based compensation</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#8212;</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,079,395</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,079,395</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProfitLoss_z58o9AydfJQj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Net loss</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8212;</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8212;</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,190,428</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,190,428</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20201001__20210630_eus-gaap--StockholdersEquity_iE_zmvPTyIIfxLe" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Balance, June 30, 2021</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20201001__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBpfrdJMQW4f" title="Balance ending, shares" style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,149,833</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,151</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">342,938,236</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">185,867,658</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,145,729</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20191001__20200630_eus-gaap--StockholdersEquity_iS_z4ZB4mSSMQUl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Balance, October 1, 2019</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20191001__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVAoZCSwHLJ4" title="Balance beginning, shares" style="color: black; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,650,521</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,652</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,633,807</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">133,396,760</ix:nonFraction></td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,289,699</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Shares issued under 2019 Purchase Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#8212;</td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueNewIssues_iP3us-gaap--SharesOutstanding_zKUT6EgDrr86" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-indent: -10pt">&#160;Purchase shares</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_iP3us-gaap--StockIssuedDuringPeriodValueNewIssues_c20191001__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJf0uf9bVmOc" title="Shares issued under 2019 purchase agreement Purchase shares, shares" style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,364,584</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,365</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,482,932</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,490,297</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_iP3us-gaap--StockIssuedDuringPeriodSharesNewIssues_z083jIuR9axi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; color: black; text-indent: -10pt">&#160;Commitment shares</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98E_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_iP3custom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_c20191001__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCYlFJjRkyUk" title="Shares issued under 2019 purchase agreement Commitment shares, shares" style="color: black; text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,465</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(<ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">65</ix:nonFraction></td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0440">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0441">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--SharesIssuedPursuantToCashlessExerciseOfOptions_iP3custom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_zAkRsGqFtaB1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Shares issued pursuant to cashless exercise of options</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98A_ecustom--SharesIssuedPursuantToCashlessExerciseOfOptionsShares_iP3custom--SharesIssuedPursuantToCashlessExerciseOfOptions_c20191001__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKNJEM6HSPTi" title="Shares issued upon exercise of options, shares" style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsShares" contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">721</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(<ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_iP3custom--SharesIssuedPursuantToCashlessExerciseOfOptionsShares_zB7lCbxhqYLe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Share based compensation</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#8212;</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,216,306</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">&#8212;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,216,306</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProfitLoss_z0q3uMo0OJci" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Net loss</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457">&#8212;</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">&#8212;</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,315,244</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,315,244</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td></tr>
  <tr id="xdx_436_c20191001__20200630_eus-gaap--StockholdersEquity_iE_zS9lbqDTEWJ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-indent: -10pt">Balance, June 30, 2020</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_c20191001__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSlAJZCf0Wqk" title="Balance ending, shares" style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,082,291</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,083</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,332,979</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">153,712,004</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,681,058</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See Accompanying Notes to Condensed Consolidated
Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0">Notes to the Condensed Consolidated Interim Financial Statements<br />

June 30, 2021<br />
 (Unaudited)</p>

<ix:nonNumeric contextRef="From2020-10-01to2021-06-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zhhjFNwEkW1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 42pt; text-align: left">Note 1</td><td style="text-align: justify"><span style="text-decoration: underline"><span id="xdx_82A_zUO5DzJkHDoa">Business Description
and Basis of Presentation</span></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42pt; text-align: justify; text-indent: 0pt">Business</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221;
or the &#8220;Company&#8221;) <span style="color: black">is a clinical stage biopharmaceutical company engaged in the development
of differentiated therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high
unmet need. Anavex analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will
receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. </span>The Company&#8217;s
lead compound ANAVEX<sup>&#174;</sup>2-73 <span style="color: black">is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s
disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological
monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">On May 25, 2021, the Company filed
a Certificate of Amendment to its Articles of Incorporation with the Secretary of the State of Nevada effecting an amendment to
increase the number of authorized shares of the Company&#8217;s common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210525_z8AbwXUUyDza" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-05-25" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction> </span>per share, from <span id="xdx_908_eus-gaap--ExcessStockSharesAuthorized_iI_c20210525__srt--RangeAxis__srt--MinimumMember_zx1M2oZ5SxFk"><ix:nonFraction name="us-gaap:ExcessStockSharesAuthorized" contextRef="AsOf2021-05-25_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span> shares
to <span id="xdx_905_eus-gaap--ExcessStockSharesAuthorized_iI_c20210525__srt--RangeAxis__srt--MaximumMember_zewSnWm0soxl"><ix:nonFraction name="us-gaap:ExcessStockSharesAuthorized" contextRef="AsOf2021-05-25_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></span> shares. The Certificate of Amendment was approved by the Company&#8217;s stockholders at an annual meeting of stockholders
on May 25, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-10-01to2021-06-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxbVJpCHdrD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 42.55pt"><span id="xdx_863_z4w2j1Gyuuce">Basis of
Presentation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">These unaudited interim condensed
consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission
(&#8220;SEC&#8221;) and accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for
interim reporting.<span style="color: black"> Accordingly, certain information and note disclosures normally included in the annual
financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the
opinion of management, the disclosures are adequate to make the information presented not misleading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">These accompanying unaudited interim
condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion
of management are necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September
30, 2020 was derived from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The
accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K for the year ended September
30, 2020 filed with the SEC on December 28, 2020. The Company follows the same accounting policies in the preparation of interim
reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="color: black">Operating
results for the three and nine months ended </span>June 30<span style="color: black">, 2021 are not necessarily indicative of the
results that may be expected for the year ending September 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" escape="true" name="avxl:LiquidityPolicyTextBlock"><p id="xdx_848_ecustom--LiquidityPolicyTextBlock_zgpITkUS9fIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span id="xdx_86C_zfo8cXMui8Uf">Liquidity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">All of the Company&#8217;s potential
drug compounds are in the clinical development stage and the Company cannot be certain that its research and development efforts
will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies
or generate commercial revenues. To date, we have not generated any revenues from our operations. The Company expects the business
to continue to experience negative cash flows for the foreseeable future and cannot predict when, if ever, our business might become
profitable.</p>

<ix:exclude><p id="xdx_23F_zKWucSsYlm83" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zsFZxUvqzwRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 9; Value: 1 -->
    <div id="xdx_238_ztHzlYojjmR9" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23A_zYNUoEnHWwQd" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_236_zW5PaafDheMa" style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_23E_zHBaVgpAS1Sj" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_230_zpcZ8KhaGp0e" style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zIqhkN2hdo5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zS77iJI7YMmh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_231_zAXjka33Gjaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0">Notes to the Condensed Consolidated Interim Financial Statements<br />

June 30, 2021<br />
 (Unaudited)</p></ix:exclude>

<ix:exclude><p id="xdx_233_zStTIHeUlLEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0">&#160;</p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_231_zj5vuhARdsm9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 42pt; text-align: left">Note 1</td><td style="text-align: justify"> <span style="text-decoration: underline">Business Description and Basis of Presentation</span> &#8211; (Continued)</td>
</tr></table></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Management believes that the current
working capital position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months
after the date that these interim condensed consolidated financial statements are issued. The process of drug development can be
costly, and the timing and outcomes of clinical trials is uncertain.&#160;The assumptions upon which the Company has based its
estimates are routinely evaluated and may be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will
vary depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials,
the progress of the Company&#8217;s research and development programs and the level of financial resources available. The Company
has the ability to adjust its operating plan spending levels based on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Other than our rights related to
the Sales Agreement (as defined below in Note 4), there can be no assurance that additional financing will be available to us when
needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional
financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and
development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">In December 2019, a novel strain
of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World Health Organization declared
COVID-19 to be a global pandemic as a result of the rapid spread of the virus beyond its point of origin.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The global outbreak of COVID-19
continues to rapidly evolve as of the date these interim condensed consolidated financial statements are issued. As such, it is
uncertain as to the full magnitude that the outbreak will have on the Company&#8217;s financial condition and future results of
operations. Management is actively monitoring the global situation on its business, including on its clinical trials and operations
and financial condition. The effects of COVID-19 did not have a material impact on the Company&#8217;s result of operations or
financial condition for the period ended June 30, 2021. However, given the daily evolution of the COVID-19 situation, and the global
responses to curb its spread, the Company is not able to estimate the effects COVID-19 may have on its future results of operations
or financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><i style="font-style: normal; font-weight: normal">Use of Estimates</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The preparation of financial statements
in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The
Company regularly evaluates estimates and assumptions related to accounting for research and development costs, valuation and recoverability
of deferred tax assets, incentive and tax receivables, asset impairment, stock-based compensation, and loss contingencies. The
Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes
to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of
assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent there are material
differences between the estimates and the actual results, future results of operations will be affected.</p>

<ix:exclude><p id="xdx_238_zk18aiHAJfGd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zlpoOY3W8485" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 1 -->
    <div id="xdx_233_zzrNvC9bRhzl" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_235_z9Gx0LSNR6Dh" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_23C_zqqP8TqHP6Sj" style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_23F_zrIkVUrPTP4a" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23B_zPdwFl2PSrt8" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_23E_zUpC2DIbybo6" style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zt3pVd2xQJld" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zlEjDY6msy44" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_239_zGE7eS5oNmAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0">Notes to the Condensed Consolidated Interim Financial Statements<br />

June 30, 2021<br />
 (Unaudited)</p></ix:exclude>

<ix:exclude><p id="xdx_237_zhMkwabcwUMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_233_zrZ3rqcewRbj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 40pt; text-align: left">Note 1</td><td style="text-align: justify"> &#9;<span style="text-decoration: underline">Business Description and Basis of Presentation</span> &#8211; (Continued)</td>
</tr></table></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Principles of Consolidation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">These consolidated financial statements
include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited., a company
incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex Canada
Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><i style="font-style: normal; font-weight: normal">Fair Value Measurements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The fair value hierarchy under
GAAP is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be
used to measure fair value which are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 1 -
&#9;quoted prices (unadjusted) in active markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 2 -
observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical
or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose
significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 3 -
&#9;assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The book value of cash and cash
equivalents and accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of those
instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">At June 30, 2021 and September
30, 2020, the Company did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><i style="font-style: normal; font-weight: normal">Basic and Diluted
Loss per Share</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Basic income/(loss) per common
share is computed by dividing net income/(loss) available to common stockholders by the weighted average number of common shares
outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common
stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive effect
of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially
dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are potentially dilutive
securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">As of June 30, 2021, loss per share
excludes <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210630_pdd" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,059,202</ix:nonFraction></span> (September 30, 2020 &#8211; <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20191001__20200930_pdd" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,576,266</ix:nonFraction></span>) potentially dilutive common shares related to outstanding options and
warrants, as their effect was anti-dilutive.</p>

<ix:exclude><p id="xdx_23E_zwTIYIRF9FPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zHsiBREXICSj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 1 -->
    <div id="xdx_233_zMQia7OfMS33" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_233_zmuufvXYx2zb" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_235_zWK0ShRQqxw2" style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_23A_zul0o7ZakNle" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_237_zPUMTINH7lPh" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_233_zMvYFUoBB3S9" style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zxkXXFliTcTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zKTXdsc3BlPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zAZsUqijmPW" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_231_zRNdJ8HK8be5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0">Notes to the Condensed Consolidated Interim Financial Statements<br />

June 30, 2021<br />
 (Unaudited)</p></ix:exclude>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" escape="true" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"><p id="xdx_80E_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_z9betADO0Syk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 42pt; text-align: left">Note 2</td><td style="text-align: justify"><span style="text-decoration: underline"><span id="xdx_82E_z0ifvhz4vHZ6">Recent Accounting Pronouncements</span></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><i>Recent Accounting Pronouncements
Not Yet Adopted</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company does not expect the
adoption of recently issued accounting pronouncements to have a significant impact on its results of operations, financial position
or cash flows.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" escape="true" name="avxl:OtherIncomeDisclosureTextBlock"><p id="xdx_80D_ecustom--OtherIncomeDisclosureTextBlock_zbJZYOkloxza" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 42pt; text-align: left">Note 3</td><td style="text-align: justify"><span style="text-decoration: underline"><span id="xdx_826_zTXy9RVvs1Ob">Other Income</span></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">Grant Income</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">During the
nine months ended June 30, 2021, the Company received $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ParkinsonMember_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-04-012021-06-30_custom_ParkinsonMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">497,931</ix:nonFraction></span> of a $995,862 research grant awarded by the Michael J. Fox Foundation
for Parkinson&#8217;s Research. The grant will be used to fund a clinical trial in the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73
for the treatment of Parkinson&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">The grant
income is being deferred when received and amortized to other income as the related research and development expenditures are incurred.
During the three and nine months ended June 30, 2021, the Company recognized $<span id="xdx_904_ecustom--NonOperatingIncomeFromGrant_c20210401__20210630_pp0p0" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,280</ix:nonFraction></span> and $<span id="xdx_908_ecustom--NonOperatingIncomeFromGrant_c20201001__20210630_pp0p0" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,100</ix:nonFraction></span>, respectively of this grant on
its statements of operations within grant income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">During the
year ended September 30, 2017, the Company was awarded grant funding in the amount of $<span id="xdx_908_ecustom--NonOperatingIncomeFromGrant_c20161001__20170930_pp0p0" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2016-10-012017-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">597,886</ix:nonFraction></span>. The grant was received in equal
quarterly installments over a period of two years ending during the year ended September 30, 2020, in exchange for a commitment
to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">The grant
income was deferred when received and amortized to other income as the related research and development expenditures were incurred.
During the three and nine months ended June 30, 2020, the Company recognized $nil and $<span id="xdx_901_ecustom--NonOperatingIncomeFromGrant_c20191001__20200630_pp0p0" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">149,888</ix:nonFraction></span>, respectively of this grant on its
statements of operations within grant income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">Research
and Development Incentive Income</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">Research
and development incentive income represents income earned by the Company&#8217;s Australian subsidiary, of the <span style="color: black">Australian
research and development incentive credit, </span>(the &#8220;ATO R&amp;D Credit&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">During the
three and nine months ended June 30, 2021, the Company recorded research and development incentive income of $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20210401__20210630_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,363,661</ix:nonFraction></span> (AUD <span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20210401__20210630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-04-012021-06-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,770,444</ix:nonFraction></span>)
and $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210630_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,593,856</ix:nonFraction> </span>(AUD <span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-012021-06-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,750,539</ix:nonFraction></span>) (2020: $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20200401__20200630_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,319,913</ix:nonFraction></span> (AUD <span id="xdx_906_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20200401__20200630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-04-012020-06-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,923,000</ix:nonFraction></span>) and $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20191001__20200630_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,980,456</ix:nonFraction></span> (AUD <span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20191001__20200630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2019-10-012020-06-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,471,000</ix:nonFraction></span>)), respectively, in respect of the
ATO R&amp;D Credit for eligible research and development expenses incurred during the period.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" escape="true" name="avxl:EquityOfferingAgreementsTextBlock"><p id="xdx_80B_ecustom--EquityOfferingAgreementsTextBlock_zJr0lD85aytc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 42pt; text-align: left">Note 4</td><td style="text-align: justify"><span style="text-decoration: underline"><span id="xdx_82A_zR1783jA5m2c">Equity Offerings</span></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Registered Direct Offering</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">On June 22, 2021, the Company and
Deep Track Capital entered into a securities purchase agreement pursuant to which the Company sold to Deep Track Capital an aggregate
of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210601__20210622__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zR6mGDdDeuo5" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-06-012021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,380,953</ix:nonFraction></span> shares of common stock at $<span id="xdx_90D_eus-gaap--SharePrice_iI_pp0p0_c20210622__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zJjzmvmTiZE2" title="Common stock price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USDPShares">21</ix:nonFraction></span> per share in a registered direct offering, for gross proceeds of $<span id="xdx_90E_ecustom--GrossProceedsFromSaleOfCommonStock_pp0p0_c20210601__20210622__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zttELwpFLcfi" title="Gross proceeds from sale of common stock"><ix:nonFraction name="avxl:GrossProceedsFromSaleOfCommonStock" contextRef="From2021-06-012021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,013</ix:nonFraction></span>. Net proceeds
of the offering were $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20210601__20210622__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z1CDELzc6tb4" title="Proceed from offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2021-06-012021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,904,062</ix:nonFraction> </span>after deducting offering fees and expenses.</p>

<ix:exclude><p id="xdx_23B_zIcjxTb4geC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_z4QHVjaCVdpl" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 12; Value: 1 -->
    <div id="xdx_23B_zgZylnT7FRbb" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23D_zjfdOGHb1Zvj" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_234_zTYXC9TlptF8" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_237_zzLr1tTESKm2" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_233_zn5c8eGOq5uc" style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zdsFkrBYrLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zPtXeUmoQivi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_23F_z96KKFkwqQci" style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0">Notes to the Condensed Consolidated Interim Financial Statements<br />

June 30, 2021<br />
 (Unaudited)</p></ix:exclude>

<ix:exclude><p id="xdx_23F_z7veyu3CMk29" style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0">&#160;</p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_231_z4cB9eJYSdZ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 42pt; text-align: left">Note 4</td><td style="text-align: justify"><span style="text-decoration: underline">Equity Offerings</span> &#8211; (Continued)</td>
</tr></table></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Sales Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company entered into a Controlled
Equity Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;Sales Agreement&#8221;)
with Cantor Fitzgerald&#160;&amp; Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company
may offer and sell shares of common stock registered under an effective registration statement from time to time through the Sales
Agents (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Upon delivery of a placement notice
based on the Company&#8217;s instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may
sell the Shares by methods deemed to be an &#8220;at the market offering&#8221; offering, in negotiated transactions at market
prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted by
law, including negotiated transactions, subject to the prior written consent of the Company. The Company is not obligated to make
any sales of Shares under the Sales Agreement. The Company or Sales Agents may suspend or terminate the offering of Shares upon
notice to the other party, subject to certain conditions. The Sales Agents will act as agent on a commercially reasonable efforts
basis consistent with their normal trading and sales practices and applicable state and federal law, rules&#160;and regulations
and the rules&#160;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company has agreed to pay the
Sales Agents commissions for their services of up to <span id="xdx_901_ecustom--PercentageOfGrossProceedsFromSales_dp_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zngz6jyIzOG4" title="Percentage of gross proceeds from sales"><ix:nonFraction name="avxl:PercentageOfGrossProceedsFromSales" contextRef="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% of the gross proceeds from the sale of the Shares pursuant to the Sales
Agreement. The Company also agreed to provide the Sales Agents with customary indemnification and contribution rights. During the
nine months ended June 30, 2021, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,634,576</ix:nonFraction></span> shares were sold pursuant to the Offering for gross proceeds of $<span id="xdx_906_ecustom--GrossProceedsFromSaleOfCommonStock_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross proceeds from sale of common stock"><ix:nonFraction name="avxl:GrossProceedsFromSaleOfCommonStock" contextRef="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">79,107,547</ix:nonFraction></span> (net proceeds
of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceed from offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">76,670,025</ix:nonFraction></span> after deducting offering expenses).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">2019 Purchase Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">On June 7, 2019, the Company entered
into a $<span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Total number of shares obligated to purchase"><ix:nonFraction name="avxl:ValueOfSharesObligatedToPurchase" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span> purchase agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln Park, as amended on July 1, 2020,
pursuant to which the Company had the right to sell and issue to Lincoln Park, and Lincoln Park was obligated to purchase, up to
$<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Proceeds from Issuance or Sale of Equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction> </span>in value of its shares of common stock from time to time over a three-year period until July 1, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">In consideration for entering into
the 2019 Purchase Agreement, the Company issued to Lincoln Park <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">324,383</ix:nonFraction></span> shares of common stock as a commitment fee during the year
ended September 30, 2019 and agreed to issue up to <span id="xdx_90A_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Pro rata basic number of shares obligated to purchase"><ix:nonFraction name="avxl:NumberOfSharesObligatedToPurchaseProrataBasic" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">162,191</ix:nonFraction></span> shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s
discretion, the $50,000,000 aggregate commitment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">During the nine months ended June
30, 2021, the Company issued to Lincoln Park an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-10-012021-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,086,209</ix:nonFraction></span> (2020 &#8211; <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,431,049</ix:nonFraction></span>) shares of common stock under the
2019 Purchase Agreement, including <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for aggregate purchase price"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextRef="From2020-10-012021-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,007,996</ix:nonFraction></span> (2020: <span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for aggregate purchase price"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,364,584</ix:nonFraction></span>) shares of common stock for an aggregate purchase price of $<span id="xdx_904_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2020-10-012021-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,111,198</ix:nonFraction></span>
(2020: $<span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,490,297</ix:nonFraction></span>) and <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2020-10-012021-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,213</ix:nonFraction> </span>(2020: <span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,465</ix:nonFraction></span>) commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">At June 30, 2021, <span id="xdx_901_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_do_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z1pZMS22sfic" title="Amount of shares remain available"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues4" contextRef="From2020-10-012021-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span> amount remained
available under the 2019 Purchase Agreement (September 30, 2020: $<span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueNewIssues4_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Amount of shares remain available"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues4" contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,111,198</ix:nonFraction></span>).</p>

<ix:exclude><p id="xdx_23F_zSmOrYHEiwqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zr6hjqR8j7F8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 13; Value: 1 -->
    <div id="xdx_23F_zifXrlwiiNMl" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_231_zbYZ3QH0AoXa" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_23A_z8vuKWBRLa4d" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_232_z3ZeDc5biSv4" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_234_zfEhxT7ZZpAl" style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zM5wVyAQk53i" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zofY4zQvWW5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_236_zzekje94ayo8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0">Notes to the Condensed Consolidated Interim Financial Statements<br />

June 30, 2021<br />
 (Unaudited)</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_807_eus-gaap--CommitmentsDisclosureTextBlock_zIkJvyhMG1I2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 42pt; text-align: left">Note 5</td><td style="text-align: justify"> <span style="text-decoration: underline"><span id="xdx_82C_zlOevWvPjd6g">Commitments and Contingencies</span></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"><span style="font-size: 11pt">a)</span><span style="font: 7pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;
</span><span style="font-size: 10pt"><i style="font-style: normal; font-weight: normal">Leases </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">During
the three and nine months ended June 30, 2021, the Company incurred office lease expense of $<span id="xdx_908_eus-gaap--LeaseAndRentalExpense_c20210401__20210630_pp0p0" title="Lease expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,994</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--LeaseAndRentalExpense_c20201001__20210630_pp0p0" title="Lease expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">117,284</ix:nonFraction></span>, respectively
(2020: $<span id="xdx_906_eus-gaap--LeaseAndRentalExpense_c20200401__20200630_pp0p0" title="Lease expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,554</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--LeaseAndRentalExpense_c20191001__20200630_pp0p0" title="Lease expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">169,469</ix:nonFraction></span>, respectively).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"><span style="font-size: 11pt">b)</span><span style="font: 7pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;
</span><span style="font-size: 10pt"><i style="font-style: normal; font-weight: normal">Litigation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain,
and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution
of any such matter will not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company
does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its consolidated
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"><span style="font-size: 11pt">c)</span><span style="font: 7pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;
</span><span style="font-size: 10pt"><i style="font-style: normal; font-weight: normal">Share Purchase Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">A summary of the status of the Company&#8217;s
outstanding share purchase warrants is presented below:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">&#160;</p>

<ix:nonNumeric contextRef="From2020-10-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zG3bATHydCJ6" summary="xdx: Disclosure - Commitments and Contingencies (Details)" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span id="xdx_8B3_zWem4hVgSjh7" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Number of Shares</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Weighted Average Exercise Price ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; width: 26%; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Balance, September 30, 2019</span></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 8%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zZt7I7LCPgp2" title="Share Purchase Warrants Balance, at beginning" style="width: 26%; color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 8%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgcydGQ8Rqha" title="Weighted Average Exercise Price warrants outstanding at beginning" style="width: 26%; color: black; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.19</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Granted</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" title="Share Purchase Warrants Granted" style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" contextRef="From2019-10-012020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" title="Weighted Average Exercise Price warrants granted" style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" contextRef="From2019-10-012020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.17</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Balance, September 30, 2020</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmCdkSLH3Dx9" title="Share Purchase Warrants Balance, at ending" style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zqlxyNN9AmMg" title="Weighted Average Exercise Price Balance, at ending" style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.88</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Granted</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" title="Share Purchase Warrants Granted" style="color: black; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" contextRef="From2020-10-012021-06-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" title="Weighted Average Exercise Price warrants granted" style="color: black; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" contextRef="From2020-10-012021-06-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Exercised</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zIG3Y1h7hoLe" title="Share Purchase Warrants Exercised" style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" contextRef="From2020-10-012021-06-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">350,000</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zAkki7I1YtZ4" title="Weighted Average Exercise Price warrants exercised" style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" contextRef="From2020-10-012021-06-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.19</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Balance, June 30, 2021</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zY7gAfHgrpP" style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-06-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">210,000</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z214rzU2BAn9" style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.69</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AC_zlJXGQXwINx1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-indent: -0.8pt">At June 30, 2021, the Company had
share purchase warrants outstanding as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-indent: -0.8pt">&#160;</p>

<ix:nonNumeric contextRef="From2020-10-01to2021-06-30" escape="true" name="avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zDKAuYt6dEG" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="color: black; text-align: center"><span id="xdx_8B0_zXQOBbmxKaSl" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="color: black; text-align: center">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="color: black; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="color: black; text-align: center">Number</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Exercise Price</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; width: 12%; color: black; text-align: right; text-indent: -10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2021-06-30_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 8%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 12%; color: black; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Exercise Price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.17</ix:nonFraction></span></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 8%; color: black">&#160;</td>
    <td style="width: 30%; color: black; text-align: right; padding-left: 0.65pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zHM2VWOB4VFk" title="Warrants and Rights Outstanding, Maturity Date"><ix:nonNumeric contextRef="AsOf2021-06-30_custom_PurchaseWarrants1Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May 6, 2024</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; color: black; text-align: right; text-indent: -10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2021-06-30_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Exercise Price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="color: black; text-align: right; padding-bottom: 1pt; padding-left: 0.65pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zG4VWGu67Aa4" title="Warrants and Rights Outstanding, Maturity Date"><ix:nonNumeric contextRef="AsOf2021-06-30_custom_PurchaseWarrants2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April 21, 2026</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; padding: 0pt 0pt 0pt 10pt; color: black; text-align: right; text-indent: -10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210630_pdd" title="Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">210,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 0.65pt">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A4_zLtsZsKbyRy" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 99.25pt; text-indent: -0.8pt">&#160;</p>

<ix:exclude><p id="xdx_23F_zPtyvohaoDr" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 99.25pt; text-indent: -0.8pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 14; Value: 1 -->
    <div id="xdx_238_zRHwZqUDs3L9" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_232_zcqsh1SPI6H1" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_234_zUsjFYrsLpFd" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23B_zfgZGiEYAZY4" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_23C_zaUMN2cHMWnk" style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zFg6PDGuRw14" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 99.25pt; text-indent: -0.8pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zimikjkwabti" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_230_zjmEjU9RKgK5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0">Notes to the Condensed Consolidated Interim Financial Statements<br />

June 30, 2021<br />
 (Unaudited)</p></ix:exclude>

<ix:exclude><p id="xdx_232_zpL82SCAzX8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0">&#160;</p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_239_zwsdsdCa6J34" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 42pt; text-align: left">Note 5</td><td style="text-align: justify"><span style="text-decoration: underline">Commitments</span> &#8211; (Continued)</td>
</tr></table></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; text-indent: -18pt; color: black"><span style="font-size: 11pt">d)</span><span style="font: 7pt Times New Roman, Times, Serif">&#160;&#160;
</span><i style="font-style: normal; font-weight: normal">Stock&#8211;based Compensation Plan</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">2015 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">On September 18, 2015, the Company&#8217;s
Board of Directors (the &#8220;Board&#8221;) approved a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided
for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">The maximum number of our common shares
reserved for issue under the plan was <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,050,553</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.
At June 30, 2021, <span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--OptionsMember_pdd" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_OptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">146,371</ix:nonFraction></span> (September 30, 2020: <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--OptionsMember_pdd" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member_custom_OptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">146,371</ix:nonFraction></span>) options remain available for issue under the 2015 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">2019 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">On January 15, 2019, the Board approved
the 2019 Omnibus Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock
awards to directors, officers, employees, consultants and advisors of the Company. Under the terms of the 2019 Plan, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000,000</ix:nonFraction></span>
additional shares of Common Stock are available for issuance under the 2019 Plan, in addition to the shares available under the
2015 Plan. Any awards outstanding under the 2015 Plan or the Company&#8217;s 2007 Stock Option Plan (the &#8220;2007 Plan&#8221;)
will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and any shares subject to outstanding awards
under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards (other than by reason of settlement of
the awards in shares) will automatically become available for issuance under the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member" title="Description of grant option"><ix:nonNumeric contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2019Member" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">The 2019 Plan provides that it may
be administered by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined
by the Board at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder
on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common
stock on the grant date. Stock options may be granted under the 2019 Plan for an exercise period of up to ten years from the date
of grant of the option or such lesser periods as may be determined by the Board, subject to earlier termination in accordance with
the terms of the 2019 Plan. At June 30, 2021, <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2021-06-30_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,706,665</ix:nonFraction></span> (September 30, 2020: <span id="xdx_907_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-09-30_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,161,665</ix:nonFraction></span>) options remain available for issue under
the 2019 Plan.</ix:nonNumeric></span></p>

<ix:exclude><p id="xdx_239_zg3qvZXvBTz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zjnkdjARXlCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 15; Value: 1 -->
    <div id="xdx_233_zS1sPtNxDzui" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23E_z3moSAwP9DX8" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_23D_zkijE097bJg1" style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_232_zkUX3rV1jsN6" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23F_zOs3LUuG7Opb" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_23D_zKW4Y830Oi94" style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zoaWuDWUVjB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_z4mahD0hb9Ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_239_zRaGeJUOhU1d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0">Notes to the Condensed Consolidated Interim Financial Statements<br />

June 30, 2021<br />
 (Unaudited)</p></ix:exclude>

<ix:exclude><p id="xdx_230_zKNTKRNuHyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0">&#160;</p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_23D_z3IeqigWleEa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 42pt; text-align: left">Note 5</td><td style="text-align: justify"><span style="text-decoration: underline">Commitments</span> &#8211; (Continued)</td>
</tr></table></ix:exclude>

<ix:exclude><p id="xdx_23E_zGNhQFIpTNDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_23A_zinRaj3EEth3" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt">d)</td><td style="text-align: justify"><i style="font-style: normal; font-weight: normal">Stock-based Compensation Plan &#8211; (Continued)</i></td></tr></table></ix:exclude>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 2cm">A summary of the status of Company&#8217;s outstanding
stock options is presented below:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 2cm">&#160;</p>

<ix:nonNumeric contextRef="From2020-10-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zcTlezsbyhr1" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span id="xdx_8B6_zp2UmFGfrnkc" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#160;</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#160;</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#160;</td><td style="color: black; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Number of Shares</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Weighted Average Exercise Price ($)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Weighted Average Grant Date Fair Value ($)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: center">Aggregate intrinsic value ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; width: 20%; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Outstanding, September 30, 2019</span></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 5%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zZi9dn5TUxF9" title="Options Outstanding at beginning" style="width: 19%; color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,462,933</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 5%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z3GmxeYlX9uf" title="Weighted Average Exercise Price Outstanding at beginning" style="width: 19%; color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.58</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; color: black">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zaIDX87OaK74" title="Aggregate intrinsic value Outstanding at beginning" style="color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,115,032</ix:nonFraction></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Granted</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Options Granted" style="color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,695,000</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Exercise Price Granted" style="color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.96</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Grant Date Fair Value Granted" style="color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.27</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Forfeited</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zWhXJEMOXRA9" title="Options Forfeited" style="color: black; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">68,332</ix:nonFraction></td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Exercise Price Forfeited" style="color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.01</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Exercised&#160;</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z9tl9xthn3Ed" title="Option Exercised" style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,335</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Exercise Price Exercised" style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.15</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Outstanding, September 30, 2020</span></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z0OqkVdTu2j1" style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,076,266</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zrpkO0nJPtAl" title="Weighted Average Exercise Price Outstanding at ending" style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.48</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zAUOsn8yz2Ll" style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,982,581</ix:nonFraction></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Granted&#160;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Options Granted" style="color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,455,000</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Exercise Price Granted" style="color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.59</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Grant Date Fair Value Granted" style="color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.02</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Forfeited</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCjQLOYsmJbc" title="Options Forfeited" style="color: black; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,167</ix:nonFraction></td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Exercise Price Forfeited" style="color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.44</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Exercised&#160;</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOJJK2IZbjX1" title="Option Exercised" style="border-bottom: Black 1pt solid; color: black; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">652,897</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Exercise Price Exercised" style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.86</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Outstanding, June 30, 2021&#160;</span></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zi0GXvSz7SV3" title="Options Outstanding at ending" style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,849,202</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zO24Gleu5ap3" style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.94</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zDIb0TSEN4Bh" style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">205,309,996</ix:nonFraction></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Exercisable, June 30, 2021&#160;</span></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Options Exercisable" style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,930,452</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Exercise Price, Exercisable" style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.64</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pp0p0" title="Aggregate intrinsic value Exercisable" style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">152,413,269</ix:nonFraction></td></tr>
  </table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">&#160;</p>

</ix:nonNumeric><p id="xdx_8A0_zKDIGJ8QmK2k" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 2cm">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the
options that were in-the-money at June 30, 2021.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 2cm">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">During the three and nine months ended
June 30, 2021, the Company recognized stock-based compensation expense of $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20210401__20210630_pp0p0" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,293,925</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20201001__20210630_pp0p0" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,079,395</ix:nonFraction></span>, respectively (2020: $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20200401__20200630_pp0p0" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,251,129</ix:nonFraction>
</span>and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20191001__20200630_pp0p0" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,216,306</ix:nonFraction></span>, respectively) in connection with the issuance and vesting &#9;of stock options and warrants in exchange for services.
These amounts have been included in general and &#9;administrative expenses and research and development expenses on the Company&#8217;s
statements of &#9;operations as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-10-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zFaM8Dq7r2Pa" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span id="xdx_8BE_z952apFZt7s" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black">&#160;</td>
    <td colspan="7" style="color: black; text-align: center">Three months ended June 30,</td><td style="color: black">&#160;</td>
    <td colspan="7" style="color: black; text-align: center">Nine months ended June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2021</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2020</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2021</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; color: black; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-04-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,048,606</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-04-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">575,451</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,265,387</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,863,869</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,245,319</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-04-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">675,678</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,814,008</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,352,437</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Total share based compensation</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,293,925</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,251,129</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,079,395</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; color: black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,216,306</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AD_zx4xeshKWBng" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_239_zIzfk6RYaER2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 16; Value: 1 -->
    <div id="xdx_237_zbcSdLItMW6e" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23D_zvXr89joZI68" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_23B_zaZWwa6krbtd" style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_232_zP26AQzuPm7i" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_236_zrVO8XIbmtlh" style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zXtk0LLZEx5g" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">An amount of approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20210630_pp0p0" title="Remaining stock based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,664,000</ix:nonFraction></span>
in stock-based compensation is expected to be recorded over the remaining term &#9;of such options through fiscal 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">The fair
value of each option award granted during the nine months ended June 30, 2021 and 2020 is estimated on the date of grant using
the Black Scholes option pricing model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-10-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zLVZvEpnKVF5" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B7_zOekhIMcCEVb" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_491_20201001__20210630_zhAydi1vKHU9" style="color: black; text-align: center">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_492_20191001__20200630_zMMdh0NXUYMg" style="color: black; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2021</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2020</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_zEzrkh4igtl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; color: black; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.71</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.57</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20210630_ztcQdR9VdBJh" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2020-10-01to2021-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.66</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20200630_zsvOeZ87iyT8" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2019-10-012020-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.53</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zr9dpGCdYKrg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95.87</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">97.80</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zOWSvay9Y7I" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-10-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-10-012020-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AA_zOv4f1JK5yae" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_81B_zfqfYJhJ4Vgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span id="a_003"></span>Item 2. Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Forward-Looking Statements</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Quarterly Report on Form 10-Q includes
forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form
10-Q, including statements regarding our anticipated future clinical and regulatory milestone events, future financial position,
business strategy and plans and objectives of management for future operations, are forward-looking statements. The words &#8220;believe,&#8221;
&#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect&#8221;
&#8220;should,&#8221; &#8220;forecast,&#8221; &#8220;could,&#8221; &#8220;suggest,&#8221; &#8220;plan&#8221; and similar expressions,
as they relate to us, are intended to identify forward-looking statements. Such forward-looking statements include, without limitation,
statements regarding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 20.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">volatility in our stock and
in the markets in general;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to successfully
conduct clinical and preclinical trials for our product candidates;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to raise additional
capital on favorable terms and the impact of such activities on our stockholders and stock price;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the impact of the COVID-19
outbreak and its effect on us;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to generate any
revenue or to continue as a going concern;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to execute our
research and development plan on time and on budget;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our products ability to demonstrate
efficacy or an acceptable safety profile of our product candidates;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to obtain the support
of qualified scientific collaborators;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability, whether alone
or with commercial partners, to successfully commercialize any of our product candidates that may be approved for sale;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to identify and
obtain additional product candidates;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our reliance on third parties
in non-clinical and clinical studies;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to defend against
product liability claims;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to safeguard against
security breaches;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to obtain and maintain
sufficient intellectual property protection for our product candidates;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to comply with
our intellectual property licensing agreements;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to defend against
claims of intellectual property infringement;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to comply with
the maintenance requirements of the government patent agencies;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to protect our
intellectual property rights throughout the world;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">competition;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the anticipated start dates,
durations and completion dates of our ongoing and future clinical studies;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the anticipated designs of
our future clinical studies;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the impact of fast track designation
on receipt of actual FDA approval;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our anticipated future regulatory
submissions and our ability to receive regulatory approvals to develop and market our product candidates, including any orphan drug or
fast track designations; and </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our anticipated future cash
position. </span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have based these forward-looking statements
largely on our current expectations and projections about future events, including the responses we expect from the U.S. Food and
Drug Administration, (&#8220;FDA&#8221;), and other regulatory authorities and financial trends that we believe may affect our
financial condition, results of operations, business strategy, preclinical and clinical trials, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions including without limitation the risks described in
&#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange Commission
on December 28, 2020. These risks are not exhaustive. Other sections of this Quarterly Report on Form 10-Q include additional factors
which could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing
environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor
can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking
statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking
statements will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.
Except as required by applicable laws including the securities laws of the United States, we assume no obligation to update or
supplement forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As used in this Quarterly Report on Form 10-Q,
the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and &#8220;Anavex&#8221; mean Anavex Life Sciences Corp., unless
the context clearly requires otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Current Business</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. is a clinical stage
biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous
system (&#8220;CNS&#8221;) diseases with high unmet need. We analyze genomic data from clinical studies to identify biomarkers,
which we use to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental
diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our lead compound, ANAVEX<sup>&#174;</sup>2-73,
is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked
gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have two core programs and two
seed programs. Our core programs are at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental
diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes key information about our programs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><img src="image_001.jpg" alt="" style="height: 237pt; width: 468pt" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex has a portfolio of compounds varying
in sigma-1 receptor (S1R) binding activities. The SIGMAR1 gene encodes the S1R protein, which is an intracellular chaperone protein
with important roles in cellular communication. S1R is also involved in transcriptional regulation at the nuclear envelope and
restores homeostasis and stimulates recovery of cell function when activated. In order to validate the ability of our compounds
to activate quantitatively the S1R, we performed, in collaboration with Stanford University, a quantitative Positron Emission Tomography
(PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX<sup>&#174;</sup>2-73 target engagement or receptor occupancy
(RO) with S1R in the brain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><img src="image_002.jpg" alt="" style="height: 329.25pt; width: 468pt" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cellular Homeostasis</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Many diseases are possibly directly caused
by chronic homeostatic imbalances or cellular stress of brain cells. In pediatric diseases like Rett syndrome or infantile spasms,
the chronic cellular stress is possibly caused by the presence of a constant genetic mutation. In neurodegenerative diseases, such
as Alzheimer&#8217;s and Parkinson&#8217;s diseases, chronic cellular stress is possibly caused by age-correlated buildup of cellular
insult and hence chronic cellular stress. Specifically, defects in homeostasis of protein or ribonucleic acid (&#8220;RNA&#8221;)
lead to the death of neurons and dysfunction of the nervous system. The spreading of protein aggregates resulting in a proteinopathy,
a characteristic finding in Alzheimer&#8217;s and Parkinson&#8217;s diseases that results from disorders of protein synthesis,
trafficking, folding, processing or degradation in cells. The clearance of macromolecules in the brain is particularly susceptible
to imbalances that result in aggregation and degeneration in nerve cells. For example, Alzheimer&#8217;s disease pathology is characterized
by the presence of amyloid plaques, neurofibrillary tangles, which are aggregates of hyperphosphorylated Tau protein that are a
marker of other diseases known as tauopathies as well as inflammation of microglia. With the SIGMAR1 activation through SIGMAR1
agonists like ANAVEX<sup>&#174;</sup>2-73, our approach is to restore cellular balance, i.e. homeostasis. Therapies that correct
defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental and neurodegenerative disease progression.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>ANAVEX</i></b><sup>&#174;</sup><b><i>2-73-specific Biomarkers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A full genomic analysis of Alzheimer&#8217;s
disease (AD) patients treated with ANAVEX<sup>&#174;</sup>2-73 resulted in the identification of actionable genetic variants. A
significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<sup>&#174;</sup>2-73 and COMT, a gene involved
in memory function, on the drug response level was identified, leading to an early ANAVEX<sup>&#174;</sup>2-73-specific biomarker
hypothesis. It is expected that <i>excluding</i> patients with these two identified biomarker variants (approximately 10%-20% of
the population) in prospective studies would identify approximately 80%-90% patients that would display clinically significant
improved functional and cognitive scores.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consistency between the identified DNA
and RNA data related to ANAVEX<sup>&#174;</sup>2-73, which are considered independent of AD pathology, as well as multiple endpoints
and time-points, provides support for precision medicine clinical development of ANAVEX<sup>&#174;</sup>2-73 by using genetic biomarkers
identified within the study population itself to target patients who are most likely to respond to ANAVEX<sup>&#174;</sup>2-73 treatment
in AD as well as indications like Parkinson&#8217;s disease dementia (PDD) or Rett syndrome (RTT) in which ANAVEX<sup>&#174;</sup>2-73
is currently studied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Clinical Studies Overview</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Alzheimer&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial, consisting of PART A and PART B, which lasted a total of 57 weeks, for ANAVEX<sup>&#174;</sup>2-73 in mild-to-moderate Alzheimer&#8217;s
patients. This open-label randomized trial met both primary and secondary endpoints and was designed to assess the safety and exploratory
efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients. ANAVEX<sup>&#174;</sup>2-73 targets sigma-1 and muscarinic receptors, which
have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and to reverse
the pathological hallmarks observed in Alzheimer&#8217;s disease. The Phase 2a trial demonstrated positive pharmacokinetic (PK)
and pharmacodynamic (PD) data, which established a concentration-effect relationship between ANAVEX<sup>&#174;</sup>2-73 and study
measurements. These measures obtained from all patients who participated in the entire 57 weeks include exploratory cognitive and
functional scores as well as biomarker signals of brain activity. Additionally, the study appears to show that ANAVEX<sup>&#174;</sup>2-73
activity is enhanced by its active metabolite (ANAVEX19-144), which also targets the sigma-1 receptor and has a half-life approximately
twice as long as the parent molecule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Two consecutive trial extensions for the Phase
2a trial have allowed participants who completed the 52-week PART B of the study to continue taking ANAVEX<sup>&#174;</sup>2-73,
providing an opportunity to gather extended safety data for a cumulative time period of five years. In August 2020, patients completing
these Phase 2a trial extensions were granted continued access to treatment with ANAVEX<sup>&#174;</sup>2-73 through the Australian
Government Department of Health &#8211; Therapeutic Goods Administration (TGA) compassionate use Special Access Scheme.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A larger Phase 2b/3 double-blind, placebo-controlled
450-patient study of ANAVEX<sup>&#174;</sup>2-73 in Alzheimer&#8217;s disease commenced in August 2018. The Phase 2b/3 study is
a 48-week study, with participants randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses or placebo. The trial commenced
in Australia; and additional regions were added in the United Kingdom, The Netherlands, Germany and Canada. The ANAVEX<sup>&#174;</sup>2-73
Phase 2b/3 study design incorporates genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a
study. Primary and secondary endpoints will assess safety and both cognitive and functional efficacy, measured through Alzheimer&#8217;s
Disease Assessment Scale &#8211; Cognition (ADAS-Cog), ADCS-ADL and Clinical Dementia Rating &#8211; Sum of Boxes for cognition
and function (CDR-SB). The study completed enrollment in June 2021, exceeding the enrollment beyond 450 patients at 52 sites across
North America, Europe and Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2019, we initiated a long-term open
label extension study of ANAVEX<sup>&#174;</sup>2-73, entitled the ATTENTION-AD study, for patients who have completed the 48-week
Phase 2b/3 placebo-controlled trial referenced above. This study is expected to last two years and will give patients the opportunity
to continue their treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Rett Syndrome </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in Rett syndrome, a rare neurodevelopmental disease. The study was funded by the International
Rett Syndrome Foundation (&#8220;Rettsyndrome.org&#8221;). In January 2017, we were awarded a financial grant from Rettsyndrome.org
of a minimum of $0.6 million to cover some of the costs of a multicenter Phase 2 clinical trial of ANAVEX<sup>&#174;</sup>2-73 for
the treatment of Rett syndrome. This award was received in quarterly instalments which commenced during fiscal 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2019, we commenced the first Phase
2 clinical trial in a planned Rett syndrome program of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome. The studies
are being conducted in a range of patient age demographics and geographic regions, utilizing a convenient oral liquid once-daily
formulation of ANAVEX<sup>&#174;</sup>2-73.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The first Phase 2 study, which took place in
the United States, was completed in December 2020. This trial was a randomized double-blind, placebo-controlled safety, tolerability,
pharmacokinetic and efficacy study of oral liquid ANAVEX<sup>&#174;</sup>2-73 formulation in 25 adult female patients with Rett
syndrome over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73-specific genomic precision medicine biomarkers. The
primary endpoint of the trial was safety. The dosing of 5 mg ANAVEX<sup>&#174;</sup>2-73 was well-tolerated and demonstrated dose-proportional
PK (pharmacokinetics). All secondary efficacy endpoints of the trial showed statistically significant and clinically meaningful,
drug exposure-dependent response in the Rett Syndrome Behaviour Questionnaire (RSBQ) Total scores, when compared to placebo, in
the ITT cohort (all participants, p = 0.048). 66.7% of ANAVEX<sup>&#174;</sup>2-73 treated subjects showed a statistically significant
improvement in drug exposure-dependent RSBQ response as compared to 10% of the subjects on placebo in the ITT cohort (all participants,
p = 0.011). ANAVEX<sup>&#174;</sup>2-73 treatment resulted in a sustained improvement in Clinical Global Impression Improvement
(CGI-I) scores throughout the 7-week study, when compared to placebo in the ITT cohort (all participants, p = 0.014). 86.7% of
ANAVEX<sup>&#174;</sup>2-73 treated subjects showed a statistically significant CGI-I response, defined as sustained improvement
to treatment, as compared to 40% of the subjects on placebo in the ITT cohort (all participants, p = 0.014). Consistent with previous
ANAVEX<sup>&#174;</sup>2-73 clinical trials, patients carrying the common form of the SIGMAR1 gene treated with ANAVEX<sup>&#174;</sup>2-73
experienced stronger improvements in the prespecified efficacy endpoints.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The second Phase 2 study of ANAVEX<sup>&#174;</sup>2-73
for the treatment of Rett syndrome, called the AVATAR study, commenced in June 2019. This study is taking place in Australia and
the United Kingdom using a higher dose than the U.S. based Phase 2 study for Rett syndrome. The study will evaluate the safety
and efficacy of ANAVEX<sup>&#174;</sup>2-73 in approximately 33 patients over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73
specific precision medicine biomarkers. All patients who participate in the study will be eligible to receive ANAVEX<sup>&#174;</sup>2-73
under a voluntary open label extension protocol.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the third study
of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the EXCELLENCE study. This Phase 2/3 study in pediatric
patients with Rett syndrome will evaluate the safety and efficacy of ANAVEX<sup>&#174;</sup>2-73 in at least 69 pediatric patients,
aged 5 to 18, over a 12-week treatment period incorporating ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers.
All patients who participate in the study will be eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label extension
protocol.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Parkinson&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in an animal model of Parkinson&#8217;s disease, which demonstrated significant improvements
on behavioral, histopathological, and neuroinflammatory endpoints. The study was funded by the Michael J. Fox Foundation. Additional
data announced in October 2017 indicates that ANAVEX<sup>&#174;</sup>2-73 induces robust neurorestoration in experimental Parkinsonism.
The encouraging results we have gathered in this model, coupled with the favorable profile of this compound in the Alzheimer&#8217;s
disease trial, support the notion that ANAVEX<sup>&#174;</sup>2-73 is a promising clinical candidate drug for Parkinson&#8217;s
disease dementia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, we completed a double-blind,
randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s Disease Dementia
(PDD), to study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease. The Phase 2
study enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses, 30mg
and 50mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73 Phase 2 PDD study design incorporated genomic precision medicine biomarkers
identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a Alzheimer&#8217;s disease study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Within this study ANAVEX<sup>&#174;</sup>2-73
was safe and well tolerated in oral doses up to 50mg once daily. The results show clinically meaningful, dose-dependent, and statistically
significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis. The study confirmed the
precision medicine approach of targeting SIGMAR1 as a genetic biomarker in response to ANAVEX<sup>&#174;</sup>2-73.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2020, we announced a financial commitment
by Shake It Up Australia Foundation for Parkinson&#8217;s Research to fund up to 50% of the costs of an Australian clinical study
to develop ANAVEX<sup>&#174;</sup>2-73 for the disease modifying treatment of Parkinson&#8217;s disease. The financial commitment
would be made through private placement purchases of our common stock at 200% of the fair market value on the purchase date and
will be contingent upon the completion of certain clinical trial milestones relating to the proposed clinical trial. The proposed
clinical trial will use a convenient, once-daily oral ANAVEX<sup>&#174;</sup>2-73 formulation to confirm the potential disease modifying
features of ANAVEX<sup>&#174;</sup>2-73 in an animal model of Parkinson&#8217;s disease. Safety and efficacy will be investigated
in an appropriately powered placebo-controlled clinical study of Parkinson&#8217;s disease patients over at least 48-weeks including
ANAVEX<sup>&#174;</sup>2-73-specific precision medicine biomarkers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2021, we announced we were awarded
a research grant of $1.0 million from&#160;<span style="text-underline-style: none; color: windowtext">The Michael J. Fox Foundation
for Parkinson&#8217;s Research</span>&#160;(MJFF) to develop ANAVEX<sup>&#174;</sup>2-73 for the treatment of Parkinson&#8217;s
disease. The award will explore utilization of PET imaging biomarkers to enable measurement of target engagement and pathway activation
of the sigma-1 receptor (SIGMAR1) with clinically relevant doses in people with Parkinson&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Frontotemporal Dementia</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the First-in-Human
Phase 1 clinical trial of ANAVEX<sup>&#174;</sup>3-71, which was previously granted orphan drug designation for the treatment of
Frontotemporal Dementia (FTD) by the FDA. ANAVEX<sup>&#174;</sup>3-71 is an orally administered small molecule targeting sigma-1
and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases. In preclinical studies, <span style="background-color: white">ANAVEX<sup>&#174;</sup>3-71
demonstrated disease-modifying activity against the major hallmarks of Alzheimer&#8217;s disease in transgenic (3xTg-AD) mice,
including cognitive deficits, amyloid and tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Phase
1 clinical trial will be a prospective double-blind, randomized, placebo-controlled study. A total of at least 36 healthy male
and female subjects will be included. Single escalating doses of ANAVEX<sup>&#174;</sup>3-71 will be administered in order to evaluate
the safety, tolerability, and pharmacokinetics (PK) of ANAVEX<sup>&#174;</sup>3-71 and the effects of food and gender on its PK
in healthy volunteers. This study is expected to be followed by longer duration dosing including patients with FTD or other dementia
indications with unmet medical need, incorporating exploratory efficacy and disease biomarker measures<span style="color: #1F1F1F">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Pipeline</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development pipeline includes
ANAVEX<sup>&#174;</sup>2-73 currently in three different clinical study indications, and several other compounds in different stages
of clinical and pre-clinical study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our proprietary SIGMACEPTOR&#8482; Discovery
Platform produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma
receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer&#8217;s
disease, as well as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate ligands, sigma receptors influence
the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease. Multiple
viruses including SARS-CoV-2 (COVID-19) induce cellular stress by intrinsic mitochondrial apoptosis and other related cellular
processes, in order to ensure survival and replication. Hence, it is possible that S1R could play a role in modulating the cellular
response to viral infection and ameliorate pathogenesis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compounds that have been subjects of our research
include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>2-73 <i>(blarcamesine)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>2-73 may offer a disease-modifying
approach in neurodegenerative and neurodevelopmental diseases by activation of sigma-1 receptors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Rett syndrome, administration of ANAVEX<sup>&#174;</sup>2-73
resulted in both significant and dose related improvements in an array of behavioral paradigms in the MECP2 HET Rett syndrome disease
model. In addition, in a further experiment sponsored by Rettsyndrome.org, ANAVEX<sup>&#174;</sup>2-73 was evaluated in automatic
visual response and respiration tests in 7-month old mice, an age at which advanced pathology is evident. Vehicle-treated MECP2
mice demonstrated fewer automatic visual responses than wild-type mice. Treatment with ANAVEX<sup>&#174;</sup>2-73 for four weeks
significantly increased the automatic visual response in the MECP2 Rett syndrome disease mouse. Additionally, chronic oral dosing
daily for 6.5 weeks of ANAVEX<sup>&#174;</sup>2-73 starting at ~5.5 weeks of age was conducted in the MECP2 HET Rett syndrome disease
mouse model assessed the different aspects of muscular coordination, balance, motor learning and muscular strengths, some of the
core deficits observed in Rett syndrome. Administration of ANAVEX<sup>&#174;</sup>2-73 resulted in both significant and dose related
improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome disease model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2019, we commenced the first Phase
2 clinical trial in a planned Rett syndrome program of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome. This study,
which took place in the United States, was completed in December 2020, however two other clinical trials in Rett syndrome, the
AVATAR study and the EXCELLENCE study, are still underway. The studies are being conducted in a range of patient age demographics
and geographic regions, as more fully described above under <i>Clinical Studies Overview &#8211; Rett Syndrome</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2016 and June 2016, the FDA granted
Orphan Drug Designation to ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome and infantile spasms, respectively. In
November 2019, the FDA granted to ANAVEX<sup>&#174;</sup>2-73 the Rare Pediatric Disease (RPD) designation for the treatment of
Rett syndrome. The RPD designation provides priority review by the FDA to encourage the development of treatments for rare pediatric
diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, in February 2020, the FDA granted
Fast Track designation for the ANAVEX<sup>&#174;</sup>2-73 clinical development program for the treatment of Rett syndrome. The
FDA Fast Track program is designed to facilitate and expedite the development and review of new drugs to address unmet medical
needs in the treatment of serious and life-threatening conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For Parkinson&#8217;s disease, data demonstrates
significant improvements and restoration of function in a disease modifying animal model of Parkinson&#8217;s disease. Significant
improvements were seen on all measures tested: behavioral, histopathological, and neuroinflammatory endpoints. In October 2020,
we completed a double-blind, randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s
Disease Dementia (PDD), to study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease.
The Phase 2 study enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73
doses, 30mg and 50mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73 Phase 2 PDD study design incorporated genomic precision medicine
biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a Alzheimer&#8217;s disease study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The study found that ANAVEX<sup>&#174;</sup>2-73
was safe and well tolerated in oral doses up to 50mg once daily. The results show clinically meaningful, dose-dependent, and statistically
significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis. We anticipate conducting
further clinical trials of ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia after submitting the results of the
study to the FDA to obtain regulatory guidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Alzheimer&#8217;s disease (AD) animal models,
ANAVEX<sup>&#174;</sup>2-73 has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic,
anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity to sigma-1 receptors and moderate affinities
to M1-4 type muscarinic receptors. In addition, ANAVEX<sup>&#174;</sup>2-73 has shown a potential dual mechanism which may impact
amyloid, tau pathology and inflammation. In a transgenic AD animal model Tg2576, ANAVEX<sup>&#174;</sup>2-73 induced a statistically
significant neuroprotective effect against the development of oxidative stress in the mouse brain, as well as significantly increased
the expression of functional and synaptic plasticity markers that is apparently amyloid-beta independent. It also statistically
alleviated the learning and memory deficits developed over time in the animals, regardless of sex, both in terms of spatial working
memory and long-term spatial reference memory.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the results of pre-clinical testing,
we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX<sup>&#174;</sup>2-73. In this Phase 1
SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent dose shown
to have positive effects in mouse models of AD. There were no significant changes in laboratory or electrocardiogram (ECG) parameters.
ANAVEX<sup>&#174;</sup>2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some subjects. Observed
adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were moderate in severity
and reversible. These side effects are often seen with drugs that target CNS conditions, including AD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2014, a Phase 2a clinical trial
was initiated for ANAVEX<sup>&#174;</sup>2-73, for the treatment of Alzheimer&#8217;s disease. The open-label randomized trial was
designed to assess the safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients with mild-to-moderate Alzheimer&#8217;s
disease. ANAVEX<sup>&#174;</sup>2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1
and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer&#8217;s.
The Phase 2a study met both primary and secondary objectives of the study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In July 2018, we presented
the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a study. More than 33,000 genes were analyzed
using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA &amp; RNA data in patients
exposed to ANAVEX<sup>&#174;</sup>2-73. The analysis identified genetic variants that impacted response to ANAVEX<sup>&#174;</sup>2-73,
among them variants related to the Sigma-1 receptor (SIGMAR1), the target for ANAVEX<sup>&#174;</sup>2-73. Results showed that study
participants with the common SIGMAR1 wild type gene variant, which is about 80 percent of the population worldwide, demonstrated
improved cognitive (MMSE) and the functional (ADCS-ADL) scores. The results from this evaluation have been used to establish a
precision medicine approach in subsequent clinical trials, since these signatures can now be applied to neurological indications
tested in clinical studies with ANAVEX<sup>&#174;</sup>2-73 including Alzheimer&#8217;s disease, Parkinson&#8217;s disease dementia
and Rett syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">ANAVEX<sup>&#174;</sup>2-73
data presented met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled study. On July 2, 2018, the
Human Research Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled
48-week safety and efficacy trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of early Alzheimer&#8217;s disease. Clinical
trial sites in Canada, the United Kingdom, the Netherlands and Germany were also added. This Phase 2b/3 study design incorporates
inclusion of genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a study. The Phase 2b/3
study, which has completed enrollment, randomized 1:1:1 to either two different ANAVEX<sup>&#174;</sup>2-73 doses or placebo, commenced
in October 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data also validates ANAVEX<sup>&#174;</sup>2-73
as a prospective platform drug for other neurodegenerative diseases beyond Alzheimer&#8217;s disease, Parkinson&#8217;s disease
or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis and,
more recently, tuberous sclerosis complex (TSC). ANAVEX<sup>&#174;</sup>2-73 demonstrated significant improvements in all of these
indications in the respective preclinical animal models.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a study sponsored by the Foundation for
Angelman Syndrome, ANAVEX<sup>&#174;</sup>2-73 was assessed in a mouse model for the development of audiogenic seizures. The results
indicated that ANAVEX<sup>&#174;</sup>2-73 administration significantly reduced audiogenic-induced seizures. In a study sponsored
by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<sup>&#174;</sup>2-73 restored hippocampal
brain-derived neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed in many neurodevelopmental
and neurodegenerative pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory synapses. ANAVEX<sup>&#174;</sup>2-73
normalization of BDNF expression could be a contributing factor for the positive data observed in both neurodevelopmental and neurodegenerative
disorders like Angelman and Fragile X syndromes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data presented also indicates that
ANAVEX<sup>&#174;</sup>2-73 demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions, which,
if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data on ANAVEX<sup>&#174;</sup>2-73
related to multiple sclerosis indicates that ANAVEX<sup>&#174;</sup>2-73 may promote remyelination in multiple sclerosis disease.
Further, data also demonstrates that ANAVEX<sup>&#174;</sup>2-73 provides protection for oligodendrocytes (&#8220;OL&#8217;s&#8221;)
and oligodendrocyte precursor cells (&#8220;OPC&#8217;s&#8221;), as well as central nervous system neurons in addition to helping
repair by increasing OPC proliferation and maturation in tissue culture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2018, we presented preclinical data
of ANAVEX<sup>&#174;</sup>2-73 in a genetic mouse model of tuberous sclerosis complex (&#8220;TSC&#8221;). TSC is a rare genetic
disorder characterized by the growth of numerous benign tumors in many parts of the body with a high incidence of seizures. The
new preclinical data demonstrates that treatment with ANAVEX<sup>&#174;</sup>2-73 significantly increases survival and reduces seizures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>3-71</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>3-71 is a clinical drug
candidate with a novel mechanism of action via sigma-1 receptor activation and M1 muscarinic allosteric modulation, which has been
shown to enhance neuroprotection and cognition in Alzheimer&#8217;s disease models. ANAVEX<sup>&#174;</sup>3-71 is a CNS-penetrable
potential disease modifying treatment for cognitive impairments. It is highly effective in very small doses against the major Alzheimer&#8217;s
hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects
on inflammation and mitochondrial dysfunctions. ANAVEX<sup>&#174;</sup>3-71 indicates extensive therapeutic advantages in Alzheimer&#8217;s
and other protein-aggregation-related diseases given its ability to enhance neuroprotection and cognition via sigma-1 receptor
activation and M1 muscarinic allosteric modulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A preclinical study examined the response of
ANAVEX<sup>&#174;</sup>3-71 in aged transgenic animal models and showed a significant reduction in the rate of cognitive deficit,
amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. In April 2016, the FDA granted Orphan Drug Designation
to ANAVEX<sup>&#174;</sup>3-71 for the treatment of Frontotemporal dementia (FTD).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During pathological conditions ANAVEX<sup>&#174;</sup>3-71
demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number
of astrocytes. In neurodegenerative diseases such as Alzheimer&#8217;s and Parkinson&#8217;s disease, synaptogenesis is believed
to be impaired. Additional preclinical data presented also indicates that in addition to reducing oxidative stress, ANAVEX<sup>&#174;</sup>3-71
demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired, are believed
to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the first Phase
1 clinical trial of ANAVEX<sup>&#174;</sup>3-71, with focus on the treatment of Frontotemporal Dementia (FTD) and <span style="background-color: white">other
dementia indications with unmet medical need</span>. The study is more fully described above under <i>Clinical Studies Overview
&#8211; Frontotemporal Dementia</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ANAVEX<sup>&#174;</sup>1-41</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1-41 is a sigma-1 receptor
agonist. Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death)
through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell viability.
In addition, in animal models, ANAVEX<sup>&#174;</sup>1-41 prevented the expression of caspase-3, an enzyme that plays a key role
in apoptosis (programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates learning, emotion
and memory. These activities involve both muscarinic and sigma-1 receptor systems through a novel mechanism of action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data presented also indicates that
ANAVEX<sup>&#174;</sup>1-41 demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions, which,
if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1066</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1066, a mixed sigma-1/sigma-2
ligand is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<sup>&#174;</sup>1066 was tested in two preclinical
models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic constriction injury model
of neuropathic pain, a single oral administration of ANAVEX<sup>&#174;</sup>1066 dose-dependently restored the nociceptive threshold
in the affected paw to normal levels while leaving the contralateral healthy paw unchanged. Efficacy was rapid and remained significant
for two hours. In a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory agent
directly into the colon and a single oral administration of ANAVEX<sup>&#174;</sup>1066 returned the nociceptive threshold to control
levels in a dose-dependent manner. Companion studies in rats demonstrated the lack of any effects on normal gastrointestinal transit
with ANAVEX<sup>&#174;</sup>1066 and a favorable safety profile in a battery of behavioral measures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1037 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is designed for
the treatment of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high affinity for
sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. In
advanced pre-clinical studies, this compound revealed antitumor potential. It has also been shown to selectively kill human cancer
cells without affecting normal/healthy cells and also to significantly suppress tumor growth in immune-deficient mice models. Scientific
publications highlight the possibility that these ligands may stop tumor growth and induce selective cell death in various tumor
cell lines. Sigma receptors are highly expressed in different tumor cell types. Binding by appropriate sigma-1 and/or sigma-2 ligands
can induce selective apoptosis. In addition, through tumor cell membrane reorganization and interactions with ion channels, our
drug candidates may play an important role in inhibiting the processes of metastasis (spreading of cancer cells from the original
site to other parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our compounds are in the clinical and pre-clinical
testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical models will be shown in
human testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We continue to identify and initiate discussions
with potential strategic and commercial partners to most effectively advance our programs and realize maximum shareholder value.
Further, we may acquire or develop new intellectual property and assign, license, or otherwise transfer our intellectual property
to further our goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Target Indications</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have developed compounds with potential
application to two broad categories and several specific indications. including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Central Nervous System Diseases</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top"><td style="width: 20px"></td><td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Alzheimer&#8217;s
                                            disease &#8211; In 2020, an estimated 5.8 million Americans were suffering from Alzheimer&#8217;s
                                            disease. The Alzheimer&#8217;s Association<sup>&#174;</sup> estimates that by 2050, this number
                                            will rise to nearly 14 million Americans. Medications on the market today treat only the
                                            symptoms of Alzheimer&#8217;s disease and do not have the ability to stop its onset or its
                                            progression. There is an urgent and unmet need for both a disease modifying cure for Alzheimer&#8217;s
                                            disease as well as for better symptomatic treatments.</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top"><td style="width: 20px"></td><td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Parkinson&#8217;s
                                            disease &#8211; Parkinson&#8217;s disease is a progressive disease of the nervous system
                                            marked by tremors, muscular rigidity, and slow, imprecise movement. It is associated with
                                            degeneration of the basal ganglia of the brain and a deficiency of the neurotransmitter dopamine.
                                            Parkinson&#8217;s disease afflicts more than 10 million people worldwide, typically middle-aged
                                            and elderly people. The Parkinson&#8217;s disease market is expected to expand to $11.5 billion
                                            by 2029, according to business intelligence provider GBI Research.</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top"><td style="width: 20px"></td><td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Rett
                                            syndrome &#8211; Rett syndrome is a rare X-linked genetic neurological and developmental
                                            disorder that affects the way the brain develops, including protein transcription, which
                                            is altered and as a result leads to severe disruptions in neuronal homeostasis. It is considered
                                            a rare, progressive neurodevelopmental disorder and is caused by a single mutation in the
                                            MECP2 gene. Because males have a different chromosome combination from females, boys who
                                            have the genetic MECP2 mutation are affected in devastating ways. Most of them die before
                                            birth or in early infancy. For females who survive infancy, Rett syndrome leads to severe
                                            impairments, affecting nearly every aspect of the child&#8217;s life; severe mental retardation,
                                            their ability to speak, walk and eat, sleeping problems, seizures and even the ability to
                                            breathe easily. Rett syndrome affects approximately 1 in every 10,000-15,000 females.</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top"><td style="width: 20px"></td><td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Depression
                                            &#8211; Depression is a major cause of morbidity worldwide according to the World Health
                                            Organization. Pharmaceutical treatment for depression is dominated by blockbuster brands,
                                            with the leading nine brands historically accounting for approximately 75% of total sales.
                                            However, the dominance of the leading brands is waning, largely due to the effects of patent
                                            expiration and generic competition.</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt">
<tr style="vertical-align: top"><td style="width: 20px"></td><td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Epilepsy
                                            &#8211; Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked
                                            seizures. These seizures are transient signs and/or symptoms of abnormal, excessive or synchronous
                                            neuronal activity in the brain. According to the Centers for Disease Control and Prevention,
                                            in 2015 epilepsy affected 3.4 million Americans. Today, epilepsy is often controlled, but
                                            not cured, with medication that is categorized as older traditional anti-epileptic drugs
                                            and second generation anti-epileptic drugs. Because epilepsy afflicts sufferers in different
                                            ways, there is a need for drugs used in combination with both traditional anti-epileptic
                                            drugs and second generation anti-epileptic drugs.</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Neuropathic Pain &#8211;
    We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of the body.
    Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal pain medications. Special
    medications have become more specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cancer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top"><td style="width: 20px"></td><td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Malignant
                                            Melanoma &#8211; Predominantly a skin cancer, malignant melanoma can also occur in melanocytes
                                            found in the bowel and the eye. Malignant melanoma accounts for 75% of all deaths associated
                                            with skin cancer. The treatment includes surgical removal of the tumor, adjuvant treatment,
                                            chemo and immunotherapy, or radiation therapy. According to IMS Health the worldwide malignant
                                            melanoma market is expected to grow to $4.4 billion by 2022.</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top"><td style="width: 20px"></td><td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Prostate
                                            Cancer &#8211; Specific to men, prostate cancer is a form of cancer that develops in the
                                            prostate, a gland in the male reproductive system. The cancer cells may metastasize from
                                            the prostate to other parts of the body, particularly the bones and lymph nodes. Drug therapeutics
                                            for prostate cancer are expected to increase to nearly $13.5 billion in 2024 according to
                                            Datamonitor Healthcare.</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top"><td style="width: 20px"></td><td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Pancreatic
                                            Cancer &#8211; Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States,
                                            approximately 55,000 new cases of pancreatic cancer will be diagnosed this year and approximately
                                            44,000 patients will die as a result of their cancer, according to the American Cancer Society.
                                            Sales predictions by GBI Research forecast that the market for the pharmaceutical treatment
                                            of pancreatic cancer in the United States and five largest European countries willincrease
                                            to $2.9 billion by 2021.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Patents, Trademarks and Intellectual
Property </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hold ownership or exclusive rights to thirteen
U.S. patents, seventeen U.S. patent applications, and various PCT or ex-U.S. patent applications relating to our drug candidates,
methods associated therewith, and to our research programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We own one issued U.S. patent entitled &#8220;ANAVEX<sup>&#174;</sup>2-73
and certain anticholinesterase inhibitors composition and method for neuroprotection&#8221; claims a composition of matter of ANAVEX<sup>&#174;</sup>2-73
directed to a novel and synergistic neuroprotective compound combined with donepezil and other cholinesterase inhibitors. This
patent is expected to expire in June 2034, absent any patent term extension for regulatory delays. We own two issued U.S. patents
each with claims directed to crystalline forms of ANAVEX<sup>&#174;</sup>2-73. The first of these two patents claims crystalline
forms of ANAVEX<sup>&#174;</sup>2-73, dosage forms and compositions containing crystalline ANAVEX<sup>&#174;</sup>2-73, and methods
of treatment for Alzheimer&#8217;s disease using them. This patent is expected to expire in July 2036, absent any patent term extension
for regulatory delays. The second of these two patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73,
and methods of treatment for Alzheimer&#8217;s disease using the compositions. This patent is expected to expire in June 2037,
absent any patent term extension for regulatory delays. We also own two issued U.S. patents on seizure treatment. The first of
these two patents claims methods and dosage forms for treating seizures, the dosage forms containing a low-dose anti-epilepsy drug
combined with either: (i) ANAVEX<sup>&#174;</sup>2-73 and its active metabolite ANAVEX<sup>&#174;</sup>19-144; or (ii) ANAVEX<sup>&#174;</sup>19-144.
The second of these two patents further claims the seizure treatment being co-timely or coordinated administration of anti-epilepsy
drugs and (i) ANAVEX<sup>&#174;</sup>19-144 or (ii) ANAVEX 19-144<sup>&#174;</sup> with ANAVEX 2-73<sup>&#174;</sup>. Both patents
are expected to expire in October 2035, absent any patent term extension for regulatory delays. We also own two issued U.S. patents
with claims directed to treating neurodevelopmental disorders. These patents claim methods for treating a neurodevelopmental disorder
or multiple sclerosis by administering ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144, and/or ANAVEX<sup>&#174;</sup>1-41
(another sigma receptor ligand similar to ANAVEX<sup>&#174;</sup>2-73), or compositions thereof. Both patents are expected to expire
in January 2037, absent any patent term extension for regulatory delays. In addition, we own one issued U.S. Patent with claims
directed to methods of treating melanoma with a compound related to ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire
in February 2030, absent any patent term extension for regulatory delays. We also own an issued U.S. patent that claims crystalline
forms of ANAVEX<sup>&#174;</sup>19-144, dosage forms and compositions containing the crystalline forms of ANAVEX<sup>&#174;</sup>19-144,
and methods of treatment for Alzheimer&#8217;s disease. This patent is expected to expire in July 2036, absent any patent term
extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own two issued U.S. patents related
to ANAVEX<sup>&#174;</sup>1066. The first of these two patents claims methods for treating or preventing pain using (+) ANAVEX<sup>&#174;</sup>1066
isomer. The second patent claims methods for treating or preventing pain using (-) ANAVEX<sup>&#174;</sup>1066 isomer Both patents
are expected to expire in November 2036, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
ANAVEX<sup>&#174;</sup>1-41, and ANAVEX<sup>&#174;</sup>1066, we also have granted or pending applications in Australia, Canada,
China, Europe, Japan, and Hong Kong, and are expected to expire after 2035.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With regard to ANAVEX<sup>&#174;</sup>3-71,
we own exclusive rights to two issued U.S. patents with claims respectively directed to the ANAVEX<sup>&#174;</sup>3-71 compound
and methods of treating various diseases including Alzheimer&#8217;s with the same. These patents are expected to expire in April
2030, and January 2030, respectively, absent any patent term extension for regulatory delays. We also own exclusive rights to related
patents or applications that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand, Russia, and
South Africa, and are expected to expire in January 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own other patent applications directed
to enantiomers, crystals, formulations, uses, and patient selection methods that may provide additional protection for one or more
of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We regard patents and other intellectual property
rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual property in developing our business strategy
including the selective development, protection, and exploitation of our intellectual property rights. In addition to filings made
with intellectual property authorities, we protect our intellectual property and confidential information by means of carefully
considered processes of communication and the sharing of information, and by the use of confidentiality and non-disclosure agreements
and provisions for the same in contractor&#8217;s agreements. While no agreement offers absolute protection, such agreements provide
some form of recourse in the event of disclosure, or anticipated disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our intellectual property position, like that
of many biomedical companies, is uncertain and involves complex legal and technical questions for which important legal principles
are unresolved. For more information regarding challenges to our existing or future patents, see &#8220;Risk Factors&#8221; &#8220;
in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange Commission on December 28, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial Highlights</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">At June 30, 2021, our cash position had increased
to $157.6 million, from $29.2 million at our fiscal year end of September 30, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Operating expenses for the third quarter of
fiscal 2021 were $11.4 million, compared to $8.1 million for the comparable quarter in fiscal 2020. The operating expenses include an
aggregate of $2.3 million, as compared to $1.3 million in the third quarter of fiscal 2020, in non-cash charges related to the issuance
and vesting of stock options. Our research and development expenses for the third quarter of fiscal 2021 were $9.0 million, compared
to $6.7 million in the comparable period in fiscal 2020. The increase is attributable to the continued advancement of our ongoing clinical
trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Net loss for the third quarter of fiscal 2021
was $10.2 million, or $0.14 per share, as compared to $6.5 million, or $0.11 per share in the comparative quarter of fiscal 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Results of Operations</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">We
are in the development stage and have not earned any revenues since our inception and we do not anticipate earning any revenues
until we can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal"><b>Three
and nine months ended June 30, 2021 compared to three and nine months ended June 30, 2020.</b></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal"><b>&#160;</b></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating Expenses</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: black">Total operating
expenses for the third quarter of fiscal 2021 were $11.4 million, compared to $8.1 million for the comparable quarter of fiscal
2020.</span> <span style="color: black">Total operating expenses for the nine-month period ended June 30, 2021 were $29.8 million
compared to $23.6 million for the same period in fiscal 2020. This represents an increase of $3.3 million for the three-month period
and $6.2 million for the nine-month period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: black">Research and development
expenses for the third quarter of fiscal 2021 were $9.0 million, compared to $6.7 million for the third quarter of fiscal 2020
and $23.6 million for the nine-month period ended June 30, 2021, as compared to $19.1 million for the applicable prior year period.
This increase in both the current quarter and the year-to-date period is attributable to the continued advancement of our ongoing
clinical trials, most notably, the </span>expansion of our Phase 2b/3 Alzheimer&#8217;s disease trial internationally, and the
continued enrollment and advancement of the international Rett syndrome program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses increased
to $2.4 million for the three months ended June 30, 2021, as compared to $1.4 million for the third quarter of fiscal 2020. Similarly,
general and administrative expenses increased to $6.1 million for the nine-month period ended June 30, 2021, as compared to $4.5
million for the applicable prior year period. The increase in general and administrative expenses was primarily related to an increase
in our staff, corporate activities and transactions, and an increase in non-cash stock option compensation charges.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Other income </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The net amount of other income was $1.3 million
for the three-month period ended June 30, 2021 as compared to $1.6 million for the three-month period ended June 30, 2020 and $3.7
million for the nine-month period as compared to $3.3 million for the comparable nine-month period in fiscal 2020. The Company
experienced an increase in Australian research and development incentive income for the nine-month period, in connection with the
increase in eligible clinical activities in Australia over the comparable year to date period, however in the current quarter the
Company incurred foreign exchange losses which were related to the fluctuations in the Australian dollar against the US dollar
and its related impact on incentive and tax receivables.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Liquidity and Capital Resources</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Working Capital</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Current Assets</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">166,419,501</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">34,542,197</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,273,772</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,305,628</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Working Capital</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">157,145,729</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">27,236,569</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><br />
At June 30, 2021, we had $157.6 million in cash and cash equivalents, an increase of $128.3 million from September 30, 2020. During
the nine-month period ended June 30, 2021, we received cash of $151.0 million, net of issuance costs, primarily from the issuance
of shares of common stock under the 2019 Purchase Agreement, through the Sales Agreement, as well as a registered direct offering,
each as more fully described elsewhere in this Quarterly Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash Flows&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">Nine months ended June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net cash flows used in operating activities</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(22,709,166</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(15,032,274</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">151,020,193</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,465,789</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">128,311,027</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,433,515</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash flow used in operating activities</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Net cash used in operating activities for the
<span style="color: black">first nine months of fiscal 2021 </span>was $22.7 million, compared to $15.0 million during the comparable
period of fiscal 2020. The principal reason for this increase in net cash used from operating activities in the current period is due
to an increase in research and development expenses and an increase in research and development incentive income receivable, as compared
to the comparable period.</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash flow provided by financing activities</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Cash provided by financing activities for the
<span style="color: black">first nine months in fiscal 2021 </span>was $151.0 million, net of financing costs, primarily attributable
to cash received from the issuance of common shares at various market prices under the 2019 Purchase Agreement, the Sales Agreement and
a direct registered offering we completed for net proceeds of $46.9 million, after deducting expenses associated with the offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Cash provided by financing activities for the
<span style="color: black">first nine months in fiscal 2020 </span>was $20.5 million, attributable to cash received from the issuance
of common shares at various market prices under the 2019 Purchase Agreement<span style="color: black">.</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other Financing</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>Purchase Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On June 7, 2019, we
entered into a Purchase Agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln
Park&#8221;), as amended on July 1, 2020, pursuant to which Lincoln Park committed to purchase up to $50.0 million of our common
stock. Concurrently with the execution of the 2019 Purchase Agreement in 2019, we issued 324,383 shares of our common stock to
Lincoln Park as a fee for its commitment to purchase shares of our common stock under the 2019 Purchase Agreement and became obligated
to issue up to 162,191 shares pro rata, when and if Lincoln Park purchased, at our discretion, the $50.0 million aggregate commitment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended June 30, 2021,
the Company issued to Lincoln Park an aggregate of 4,086,209 shares of common stock under the 2019 Purchase Agreement, including
4,007,996 shares of common stock for an aggregate purchase price of $24.1 million and 78,213 commitment shares. As of<span style="color: black">
June 30, 2021, no shares of our common stock remain available for purchase by Lincoln Park under the 2019 Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Controlled Equity Offering Sales Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May
1, 2020, we entered into an Amended and Restated&#160;Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald
&amp; Co. and SVB Leerink LLC (the &#8220;Sales Agents&#8221;), pursuant to which we may offer and sell shares of common stock
registered under an effective registration statement from time to time through the Sales Agents (the &#8220;At-the-Market Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on
our instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell shares of common stock
by methods deemed to be an &#8220;at the market offering&#8221;, in negotiated transactions at market prices prevailing at the
time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated
transactions, subject to our prior written consent. We are not obligated to make any sales of shares under the Sales Agreement.
We or the Sales Agents may suspend or terminate the At-the-Market Offering upon notice to the other party, subject to certain conditions.
The Sales Agents will act as agents on a commercially reasonable efforts basis consistent with their normal trading and sales practices
and applicable state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have agreed to pay the Sales Agents commissions
for their services of 3.0% of the gross proceeds from the sale of the shares pursuant to the Sales Agreement. We have also agreed
to provide the Sales Agents with customary indemnification and contribution rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended June 30, 2021,
5,634,576 shares were sold pursuant to the At-the-Market Offering for gross proceeds of $79.1 million (net proceeds of $76.7 million
after deducting commissions and offering expenses).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Registered Direct Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 24, 2021, the Company completed a registered
direct offering off of the Company&#8217;s shelf registration statement on Form S-3 filed with the SEC on July 3, 2019. The Company
issued 2,380,953 common shares at $21.00 per share for gross proceeds of $50.0 million (net proceeds of $46.9 million after deducting
offering fees and expenses).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">Off-Balance
Sheet Arrangements</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal; font-style: normal">We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources
that are material to our stockholders.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal; font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>CRITICAL ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">We prepare our interim condensed
consolidated financial statements in accordance with accounting principles generally accepted in the United States of America,
and make estimates and assumptions that affect our reported amounts of assets, liabilities, revenue and expenses, and the related
disclosures of contingent liabilities. We base our estimates on historical experience and other assumptions that we believe are
reasonable in the circumstances. Actual results may differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">There have been no significant
changes in the critical accounting policies and estimates described in our Annual Report on Form 10-K for the year ended September
30, 2020 as filed with the SEC on December 28, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.6pt; text-indent: -21.6pt"><b>RECENT ACCOUNTING PRONOUNCEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.6pt; text-indent: -21.6pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">Please refer to Note 2 &#8220;Recent
Accounting Pronouncements&#8221; in notes to our Interim Condensed Consolidated Financial Statements included in this Form 10-Q.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span id="a_004"></span>Item 3. Quantitative
and Qualitative Disclosures about Market Risks.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span id="a_005"></span>Item 4. Controls
and Procedures.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Disclosure Controls and Procedures
</b></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain disclosure controls and procedures
that are designed to provide reasonable assurance that material information required to be disclosed in our periodic reports filed
under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules
and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, our chief
executive officer and our principal financial officer, to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We carried out an evaluation, under the supervision
and with the participation of our management, including our principal executive officer and principal financial officer, of the
effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a 15(e) under the Exchange
Act, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive
officer and principal financial officer concluded that our disclosure controls and procedures were effective as of June 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in Internal Control over Financial
Reporting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the quarter ended June 30, 2021, there
were no changes in our internal control over financial reporting identified in management&#8217;s evaluation pursuant to Rules
13a 15(d) or 15d 15(d) of the Exchange Act that materially affected, or are reasonably likely to materially affect, our internal
controls over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span id="a_006"></span>PART II &#8211;
OTHER INFORMATION</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span id="a_007"></span>Item 1. Legal
Proceedings.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">We
know of no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our
Company or our subsidiary is a party or of which any of their property is subject. There are no proceedings in which any of our
directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse
party or has a material interest adverse to our or our subsidiary&#8217;s interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span id="a_008"></span>Item 1A. Risk
Factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There have been no material changes to the
risk factors discussed in &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended
September 30, 2020 filed with the SEC on December 28, 2020 except for the following new risks:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our stock price has recently been volatile
and may be volatile in the future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our stock price has recently been volatile
and may be volatile in the future. For example, on February 1, 2021, the price of our common stock closed at $6.53 per share while
on February 9, 2021, the price of our common stock closed at $14.99 per share without disclosure of news or other developments
by us. On February 4, 2021, the opening price of our common stock was $19.94 and the intra-day sales price of our common stock
fluctuated between a reported low sale price of $13.80 and a reported high sales price of $28.70, closing at $14.91. Our volume
on this day was 116,590,800, which was a substantial increase from the volume of 18,086,230 and 3,161,525 on the two days immediately
preceding February 4, 2021. We may incur rapid and substantial increases or decreases in our stock price in the foreseeable future
that are do not coincide in timing with the disclosure of news or developments by us. The stock market in general, and the market
for biotechnology and pharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated
to the operating performance of particular companies. The market price for our common stock may be influenced by many factors,
including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">announcements of new data,
clinical trial results or those of companies that are perceived to be similar to us;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">announcements related to any
delays in any preclinical or clinical trials related to our products;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">announcements related to our
products&#8217; ability to demonstrate efficacy or an acceptable safety profile of our product candidates or similar announcements by
companies that are perceived to be similar to us;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to meet or exceed
expectations of analysts or investors;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">news that the number of patients
required for clinical trials for our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower
than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or the duration of these clinical
trials may be longer than we anticipate;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">actions taken by regulatory
agencies with respect to our product candidates or the progress of our clinical studies, including with respect to any fast track or
orphan drug designations;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">announcements of significant
acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partners or our competitors;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">grants awarded to us or companies
that are perceived to be similar to us from outside entities;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">variations in our financial
results or those of companies that are perceived to be similar to us;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">trading volume of our common
stock;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">developments concerning our
collaborations or partners;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the impact of the COVID-19
outbreak and its effect on us;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the perception of the biotechnology
or pharmaceutical industries by the public, legislatures, regulators and the investment community;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">developments or disputes concerning
intellectual property rights;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">significant lawsuits, including
patent or stockholder litigation;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability or inability to
raise additional capital and the terms on which we raise it;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">sales of our common stock by
us or our stockholders;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">declines in the market prices
of stocks generally or of companies that are perceived to be similar to us; and</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">general economic, industry
and market conditions.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, companies trading in the stock
market in general, and The Nasdaq Capital Market in particular, have experienced extreme price and volume fluctuations that have
often been unrelated or disproportionate to the operating performance of these companies. These broad market and industry factors
may seriously harm the market price of our common stock, regardless of our operating performance. In the past, following periods
of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if
instituted against us, could result in substantial costs and diversion of management&#8217;s attention and resources, which could
materially and adversely affect our business, financial condition, results of operations and growth prospects. There can be no
guarantee that our stock price will remain at current prices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our common stock may become the target
of a &#8220;short squeeze.&#8221;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the past several months prior to the filing
of this Quarterly Report on Form 10-Q, securities of certain companies have increasingly experienced significant and extreme volatility
in stock price due to short sellers of shares of common stock, known as a &#8220;short squeeze.&#8221; These short squeezes have
caused extreme volatility in those companies and in the market and have led to the price per share of those companies to trade
at a significantly inflated rate that is disconnected from the underlying value of the company. Many investors who have purchased
shares in those companies at an inflated rate face the risk of losing a significant portion of their original investment as the
price per share has declined steadily as interest in those stocks have abated. There can be no assurance that we will not, in the
future be, a target of a short squeeze, and you may lose a significant portion or all of your investment if you purchase our shares
at a rate that is significantly disconnected from our underlying value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the information set forth in
this Form 10-Q, you should carefully review and consider the risk factors discussed in &#8220;Risk Factors&#8221; in Part I, Item
1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2020 filed with the SEC on December 28, 2020. These
risks could materially and adversely affect our business, financial condition and results of operations. The risks described in
herein and in our Form 10-K are not the only risks we face. Our operations could also be affected by additional factors that are
not presently known to us or by factors that we currently consider immaterial to our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span id="a_009"></span>Item 2. Unregistered
Sales of Equity Securities and Use of Proceeds.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">During the period covered by this Quarterly
Report on Form 10-Q, we have not sold any equity securities that were not registered under the Securities Act of 1933 that were
not previously reported in a Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span id="a_010"></span>Item 3. Defaults
Upon Senior Securities.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span id="a_011"></span>Item 4. Mine
Safety Disclosures</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span id="a_012"></span>Item 5. Other
Information.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">None.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span id="a_013"></span>Item 6. Exhibits.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border: windowtext 1pt solid; width: 12%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit </b><br /> <b>Number </b></span></td>
<td style="border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; width: 88%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><br /><b>Description</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(3) </b></span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Articles of Incorporation and Bylaws </b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">3.1</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/s118023_ex3-1.htm">Articles of Incorporation (incorporated by reference to Exhibit 3.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed on May 9, 2019)</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">3.2&#160;</td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112221000974/e2796_ex3-1.htm">Certificate of Amendment to Articles of Incorporation (incorporated by reference to our Current Report on Form 8-K filed on May 28, 2021)</a>&#160;</td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">3.3</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm">Bylaws (incorporated by reference to our Current Report on Form 8-K filed on September 28, 2007)</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">3.4</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707000198/form8kexh99_1.htm">Articles of Merger filed with the Secretary of State of Nevada on January 10, 2007 and which is effective January 25, 2007 (incorporated by reference to our Current Report on Form 8-K filed on January 25, 2007)</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(31) </b></span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Rule 13a-14(a)/15(d)-14(a)Certifications</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">31.1*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="e3018_ex31-1.htm">Certification of Christopher Missling, PhD.</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">31.2*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="e3018_ex31-2.htm">Certification of Sandra Boenisch</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(32) </b></span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Section 1350 Certifications</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">32.1*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="e3018_ex32-1.htm">Certification of Christopher Missling, PhD and Sandra Boenisch.</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(101)</b></span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>XBRL</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.INS*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL INSTANCE DOCUMENT</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.SCH*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL TAXONOMY EXTENSION SCHEMA</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.CAL*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.DEF*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL TAXONOMY EXTENSION DEFINITION LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.LAB*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL TAXONOMY EXTENSION LABEL LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.PRE*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt">* Filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"></p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><span id="a_014"></span>SIGNATURES</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX LIFE SCIENCES CORP. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 45%"><span style="font: 10pt Times New Roman, Times, Serif">/s/Christopher Missling, PhD</span></td>
    <td style="width: 55%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif"></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">Christopher Missling, PhD</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">Date: August <span>12, </span>2021</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">/s/Sandra Boenisch</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif"></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">Sandra Boenisch, CPA, CGA</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">Principal Financial Officer</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">(Principal Financial and Accounting Officer)</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">Date: August <span>12, </span>2021</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">34</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>e3018_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Christopher Missling, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this Quarterly Report on
Form 10-Q for the three months ended June 30, 2021 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f)
and 15d&ndash;15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(c) evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(d) disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control
over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying
officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) all significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Date: August 12, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/Christopher Missling, PhD </U><BR>
Christopher Missling, PhD<BR>
Chief Executive Officer, President and Secretary<BR>
(Principal Executive Officer)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>e3018_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Sandra Boenisch, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this Quarterly Report on
Form 10-Q for the three months ended June 30, 2021 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f)
and 15d&ndash;15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(c) evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(d) disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control
over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying
officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) all significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Date: August 12, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>/s/Sandra Boenisch</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sandra Boenisch, CPA, CGA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 219.75pt; text-indent: -219.75pt; background-color: white">Principal
Financial Officer, Treasurer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 219.75pt; text-indent: -219.75pt; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Principal Financial and Accounting Officer)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>e3018_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO<BR>
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Quarterly Report of
Anavex Life Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-Q for the three months ended June 30, 2021 as filed with the
Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned, in the capacities and on the
date indicated below, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that to the best of our knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(1) the Report fully complies with
the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(2) the information contained in
the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: August
12, 2021</FONT></TD>
<TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/<U>s/Christopher
Missling, PhD </U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Christopher Missling, PhD</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;Chief Executive Officer,
President, Secretary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer) &nbsp;</FONT></P>
    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>/s/Sandra Boenisch</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandra Boenisch, CPA, CGA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Principal Financial
Officer, Treasurer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial and Accounting
Officer)</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing certification is being furnished
solely to accompany the Report pursuant to 18 U.S.C. &sect; 1350, and is not being filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before
or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement
required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed
form within the electronic version of this written statement required by Section 906, has been provided to the Company and will
be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .D!S # 2(  A$! Q$!_\0
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M34=0M;!Y;6+S(1;S/MD]F!7*XXY&<^U:.FG6C*_]J1Z>L>WY/LKNQS[[@.*
M-*BLS4Y-;615TJWL'0*69[J9URW90%4_]]9X]#3]"U5-=T&QU1(FB6ZA67RV
M.2A(Y&>_/?O0!H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !114-U-]FLYY]N[RHV?&<9P,T 345R6E
M>)M6=M"?5+"S2VUI0()+69F:-S$TH5U91P55N0>HZ<YK9T;5GU2SNYVB6,P7
MEQ;  YR(I&0'\=N: -2BN:/B>=_ FFZY#:(]]J-O;-;VI?"F:8+M7=Z MDGT
M!-.G\5QIX)B\116X;S4BQ#(^P)([JFUVP=H5F^8XX - '1T5SE_J^M:-X<U3
M4=0M;!Y;6+S(1;S/MD]F!7*XXY&<^U:.FG6C*_\ :D>GK'M^3[*[L<^^X#B@
M#2HK+U276T<#2X+!HU0L\EW,RY/]T!5.!_M$\>AJ30M577- T_54A:%;RW2<
M1L<E=P!QGO\ 7O0!H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !65XGANKGPGK,
M%B&-W+8SI %Z[RA"X_'%:M% &1HFJ:5)X;TVZM;F!+*2**.$EPH!("JG^]GY
M=O7/%<5JIU/7)O$%]I^BW=W)'+'!IES')"$5[5RV<,X;F;>IP.54=>E=TGAW
M1(]3.IIH^GK?D[C="V02Y]=V,YJ[;VT%I L%M#'#$N=J1J%49.3@#W- '"WD
M5MXRUK3Y;>5HEN]":YM9@/F@D\Z)T?ZJV./8BLT:J^KZ?X\FN(A#>Q:&D%W"
M/^6<R)<A@/;/(/<$'O7I$&G65JZ-;V=O"R*R*8XPI56;<P&!P">2/6@Z=8L]
MTYL[<M=J$N28ES,H& 'X^88)'/8T <SXKDBE\-:;IT;J=1N;FT^R1@_/N65'
M+@=<*JLQ/H#65KO_ ""_B)_UUB_])H:[33M T;1V9M,TFPL6888VULD1(]]H
M%3RZ=8SQW4<UG;R1W?\ Q\*\2D3<!?G!'S< #GL* ,#Q?)%/<:'I\+JVH-JE
MO/%&""ZI&VZ5\=E\O<I/^T!WQ7-ZJ=3UR;Q!?:?HMW=R1RQP:9<QR0A%>U<M
MG#.&YFWJ<#E5'7I7>Z=HFDZ.'&F:7960?[PMK=(MWUV@9JU;VT%I L%M#'#$
MN=J1J%49.3@#W- '+>)-1@UCX>)J5L3Y-T;29,]0&FC.#[BG^*H;F?Q#X8CM
M+H6LQN9\2F,28_</G@UT0TZR%G]C%G;BU!W>3Y8V9W;L[<8^]S]>:CU+1],U
MF%(=4TZTOHD;<J74"RJK8QD!@<&@":RBN(;1([JY%S,,[I1&$W<\<#IQQ4]5
M=/TS3])MOLVFV-M90;BWE6T2QKD]3A0!FK5 !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5;449]+NT12S-"X
M  R2=IJS10!ROA+PS!9:1HMY=M>S7T%E&J+=RLWV<F,!@J'A3U'3..,]:Y\^
M&GM["\U^*QNY-3L=9N;U+=B[+/$)V)"Q'Y=Q0DHP&=VT@^OI5% ' ZC;Z6OC
M;5+G6--U2:*:VMA;R6UC=2J<>9N&85(!&1P>>:T7NGT3Q3=ZK+97TVFZI:P8
MEM[225X9(]WRO&H+@%64@[>""#BNMHH X_7=1-W#H.J+IVIK;V^JAW7[%(TH
MC\F5=_E*"X&6 Y4'GD"I[BY&LZ[X<O;.VO?(ANIQ*T]G+ 4_<, 2)%4@$D '
M&">*ZFB@#A8M'OUT>XU"UMI%U73]7O;NUC==IGC:9]T?/:1#P>F=I[5'H%C>
MIIO@/S+*YB:!93.LD14PY@<#>/X>2!SWKOJ* .,T34F\+V,NBZAINIO+!<3&
MWDM;*2=+B-Y&=2&0$*V&P0Y'()Z<TG]FZSKNOZK?JT-C;>2NGQP7]DTI=-N^
M1AB11@L^TXR#Y8P?7M** //5.H6.@>&H]1M;Z:31M5,$\D-I)*TD:13(DP5
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MEI:V4L^<,I.2BD+^.,UT=G=QWUJES"LRQOG G@>%^#CE' 8=.XJ>B@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "JVHHSZ7=HBEF:%P !DD[35FB@#E?"7AF"RTC1;R[:]FOH+*-46
M[E9OLY,8#!4/"GJ.F<<9ZU3T7PC875MJEQJ&GS"YEU*\<%I)$W*9G*D $<$8
M(/>NVHH \[TC3=;N]/\ !MC"/L']DZ1!<3/>6C.OGM%Y2IMW)\RKYN1GC*Y'
M(J_I<=SH,.NZ;K%G+J-DTWVI&M;%FC>.<GS$$>6)VN')4$G#CCFNUHH \QN[
M&67P[XHM=&M-4.AO8(+:UN()0PFRV]84<>9LV[.,8S]WO76^''T59IXM)L]1
MMV90TAN[*ZA! Z8,R@9YZ#FNAHH Y3Q=J\\4L.CQ0ZG%%=(6N;^TL)Y_*CS@
MHAC1L2-R 3]T<]< [VD-:'2+5;""6"T2,1PQ2P/"R*OR@;' 8=.XZ5=HH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ JMJ*,^EW:(I9FA<  9).TU9HH Y7PEX9@LM(T6\NVO9KZ"R
MC5%NY6;[.3& P5#PIZCIG'&>M4]%\(V%U;:I<:AI\PN9=2O'!:21-RF9RI !
M'!&"#WKMJ* /.](TW6[O3_!MC"/L']DZ1!<3/>6C.OGM%Y2IMW)\RKYN1GC*
MY'(J_I<=SH,.NZ;K%G+J-DTWVI&M;%FC>.<GS$$>6)VN')4$G#CCFNUHH \Q
MN[&67P[XHM=&M-4.AO8(+:UN()0PFRV]84<>9LV[.,8S]WO76^''T59IXM)L
M]1MV90TAN[*ZA! Z8,R@9YZ#FNAHH YGQ6-%N]MAK5AJEQ$T996M+>XD1L\%
M280>>!PWKQWJ]X534(_#%@FJ!Q=K&01( '"Y.P-CC=MVYQWS6Q10 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7OK
M&WU*SDM+N/S(),;EW$9P01R.>H%8_P#PA'AW_H'_ /D:3_XJN@HH Y__ (0C
MP[_T#_\ R-)_\51_PA'AW_H'_P#D:3_XJN@JM+J%E!(8YKRWC<=5>4 C\":F
M4HQ5Y.PU%O1&1_PA'AW_ *!__D:3_P"*H_X0CP[_ - __P C2?\ Q5:G]K:=
M_P!!"U_[_+_C1_:VG?\ 00M?^_R_XU'MZ7\R^\KV4^S,O_A"/#O_ $#_ /R-
M)_\ %4?\(1X=_P"@?_Y&D_\ BJU/[6T[_H(6O_?Y?\:/[6T[_H(6O_?Y?\:/
M;TOYE]X>RGV9E_\ "$>'?^@?_P"1I/\ XJC_ (0CP[_T#_\ R-)_\56I_:VG
M?]!"U_[_ "_XT?VMIW_00M?^_P O^-'MZ7\R^\/93[,R_P#A"/#O_0/_ /(T
MG_Q5'_"$>'?^@?\ ^1I/_BJU/[6T[_H(6O\ W^7_ !H_M;3O^@A:_P#?Y?\
M&CV]+^9?>'LI]F9?_"$>'?\ H'_^1I/_ (JC_A"/#O\ T#__ "-)_P#%5J?V
MMIW_ $$+7_O\O^-']K:=_P!!"U_[_+_C1[>E_,OO#V4^S,O_ (0CP[_T#_\
MR-)_\51_PA'AW_H'_P#D:3_XJM3^UM._Z"%K_P!_E_QH_M;3O^@A:_\ ?Y?\
M:/;TOYE]X>RGV9E_\(1X=_Z!_P#Y&D_^*H_X0CP[_P! _P#\C2?_ !5:G]K:
M=_T$+7_O\O\ C1_:VG?]!"U_[_+_ (T>WI?S+[P]E/LS+_X0CP[_ - __P C
M2?\ Q5'_  A'AW_H'_\ D:3_ .*K4_M;3O\ H(6O_?Y?\:/[6T[_ *"%K_W^
M7_&CV]+^9?>'LI]F9?\ PA'AW_H'_P#D:3_XJC_A"/#O_0/_ /(TG_Q5:G]K
M:=_T$+7_ +_+_C1_:VG?]!"U_P"_R_XT>WI?S+[P]E/LS+_X0CP[_P! _P#\
MC2?_ !5'_"$>'?\ H'_^1I/_ (JM3^UM._Z"%K_W^7_&C^UM._Z"%K_W^7_&
MCV]+^9?>'LI]F9?_  A'AW_H'_\ D:3_ .*H_P"$(\._] __ ,C2?_%5J?VM
MIW_00M?^_P O^-']K:=_T$+7_O\ +_C1[>E_,OO#V4^S,O\ X0CP[_T#_P#R
M-)_\51_PA'AW_H'_ /D:3_XJM3^UM._Z"%K_ -_E_P :/[6T[_H(6O\ W^7_
M !H]O2_F7WA[*?9F7_PA'AW_ *!__D:3_P"*H_X0CP[_ - __P C2?\ Q5:G
M]K:=_P!!"U_[_+_C1_:VG?\ 00M?^_R_XT>WI?S+[P]E/LS+_P"$(\._] __
M ,C2?_%4?\(1X=_Z!_\ Y&D_^*K4_M;3O^@A:_\ ?Y?\:/[6T[_H(6O_ '^7
M_&CV]+^9?>'LI]F9?_"$>'?^@?\ ^1I/_BJ/^$(\._\ 0/\ _(TG_P 56I_:
MVG?]!"U_[_+_ (T?VMIW_00M?^_R_P"-'MZ7\R^\/93[,R_^$(\._P#0/_\
M(TG_ ,51_P (1X=_Z!__ )&D_P#BJU/[6T[_ *"%K_W^7_&C^UM._P"@A:_]
M_E_QH]O2_F7WA[*?9F7_ ,(1X=_Z!_\ Y&D_^*H_X0CP[_T#_P#R-)_\56I_
M:VG?]!"U_P"_R_XT?VMIW_00M?\ O\O^-'MZ7\R^\/93[,R_^$(\._\ 0/\
M_(TG_P 51_PA'AW_ *!__D:3_P"*K4_M;3O^@A:_]_E_QI\6H64\HBBO+>21
MNBI*I)_#--5:;=E)?>#IS6K1D?\ "$>'?^@?_P"1I/\ XJC_ (0CP[_T#_\
MR-)_\57045H0<_\ \(1X=_Z!_P#Y&D_^*H_X0CP[_P! _P#\C2?_ !5=!10!
MS_\ PA'AW_H'_P#D:3_XJC_A"/#O_0/_ /(TG_Q5=!10!S__  A'AW_H'_\
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M /(TG_Q5=!10!S__  A'AW_H'_\ D:3_ .*H_P"$(\._] __ ,C2?_%5T%%
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M ,57044 <_\ \(1X=_Z!_P#Y&D_^*H_X0CP[_P! _P#\C2?_ !5=!10!S_\
MPA'AW_H'_P#D:3_XJC_A"/#O_0/_ /(TG_Q5=!10!S__  A'AW_H'_\ D:3_
M .*H_P"$(\._] __ ,C2?_%5T%% '/\ _"$>'?\ H'_^1I/_ (JC_A"/#O\
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MG_Q5=!10!S__  A'AW_H'_\ D:3_ .*H_P"$(\._] __ ,C2?_%5T%% '/\
M_"$>'?\ H'_^1I/_ (JC_A"/#O\ T#__ "-)_P#%5T%% '/_ /"$>'?^@?\
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M)_\ %5T%% '/_P#"$>'?^@?_ .1I/_BJ/^$(\._] _\ \C2?_%5T%% '/_\
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M/^$(\._] _\ \C2?_%5T%% '/_\ "$>'?^@?_P"1I/\ XJC_ (0CP[_T#_\
MR-)_\57044 <_P#\(1X=_P"@?_Y&D_\ BJ/^$(\._P#0/_\ (TG_ ,57044
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M - __P C2?\ Q5=!10!S_P#PA'AW_H'_ /D:3_XJC_A"/#O_ $#_ /R-)_\
M%5T%% '/_P#"$>'?^@?_ .1I/_BJ/^$(\._] _\ \C2?_%5T%% '/_\ "$>'
M?^@?_P"1I/\ XJC_ (0CP[_T#_\ R-)_\57044 <_P#\(1X=_P"@?_Y&D_\
MBJ/^$(\._P#0/_\ (TG_ ,57044 <_\ \(1X=_Z!_P#Y&D_^*H_X0CP[_P!
M_P#\C2?_ !5=!10!S_\ PA'AW_H'_P#D:3_XJC_A"/#O_0/_ /(TG_Q5=!10
M!S__  A'AW_H'_\ D:3_ .*H_P"$(\._] __ ,C2?_%5T%% '/\ _"$>'?\
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M1_PA>H_\]K7_ +[;_P")KNJ*/[#PG9_>']IXCNON.%_X0O4?^>UK_P!]M_\
M$T?\(7J/_/:U_P"^V_\ B:[JBC^P\)V?WA_:>([K[CA?^$+U'_GM:_\ ?;?_
M !-'_"%ZC_SVM?\ OMO_ (FNZHH_L/"=G]X?VGB.Z^XX7_A"]1_Y[6O_ 'VW
M_P 31_PA>H_\]K7_ +[;_P")KNJ*/[#PG9_>']IXCNON.%_X0O4?^>UK_P!]
MM_\ $T?\(7J/_/:U_P"^V_\ B:[JBC^P\)V?WA_:>([K[CA?^$+U'_GM:_\
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M9QUKV?JF&O;E1XOUO$VOS,[7_A;&N_\ /IIO_?M__BZ/^%L:[_SZ:;_W[?\
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M\\<]#D=OI4]MX>O;K4+JTC\H?921+*S8C7'?./;TH>&PJUY4"Q6*>G,SIO\
MA;&N_P#/IIO_ '[?_P"+H_X6QKO_ #Z:;_W[?_XNN9U#0+O3Q [/!-%.VQ)(
M9-REO3M5Y_!MY'(8Y+_3D<=0TQ!_E2>'PB5^5%+$8MNW,S8_X6QKO_/IIO\
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MB#Z[B/YV=W_PMC7?^?33?^_;_P#Q='_"V-=_Y]--_P"_;_\ Q=<)11]2P_\
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ME%'U+#_R(/KN(_G9W?\ PMC7?^?33?\ OV__ ,71_P +8UW_ )]--_[]O_\
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M ,77"44?4L/_ "(/KN(_G9W?_"V-=_Y]--_[]O\ _%T?\+8UW_GTTW_OV_\
M\77"44?4L/\ R(/KN(_G9W?_  MC7?\ GTTW_OV__P 71_PMC7?^?33?^_;_
M /Q=<)11]2P_\B#Z[B/YV=W_ ,+8UW_GTTW_ +]O_P#%T?\ "V-=_P"?33?^
M_;__ !=<)11]2P_\B#Z[B/YV=W_PMC7?^?33?^_;_P#Q='_"V-=_Y]--_P"_
M;_\ Q=<)11]2P_\ (@^NXC^=G=_\+8UW_GTTW_OV_P#\71_PMC7?^?33?^_;
M_P#Q=<)11]2P_P#(@^NXC^=G=_\ "V-=_P"?33?^_;__ !='_"V-=_Y]--_[
M]O\ _%UPE%'U+#_R(/KN(_G9W?\ PMC7?^?33?\ OV__ ,71_P +8UW_ )]-
M-_[]O_\ %UPE%'U+#_R(/KN(_G9W?_"V-=_Y]--_[]O_ /%T?\+8UW_GTTW_
M +]O_P#%UPE%'U+#_P B#Z[B/YV=W_PMC7?^?33?^_;_ /Q='_"V-=_Y]--_
M[]O_ /%UPE%'U+#_ ,B#Z[B/YV=W_P +8UW_ )]--_[]O_\ %T?\+8UW_GTT
MW_OV_P#\77"44?4L/_(@^NXC^=G=_P#"V-=_Y]--_P"_;_\ Q='_  MC7?\
MGTTW_OV__P 77"44?4L/_(@^NXC^=G=_\+8UW_GTTW_OV_\ \71_PMC7?^?3
M3?\ OV__ ,77"44?4L/_ "(/KN(_G9W?_"V-=_Y]--_[]O\ _%T?\+8UW_GT
MTW_OV_\ \77"44?4L/\ R(/KN(_G9W?_  MC7?\ GTTW_OV__P 71_PMC7?^
M?33?^_;_ /Q=<)11]2P_\B#Z[B/YV=W_ ,+8UW_GTTW_ +]O_P#%T?\ "V-=
M_P"?33?^_;__ !=<)11]2P_\B#Z[B/YV=W_PMC7?^?33?^_;_P#Q='_"V-=_
MY]--_P"_;_\ Q=<)11]2P_\ (@^NXC^=G=_\+8UW_GTTW_OV_P#\71_PMC7?
M^?33?^_;_P#Q=<)11]2P_P#(@^NXC^=G=_\ "V-=_P"?33?^_;__ !='_"V-
M=_Y]--_[]O\ _%UPE%'U+#_R(/KN(_G9W?\ PMC7?^?33?\ OV__ ,71_P +
M8UW_ )]--_[]O_\ %UP\,+W$\<,8S)(P51ZDG K<\2Z!%HWV:2VE>6&0%69L
M<.#ST_E[&H>%PRDHN*NREBL2XN2D[(W/^%L:[_SZ:;_W[?\ ^+H_X6QKO_/I
MIO\ W[?_ .+K'M=(TA- MM2U&XNU,\C(!"%P,$^H]JKZGH<,&GKJ6G77VJR+
M;6)7#1GT8?YZCUJ5A\*W;D*>(Q25^<Z#_A;&N_\ /IIO_?M__BZ/^%L:[_SZ
M:;_W[?\ ^+KA*Z/4/#2V?AR#4%D<W.%:>,D856Z<=1V'YU4L+AHM)Q6I,<5B
M9)M2>AL?\+8UW_GTTW_OV_\ \71_PMC7?^?33?\ OV__ ,76)X=\/0ZW:7K/
M.\<L6T18QMR<]?TZ5!HNC+?ZE=6=V9(F@A=R%QD,I P<_6I>'PJNN5:%+$8I
MV]YZG1?\+8UW_GTTW_OV_P#\71_PMC7?^?33?^_;_P#Q=<KH6F#5M5BM79DB
MP6D=>JJ!_P#J'XU/J6DP:9XB6SGDD^QLZD2<;O+/?TXY_*J>&PRER\JN)8G%
M./-S.QT?_"V-=_Y]--_[]O\ _%T?\+8UW_GTTW_OV_\ \77*:WIO]DZM-: L
MT:D&-FZE3R/\/PK:B\,V?]H:78RS7 GN(&FN ,#9QD <>N<YSTJ7A\*DGR[C
M6(Q3;7-L:/\ PMC7?^?33?\ OV__ ,71_P +8UW_ )]--_[]O_\ %U@7,/AI
M+>;R+C46G"GRPRKC=VSQTI=1T) EC<Z499[6\PB;\;E?^Z<#'_ZC0L/ANL+
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M:;_W[?\ ^+H_X6QKO_/IIO\ W[?_ .+KA**/J6'_ )$'UW$?SL[O_A;&N_\
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MW;";BXQVT^_<Z2!BGCG6V4D,+1B".W"5FZUIYUJ\TS4+1<#40$DP,A''!S^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAAZY[$>M86G:==:K?16=G$99Y#A5'\SZ#WKW/PIX4M?#-CM7$MY(/WT^.O\
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M^T +D+VZYQWSS6/\1&?Q;XVT#P'#N-J6_M'5"N>(4.%4D=,G(^I2O4J3 SG
MSTS0!R_CCQ#I'AO1(FUO2YKW2KB403A+82QQ+C(9U/&W( KRT7'AS7_BIX7F
M^'%@T#VLF_4[FTM3;P>03RK# YP&&< '<!DGI[W34C2,81%4=<*,4 .HHHH
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M_P (UKO_ $!-2_\  5_\*]RL?%GAO4[R.SL/$&E7=U)G9#!>QR.V 2<*#DX
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M9G@?_"-:[_T!-2_\!7_PH_X1K7?^@)J7_@*_^%>U?\)WX/\ ^AKT/_P8P_\
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M?@__ *&O0_\ P8P__%4?VO/^5!_9$/YF>*_\(UKO_0$U+_P%?_"C_A&M=_Z
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M 3]!1_:\_P"5!_9$/YF>!_\ "-:[_P! 34O_  %?_"C_ (1K7?\ H":E_P"
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M &ZC^UY_RH/[(A_,SQ/_ (1K7?\ H":E_P" K_X4?\(UKO\ T!-2_P# 5_\
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M)J7_ ("O_A1_PC6N_P#0$U+_ ,!7_P *^BJ*/[7G_*@_LB'\S/G7_A&M=_Z
MFI?^ K_X4?\ "-:[_P! 34O_  %?_"OHJBC^UY_RH/[(A_,SYU_X1K7?^@)J
M7_@*_P#A1_PC6N_] 34O_ 5_\*^BJ*/[7G_*@_LB'\S/G7_A&M=_Z FI?^ K
M_P"%'_"-:[_T!-2_\!7_ ,*^BJ*/[7G_ "H/[(A_,SYU_P"$:UW_ * FI?\
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MN2EJN:3N]CDXM M)UD:'2(9%C7<Y2V!"CU.!P*F.G+J3K";,73#)5/*WD>I
MQ7=:(T6B2^(ODW002Q@J>?DW-Q^1I='TW^R_&+"!LVEQ;O)"P/!0X./P_P *
MAU(KF2C_ ,'J6J<GRMR_X'0X./PO!+ITU^FE6IM86"N_E)P3CMU[C\ZF&BRZ
MA:C&F/<VZGC]P70$?ABM"75E&@0Z7;1M&"QDN7)_UC9X_  #_(YZBYDU*]L;
M*[\.W8\B"%5>UC(W(PZY!Z_3VXSFJD^33E2O_6I"7/KS-V_K0\W_ +)TW/\
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M*UKE>>QL[IP]Q:02N!@-)&&./3FF)I>GQNKI86JNIRK+"H(/J.*MT4^2+=[
MJDDK7.D\)>"](\6O>'5(BQM@@0JJ'[V[/WE/H*Z<?!SPHOS+%(&!R#MBX_\
M'*I_#2XCMTU5I&P/W/\ [/7I2-'($>-@P-?.9ABI4\3**=MOR1]'E^&C/#1D
MUW_-G#3_  F\-W>S[1)<3;>@D,;8SUQE*C'P8\)G_EA)_P!\1?\ Q%>A':,E
MA&JCN:@?4K&(X-PA/H#7(\;4D[N1UK!TDK*)QL_PD\/70"W!NYU7D;S&P'TR
ME0_\*7\)?\\)?^^(O_B*[ ZU '.R.9Q_L#BI8]8A;[ZM$/5^*B68S;U94<!3
M2TB<C+\)/#ES"(YGNY(U^ZCF,@'Z%*JCX.>#&E,8CDW*,L-L7_Q%=7+<&+68
MIUGW6\BXQGC-37L<=M(+^)BPS\P'<5$LQJO5LN.7T5IRG-/\(?#DULL+27;P
M  +&QC*C'3C9BH?^%*>$0/FAES[)%_\ $5W-XDDEHA4LIX/R55W7L8;R_F 4
M_?ZUI/&UNK,X8*CT1RY^$/AQK?[,7NS!C B)CV^O39BH/^%*>$.GD3$^R1?_
M !NNLLIKMY5,_&!39[F\%S)'$I*L.#4/,:O5EK+Z2>B.;7X1>'$MOLVZ\$!R
M/*!CV^O39BH?^%*^$00#;RY/?9%C_P!%UTT=QJ#,$*OL[M5GSKE)T6#<Z8Y+
M<T?VG4>[8_[/I)Z)',)\(O#D5NT$;W:0L"&C4QA3GKQLQ4 ^"OA G!A?/ILB
M_P#B*ZF2[U !AY1^]Z4":[DO&;:558Q^)I?VG4DTKA_9])*]CG(/A)X<MX&B
MA:ZB1CEDC,:J<\= E1?\*5\(=?L\F,?W(O\ XBNT^TL+ N1\^:ANY;A[*-X-
MWF%P"!Z5;Q]9[LA8&BGHCF+;X2^&[5"+9KJ!6.2$,:Y_)*@_X4OX1R,6TF._
MR1?_ !%=8S3%G\PN-BY&.YJ.*:\-W"I5_)8\FE]?K/2X_J%%:I'.V_PC\.6A
M<6OVJ$MC=Y?EKG'KA/>HV^#'A%F+&WD8GDDI$23_ -\5U<K77VJ1U+>6.@J*
M2:X0)Y'F-\I+9]:3Q]:UFQK 4KW2.>MOA%X:M&+6RW,!88)C\M2?R2HW^#7A
M.1VDD@D9V)9F9(B23W)V5TLMU=R;$B#AS'D_6D%S=O<>7(D@7:!D#O2>8U;6
MN-9?3O>QST'PB\,V<GFVRSPL1M+1"-21Z9"4V3X.^%;B5I98)7=CEF=8B2?K
MLKHVN[I0\<<<C>AQ3E>ZFEA9MZDQ,Q ]:/[1K-6N#P%).]CG+?X0>&+67S((
MYH9!P'C6)3CZA*2;X0>%;B5I9XI993]YY%B8GMR2E=*LUT;<L^\2 94>M1?:
MK]0Y:+[RCM1_:-79L/[/I?%;4\V\6>!M"\*S6$NF6J"67S,NT: KC:."JC'W
MC7+SZ9874OFW%C;328QNDB5C^9%>E?$TEH]()&"1+G_QRO/Z^FP+53#1E+K?
M\SYG')T\1)1>UOR*D6DZ;!*LL6GVD<BG*ND*@CZ'%27&G6-Y()+FRMYW VAI
M8E8@>F2*L4M=?)&UK'+SRO>Y3CT?2XI%DCTVS1U(966!001T(.*EN=/LKQE:
MZL[>=E& 98PQ _$58I:.2-K6#GE>]RBNB:2K!ETRR# Y!%NN0?RJQ<V-G>[/
MM5K!/LSM\V,-MSUQGZ"IZ6CDC:U@YY7O<H?V%I'_ $"K'_P'3_"K5S96MZJK
M=6T,ZJ<J)8PP!_&IA2TN2*5K#<Y-WN4/["T?_H%6/_@.G^%69[*UNH5AN+:&
M:)2"J21AE! P, U/0*.2*V0<\F]64?[!T?\ Z!-C_P" Z?X5:DLK2:U6VEM8
M7MU "Q-&"H Z8'3BIA2TE"*V0.<GNRA_8.C_ /0)L/\ P&3_  JT;*T:S^R-
M:PFVP!Y)C&S .1\O3K4U+0H16R!SD]V9_P#8&C?] FP_\!D_PJTMC:+:?9%M
M81;8(\D1C9@G)^7IUJ<4HH4(K9#<Y/=F?_8&C?\ 0(L/_ 9/\*M16-I#;-:Q
M6L"6[ AHEC 0@]<CIS4PI:%"*V0.<GNS/_L#1O\ H$6'_@,G^%6[>QM+2!H+
M>U@AA<DM''&%4DC!R![5-2TE"*V0W.3W9G_\(_HO_0(L/_ 9/\*MVEC:6*LM
MI:P6ZL<L(8P@)]\5-3A0H16J0.<GHV9W_"/:+_T!]/\ _ 9/\*M6FGV5AO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSZ+#8=4(V04445SG0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P O^-'MZ7\R^\/93[,N453_ +6T[_H(6O\ W^7_ !H_M;3O^@A:_P#?Y?\
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M*'CL0_M L#AU]D\<T[X1:ZVF3-JFJZ='J +>4EK&[Q$8^7<S8(YSG /%8_\
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M5TX:SM/[H1O]GSNX^?[V,?[/6O8:*%CL0OM \!AW]@\%_P"%4?$+_G[\,?\
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MM L#AU]D\HTSX9:^VE3'5=1TU-1!;RDM8Y'B(P-NYFP1SG. >*Q?^%;?$?\
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M)(+;=D;L,/FQC...M>ET4+&5U]H;P=!_9/&/^$$^)?\ SW\)?]]W/_Q-;J>
MO$/_  CA9[[2_P"W-I^0))]FW;N/F^]C;[=:]*HH6,KK[0/!T']D\8_X07XF
M?\]_"7_?=S_\36]:> _$)T"4WM]I8UG:_EI"DAMRW\&6.&QTSQ]*])HH6,KK
M[0/!T']D\9_X0?XF?\]_"7_?=S_\36[I?@7Q$=(G.KWNEIJ66\E;1)&A(P-N
MXMANN<X'2O2:*%C*Z^T#P=!_9/&6\"_$UT91=>$X]PQO5K@E?<97&?K7IOA;
MP[#X7T&#3(KF>Z927EN)V):61CEF]N>@[>_6MFBLJE:=3XW<UIT:=/X%8***
M*S- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N-O\
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M<?0\_2J?LU)1<=R5[1Q<E+8R/^$EUW_H-ZE_X%/_ (T?\)+KO_0;U+_P*?\
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M&HV9\.'4_P"Q-/\ ,%QY.SRAC&,YH;CTAUMT&E+K/I?J8'_"2Z[_ -!O4O\
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MQORHSJ2G"5N9FG_PDNN_]!O4O_ I_P#&C_A)==_Z#>I?^!3_ .-=?>:I>_\
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MJ?4?-6VU0M5JA2O?E7W(AXBK:W,_O9G:WIMMXAO$N]7\Z\N$C$2R2SN2%!)
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M$$#<3V89&?7ZUXF,PKHRYH_">W@\6JT>67Q'I%%%%<1W!1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "O*=7^&6M7^M7]Y%=6 CN+B2
M5 TCY 9B1GY.O->K45O0Q$Z#;AU,*^&A724^AXY_PJ?7?^?O3?\ OX__ ,11
M_P *GUW_ )^]-_[^/_\ $5['173_ &GB.Z^XY?[+P_9_>>.?\*GUW_G[TW_O
MX_\ \11_PJ?7?^?O3?\ OX__ ,17L=%']IXCNON#^R\/V?WGCG_"I]=_Y^]-
M_P"_C_\ Q%'_  J?7?\ G[TW_OX__P 17L=%']IXCNON#^R\/V?WGCG_  J?
M7?\ G[TW_OX__P 11_PJ?7?^?O3?^_C_ /Q%>QT4?VGB.Z^X/[+P_9_>>.?\
M*GUW_G[TW_OX_P#\11_PJ?7?^?O3?^_C_P#Q%>QT4?VGB.Z^X/[+P_9_>>.?
M\*GUW_G[TW_OX_\ \11_PJ?7?^?O3?\ OX__ ,17L=%']IXCNON#^R\/V?WG
MCG_"I]=_Y^]-_P"_C_\ Q%'_  J?7?\ G[TW_OX__P 17L=%']IXCNON#^R\
M/V?WGCG_  J?7?\ G[TW_OX__P 11_PJ?7?^?O3?^_C_ /Q%>QT4?VGB.Z^X
M/[+P_9_>>.?\*GUW_G[TW_OX_P#\11_PJ?7?^?O3?^_C_P#Q%>QT4?VGB.Z^
MX/[+P_9_>>.?\*GUW_G[TW_OX_\ \11_PJ?7?^?O3?\ OX__ ,17L=%']IXC
MNON#^R\/V?WGCG_"I]=_Y^]-_P"_C_\ Q%'_  J?7?\ G[TW_OX__P 17L=%
M']IXCNON#^R\/V?WGCG_  J?7?\ G[TW_OX__P 11_PJ?7?^?O3?^_C_ /Q%
M>QT4?VGB.Z^X/[+P_9_>>.?\*GUW_G[TW_OX_P#\11_PJ?7?^?O3?^_C_P#Q
M%>QT4?VGB.Z^X/[+P_9_>>.?\*GUW_G[TW_OX_\ \11_PJ?7?^?O3?\ OX__
M ,17L=%']IXCNON#^R\/V?WGCG_"I]=_Y^]-_P"_C_\ Q%'_  J?7?\ G[TW
M_OX__P 17L=%']IXCNON#^R\/V?WGCG_  J?7?\ G[TW_OX__P 11_PJ?7?^
M?O3?^_C_ /Q%>QT4?VGB.Z^X/[+P_9_>>.?\*GUW_G[TW_OX_P#\11_PJ?7?
M^?O3?^_C_P#Q%>QT4?VGB.Z^X/[+P_9_>>.?\*GUW_G[TW_OX_\ \11_PJ?7
M?^?O3?\ OX__ ,17L=%']IXCNON#^R\/V?WGCG_"I]=_Y^]-_P"_C_\ Q%'_
M  J?7?\ G[TW_OX__P 17L=%']IXCNON#^R\/V?WGCG_  J?7?\ G[TW_OX_
M_P 11_PJ?7?^?O3?^_C_ /Q%>QT4?VGB.Z^X/[+P_9_>>.?\*GUW_G[TW_OX
M_P#\11_PJ?7?^?O3?^_C_P#Q%>QT4?VGB.Z^X/[+P_9_>>2VGPX\5V!<V6KV
MUMOQN\FYE3=CIG"\]35K_A"O'7_0RC_P.G_^)KU"BI>856[M+[BUEU%*R;^\
M\O\ ^$)\<XQ_PD@Q_P!?T_\ \30/!7CH=/$@'_;]/_\ $UZA12^OU>R^X/J%
M+N_O/,/^$+\=?]#+_P"3T_\ \31_PA?CO_H9?_)^?_XFO3Z*/K]3LON']0I=
MW]YYA_PA?CH?\S+_ .3T_P#\31_PA7CK_H9?_)Z?_P")KT^BCZ_5[+[@^H4N
M[^\\P_X0OQW_ -#+_P"3\_\ \31_PA?CO_H9?_)^?_XFO3Z*/K]7LON#ZA2[
MO[SS#_A"_'?_ $,O_D_/_P#$T?\ "%^.O^AE_P#)Z?\ ^)KT^BCZ_4[+[@^H
M4N[^\\O_ .$*\=?]#*/_  .G_P#B:/\ A"O'7_0RC_P.G_\ B:]0HH^OU>R^
MX7U"EW?WGF'_  A?CK_H9?\ R>G_ /B:3_A"O'7_ $,O_D]/_P#$UZA11]?J
M]E]P?4*7=_>>7_\ "%>.O^AE'_@=/_\ $TO_  A?CO\ Z&7_ ,GY_P#XFO3Z
M*/K]7LON#ZA2[O[SS#_A"_'7_0R_^3T__P 31_PA?CK_ *&7_P GI_\ XFO3
MZ*/K]7LON']0I=W]YYA_PA7CK_H9?_)Z?_XFC_A"_'?_ $,O_D_/_P#$UZ?1
M1]?J]E]P?4*7=_>>8?\ "%^._P#H9?\ R?G_ /B:/^$+\=_]#+_Y/3__ !->
MGT4?7ZO9?<'U"EW?WGF'_"%^.O\ H9?_ ">G_P#B:3_A"O'6<_\ "2#_ ,#I
M_P#XFO4**/K]7LON#ZA3[O[SS#_A"_'7_0R_^3T__P 31_PA?CO_ *&7_P G
MY_\ XFO3Z*/K]7LON#ZA2[O[SR:\^'/BS4=GVW6+:YV9V>?<ROMSUQE>.@_*
MJO\ PJ?7?^?O3?\ OX__ ,17L=%6LRKI65ON(>64&[N_WGCG_"I]=_Y^]-_[
M^/\ _$4?\*GUW_G[TW_OX_\ \17L=%']IXCNON%_9>'[/[SQS_A4^N_\_>F_
M]_'_ /B*/^%3Z[_S]Z;_ -_'_P#B*]CHH_M/$=U]P?V7A^S^\\<_X5/KO_/W
MIO\ W\?_ .(H_P"%3Z[_ ,_>F_\ ?Q__ (BO8Z*/[3Q'=?<']EX?L_O/'/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>YAM["8M&1?$B)0W(P0.>PZBA87"M)J*U!XK%)M.3T.L_P"%L:[_ ,^FF_\
M?M__ (NC_A;&N_\ /IIO_?M__BZQY/!>HH[1K/922K_RR6;YOR(%95KI%W<Z
MLNF;!%<DD$2_+C SS^%)8?"-744-XC%IV<F=;_PMC7?^?33?^_;_ /Q='_"V
M-=_Y]--_[]O_ /%US]WX6O[6TDN4>WN8XQF3[/)N*CU(Q572]%O-6,AMU18X
M^7ED;:B_4T+#85J_*K \3BT[<SN=5_PMC7?^?33?^_;_ /Q='_"V-=_Y]--_
M[]O_ /%USE]X;O;*S-V'@N;<'#26[[POUX%1Q:#>S:(^K1B-K="05#?/@=3C
MT_&CZMA;7Y4'UG%WMS,Z?_A;&N_\^FF_]^W_ /BZ/^%L:[_SZ:;_ -^W_P#B
MZX:*-YI4BC4L[L%51W)Z"M6\\.WMEJEMI\CPF:X *E6.T9..>*IX3#)V<4)8
MO$M74F=)_P +8UW_ )]--_[]O_\ %T?\+8UW_GTTW_OV_P#\76(_A&ZCWA]0
MTU2N<@SXQC\*Y^E'"X67PQ02Q6*C\4F=W_PMC7?^?33?^_;_ /Q='_"V-=_Y
M]--_[]O_ /%UPE>CZ+H_A2#P/::QK5J&D?S-S^=(-Q#L!P& Z 5GB*6%H1YI
M0^XVPU3%8B?)"?GJ4_\ A;&N_P#/IIO_ '[?_P"+H_X6QKO_ #Z:;_W[?_XN
MN=FUO0+R\:'3O#:K&IQYC7<G/YM4UEK7AB&_6UU3P^J*>L@NY#@>O#5R>WP7
M_/M_U\SM^J8__GXOO?\ D;G_  MC7?\ GTTW_OV__P 71_PMC7?^?33?^_;_
M /Q=='<Z!X&MM$_M<V&ZUP,,L\IZ_P# J33O#_@C4KG[/'IK)-C<%>:49'XM
M4O$8%?\ +M_<O\P^JX__ )^+[W_D<[_PMC7?^?33?^_;_P#Q='_"V-=_Y]--
M_P"_;_\ Q==@W@KPA'&\LEA$J+W%W(1_Z%0G@WP9)*D:6<1=E#X%W)R/;YJ?
MUC _\^W_ %\Q?5<?_P _%][_ ,CC_P#A;&N_\^FF_P#?M_\ XNC_ (6QKO\
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MB#Z[B/YV=W_PMC7?^?33?^_;_P#Q='_"V-=_Y]--_P"_;_\ Q=<)11]2P_\
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M #Z:;_W[?_XNN+LEM6O(A>O(EL3\[1@%@/;-=)IND>'-4O!;6UQJ1<@L20H
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M #Z:;_W[?_XNC_A;&N_\^FF_]^W_ /BZX2BCZEA_Y$'UW$?SL[O_ (6QKO\
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M-:[_ - 34O\ P%?_  H_X1K7?^@)J7_@*_\ A7T511_:\_Y4']D0_F9\Z_\
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MU+_P%?\ PKZ*HH_M>?\ *@_LB'\S/G7_ (1K7?\ H":E_P" K_X4?\(UKO\
MT!-2_P# 5_\ "OHJBC^UY_RH/[(A_,SYU_X1K7?^@)J7_@*_^%'_  C6N_\
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M (4?\(UKO_0$U+_P%?\ PKZ*HH_M>?\ *@_LB'\S/G7_ (1K7?\ H":E_P"
MK_X4?\(UKO\ T!-2_P# 5_\ "OHJBC^UY_RH/[(A_,SYU_X1K7?^@)J7_@*_
M^%'_  C6N_\ 0$U+_P !7_PKZ*HH_M>?\J#^R(?S,^=?^$:UW_H":E_X"O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>844?V=AOY?Q?^8?VCB?YOP7^1Z?_P +?_Z@7_DW_P#84?\ "W_^H%_Y-_\
MV%>844?V=AOY?Q?^8?VCB?YOP7^1Z?\ \+?_ .H%_P"3?_V%'_"W_P#J!?\
MDW_]A7F%%']G8;^7\7_F']HXG^;\%_D>G_\ "W_^H%_Y-_\ V%'_  M__J!?
M^3?_ -A7F%%']G8;^7\7_F']HXG^;\%_D>G_ /"W_P#J!?\ DW_]A1_PM_\
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M;_A;_P#U O\ R;_^PH_X6_\ ]0+_ ,F__L*\PI\,3SS1PQC<\C!5'J3P*O\
ML[#?R_B_\R/[1Q/\WX+_ "/3/^%O_P#4"_\ )O\ ^PH_X6__ -0+_P F_P#[
M"N'U_0GT*XAC,PG2521(%V\@X(ZGIQ^=2?\ "-S-X:76(Y0X)):()RJ@D9SG
MGIZ5'U/!V4K:/S9I]<QEW&^J\D=I_P +?_Z@7_DW_P#84?\ "W_^H%_Y-_\
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M\WX+_(]/_P"%O_\ 4"_\F_\ ["C_ (6__P!0+_R;_P#L*\PHH_L[#?R_B_\
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M/3X&19;JTEA0N<*&9"HSCMDT <]X2UW4I='T6U?PMJD,!M84-V\MN8P-@^;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?N_[8^R?]M?)S^><?K[US/AWQ%_8N^*:#SH&;>N,!HWQC(S[<5#_ ,)%=?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5XY\6/^1IM?^O)/_0WKV.BNC"U_85.>USGQ6']
MO3Y+V/F&BOIZBO2_MC^Y^/\ P#S/['_O_A_P3YAHKZ>HH_MC^Y^/_ #^Q_[_
M .'_  3YAHKZ>HH_MC^Y^/\ P _L?^_^'_!/F&BOIZBC^V/[GX_\ /['_O\
MX?\ !/F&BOIZBC^V/[GX_P# #^Q_[_X?\$^8:*^GJ*/[8_N?C_P _L?^_P#A
M_P $^8:*^GJ*/[8_N?C_ , /['_O_A_P3YAHKZ>HH_MC^Y^/_ #^Q_[_ .'_
M  3YAHKZ>HH_MC^Y^/\ P _L?^_^'_!/F&BOIZBC^V/[GX_\ /['_O\ X?\
M!/F&BOIZBC^V/[GX_P# #^Q_[_X?\$^8:*^GJ*/[8_N?C_P _L?^_P#A_P $
M^8:U-'\0ZKH/G?V9=>1YVWS/W:MNQG'W@?4U]%44I9K&2M*G=>O_  "HY3*+
MYHU+/T_X)X1_PL/Q3_T%/_)>+_XFC_A8?BK_ *"G_DO%_P#$U[O167U^A_SY
M7X?Y&OU"O_S^?X_YGA'_  L/Q3C_ )"G_DO%_P#$U"/''B,+M_M'C_KA'_\
M$U[[12^O4/\ GROP_P @^H5_^?S_ !_S/ CXY\1D ?VCP/\ IA'_ /$TH\=>
M)%;(U$9_ZX1__$U[Y11]>H?\^5^'^0?4*_\ S^?X_P"9X'_PG7B3.?[1&?\
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M /['_O\ X?\ !/F&BOIZBC^V/[GX_P# #^Q_[_X?\$^8:*^GJ*/[8_N?C_P
M_L?^_P#A_P $^8:*^GJ*/[8_N?C_ , /['_O_A_P3YAHKZ>HH_MC^Y^/_ #^
MQ_[_ .'_  3YAHKZ>HH_MC^Y^/\ P _L?^_^'_!/F&BOIZBC^V/[GX_\ /['
M_O\ X?\ !/F&BOIZBC^V/[GX_P# #^Q_[_X?\$^8:*^GJ*/[8_N?C_P _L?^
M_P#A_P $^8:*^GJ*/[8_N?C_ , /['_O_A_P3YAHKZ>HH_MC^Y^/_ #^Q_[_
M .'_  3YAHKZ>HH_MC^Y^/\ P _L?^_^'_!/F&BOIZBC^V/[GX_\ /['_O\
MX?\ !/F&BOIZBC^V/[GX_P# #^Q_[_X?\$^8:*^GJ*/[8_N?C_P _L?^_P#A
M_P $^8:*^GJ*/[8_N?C_ , /['_O_A_P3YAHKZ>HH_MC^Y^/_ #^Q_[_ .'_
M  3YAHKZ>HH_MC^Y^/\ P _L?^_^'_!/F&BOIZBC^V/[GX_\ /['_O\ X?\
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M\'PZ-=:CK%E/=7VKW-F8&>]E#"9@25+8  Y(7 PH Z4 >76VDZ;XF\#V%O\
M\(W=7/BNYGBG;4)M.<K+F4,TS3LNUHBF?E)Z$ "O=8((;6WBM[>)(H8D"1QH
MH544#   Z "O'+"RL['PE%9V"^-+;Q)';X6WA6[2-;C'8'_1Q&&_X#@5Z]IX
MNAIMJ+]D:\$*>>4^Z9,#=CVSF@#EO 1\R\\7R.293K\RMGL%CB"C_OG%2?#@
M@>%YXC_K(=3ODD7^ZWVF0X_45+I-E<Z5X\UQ!!(=/U2*.^CE53L290(I$)Z
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M5_Z"G_DO+_\ $UX111_9-'N_P_R#^UJ_9?C_ )GN_P#PL3PK_P!!3_R7E_\
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M-'N_P_R#^UJ_9?C_ )GN_P#PL3PK_P!!3_R7E_\ B:/^%B>%?^@I_P"2\O\
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M]!3_ ,EY?_B:/^%B>%?^@I_Y+R__ !->$44?V31[O\/\@_M:OV7X_P"9[O\
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M]!3_ ,EY?_B:/^%B>%?^@I_Y+R__ !->$44?V31[O\/\@_M:OV7X_P"9[O\
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M*/[)H]W^'^0?VM7[+\?\SW?_ (6)X5_Z"G_DO+_\31_PL3PK_P!!3_R7E_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=W+X,\3)9 F4BW/R]<9DS7,UZ;\(T61=:1@"K"$$'_MI49@[8>3]/S1IEO\
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M_*K^GWEGKNF7VCVVGK:.8S-$JR;MSC'J..WZU#X32+5K&XT>XP521+E,CL"
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MNR_VWME[+Y]K'J5%%%?,'TX4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7A/Q$_Y'K4O^V7_HI*]VK!U'P9H&K7\E[>V'FW$N-[^=(N
M<  <!@.@%=F!Q$</4<I=CBQV'EB*:A#O?7YGS_17N_\ PKOPK_T"_P#R8E_^
M*H_X5WX5_P"@7_Y,2_\ Q5>K_:U'L_P_S/+_ +)K]U^/^1X1G'2@$CI7N_\
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M/&?[?UG_ *"]_P#^!+_XT#Q!K0.1J]^#_P!?+_XU[-_PKOPK_P! O_R8E_\
MBJ/^%=^%?^@7_P"3$O\ \51_:.%_D?W+_,/[-Q7\Z^]_Y'C/_"0:UG/]KW^?
M^OE_\:#X@UHG)U>_SZ_:7_QKV;_A7?A7_H%_^3$O_P 51_PKOPK_ - O_P F
M)?\ XJG_ &CA?Y']R_S#^S<5_.OO?^1XQ_;NL#IJM]_X$/\ XTO_  D&M?\
M07O_ /P)?_&O9O\ A7?A7_H%_P#DQ+_\51_PKOPK_P! O_R8E_\ BJ7]HX7^
M1_<O\P_L[%?SK[W_ )'C)\0:TQR=7U GWN7_ ,:#X@UH]=7O_P#P)?\ QKV;
M_A7?A7_H%_\ DQ+_ /%4?\*[\*_] O\ \F)?_BJ/[1PO\C^Y?YA_9V*_G7WO
M_(\9_M_6?^@M?^O_ !\O_C2_\)#K6<_VQJ&?^OE_\:]E_P"%=^%?^@7_ .3$
MO_Q5'_"N_"O_ $"__)B7_P"*H_M'"_R/[E_F']G8K^=?>_\ (\9.OZR3DZO?
MG_MY?_&C^W]9_P"@M?\ _@2_^->S?\*[\*_] O\ \F)?_BJ/^%=^%?\ H%_^
M3$O_ ,53_M'"_P C^Y?YA_9N*_G7WO\ R/%WUO5I(GB?5+UHW4JR&X<A@>H(
MSTJA7N__  KOPK_T"_\ R8E_^*H_X5WX5_Z!?_DQ+_\ %4UFF'CM%_<O\R7E
M>(EO)?>_\CPBBO=_^%=^%?\ H%_^3$O_ ,51_P *[\*_] O_ ,F)?_BJK^UJ
M/9_A_F+^R:_=?C_D>$45[O\ \*[\*_\ 0+_\F)?_ (JC_A7?A7_H%_\ DQ+_
M /%4?VM1[/\ #_,/[)K]U^/^1X117N__  KOPK_T"_\ R8E_^*H_X5WX5_Z!
M?_DQ+_\ %4?VM1[/\/\ ,/[)K]U^/^1X117N_P#PKOPK_P! O_R8E_\ BJ/^
M%=^%?^@7_P"3$O\ \51_:U'L_P /\P_LFOW7X_Y'A%%>[_\ "N_"O_0+_P#)
MB7_XJC_A7?A7_H%_^3$O_P 51_:U'L_P_P P_LFOW7X_Y'A%%>[_ /"N_"O_
M $"__)B7_P"*H_X5WX5_Z!?_ ),2_P#Q5']K4>S_  _S#^R:_=?C_D>$45[O
M_P *[\*_] O_ ,F)?_BJ/^%=^%?^@7_Y,2__ !5']K4>S_#_ ##^R:_=?C_D
M>$45[O\ \*[\*_\ 0+_\F)?_ (JC_A7?A7_H%_\ DQ+_ /%4?VM1[/\ #_,/
M[)K]U^/^1X117N__  KOPK_T"_\ R8E_^*H_X5WX5_Z!?_DQ+_\ %4?VM1[/
M\/\ ,/[)K]U^/^1X117N_P#PKOPK_P! O_R8E_\ BJ/^%=^%?^@7_P"3$O\
M\51_:U'L_P /\P_LFOW7X_Y'A%%>[_\ "N_"O_0+_P#)B7_XJC_A7?A7_H%_
M^3$O_P 51_:U'L_P_P P_LFOW7X_Y'A%%>[_ /"N_"O_ $"__)B7_P"*H_X5
MWX5_Z!?_ ),2_P#Q5']K4>S_  _S#^R:_=?C_D>$45[O_P *[\*_] O_ ,F)
M?_BJ/^%=^%?^@7_Y,2__ !5']K4>S_#_ ##^R:_=?C_D>$45[O\ \*[\*_\
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M^*H_X5WX5_Z!?_DQ+_\ %4?VM1[/\/\ ,/[)K]U^/^1X117N_P#PKOPK_P!
MO_R8E_\ BJ/^%=^%?^@7_P"3$O\ \51_:U'L_P /\P_LFOW7X_Y'A%%>[_\
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MU^/^1X117N__  KOPK_T"_\ R8E_^*H_X5WX5_Z!?_DQ+_\ %4?VM1[/\/\
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M^*H_X5WX5_Z!?_DQ+_\ %4?VM1[/\/\ ,/[)K]U^/^1X117N_P#PKOPK_P!
MO_R8E_\ BJ/^%=^%?^@7_P"3$O\ \51_:U'L_P /\P_LFOW7X_Y'A%%>[_\
M"N_"O_0+_P#)B7_XJC_A7?A7_H%_^3$O_P 51_:U'L_P_P P_LFOW7X_Y'A%
M%>[_ /"N_"O_ $"__)B7_P"*H_X5WX5_Z!?_ ),2_P#Q5']K4>S_  _S#^R:
M_=?C_D>$9SUI0Q4Y!(/M7NW_  KOPK_T"_\ R8E_^*H_X5WX5_Z!?_DQ+_\
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MQ+_\51_PKOPK_P! O_R8E_\ BJ/[6H]G^'^8?V37[K\?\CPBBO=_^%=^%?\
MH%_^3$O_ ,51_P *[\*_] O_ ,F)?_BJ/[6H]G^'^8?V37[K\?\ (\(HKW?_
M (5WX5_Z!?\ Y,2__%5)!X"\,VUQ'/'I:[XV#+NED89'L6(/XTGFU&VB?X?Y
M@LIK7U:_'_(Y#P'X#\SRM8UB+Y.&M[9Q][T9AZ>@_P GU*BBO%KUYUY\TCVZ
M%"%"') ****Q-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M006\US)Y=O#)*^,[8U+'\A2RVMQ!,(9H)8Y3C".A#'\#2_LW#[?J']IXG?\
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MZ/\ A;&A?\^FI?\ ?M/_ (NO'**/[,P_9_>']J8CNON/8_\ A;&A?\^FI?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA1_:\/Y6']D3_F1\ZT5]%?\ "-:%_P! 33?_  %3_"C_ (1K0O\ H":;_P"
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M?_ 5/\*/^$:T+_H":;_X"I_A1_:\/Y6']D3_ )D?.M%?17_"-:%_T!--_P#
M5/\ "C_A&M"_Z FF_P#@*G^%']KP_E8?V1/^9'SK17T5_P (UH7_ $!--_\
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M^ J?X4?VO#^5A_9$_P"9'SK17T5_PC6A?] 33?\ P%3_  H_X1K0O^@)IO\
MX"I_A1_:\/Y6']D3_F1\ZT5]%?\ "-:%_P! 33?_  %3_"C_ (1K0O\ H":;
M_P" J?X4?VO#^5A_9$_YD?.M%?17_"-:%_T!--_\!4_PH_X1K0O^@)IO_@*G
M^%']KP_E8?V1/^9'SK17T5_PC6A?] 33?_ 5/\*/^$:T+_H":;_X"I_A1_:\
M/Y6']D3_ )D?.M%?17_"-:%_T!--_P# 5/\ "C_A&M"_Z FF_P#@*G^%']KP
M_E8?V1/^9'SK17T5_P (UH7_ $!--_\  5/\*/\ A&M"_P"@)IO_ ("I_A1_
M:\/Y6']D3_F1\ZTJJ68*H)). !WKZ)_X1K0O^@)IO_@*G^%20Z#HUO,DT&DV
M$4J'*NELBLI]00.*3S>%M(C643OK)'(>!? HTQ8]5U6,&](S%"P_U/N?]K^7
MUZ=_117CUJTZT^>>Y[%&C"C!0@M HHHK(U"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME%'U+#_R(/KN(_G9W?\ PMC7?^?33?\ OV__ ,71_P +8UW_ )]--_[]O_\
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M ,77"44?4L/_ "(/KN(_G9W?_"V-=_Y]--_[]O\ _%T?\+8UW_GTTW_OV_\
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M7OC[Q"="A6PL=+76-J>:\[R&W+8^?:HPV,],GZUA_P#"=?$S_GAX2_[XN?\
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV2.]HHHKPCW0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O!O$'A_6IO$FJ2Q:1?R1O>2LCK;.0P+G!!QR*]YHKJPN*>';:5[G+BL*L
M0DF[6/G7_A&M=_Z FI?^ K_X4?\ "-:[_P! 34O_  %?_"OHJBNW^UY_RHXO
M[(A_,SYU_P"$:UW_ * FI?\ @*_^%'_"-:[_ - 34O\ P%?_  KZ*HH_M>?\
MJ#^R(?S,^=?^$:UW_H":E_X"O_A1_P (UKO_ $!-2_\  5_\*^BJ*/[7G_*@
M_LB'\S/G7_A&M=_Z FI?^ K_ .%'_"-:[_T!-2_\!7_PKZ*HH_M>?\J#^R(?
MS,^=?^$:UW_H":E_X"O_ (4?\(UKO_0$U+_P%?\ PKZ*HH_M>?\ *@_LB'\S
M/G7_ (1K7?\ H":E_P" K_X4?\(UKO\ T!-2_P# 5_\ "OHJBC^UY_RH/[(A
M_,SYU_X1K7?^@)J7_@*_^%'_  C6N_\ 0$U+_P !7_PKZ*HH_M>?\J#^R(?S
M,^=?^$:UW_H":E_X"O\ X4?\(UKO_0$U+_P%?_"OHJBC^UY_RH/[(A_,SYU_
MX1K7?^@)J7_@*_\ A1_PC6N_] 34O_ 5_P#"OHJBC^UY_P J#^R(?S,^=?\
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M"O\ X4?\(UKO_0$U+_P%?_"OHJBC^UY_RH/[(A_,SYU_X1K7?^@)J7_@*_\
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MU+_P%?\ PKZ*HH_M>?\ *@_LB'\S/G7_ (1K7?\ H":E_P" K_X4?\(UKO\
MT!-2_P# 5_\ "OHJBC^UY_RH/[(A_,SYU_X1K7?^@)J7_@*_^%'_  C6N_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'_:_G]>O@X_ <EZE-:=5V/>P&/Y[4JKUZ/N=_1117DGKA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN^Q0N]SEFP.I/<T^BBOG3Z,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2G_V=>GT4?VCB?YOP7^0?V=AOY?Q?^9YA_PJ#_J._P#DI_\ 9T?\*@_ZCO\
MY*?_ &=>GT4?VCB?YOP7^0?V=AOY?Q?^9YA_PJ#_ *CO_DI_]G1_PJ#_ *CO
M_DI_]G7I]%']HXG^;\%_D']G8;^7\7_F>8?\*@_ZCO\ Y*?_ &='_"H/^H[_
M .2G_P!G7I]%']HXG^;\%_D']G8;^7\7_F>8?\*@_P"H[_Y*?_9T?\*@_P"H
M[_Y*?_9UZ?11_:.)_F_!?Y!_9V&_E_%_YGF'_"H/^H[_ .2G_P!G1_PJ#_J.
M_P#DI_\ 9UZ?11_:.)_F_!?Y!_9V&_E_%_YGF'_"H/\ J._^2G_V='_"H/\
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M=**LIM1</LP6+$=>Y)-/I:%AZ2VBON0/$57O)_>S"_X0OP__ - __P C2?\
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M^YOK-(;NTCW+=(NT2$#[I]3Q^O:N;M]3O;2]:\AN9%N&SN?.2V?7/7\:GO\
M7]3U.$0W5T6BSG8%"@GWP.:CV,E9+IU_,OVT7=OKT_(Z74-5N-.T/1%AM+><
M/; DS1%\<#IS5'PY/)<ZSJL\L2QO)92,41-H&2O05FV_B?6+6WCMX;S;%&NU
M08D.!]2*C7Q!JBZB]^MUBY>/RV?8OW>.,8QV%)49*+5E_3]!NM%R3N_Z7J6_
M"VGW,NMP7'END$!\R25AA5 'J:R]3G2YU6[GC^Y),[K]"3BK-YX@U6_A,-S>
M.T9ZJJA0?K@#-9E;1C+FYI&,I1Y>6)WDVM1:4N@":T@EC:TB+2,F73@<J?;K
M59=*D_X3J66\E9X(1]K,K]T'W?R/'_ :Y6ZU"ZO8[>.XEWI;QB.(;0-JCZ5;
M;Q#JC6C6INOW31"$C8N2@[9QFL?822]W=[FWMXM^]LMCJ;&72;^^U"W35&G?
M4P1Y;0LH4\D8)]!_2J6ES/I7A'4C);PRO%>!&BF7<N?E!R*Y.">2VN(YX6VR
M1L&5L9P15R;6]0N+>Y@DG!BN7$DJB-1N88YX'L*;H/9/33\!*NMVM=?Q-KQ1
M*=3TK3=4@REJ5,1@XQ$X]/R_("M#Q)KES8:V\,-A:3*%4[Y(2S$X]<UQ\>I7
M<>G2Z>DN+65@[IM!R>.^,CH*TO\ A+]=_P"?X?\ ?E/_ (FE[!Z*R:5_Q'[=
M:N[3=OP,1L[CD8.>1C%=+XBCDDT?0-B,W^BX^49[+7.SSR7-Q)/*VZ21B['&
M,DG)K3@\3ZQ;6T=O#>;8HUVJ/+0X'U(S6TXR;370RA**33ZFG/#)IOA*SM;E
M2EQ<7?FK&W#*H[D?E^=+KKZC;>*[N]T]9=T"IO=%W!05'7VKF[B\N;NX^T7$
MSRR_WF.:N+X@U1+^2]2[99Y0%<A1A@.!D8Q6?LI)WT>_XV+]K%JVJV_"YLWQ
MAUOPU<:K/9+;7L$BCS8QM6;) _/G]!S5W7M9N=.GLHX;*UG4VD;[I82Q!YXS
MGIQ7+:AK>HZHBI=W+.BG(0 *,^N!5J/Q9K<<:1K>X5%"C,2'@?A4^QEIMUTN
M5[:.N_36QH^&%CA;4=:O&6W2,&-6$?".Q[*/3CCWJRMOI]]X8N].L;]KN6W)
MN8P\94C'4#/7O^)KF[S6]0OX'AN;C>CR>:PV@9;&.P].U06&H76FW/VBTE\N
M3:5S@'(/L:IT9.\KZ_AH2JT5:-M/QU^9N:=J6I::8M*U#3WN;5R,6\T7S#/]
MW/\ +^5:EG:0Z/XAUF.U4-''9EUC?Y@. =I]1_2N>A\4ZS! L*7IVJ,+N120
M/J156TU>_L;N6ZM[AEGE!#NP#%LG/<&E*C)WV5_Q&JT5;=V_ L:GK%QJ%LL4
MMC:P*K[@T4)4YP1C.>G^%9-:MWXCU:_M'M;FZWPR8W+Y:#.#D<@9ZBLJMJ::
M5FK&-1INZ=PHHHJR HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "MOP]I$][<I<[FB@B;.\<%CZ"FZ%H
M4FJ2^;+E+53\S=V/H*[N.*.")8HD"(HPJCH!7/6K<ONK<Z*-'F]Y["FFFG&F
MFN-'8(:8:>:8:8A#333C333$----.---,0TTTTXTTTQ"&FFG&FFF(::::<::
M:8AII#2FD-,0VFFG4TTQ#3333C333$----.---,0TTAI32&F(::::<:::8AI
MIIIQIIIB&FD-*:0TQ##333C333$(:::<:::9(VFFG4TTQ#3333C333$(:;3C
M3:8AIIIIQIIIB&FFFG&FFJ$ I12"E% "BE%(*44@%%.%-%.% Q12T@I:0"TM
M)2T#%I:2EH 44ZFBG4@%I:2EH&+2TE+2 6EI*6@8HIU-%.H 6E%)2BD HIPI
MHIPI#%%**04HH 44HI!2B@8M+24M(!13A313A0,6EI*6D M+24M Q:6DI:0"
MTM)2T#%IPIM.% "BE%(*44@%%**04HH&.%9UO_:OB;73H?AN8P/ P-_J@&5L
MU]%]9#V';\"1I^'%M_$WB*YT>$S&.UCW7=Q$/DC).!'N[.>?I@^F*]-\/^']
M,\,:1%IFE6P@MH\D\Y9V/5F/4L?7^@KR\;B[+V<'KU/4P6#N_:5%IT+EG;?8
M[&WM?.FF\F-8_-G?=(^!C<S=V.,D^M3T45XY[(4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7">(OAO_;^NW.I_VMY'G;?W?V?=MPH7
MKN'IZ5W=%:TJTZ,N:F[,RK485H\M171YA_PJ#_J._P#DI_\ 9T?\*@_ZCO\
MY*?_ &=>GT5T?VCB?YOP7^1S_P!G8;^7\7_F>8?\*@_ZCO\ Y*?_ &='_"H/
M^H[_ .2G_P!G7I]%']HXG^;\%_D']G8;^7\7_F>8?\*@_P"H[_Y*?_9T?\*@
M_P"H[_Y*?_9UZ?11_:.)_F_!?Y!_9V&_E_%_YGF'_"H/^H[_ .2G_P!G1_PJ
M#_J._P#DI_\ 9UZ?11_:.)_F_!?Y!_9V&_E_%_YGF'_"H/\ J._^2G_V='_"
MH/\ J._^2G_V=>GT4?VCB?YOP7^0?V=AOY?Q?^9YA_PJ#_J._P#DI_\ 9T?\
M*@_ZCO\ Y*?_ &=>GT4?VCB?YOP7^0?V=AOY?Q?^9YA_PJ#_ *CO_DI_]G1_
MPJ#_ *CO_DI_]G7I]%']HXG^;\%_D']G8;^7\7_F>8?\*@_ZCO\ Y*?_ &='
M_"H/^H[_ .2G_P!G7I]%']HXG^;\%_D']G8;^7\7_F>8?\*@_P"H[_Y*?_9T
M?\*@_P"H[_Y*?_9UZ?11_:.)_F_!?Y!_9V&_E_%_YGF'_"H/^H[_ .2G_P!G
M1_PJ#_J._P#DI_\ 9UZ?11_:.)_F_!?Y!_9V&_E_%_YGF'_"H/\ J._^2G_V
M='_"H/\ J._^2G_V=>GT4?VCB?YOP7^0?V=AOY?Q?^9YA_PJ#_J._P#DI_\
M9T?\*@_ZCO\ Y*?_ &=>GT4?VCB?YOP7^0?V=AOY?Q?^9YA_PJ#_ *CO_DI_
M]G1_PJ#_ *CO_DI_]G7I]%']HXG^;\%_D']G8;^7\7_F>8?\*@_ZCO\ Y*?_
M &='_"H/^H[_ .2G_P!G7I]%']HXG^;\%_D']G8;^7\7_F>8?\*@_P"H[_Y*
M?_9T?\*@_P"H[_Y*?_9UZ?11_:.)_F_!?Y!_9V&_E_%_YGF'_"H/^H[_ .2G
M_P!G1_PJ#_J._P#DI_\ 9UZ?11_:.)_F_!?Y!_9V&_E_%_YGF'_"H/\ J._^
M2G_V='_"H/\ J._^2G_V=>GT4?VCB?YOP7^0?V=AOY?Q?^9YA_PJ#_J._P#D
MI_\ 9T?\*@_ZCO\ Y*?_ &=>GT4?VCB?YOP7^0?V=AOY?Q?^9YA_PJ#_ *CO
M_DI_]G1_PJ#_ *CO_DI_]G7I]%']HXG^;\%_D']G8;^7\7_F>8?\*@_ZCO\
MY*?_ &='_"H/^H[_ .2G_P!G7I]%']HXG^;\%_D']G8;^7\7_F>8?\*@_P"H
M[_Y*?_9T?\*@_P"H[_Y*?_9UZ?11_:.)_F_!?Y!_9V&_E_%_YGF'_"H/^H[_
M .2G_P!G1_PJ#_J._P#DI_\ 9UZ?11_:.)_F_!?Y!_9V&_E_%_YGF'_"H/\
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M!4*:^RCB7\!WC>&A9+XAE75]H']H_9$*YW9)\KITXQGWK!_X5?XN_P"BB_\
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M+JH<+Y0CLX[;R\9SG!;=GCTQCWK*N/A3XDDN)7A\?&*)G)2,Z/$Q1<\#._G
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M)CFBMT@5!@8!7YL\Y/4=:]-HIK%5U]M_>#PE!_87W'C/_"D-;_Z'O_RD)_\
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M5_\ R?C_ ,* .@HKG_[7\1?]"O\ ^3\?^%']K^(O^A7_ /)^/_"@#H**Y_\
MM?Q%_P!"O_Y/Q_X4?VOXB_Z%?_R?C_PH Z"BN?\ [7\1?]"O_P"3\?\ A1_:
M_B+_ *%?_P GX_\ "@#H**Y_^U_$7_0K_P#D_'_A1_:_B+_H5_\ R?C_ ,*
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M5_\ R?C_ ,* .@HKG_[7\1?]"O\ ^3\?^%']K^(O^A7_ /)^/_"@#H**Y_\
MM?Q%_P!"O_Y/Q_X4?VOXB_Z%?_R?C_PH Z"BN?\ [7\1?]"O_P"3\?\ A1_:
M_B+_ *%?_P GX_\ "@#H**Y_^U_$7_0K_P#D_'_A1_:_B+_H5_\ R?C_ ,*
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M5_\ R?C_ ,* .@HKG_[7\1?]"O\ ^3\?^%']K^(O^A7_ /)^/_"@#H**Y_\
MM?Q%_P!"O_Y/Q_X4?VOXB_Z%?_R?C_PH Z"BN?\ [7\1?]"O_P"3\?\ A1_:
M_B+_ *%?_P GX_\ "@#H**Y_^U_$7_0K_P#D_'_A1_:_B+_H5_\ R?C_ ,*
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M5_\ R?C_ ,* .@HKG_[7\1?]"O\ ^3\?^%']K^(O^A7_ /)^/_"@#H**Y_\
MM?Q%_P!"O_Y/Q_X4?VOXB_Z%?_R?C_PH Z"BN?\ [7\1?]"O_P"3\?\ A1_:
M_B+_ *%?_P GX_\ "@#H**Y_^U_$7_0K_P#D_'_A1_:_B+_H5_\ R?C_ ,*
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M5_\ R?C_ ,* .@HKG_[7\1?]"O\ ^3\?^%']K^(O^A7_ /)^/_"@#H**Y_\
MM?Q%_P!"O_Y/Q_X4?VOXB_Z%?_R?C_PH Z"BN?\ [7\1?]"O_P"3\?\ A1_:
M_B+_ *%?_P GX_\ "@#H**Y_^U_$7_0K_P#D_'_A1_:_B+_H5_\ R?C_ ,*
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M_%5]!T4?VC5[+^OF']F4N[_#_(^?/^%:>+O^@1_Y,Q?_ !5'_"M/%W_0(_\
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MSU/_ +]1_P#Q=>/2Z3J,$9DFT^ZCC! +/"P )X')%$NDZE A>;3[N-%ZL\+
M#\Q1]1H?TP^OXC^D>P_\+B\/?\^>I_\ ?J/_ .+H_P"%Q>'O^?/4_P#OU'_\
M77CNGZ;=:I.\-H@>18S)MW $@>F>I]JJ4_J%$7]H5]_T/;?^%Q>'O^?/4_\
MOU'_ /%T?\+B\/?\^>I_]^H__BZ\2HH^H41?VA7\CVW_ (7%X>_Y\]3_ ._4
M?_Q='_"XO#W_ #YZG_WZC_\ BZ\2HH^H40_M"OY'MO\ PN+P]_SYZG_WZC_^
M+H_X7%X>_P"?/4_^_4?_ ,77B5%'U"B']H5_(]M_X7%X>_Y\]3_[]1__ !='
M_"XO#W_/GJ?_ 'ZC_P#BZ\2HH^H40_M"OY'MO_"XO#W_ #YZG_WZC_\ BZ/^
M%Q>'O^?/4_\ OU'_ /%UXE11]0HA_:%?R/;?^%Q>'O\ GSU/_OU'_P#%T?\
M"XO#W_/GJ?\ WZC_ /BZ\2HH^H40_M"OY'MO_"XO#W_/GJ?_ 'ZC_P#BZ/\
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M"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4-/M[^TE66UN(EEBD' 9&&0>?8UG^'?%6B>++2:ZT._2\AAD\J0JK*5;&>C
M''OT- &Q167I?B/2=:O]2L=.O4N+C391#=HJL/*?GC)&#T(XST-,?Q1HJ>*$
M\--?QC6)(?.6VVMDKR>N-N< G&<XYQB@#7HK+D\1:3%XEB\.R7BKJTMO]ICM
MRC?-'DC(;&WJIXSG@G%+KWB'2O#&E/J>LWBVMFC*AD*LQ+$X "J"2?H/4]J
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MQ^-0V*6/A&WN;QM2M[O49(FB@BMFW!,X^8G_ /5T[YXH^![B"U\0[[B>*%#
MXWR.%&>.YH:34FEH.,FG%-ZEKPKK&HZCXKTZ*[O)IHU:1@KMQGRVYJ;6;7Q5
M;6E[/<7K"R&0RF<'Y&.,8_&L?P?<0VOBJRFN)4BB7?N>1@JC*,.2:L7_ (=B
MW75TNNZ4X^>0(EP"QZG '<TVDI_\ F+;A_P3I=-CBU#P98Z/(0&O()3$Q/1T
M;(_Q_"N:\*6:PZC<ZE>(5@TQ#(X/&9.BK]<Y_$"I;C4UL] \.36T\;7%M)([
M1A^1\W0@= :N>+M5T_\ LY;;2I$87\GVNYV-G!P, ^ASSCL1[U*3U7<IM:2?
M0U;DEOBGIK'J;?/_ (X]1Z:^K,=8&NB7^R!$_P#Q\C'.?EVYYZ?KCOBHKB_L
MC\2-.N1>6Y@6WPTHE4H#L<8)SCT_.N/U74KR\NIXY;Z:XA$K; TI9<9." :(
MP<K+R0Y34;OS9T$UY-X<\(::M@1%<ZCOEEG ^; Q@ ]N"/U]:70M1N/$&F:G
MI6I.;D);-/#))RT;+[]>X_7UJ*W>Q\0^&[73Y[Z*SO[$L(FG;"2(3TSV[?E[
M\.B%AX6TF](U""\U.[B,*+;-N6-3U)/^>WUIV5K=;B3=T[^[8TK&#6I_!.CC
M19'2022^85<+QO;&<]:R/&[I-JUI!E)=0C@6.Z>(<-)_7_ZX%1WMXB>"=$6"
MZ1;J&:1BB2?.GS,0<#D=OS%;<;:7J^J:/KMS?6D+K$6NHGD56+IT./K^@%)>
MZ^;U!^\N5>19D@@DT^7P>H4SPV2RJV?^6V=Q'XY!^A-<_P"%B1H7B5>1_H@R
M/P:I(_'ES_:BW#V%B$,F6<1'S-G0_-GKBM."/38M2\1VL>I64<5] &AD:==N
M6W9&0<<$]/3%%G%-,=XR::Z:?Y'GU=5X<N9K3PKKL]O*T<J>4593@CDUEZIH
MB:;;+,NJZ?=EGV>7;S!F'!.<>G'ZBM+PV+>XT#6+&6]M;62?RMAN)0@."2>O
M6M9M.-S*FFI6+WA[4;CQ,EWHNJN+A7A:2&5U&Z-QT(/X_P!.]6],@U>X\!V"
MZ1.8YEG?<=^WY<MZ^^*SK1M.\)VUU<1ZE#?:E-$8H4MCE(P>K%OR_P GAUO!
M:ZKX(L;'^U+&UGAN'=EN)@IQ\W;\164EU6US6+Z/>Q)I"ZK%X_TZ#5K@S3QH
M^/W@; ,;'MT_S[56\:VZW)M=;A'R7(,4V!TD3C^G_CM)H=G;Z)XOTUI=4L9H
MV61FDBE!5/D8 $].:N>'-0TZ674=-U*>$6JW'VN&1V 4E6Y )ZYXX],TWI+F
M71"6L>5]7_D:EG NE>$K[2NES_9TES<#T9P0!^ &/PJIID&KW'@.P72)S',L
M[[COV_+EO7WQ6=INLQWTGB:ZN9HXGN;1Q$LC@$\$!1ZG&!3K>"UU7P18V/\
M:EC:SPW#NRW$P4X^;M^(J7%K?N4I)[=OU)-(758O'^G0:M<&:>-'Q^\#8!C8
M]NG^?:EUVW2_NK+Q!9C!^TK#=!?X)%8 '\>/T]:J:'9V^B>+]-:75+&:-ED9
MI(I053Y& !/3FF^']8M[+7KNTNW1].O)65V)^4'<=KY[#W_'M5-.]UV)35N6
M75_Y$GBK6=2T[Q3J4-G>2PQNT;%5/&?+7G_/M5GQMK6I6>M^1;7LT436ZDJC
M8&3G-8GC">&Y\57LT$L<L3;,/&P93\BCJ*L^.;B"YU]9+>XBG3[.@W1.& //
M&13C%>[IT_R)E)^]KU_S'^+$>:31(T!:1[&)5'<DUT-U!!<6%WX3B ::SLTE
MC('64?,V/KD?F:JQRZ;-KFC7-Q>VPAL].61LR#[Z]%Z_>!.<=>*S[7QU.-4C
MFFL+!(VD_>.D)WA2>3G/7%3:322Z%WBFVWN<A74:XIL?".A628 G#74F.Y.-
MOZ,1^%9?B*WM[;7KI;2:*6W9]Z-$P90#SCCTZ5J^(3]K\*^'[U!\L<;6[GT*
MX _]!-:MW<68I64E_6YNZC;^))K32VT9I1 +*,/MF51NQZ$CMBL32=8UQ/$]
MM87E].2MSLEC+Y&=W(X]Z@\47<<BZ3]FN5?;8QJXC?.TCL<=#[5G:!*D?B*Q
MEFD55$ZEG=L <]2341C[NII*?OJQL7FLZE)XN:R>\F-L-0"B/=Q@2#'Y8%6?
M$/B;5M+\67:6]VWDQNN(7Y0C:"1BL6YGA_X322X\U#"+_?Y@.5V[\YSZ5NZW
MH^FZCKUSJ$OB#3X[61@Q$<H>3  !  ^E%HIJZZ!>33L];C=2,.G^,-'U2SC$
M$=ZL<SH.VXX;\P?SS6!XFLUL?$M_;H %$NX =@P#8_6M.YO8O$'B_3H;*-A:
M0M'#$".2BG)./IG\ *S_ !7<K=^*-0E3[OF;/^^0%_I3@FFK]B:C33MW,:BB
MBMC$**** "BBB@ HHHH **** "BBB@ HHHH **** )+>"2ZN8K>(9DE<(H]2
M3@5Z1,L=XU[X6C0^3#9HL#D8!E3D\^IR,_[IKCO"MU86.LB]U"38D$;/&H4M
MO?& /U/7TJU;>.-;2^BEGN]\(D!>,1H,KGD=/2L:BE)Z=#:G*,5KU+O@N\?3
M-+UV["Y:!86*GO@MD5JZ5IL5KXU@O[+FPOH'EB(Z*2.5]OI[X[5ES:GHT(\3
M);W@*7R(T $;?,WS%AR..3^M+X,\46FFP/9:G)LA0F2"0J6V$\$<9ZYS^=1)
M-WDE_5C2+BG&+>W^91\'0"&>\UATW)80ED']Z1AA1_/\Q4WBE7O=.TK7@K++
M(GDSG&")%Z'\>?R%1P>(%T;PO:VNDW.V^EE:6Y81YVCH!\PQTQT]#ZT^'Q)_
M:VAZE8ZW=YD*"2U?RA]\?P_*._'ZU34N;FL0G'EY+_\ #C_$=JVM#1]5ME!>
M_18),# $H./\?^^:UH[E#\0]*TV _P"CZ?$T"\]_+;)_D/PK+\)^(;#3M-N(
M-1.3 _VBU!4G+[2"!Z?CZFLKP[JD5MXK@U&_E*IOD>63:3RRMS@<]32Y79KM
M<:DKI]VKES6-*-O%>7 \06DI5B?L\<Y+'+8VX_&M7PK%#XETE;#48GD&G2+)
M%(.ZG_EF?;C\L>E8][8>'9/M-Q'K[/*V]UC^RN-S<D#)]^*EN]=@TK3=/T_0
M[G?Y;"XN)PK+YDGI@@<<?EBFTW&RW!-1E=[?>$/B-)_%=Q=:B)(K::-[7"CY
MH$/ Q[CO]3]*Z;Q%XHTLZ;<^3=K/-)$\$,<+$@JZ@%GXX((/'^/'&>)KC3;^
M\BU"P?$ERFZX@VD>7)WYP <^WH?6L.G[*,K/87M91O'<Z;1K2YU>"T\[Q#!9
MQV[^7%$\VV1.<Y5<C/)Z^WM4WB^SOM2\77$5O83%TB4@!<EU'&_CMDX_P/%5
M(-/\-7-I;R-K$]I,$'GQR0%_F[[2.WIUH\0>(/M6J1OI<]S%%! +=9=Y5Y .
M23C\/RS0K\]T#MR6?YF9=6.I:0R?:(9[4RJ=I.5W 'G^GZ5OB:72/!+RRR.;
MO56V)N8DK".IY]?ZBN=6X>_OH!J-Y*8MP5I9&9RB9YQU/K6AXHU6'5-6_P!$
M/^A6Z"&W&,#:.^/K^F*IIMI,A-)-HVO!.LWDVIV6F;E2UB20[47&\\G+>O7]
M*Y2UT^[U&9X[.WDG91N8(,X&:Z+PI+HFESP:E=:L4N K![?[.YQG('S 'M@U
MD7K0:7=*=&U>:8.G[R2-&A(Y^[ZGH#27Q.R*>L%=F_X>T^]T33M<O9X);>ZC
MM!Y+,,$!BV2/Q456\*7$MS9:W8S2-)"]F\F'.<,.X]^?T%5]!\0+%<74&L3W
M$UI>0>1)(6+L@YP1G/ R?SJP+O1]!TF^BT^^>_O+Q/*W^446-#UZ]_\ ZW2I
M:>J>[L4FK)IZ*X_QG//8W.EV%O,\<-O:1N@0[<-DC=QWX%3>(=1FLKO0]:C6
M)KN:Q5F+ID;BOWL>OS<?2H;BZT/Q%:6,VH:C)8WEO$(9AY)?S%'0C'3J?SZ5
M3U;4-.UO7+>'SWL],MX1!'*R%R H.#M'/)P/I1%;)K:]PD]VGO:Q9\47,UWX
M<T"XN)&DED69F9NI.5KE*[+5'\/7>B65FFN$O8QR;,6K_O"<$#GITKC:NGM8
MSJ_%<****T,RWIFIW>CZA%?6,S13Q'(8=_4$=P?2OH#PAXOM/%>G[TVQ7L0'
MGV^>G^T/53^E?.JJSL%4%F)P !DDU[9\._ CZ(JZOJ08:A(A$<.?]2I]?5CZ
M=OK7GX^-/DYI;]#T<NE4Y^6/P]3T*BBBO&/;"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>T5Z%_PIWQ#_ ,_FF?\ ?V3_ .(H_P"%.^(?^?S3/^_LG_Q%'UJC_,'U2O\
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M>>T5Z%_PIWQ#_P _FF?]_9/_ (BC_A3OB'_G\TS_ +^R?_$4?6J/\P?5*_\
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M*/\ A3OB'_G\TS_O[)_\10\30?VD-86NMHL\]HKT+_A3OB'_ )_-,_[^R?\
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MP^E_%<WFH70M+"U.V63&26_NCW_Q'!J]#H.AZS'+%HM]<B]12ZPW84"0#T(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,'_DG_\ ;*/^%*_]3!_Y)_\ VRCZ[0_F_!A]1Q'\OXK_ #/)Z*]8_P"%*_\
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M /;*/^%*_P#4P?\ DG_]LH^NT/YOP8?4<1_+^*_S/)Z*]8_X4K_U,'_DG_\
M;*/^%*_]3!_Y)_\ VRCZ[0_F_!A]1Q'\OXK_ #/)Z*]8_P"%*_\ 4P?^2?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***PY_#7GW$LW]MZS'YCEMD=
MUA5R<X QP* -RO$?$OPZ\27/B34;JSLEN+>XN'F1Q,B\,Q."&8'O7IW_  BO
M_4>US_P,_P#K4?\ "*_]1[7/_ S_ .M6U&O*B[Q,*^'A65I'CG_"M/%W_0(_
M\F8O_BJ/^%:>+O\ H$?^3,7_ ,57L?\ PBO_ %'M<_\  S_ZU'_"*_\ 4>US
M_P #/_K5T_VC5[+^OF<O]F4N[_#_ "/'/^%:>+O^@1_Y,Q?_ !5'_"M/%W_0
M(_\ )F+_ .*KV/\ X17_ *CVN?\ @9_]:C_A%?\ J/:Y_P"!G_UJ/[1J]E_7
MS#^S*7=_A_D>.?\ "M/%W_0(_P#)F+_XJC_A6GB[_H$?^3,7_P 57L?_  BO
M_4>US_P,_P#K4?\ "*_]1[7/_ S_ .M1_:-7LOZ^8?V92[O\/\CQS_A6GB[_
M *!'_DS%_P#%4?\ "M/%W_0(_P#)F+_XJO8_^$5_ZCVN?^!G_P!:C_A%?^H]
MKG_@9_\ 6H_M&KV7]?,/[,I=W^'^1XY_PK3Q=_T"/_)F+_XJC_A6GB[_ *!'
M_DS%_P#%5['_ ,(K_P!1[7/_  ,_^M1_PBO_ %'M<_\  S_ZU']HU>R_KYA_
M9E+N_P /\CQS_A6GB[_H$?\ DS%_\51_PK3Q=_T"/_)F+_XJO8_^$5_ZCVN?
M^!G_ -:C_A%?^H]KG_@9_P#6H_M&KV7]?,/[,I=W^'^1XY_PK3Q=_P! C_R9
MB_\ BJ/^%:>+O^@1_P"3,7_Q5>Q_\(K_ -1[7/\ P,_^M1_PBO\ U'M<_P#
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M_P! C_R9B_\ BJ/^%:>+O^@1_P"3,7_Q5>Q_\(K_ -1[7/\ P,_^M1_PBO\
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M /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^M0!T%%<__P (K_U'M<_\#/\
MZU'_  BO_4>US_P,_P#K4 =!17/_ /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\
MP,_^M0!T%%<__P (K_U'M<_\#/\ ZU'_  BO_4>US_P,_P#K4 =!17/_ /"*
M_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^M0!T%%<__P (K_U'M<_\#/\ ZU'_
M  BO_4>US_P,_P#K4 =!17/_ /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^
MM0!T%%<__P (K_U'M<_\#/\ ZU'_  BO_4>US_P,_P#K4 =!17/_ /"*_P#4
M>US_ ,#/_K4?\(K_ -1[7/\ P,_^M0!T%%<__P (K_U'M<_\#/\ ZU'_  BO
M_4>US_P,_P#K4 =!17/_ /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^M0!T
M%%<__P (K_U'M<_\#/\ ZU'_  BO_4>US_P,_P#K4 =!17/_ /"*_P#4>US_
M ,#/_K4?\(K_ -1[7/\ P,_^M0!T%%<__P (K_U'M<_\#/\ ZU'_  BO_4>U
MS_P,_P#K4 =!17/_ /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^M0!T%%<_
M_P (K_U'M<_\#/\ ZU'_  BO_4>US_P,_P#K4 =!17/_ /"*_P#4>US_ ,#/
M_K4?\(K_ -1[7/\ P,_^M0!T%%<__P (K_U'M<_\#/\ ZU'_  BO_4>US_P,
M_P#K4 =!17/_ /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^M0!T%%<__P (
MK_U'M<_\#/\ ZU'_  BO_4>US_P,_P#K4 =!17/_ /"*_P#4>US_ ,#/_K4?
M\(K_ -1[7/\ P,_^M0!T%%<__P (K_U'M<_\#/\ ZU'_  BO_4>US_P,_P#K
M4 =!17/_ /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^M0!T%%<__P (K_U'
MM<_\#/\ ZU'_  BO_4>US_P,_P#K4 =!17/_ /"*_P#4>US_ ,#/_K4?\(K_
M -1[7/\ P,_^M0!T%%<__P (K_U'M<_\#/\ ZU'_  BO_4>US_P,_P#K4 =!
M17/_ /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^M0!T%%<__P (K_U'M<_\
M#/\ ZU'_  BO_4>US_P,_P#K4 =!17/_ /"*_P#4>US_ ,#/_K4?\(K_ -1[
M7/\ P,_^M0!T%%<__P (K_U'M<_\#/\ ZU'_  BO_4>US_P,_P#K4 =!17/_
M /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^M0!T%%<__P (K_U'M<_\#/\
MZU'_  BO_4>US_P,_P#K4 =!17/_ /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\
MP,_^M0!T%%<__P (K_U'M<_\#/\ ZU'_  BO_4>US_P,_P#K4 =!17/_ /"*
M_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^M0!T%%<__P (K_U'M<_\#/\ ZU'_
M  BO_4>US_P,_P#K4 =!17/_ /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^
MM0!T%%<__P (K_U'M<_\#/\ ZU'_  BO_4>US_P,_P#K4 =!17/_ /"*_P#4
M>US_ ,#/_K4?\(K_ -1[7/\ P,_^M0!T%%<__P (K_U'M<_\#/\ ZU'_  BO
M_4>US_P,_P#K4 =!17/_ /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^M0!T
M%%<__P (K_U'M<_\#/\ ZU'_  BO_4>US_P,_P#K4 =!17/_ /"*_P#4>US_
M ,#/_K4?\(K_ -1[7/\ P,_^M0!T%%<__P (K_U'M<_\#/\ ZU'_  BO_4>U
MS_P,_P#K4 =!17/_ /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^M0!T%%<_
M_P (K_U'M<_\#/\ ZU'_  BO_4>US_P,_P#K4 =!17/_ /"*_P#4>US_ ,#/
M_K4?\(K_ -1[7/\ P,_^M0!T%%<__P (K_U'M<_\#/\ ZU'_  BO_4>US_P,
M_P#K4 =!17/_ /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^M0!T%%<__P (
MK_U'M<_\#/\ ZU'_  BO_4>US_P,_P#K4 =!17/_ /"*_P#4>US_ ,#/_K4?
M\(K_ -1[7/\ P,_^M0!T%%<__P (K_U'M<_\#/\ ZU'_  BO_4>US_P,_P#K
M4 =!17/_ /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^M0!T%%<__P (K_U'
MM<_\#/\ ZU'_  BO_4>US_P,_P#K4 =!17/_ /"*_P#4>US_ ,#/_K4?\(K_
M -1[7/\ P,_^M0!T%%<__P (K_U'M<_\#/\ ZU'_  BO_4>US_P,_P#K4 =!
M17/_ /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^M0!T%%<__P (K_U'M<_\
M#/\ ZU'_  BO_4>US_P,_P#K4 =!17/_ /"*_P#4>US_ ,#/_K4?\(K_ -1[
M7/\ P,_^M0!T%%<__P (K_U'M<_\#/\ ZU'_  BO_4>US_P,_P#K4 =!17/_
M /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^M0!T%%<__P (K_U'M<_\#/\
MZU'_  BO_4>US_P,_P#K4 =!17/_ /"*_P#4>US_ ,#/_K4?\(K_ -1[7/\
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MG_DO%_\ $U[M11]?H_\ /E?A_D'U"O\ \_G^/^9X3_PL/Q3_ -!3_P EXO\
MXFC_ (6'XI_Z"G_DO%_\37NU%'U^C_SY7X?Y!]0K_P#/Y_C_ )GA/_"P_%/_
M $%/_)>+_P")H_X6'XI_Z"G_ )+Q?_$U[M11]?H_\^5^'^0?4*__ #^?X_YG
MA/\ PL/Q3_T%/_)>+_XFC_A8?BG_ *"G_DO%_P#$U[M11]?H_P#/E?A_D'U"
MO_S^?X_YGA/_  L/Q3_T%/\ R7B_^)H_X6'XI_Z"G_DO%_\ $U[M11]?H_\
M/E?A_D'U"O\ \_G^/^9X3_PL/Q3_ -!3_P EXO\ XFC_ (6'XI_Z"G_DO%_\
M37NU%'U^C_SY7X?Y!]0K_P#/Y_C_ )GA/_"P_%/_ $%/_)>+_P")H_X6'XI_
MZ"G_ )+Q?_$U[M11]?H_\^5^'^0?4*__ #^?X_YGA/\ PL/Q3_T%/_)>+_XF
MC_A8?BG_ *"G_DO%_P#$U[M11]?H_P#/E?A_D'U"O_S^?X_YGA/_  L/Q3_T
M%/\ R7B_^)H_X6'XI_Z"G_DO%_\ $U[M11]?H_\ /E?A_D'U"O\ \_G^/^9X
M3_PL/Q3_ -!3_P EXO\ XFC_ (6'XI_Z"G_DO%_\37NU%'U^C_SY7X?Y!]0K
M_P#/Y_C_ )GA/_"P_%/_ $%/_)>+_P")H_X6'XI_Z"G_ )+Q?_$U[M11]?H_
M\^5^'^0?4*__ #^?X_YGA/\ PL/Q3_T%/_)>+_XFC_A8?BG_ *"G_DO%_P#$
MU[M11]?H_P#/E?A_D'U"O_S^?X_YGA/_  L/Q3_T%/\ R7B_^)H_X6'XI_Z"
MG_DO%_\ $U[M11]?H_\ /E?A_D'U"O\ \_G^/^9X3_PL/Q3_ -!3_P EXO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;X"^(B>.[[6H8M)GL(M.:((;A_GE#AB"4Q\GW?4]: .VHHHH **** "BBB@
MHHHH *\)_P":I?\ <:_]KU[M7A/_ #5+_N-?^UZ]3+?^7GH>7F?_ "[]3W:B
MBBO+/4"BBB@ HHHH **** "BBB@ HHHH QO%6DSZYX;N].MGC2:;9M:4D*,.
MK'. 3T'I7FW_  J?7?\ G[T[_OX__P 17H'CNYGL_!E_/;3R03+Y>V2)RK#,
MB@X(YZ5XQ_PDFN_]!K4?_ I_\:]G+XUW2?LY)*_;T/&S&5!55[2+;MT?FSI_
M^%3Z[_S]Z=_W\?\ ^(H_X5/KO_/WIW_?Q_\ XBN8_P"$DUW_ *#6H_\ @4_^
M-'_"2:[_ -!K4?\ P*?_ !KNY,7_ #K[CS_:83^1_>=/_P *GUW_ )^]._[^
M/_\ $4?\*GUW_G[T[_OX_P#\17,?\))KO_0:U'_P*?\ QH_X237?^@UJ/_@4
M_P#C1R8O^=?<'M,)_(_O.G_X5/KO_/WIW_?Q_P#XBC_A4^N_\_>G?]_'_P#B
M*YC_ (237?\ H-:C_P"!3_XT?\))KO\ T&M1_P# I_\ &CDQ?\Z^X/:83^1_
M>=/_ ,*GUW_G[T[_ +^/_P#$4?\ "I]=_P"?O3O^_C__ !%<Q_PDFN_]!K4?
M_ I_\:/^$DUW_H-:C_X%/_C1R8O^=?<'M,)_(_O.G_X5/KO_ #]Z=_W\?_XB
MC_A4^N_\_>G?]_'_ /B*YC_A)-=_Z#6H_P#@4_\ C1_PDFN_]!K4?_ I_P#&
MCDQ?\Z^X/:83^1_>=/\ \*GUW_G[T[_OX_\ \11_PJ?7?^?O3O\ OX__ ,17
M,?\ "2:[_P!!K4?_  *?_&C_ (237?\ H-:C_P"!3_XT<F+_ )U]P>TPG\C^
M\Z?_ (5/KO\ S]Z=_P!_'_\ B*/^%3Z[_P _>G?]_'_^(KF/^$DUW_H-:C_X
M%/\ XT?\))KO_0:U'_P*?_&CDQ?\Z^X/:83^1_>=/_PJ?7?^?O3O^_C_ /Q%
M'_"I]=_Y^]._[^/_ /$5S'_"2:[_ -!K4?\ P*?_ !H_X237?^@UJ/\ X%/_
M (T<F+_G7W![3"?R/[SI_P#A4^N_\_>G?]_'_P#B*/\ A4^N_P#/WIW_ '\?
M_P"(KF/^$DUW_H-:C_X%/_C1_P ))KO_ $&M1_\  I_\:.3%_P Z^X/:83^1
M_>=/_P *GUW_ )^]._[^/_\ $4?\*GUW_G[T[_OX_P#\17,?\))KO_0:U'_P
M*?\ QH_X237?^@UJ/_@4_P#C1R8O^=?<'M,)_(_O.G_X5/KO_/WIW_?Q_P#X
MBC_A4^N_\_>G?]_'_P#B*YC_ (237?\ H-:C_P"!3_XT?\))KO\ T&M1_P#
MI_\ &CDQ?\Z^X/:83^1_>=/_ ,*GUW_G[T[_ +^/_P#$4?\ "I]=_P"?O3O^
M_C__ !%<Q_PDFN_]!K4?_ I_\:/^$DUW_H-:C_X%/_C1R8O^=?<'M,)_(_O.
MG_X5/KO_ #]Z=_W\?_XBC_A4^N_\_>G?]_'_ /B*YC_A)-=_Z#6H_P#@4_\
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M*/\ A4^N_P#/WIW_ '\?_P"(KF/^$DUW_H-:C_X%/_C1_P ))KO_ $&M1_\
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MYC_A)-=_Z#6H_P#@4_\ C1_PDFN_]!K4?_ I_P#&CDQ?\Z^X/:83^1_>=/\
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M6:/\Z^]!]6K_ ,C^YG,45T__  KSQ3_T"_\ R8B_^*H_X5YXI_Z!?_DQ%_\
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MQ3_T"_\ R8B_^*H_X5YXI_Z!?_DQ%_\ %4?6:/\ .OO0?5J_\C^YG,45T_\
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M_P \GWJS7SV+Q<L1+RZ(^CPF$CAX]WU84445R'6%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7A/_-4O^XU_[7KW:O"?^:I?]QK_ -KUZF6_\O/0\O,_^7?J>[4445Y9
MZ@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU(QP/>H8XWFD6.)&=V.%51DD^PH^IX;^5!]<Q/\ ,SN?^%L:[_SZ:=_W[?\
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M7_Y_/\?\SPG_ (6'XI_Z"G_DO%_\31_PL/Q3_P!!3_R7B_\ B:]VHH^OT?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/,WE[8XD+,<2*3@#GI7C'_"-Z[_T!=1_\!7_ ,*]I_X3?P[_ -!#_P @R?\
MQ-'_  F_AW_H(?\ D&3_ .)KNPN.EAX."5];G!BL!'$34V[:6/%O^$;UW_H"
MZC_X"O\ X4?\(WKO_0%U'_P%?_"O:?\ A-_#O_00_P#(,G_Q-'_";^'?^@A_
MY!D_^)KI_M>?\J.;^QX?S,\6_P"$;UW_ * NH_\ @*_^%'_"-Z[_ - 74?\
MP%?_  KVG_A-_#O_ $$/_(,G_P 31_PF_AW_ *"'_D&3_P")H_M>?\J#^QX?
MS,\6_P"$;UW_ * NH_\ @*_^%'_"-Z[_ - 74?\ P%?_  KVG_A-_#O_ $$/
M_(,G_P 31_PF_AW_ *"'_D&3_P")H_M>?\J#^QX?S,\6_P"$;UW_ * NH_\
M@*_^%'_"-Z[_ - 74?\ P%?_  KVG_A-_#O_ $$/_(,G_P 31_PF_AW_ *"'
M_D&3_P")H_M>?\J#^QX?S,\6_P"$;UW_ * NH_\ @*_^%'_"-Z[_ - 74?\
MP%?_  KVG_A-_#O_ $$/_(,G_P 31_PF_AW_ *"'_D&3_P")H_M>?\J#^QX?
MS,\6_P"$;UW_ * NH_\ @*_^%'_"-Z[_ - 74?\ P%?_  KVG_A-_#O_ $$/
M_(,G_P 31_PF_AW_ *"'_D&3_P")H_M>?\J#^QX?S,\6_P"$;UW_ * NH_\
M@*_^%'_"-Z[_ - 74?\ P%?_  KVG_A-_#O_ $$/_(,G_P 31_PF_AW_ *"'
M_D&3_P")H_M>?\J#^QX?S,\6_P"$;UW_ * NH_\ @*_^%'_"-Z[_ - 74?\
MP%?_  KVG_A-_#O_ $$/_(,G_P 31_PF_AW_ *"'_D&3_P")H_M>?\J#^QX?
MS,\6_P"$;UW_ * NH_\ @*_^%'_"-Z[_ - 74?\ P%?_  KVG_A-_#O_ $$/
M_(,G_P 31_PF_AW_ *"'_D&3_P")H_M>?\J#^QX?S,\6_P"$;UW_ * NH_\
M@*_^%'_"-Z[_ - 74?\ P%?_  KVG_A-_#O_ $$/_(,G_P 31_PF_AW_ *"'
M_D&3_P")H_M>?\J#^QX?S,\6_P"$;UW_ * NH_\ @*_^%'_"-Z[_ - 74?\
MP%?_  KVG_A-_#O_ $$/_(,G_P 31_PF_AW_ *"'_D&3_P")H_M>?\J#^QX?
MS,\6_P"$;UW_ * NH_\ @*_^%'_"-Z[_ - 74?\ P%?_  KVG_A-_#O_ $$/
M_(,G_P 31_PF_AW_ *"'_D&3_P")H_M>?\J#^QX?S,\6_P"$;UW_ * NH_\
M@*_^%'_"-Z[_ - 74?\ P%?_  KVG_A-_#O_ $$/_(,G_P 31_PF_AW_ *"'
M_D&3_P")H_M>?\J#^QX?S,\6_P"$;UW_ * NH_\ @*_^%'_"-Z[_ - 74?\
MP%?_  KVG_A-_#O_ $$/_(,G_P 31_PF_AW_ *"'_D&3_P")H_M>?\J#^QX?
MS,\6_P"$;UW_ * NH_\ @*_^%'_"-Z[_ - 74?\ P%?_  KVG_A-_#O_ $$/
M_(,G_P 31_PF_AW_ *"'_D&3_P")H_M>?\J#^QX?S,\6_P"$;UW_ * NH_\
M@*_^%'_"-Z[_ - 74?\ P%?_  KVG_A-_#O_ $$/_(,G_P 31_PF_AW_ *"'
M_D&3_P")H_M>?\J#^QX?S,\6_P"$;UW_ * NH_\ @*_^%'_"-Z[_ - 74?\
MP%?_  KVG_A-_#O_ $$/_(,G_P 31_PF_AW_ *"'_D&3_P")H_M>?\J#^QX?
MS,\6_P"$;UW_ * NH_\ @*_^%'_"-Z[_ - 74?\ P%?_  KVG_A-_#O_ $$/
M_(,G_P 31_PF_AW_ *"'_D&3_P")H_M>?\J#^QX?S,\6_P"$;UW_ * NH_\
M@*_^%'_"-Z[_ - 74?\ P%?_  KVG_A-_#O_ $$/_(,G_P 31_PF_AW_ *"'
M_D&3_P")H_M>?\J#^QX?S,\6_P"$;UW_ * NH_\ @*_^%'_"-Z[_ - 74?\
MP%?_  KVG_A-_#O_ $$/_(,G_P 31_PF_AW_ *"'_D&3_P")H_M>?\J#^QX?
MS,\6_P"$;UW_ * NH_\ @*_^%'_"-Z[_ - 74?\ P%?_  KVG_A-_#O_ $$/
M_(,G_P 31_PF_AW_ *"'_D&3_P")H_M>?\J#^QX?S,\6_P"$;UW_ * NH_\
M@*_^%'_"-Z[_ - 74?\ P%?_  KVG_A-_#O_ $$/_(,G_P 31_PF_AW_ *"'
M_D&3_P")H_M>?\J#^QX?S,\6_P"$;UW_ * NH_\ @*_^%'_"-Z[_ - 74?\
MP%?_  KVG_A-_#O_ $$/_(,G_P 31_PF_AW_ *"'_D&3_P")H_M>?\J#^QX?
MS,\6_P"$;UW_ * NH_\ @*_^%'_"-Z[_ - 74?\ P%?_  KVG_A-_#O_ $$/
M_(,G_P 31_PF_AW_ *"'_D&3_P")H_M>?\J#^QX?S,\6_P"$;UW_ * NH_\
M@*_^%'_"-Z[_ - 74?\ P%?_  KVG_A-_#O_ $$/_(,G_P 31_PF_AW_ *"'
M_D&3_P")H_M>?\J#^QX?S,\6_P"$;UW_ * NH_\ @*_^%6=.\':]J%]%;?V9
M=6X<\RSPLB(.Y)(_2O8/^$W\._\ 00_\@R?_ !-'_";^'?\ H(?^09/_ (FD
M\VJ-:10XY133NY,M^'_#]EX=TU;2T7+'F64CYI&]3_0=JU:Y_P#X3?P[_P!!
M#_R#)_\ $T?\)OX=_P"@A_Y!D_\ B:\J4G)\TMSUHQ45RQV.@HKG_P#A-_#O
M_00_\@R?_$T?\)OX=_Z"'_D&3_XFD,Z"BN?_ .$W\._]!#_R#)_\31_PF_AW
M_H(?^09/_B: .@HKG_\ A-_#O_00_P#(,G_Q-'_";^'?^@A_Y!D_^)H Z"BN
M?_X3?P[_ -!#_P @R?\ Q-'_  F_AW_H(?\ D&3_ .)H Z"BN?\ ^$W\._\
M00_\@R?_ !-'_";^'?\ H(?^09/_ (F@#H**Y_\ X3?P[_T$/_(,G_Q-'_";
M^'?^@A_Y!D_^)H Z"BN?_P"$W\._]!#_ ,@R?_$T?\)OX=_Z"'_D&3_XF@#H
M**Y__A-_#O\ T$/_ "#)_P#$T?\ ";^'?^@A_P"09/\ XF@#H**Y_P#X3?P[
M_P!!#_R#)_\ $T?\)OX=_P"@A_Y!D_\ B: .@HKG_P#A-_#O_00_\@R?_$T?
M\)OX=_Z"'_D&3_XF@#H**Y__ (3?P[_T$/\ R#)_\31_PF_AW_H(?^09/_B:
M .@HKG_^$W\._P#00_\ (,G_ ,31_P )OX=_Z"'_ )!D_P#B: .@HKG_ /A-
M_#O_ $$/_(,G_P 31_PF_AW_ *"'_D&3_P")H Z"BN?_ .$W\._]!#_R#)_\
M31_PF_AW_H(?^09/_B: .@HKG_\ A-_#O_00_P#(,G_Q-'_";^'?^@A_Y!D_
M^)H Z"BN?_X3?P[_ -!#_P @R?\ Q-'_  F_AW_H(?\ D&3_ .)H Z"BN?\
M^$W\._\ 00_\@R?_ !-'_";^'?\ H(?^09/_ (F@#H**Y_\ X3?P[_T$/_(,
MG_Q-'_";^'?^@A_Y!D_^)H Z"BN?_P"$W\._]!#_ ,@R?_$T?\)OX=_Z"'_D
M&3_XF@#H**Y__A-_#O\ T$/_ "#)_P#$T?\ ";^'?^@A_P"09/\ XF@#H**Y
M_P#X3?P[_P!!#_R#)_\ $T?\)OX=_P"@A_Y!D_\ B: .@HKG_P#A-_#O_00_
M\@R?_$T?\)OX=_Z"'_D&3_XF@#H**Y__ (3?P[_T$/\ R#)_\31_PF_AW_H(
M?^09/_B: .@HKG_^$W\._P#00_\ (,G_ ,31_P )OX=_Z"'_ )!D_P#B: .@
MHKG_ /A-_#O_ $$/_(,G_P 31_PF_AW_ *"'_D&3_P")H Z"BN?_ .$W\._]
M!#_R#)_\31_PF_AW_H(?^09/_B: .@HKG_\ A-_#O_00_P#(,G_Q-'_";^'?
M^@A_Y!D_^)H Z"BN?_X3?P[_ -!#_P @R?\ Q-'_  F_AW_H(?\ D&3_ .)H
M Z"BN?\ ^$W\._\ 00_\@R?_ !-'_";^'?\ H(?^09/_ (F@#H**Y_\ X3?P
M[_T$/_(,G_Q-'_";^'?^@A_Y!D_^)H Z"BN?_P"$W\._]!#_ ,@R?_$T?\)O
MX=_Z"'_D&3_XF@#H**Y__A-_#O\ T$/_ "#)_P#$T?\ ";^'?^@A_P"09/\
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M-'_";^'?^@A_Y!D_^)H Z"BN?_X3?P[_ -!#_P @R?\ Q-'_  F_AW_H(?\
MD&3_ .)H Z"BN?\ ^$W\._\ 00_\@R?_ !-'_";^'?\ H(?^09/_ (F@#H**
MY_\ X3?P[_T$/_(,G_Q-'_";^'?^@A_Y!D_^)H Z"BN?_P"$W\._]!#_ ,@R
M?_$T?\)OX=_Z"'_D&3_XF@#H**Y__A-_#O\ T$/_ "#)_P#$T?\ ";^'?^@A
M_P"09/\ XF@#H**Y_P#X3?P[_P!!#_R#)_\ $T?\)OX=_P"@A_Y!D_\ B: .
M@HKG_P#A-_#O_00_\@R?_$T?\)OX=_Z"'_D&3_XF@#H**Y__ (3?P[_T$/\
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M]!#_ ,@R?_$T?\)OX=_Z"'_D&3_XF@#H**Q['Q3HVI7D=I:7GF3R9VKY3C.
M2>2,= :V* "BBB@ HHHH **** "BBB@ HHHH **** "H[B=;:VEG<$K$A<A>
MI &>*DJIJO\ R"+W_KA)_P"@FJBKR2)D[1;.>_X3;_J'_P#D;_[&C_A-O^H?
M_P"1O_L:R_#5C;:AJ,D5U'YB"$L!N(YR!V^M=5_PC.C_ //I_P"1'_QKTJJP
MM*7+*+_KYGF498NM'GC)?U\C)_X3;_J'_P#D;_[&C_A-O^H?_P"1O_L:UO\
MA&='_P"?3_R(_P#C1_PC.C_\^G_D1_\ &LO:8/\ D?\ 7S-?9XW^=?U\C)_X
M3;_J'_\ D;_[&C_A-O\ J'_^1O\ [&M;_A&='_Y]/_(C_P"-'_",Z/\ \^G_
M )$?_&CVF#_D?]?,/9XW^=?U\C)_X3;_ *A__D;_ .QH_P"$V_ZA_P#Y&_\
ML:UO^$9T?_GT_P#(C_XT?\(SH_\ SZ?^1'_QH]I@_P"1_P!?,/9XW^=?U\C)
M_P"$V_ZA_P#Y&_\ L:/^$V_ZA_\ Y&_^QK6_X1G1_P#GT_\ (C_XT?\ ",Z/
M_P ^G_D1_P#&CVF#_D?]?,/9XW^=?U\C)_X3;_J'_P#D;_[&C_A-O^H?_P"1
MO_L:UO\ A&='_P"?3_R(_P#C1_PC.C_\^G_D1_\ &CVF#_D?]?,/9XW^=?U\
MC)_X3;_J'_\ D;_[&C_A-O\ J'_^1O\ [&M;_A&='_Y]/_(C_P"-'_",Z/\
M\^G_ )$?_&CVF#_D?]?,/9XW^=?U\C)_X3;_ *A__D;_ .QH_P"$V_ZA_P#Y
M&_\ L:UO^$9T?_GT_P#(C_XT?\(SH_\ SZ?^1'_QH]I@_P"1_P!?,/9XW^=?
MU\C)_P"$V_ZA_P#Y&_\ L:/^$V_ZA_\ Y&_^QK6_X1G1_P#GT_\ (C_XT?\
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M,/9XW^=?U\C)_P"$V_ZA_P#Y&_\ L:/^$V_ZA_\ Y&_^QK6_X1G1_P#GT_\
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M@_[^#_&C[?9?\_<'_?P?XUPE%'U*/</KLNQW?V^R_P"?N#_OX/\ &C[?9?\
M/W!_W\'^-<)11]2CW#Z[+L=W]OLO^?N#_OX/\:/M]E_S]P?]_!_C7"44?4H]
MP^NR['=_;[+_ )^X/^_@_P :/M]E_P _<'_?P?XUPE%'U*/</KLNQW?V^R_Y
M^X/^_@_QH^WV7_/W!_W\'^-<)11]2CW#Z[+L=W]OLO\ G[@_[^#_ !H^WV7_
M #]P?]_!_C7"44?4H]P^NR['=_;[+_G[@_[^#_&C[?9?\_<'_?P?XUPE%'U*
M/</KLNQW8O[,D 7<!). /,%6*\\KH=%UK&VTNW]HY"?T/^-8UL*X+FCJ;4<4
MIOEEH=%1117(=84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@5@_#KXBV_Q!M=0DCL6L9K.55,+R[RT;#*/G QG#<<].IS0!VU%<KX,\9_\
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M /KJO124(K9#=23W9;&HSC3FLCM,1.<D<CG/%5***:BEL)R;W"BBBF(****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HZD  DG@ =Z.I  ))X '>NIT;1OLP%S<J#.?NK_<_^O65:LJ:N
M]S6C1=1V6P:-HWV8"YN5!G/W5_N?_7K:HHKR9S<W=GKP@H+EB%%%%24%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML[/-S_3'^S71>*/AW!K$6C2Z-?R:)J.B@)8W,*;PD8 &QE)&X8&.3W.<@D4
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M "JFJ_\ ((O?^N$G_H)JW535?^01>_\ 7"3_ -!-73^-$5/@9R7@W_D+R_\
M7 _^A+7<5P_@W_D+R_\ 7 _^A+7<5TX_^,<F7_P?F%%%%<9W!1110 4444 %
M%%% !1110!'//';0M-,VV-<9."?;M5+^W=-_Y^?_ !QO\*-=_P"0-<?\!_\
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M_P *XVBCZG3[L/KM3LCLO[<TW('VD?BC?X5H@@@$'(/>O/*V=&UDVA%O<-F
M\*Q_@_\ K?RK*MA.57@;4<7S.TSJJ* 00"#D'O17$=H4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !535?^01>_]<)/_035NJ]]
M"]QI]S"F-\D3(N>F2"*J#M)-DS5XM(X_P;_R%Y?^N!_]"6NXKSS_ (1G6/\
MGS_\B)_C1_PC.L?\^G_D1/\ &O3KTJ5:?/[1+^O4\K#UJM&')[-O^O0]#HKS
MS_A&=8_Y]/\ R(G^-'_",ZQ_SZ?^1$_QK'ZI2_Y^K^OF;_7*O_/I_C_D>AT5
MYY_PC.L?\^G_ )$3_&C_ (1G6/\ GT_\B)_C1]4I?\_5_7S#ZY5_Y]/\?\CT
M.BO//^$9UC_GT_\ (B?XT?\ ",ZQ_P ^G_D1/\:/JE+_ )^K^OF'URK_ ,^G
M^/\ D>AT5YY_PC.L?\^G_D1/\:/^$9UC_GT_\B)_C1]4I?\ /U?U\P^N5?\
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M +]G_"C[!>_\^D__ '[/^%'/'N')+L5Z*L?8+W_GTG_[]G_"C[!>_P#/I/\
M]^S_ (4<\>X<DNQ7HJQ]@O?^?2?_ +]G_"C[!>_\^D__ '[/^%'/'N')+L5Z
M*L?8+W_GTG_[]G_"C[!>_P#/I/\ ]^S_ (4<\>X<DNQ7HJQ]@O?^?2?_ +]G
M_"C[!>_\^D__ '[/^%'/'N')+L5Z*L?8+W_GTG_[]G_"C[!>_P#/I/\ ]^S_
M (4<\>X<DNQ7IR(\DBQQJ6=CA5'4FI_[/O20!:3Y/_3,UT^DZ2EA'YDF&N&'
M)[*/05C6KQIK35FM&A*H]=$&DZ2EA'YDF&N&')[*/05IT45Y<I.3NSU8Q459
M!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !15>[O[6Q\C[5.L7GS+!%N_C=NBCWX-6*
M"BBB@ HHIBS1.[(DB,Z?>4,"1]: 'T444 %%%06M[;7R2/:SQS+'*\+E#D*Z
MG#*?<$$&@">BBB@ HHHH **:TL:$!W52>@)QFG4 %%%% !1110 444U)8Y,[
M'5L==IS0 ZBBB@ HHIH=&=D#*67&Y0>1GIF@!U%%% !1110 444TNBLJLRAF
M^Z">3]* '4444 %%%% !14%G>6VH6<5Y9SI/;3*'CEC.5<'N#4] !1137D2,
M NZJ#_>.* '44Q)8Y 2DBL!U(.<4J2)("4=6 _NG- #J**165@2K X.#@]Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&/EJ+P3<7NL^+_%.M7UJUL5:WL+>%R"T2(AD(;'&X^<"0.AX[4 ;'CV_?3?
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M2^0Z-$DBOT&/O$8YZ=:P+RYE\::MH]M:Z?J%OIEC=I?W=Q>VKV^YX\F.)%<
ML=^"2!@!>N365KEM?W/Q#U;P]IZNL6NZ?:R7ERIQ]FB1I4D_X$Z[57ZY_AH
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M70!.H!R#D#!J3PC VGZKJL^CVFIV_AA;56@M+N*1";@%BWD1R#>J;<<8 )/
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M*#S\N<#-<_#IE_I/A/P->7=A=S)9WAOM2@A@:26-Y8Y3N,8&X[7EY !(].*
M-^3Q7K]AJ^DZ?JOARWB.J7 BAEM;_P U8\*68/E%.X*I/ (.#R.\M]XNO?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8XP1W!([U;HH 155$5$4*JC 4#  I:** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "LVST:&RUO4]5621Y]0$0<-
MC"+&I"A?;EC]36E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
3!1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /2!6\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT5&+1VO!#*&'4@]&'452_P"&@?!A) BU7(Z_Z*/_ (JO39+*TEE,LEK"\C
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M .2A&1@>IR!CU- &O17C ^+WB^^TJ?Q!I?@=I/#\.YC/),=S(O5A@=!@Y(!
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M-;3C[KC#HPZJP[$?_JR.:NQ164]D5A2"2TG4Y" %)%(P>G!!%>':5J(^"GQ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF H[5[%X+OO&FIIJ">--#L-/0!!;BWD#B4'=O# ._3Y?3KWKI_L-G_SZP?\
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M^T:E<0^3&F]4X8A6.6('"ECUH \.T#QS*?B=KWC(>'M3U>*8M:V9M8B5C08
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M@LA^\T;PPI>3^ZTP(R/KOV@CN$->UUY]\(O!=YX1\,3R:O'LUG4)S-=9<.5
M)"J6!(/=NO\ $:ZKQ38ZKJ7AF_L]$U#[!J<D>+>Y/16!!P>#@$ C(&1G(Z4
M<'JOP%\+ZK>WUZ]]JZ7%W-).Q$ZE59F+'@KDC)[G/O67\+M0U;PKX[U+X;:E
M<I>6EI&9K.95P5!P^/H0^2#G![U8AU[XTZ?']CG\,:9J$JC:MUYBJ']R X'Z
M+6I\.O FM:;X@U+Q=XLN8I=<U!=@ABP5A3C()'!/"@ < #J<\ 'I=%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 45Y/KGQ]\.:)KE[I3:=J5P]G,
MT$DD:H%+J<-C+9QD&L__ (:1\.?] ;5?_(?_ ,50![117B__  TCX<_Z VJ_
M^0__ (JC_AI'PY_T!M5_\A__ !5 'M%%>+_\-(^'/^@-JO\ Y#_^*H_X:1\.
M?] ;5?\ R'_\50![117B_P#PTCX<_P"@-JO_ )#_ /BJ/^&D?#G_ $!M5_\
M(?\ \50![117B_\ PTCX<_Z VJ_^0_\ XJC_ (:1\.?] ;5?_(?_ ,50![11
M7B__  TCX<_Z VJ_^0__ (JC_AI'PY_T!M5_\A__ !5 'M%%>+_\-(^'/^@-
MJO\ Y#_^*H_X:1\.?] ;5?\ R'_\50![117B_P#PTCX<_P"@-JO_ )#_ /BJ
M/^&D?#G_ $!M5_\ (?\ \50![117B_\ PTCX<_Z VJ_^0_\ XJC_ (:1\.?]
M ;5?_(?_ ,50![117B__  TCX<_Z VJ_^0__ (JC_AI'PY_T!M5_\A__ !5
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MTCX<_P"@-JO_ )#_ /BJ/^&D?#G_ $!M5_\ (?\ \50![117B_\ PTCX<_Z
MVJ_^0_\ XJC_ (:1\.?] ;5?_(?_ ,50![117B__  TCX<_Z VJ_^0__ (JC
M_AI'PY_T!M5_\A__ !5 'M%%>+_\-(^'/^@-JO\ Y#_^*H_X:1\.?] ;5?\
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M5?\ R'_\50![117B_P#PTCX<_P"@-JO_ )#_ /BJ/^&D?#G_ $!M5_\ (?\
M\50![117B_\ PTCX<_Z VJ_^0_\ XJC_ (:1\.?] ;5?_(?_ ,50![117B__
M  TCX<_Z VJ_^0__ (JC_AI'PY_T!M5_\A__ !5 'M%%>+_\-(^'/^@-JO\
MY#_^*H_X:1\.?] ;5?\ R'_\50![117B_P#PTCX<_P"@-JO_ )#_ /BJ/^&D
M?#G_ $!M5_\ (?\ \50![117B_\ PTCX<_Z VJ_^0_\ XJC_ (:1\.?] ;5?
M_(?_ ,50![117B__  TCX<_Z VJ_^0__ (JC_AI'PY_T!M5_\A__ !5 'M%%
M>+_\-(^'/^@-JO\ Y#_^*H_X:1\.?] ;5?\ R'_\50![117B_P#PTCX<_P"@
M-JO_ )#_ /BJ/^&D?#G_ $!M5_\ (?\ \50![117B_\ PTCX<_Z VJ_^0_\
MXJC_ (:1\.?] ;5?_(?_ ,50![117B__  TCX<_Z VJ_^0__ (JC_AI'PY_T
M!M5_\A__ !5 'M%%>+_\-(^'/^@-JO\ Y#_^*H_X:1\.?] ;5?\ R'_\50![
M117B_P#PTCX<_P"@-JO_ )#_ /BJ/^&D?#G_ $!M5_\ (?\ \50![117B_\
MPTCX<_Z VJ_^0_\ XJC_ (:1\.?] ;5?_(?_ ,50![117B__  TCX<_Z VJ_
M^0__ (JC_AI'PY_T!M5_\A__ !5 'M%%>+_\-(^'/^@-JO\ Y#_^*H_X:1\.
M?] ;5?\ R'_\50![117B_P#PTCX<_P"@-JO_ )#_ /BJ/^&D?#G_ $!M5_\
M(?\ \50![117B_\ PTCX<_Z VJ_^0_\ XJC_ (:1\.?] ;5?_(?_ ,50![11
M7B__  TCX<_Z VJ_^0__ (JC_AI'PY_T!M5_\A__ !5 'M%%>+_\-(^'/^@-
MJO\ Y#_^*H_X:1\.?] ;5?\ R'_\50![117B_P#PTCX<_P"@-JO_ )#_ /BJ
M/^&D?#G_ $!M5_\ (?\ \50![117B_\ PTCX<_Z VJ_^0_\ XJC_ (:1\.?]
M ;5?_(?_ ,50![117B__  TCX<_Z VJ_^0__ (JC_AI'PY_T!M5_\A__ !5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_1K5A4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !10*7%.P"44M
M%'*P$HI:*+ )12XI<4U!@-HIVVC;5>SD*XVBG8HQ2=-H=QM%+BC%38!**6BB
MP"44M%'* E%+1Q18!****0!1110 4444 %%%% !1110 4444 %%%% !1110
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M,I5G0-)+[25[UV4.E[$^[7T-.E&FK3/G,;F'++E3.-ET0[>%K'O=&90?DKU
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MOFJ_&F%H5'",=$>'"OF6)3G".AXP/"30]C^56(=""<-7IL]KL)#H/RK.N;-
M<JHYKW<MXDH8M7BCSZF.KQER5-&<8FC*.U2?V.I%=)Y*@\XJ:&%6.,"O5EF/
M*N:QD\7/>YPMWH!DX _2LT^"996R%/Y5ZTEI$N"5&:MQVC,/D0 ?2O"QO%>'
MP_Q+4WH8_$R]VDKGB\W@B:-#\I_*N7U31)+1CP>*^CIH-N1(HKS3QA;1J[X
M[UUY5FM#-(OE5K'?A,RK^V]G51Y"R\D5&15Z]3;.V.F:I$5EBJ7++0^JA*ZN
M-HHHK@9H(:*#14 %%%% !1110 4444 %%%% !1110 4444 %%%% !12T4 %*
M*3%*,5J@"EQ0 :LV]I)<.%1"3712HRJ/0B4DE=D*J3TKJ/#FBO=3*=N<XJ;2
MO"5Q.ZLT38KU#PWX<CL8@TD>&%>GS4L%3=6HSP\RS.G3@XP=V6='T1;>%=P
MQ6P;1 G JQMP.F!2$X4YKY5YS5Q-?W7H?&U9SD^:15CA0/@BK9B0KC;67)=!
M7SGO5F&\WX&<UZ%:C7:4TR)0EN8>OZ8)8FPO?^E>0Z_I;P2L0O2O?;B#[0AX
MS7%>(/#AEB=A&<D=J]C XF-6E[.;U/9RK'^RDHR9XHRX.#3,5NZOI$EI*WR$
M<UBLN*Y<5A7!W/M:56,XW1'24[%! Q7FO<V&T4II*D HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "E%)1F@!:**45I'408I0*DCB:1@JJ2:Z;2/
M!]YJ.UO+.#ZUW4<+*2YGHC&MB*=%7F['-)&SG %:EEIAD8%J[^U^'LT:C*"I
MF\-M9M@IP*]7#4J'V9)GD5<WI2]V#.;M]'&P?2K TG:>!7206H3C%7X[-#@D
M"O3=-1W/-GCI7.472OEY%4[S35"UWS62;/E7FLJ\TQG^ZM0G3DG8FEC;RW/,
MKK3B&XJ@]G(I^[FO4(?"\MS(,Q\?2MB/P)$T8R%!]Z\S&2PM&WM9I7/06<4Z
M>C9X@T97@BH\<UZSK/P_9(F>-5. >E>;ZCILMA,R2+C%<52A3G'FHNZ\CTL+
MCZ6)^%ZF:>M%*1S25Y\E8[Q****S8 :2E-)4#"O6?V>/^2D3?]@Z7_T-*\FK
MUG]GC_DI$W_8.E_]#2@#ZFHHHH **** "BBB@#X=\;?\C[XB_P"PI<_^C6K"
MK=\;?\C[XB_["ES_ .C6K"H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*6DI:: ***6M$(4"K%O;M/(%4=Z@6MG1(B\XX[BO2P5)3DC&M/D@V=KX4\+B
M65'9 1FO5;'3(X46.*,9 ]*PO#$!C@!VUVNEJ#)DU\YQ=FE3#+V5)V/C5S8[
M%^SF]" Z=.JYV\51FME)*NHS7:NJ^5VZ5S&H*!,<>M?#9;G.+=5+F.W-\FHX
M2GSTV<[=V00Y'2J*PG=6S?$X%4%QGFOUW 8F<\.I2/GJ<WRC$MR36A;V8QDB
MH8SSQ6E$<QUQYABJD8-HSJ38T11CC;G\*CDLX9 0T8Y]JLI@&G2$5\,\XQD:
MZ49&\:*]GS7.#\3Z#&869$'0UY'JEF8)VXQS7OFO#-LRCN#7CGB"V/G.<'K7
MZ?@YRQ.$4I[GO9+B)?"V<F:::D=2#@BHS7F5X.+/JD[C:*4TVN)LI"TE%%2
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MSG%6KJ)%C.0,U^+5\ZK+$W@^IK1RKFH>T9YSXE\.17$+R*.>O2O'=9TTV<Y
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M44Z29":2EQ25X<XGHH::*4TE<[W&%%%%( HHHH **** "BBB@ HHHH ****
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M?4U][5?[B#\C[7)6^34HFFFG&FUX=1GT*&FDI325Q2W*"BBBD 4444 %%%%
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M2J),EHZG1IMDB8/>O5?#MTS*HSQBO&]$R9D';->T^"].EU*9;> J)/++#<<
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M%%% 'P[XV_Y'WQ%_V%+G_P!&M6%6[XV_Y'WQ%_V%+G_T:U85 !1110 4444
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MH_:19DF%O)1&4G&3E0">@_*MBT^,GCRSLEM4UQG5%V))+!')(H_WF4D_4YH
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MX:BLK:EWSQCD5#+-NSZ4UU*CFJK.*QHX:#E>),8)B2)NJNZ!:D:8 =:I7-R
MIYKW<-2FW8Z(1;T*&J78B1J\[UF_W,WXUT>MWA(8;JX#4)BTA&:]"H_9QY3Z
M;+,-U92E<R/FHC3R>*8>M>)7ES,^C2LAM)3B*2N*41C:*4TE8NXP-)2FDJ&,
M****0!1110 4444 %%%% !1110 "EI**=P%I:*!5Q0A:44E**Z8)"'KP<UTF
MA7IC=:YH5?L)=D@&:]7"3Y6<V(ASP:/8--O_ #(U%:HPW-<#I6HA /FKJ+74
ME< ;J].I34U>)\=B<-*$G9&LTGE$&K$.HA>#61+<JX^]5?SP#UK/^SX5%[YS
M>QYEJ=')>B0559P367'<M[TYKEA40RY0^$E4;:(O9%,E=5&:SS><\FJUW>XC
M.#71##6=V:QHR;L4M9N_W9 ]Z\ZU64O(:Z'5K[.>?6N2NI/,D)K#%5%:R/I\
MNH<BN5FZTPT\]:8:^>K;GLH,4E+1BN=H8E%%%3J E>L_L\?\E(F_[!TO_H:5
MY-7K/[/'_)2)O^P=+_Z&E9C/J:BBB@ HHHH **** /AWQM_R/OB+_L*7/_HU
MJPJW?&W_ "/OB+_L*7/_ *-:L*@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ [TZF]Z=6D "EI*6MHB%[4"BE%;1U)%!JQ;RE)!@U7%/4X.:ZZ,FF3)71
MW.A:@8I%RQZUZ7HVJH\:JS\&O#[&^\LCG!KJ=.UMXR/F_6O1JT*>*I\E0^;S
M# .IJCV19(V&5<&GC)[UYY:^)6 &7_6M*/Q-C^,?G7S-?A2#E>!X,L)7AHCL
M"0.6( JA=Z@D0^4USTGB+>/OC\ZS+W6-RG# _C7?E_#L*$N:H*G@ZDI>\7K[
M73&3\YKFM1\2,5(WG\ZRM2U(DGYJYBZO6=B,YKW.:%%6BCZ+"9;'1M%C4M5D
MN&(WDUD-DG)ZT$Y[TTFO*Q%5U'J>_2IQ@K(::#2FD->?-&HAI*4TE8-C"BBB
MH;&%(:6D-# ****D HHHH **** "BBB@ HHHH ?11BG 5VQC=DA3A1BE KLI
MTVB6R6W($E=;HMV8V&#Z5QP.*T[*^\LUZ.'GR,X\52]I$]CTC5&V@;A73V]R
MDRC)&:\9L-<V,.376:=X@!P,G\ZPQV6TL4KI:GR6,RZ2=TCT(KZ&FXK-L-26
M515R2\C1<U\AB<FE"I91/(:G%\I*["--S=*YW5M=$*LJLH&/6C5=954(R17G
M6LZKO<X8U]'E.44J$?:5%J>C@<"ZLKR'ZUK;S%AN[^M<3>2F60DFKEQ<;V/-
M4S"7/%>K5ESK0^PPU&-%:%0TVK36SJ.E0%2#7FU:,EJ=T9)C*2EQ1BN-Q:+&
M&DIS4VN2?Q%(****@ HHHH **** "BBB@ HHHH **** "E%)2BJCN ZBBBNE
M(D6BBEQ5JX"@FM"RNVB8"L\'%/5OF!KOH5'%F<XJ2LSO-+U9E YKL;'6@0,D
M?G7E-E.%Q\U;UK?8'#5ZL7":M,^?Q>!C)['I\6JJP'3\ZMPZDN1T_.O.8M2(
M'WZL+K7ECAZQJ9;1GL['CSRYO8]"FO49:S9KE?6N*D\1/_?-0-KS-_'4T<!2
MI=2J>6S1U=S?A >:P;[6=H(S6#=ZRS _.:YR[U%W<X8FNN52%-6B>GA<MN]3
M7U+4_,W5S4TAD<FFO*[GEC49->97Q',>]0H*DK(#24M)7#+4Z ---+336$V,
M#24M&*YV4(:2E-)6;W ****0!1110 4444 %%%% !1110 4444 **<*;2UM!
MB'4E%+BMEJ(4&I(W*,"*BIX-=5*31+1M6FH%",-6Y:ZJ1C#UQBDYXK0MW8$<
MUZU*J['!7PT7J=JFJD@9>K*:BIQEA7(QS$=34OV@]C73&L>=+"1.X@OXB.HI
M)]1B4=17&K>L@SG]:AGOB_&X_G5_6-#)8!.1TKZO'N^\*K76HH\9P17*/*^<
MY- G8#DFLG79U1P45JA=3N-Q.#6,Q)-6;I]SU5->9BIW/6HPY8C33:6DKRIL
MW04M-HK*XQ32445+8"5ZS^SQ_P E(F_[!TO_ *&E>35ZS^SQ_P E(F_[!TO_
M *&E9C/J:BBB@ HHHH **** /AWQM_R/OB+_ +"ES_Z-:L*MWQM_R/OB+_L*
M7/\ Z-:L*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ [TZF]Z=6D!,6E
MQ24M=,;""E%)2UI%"8M+FDHK>+$.#$5/'=R)CDU7%.Q6\926S)<4]S1BU1QP
M215R/5C_ 'S6#1DUO&O)&,L/!]#I1JY_O&FR:KN7[QKG=Q]32ESCJ:OZPV1]
M5A<N75V9#@&J#'-*33:Y:M1RT.B$%%604E+17,U<T&TAI32&N>:&A#24II*Y
M9#"BBBD,*0TM(:3 ****D HHHH **** "BBB@ HHHH DS2BFT\"O0IW;)8HI
M:DCB+=*5XRM>C&F[&=T19H#8H(IM9-N+&68KAT(P36]IVH%2,M7,@U9AF*$#
M/%==&LS"M14U8]0TS6PBC+UH7&N@IP]>:VUVR]ZLOJ#;>M=G/'=H\.>6Q<[F
MIJVLLQ;#UR-U>-*YYS2W=TSL1FJ(ZUS8C$-Z(]?"X:--$J.2_-;5C K@9%8L
M"%Y!75:=;$(#3PZ<MPQ4U%:$=Q9H$Z#I7.W<820XKK[M"(S7+7R?.3[UI7CH
M982;;U,XTAIQIIKQYQ/20QNU-IS]J;7F5?C9:"BBBLQA1110 4444 %%%% !
M1110 4444 %**2E%5'<!PI12"EKK@2**6D%+71&*8KA2@4N**WC"PKCT=E/%
M7X+ID')K.#8HW5TQJ)(SG!2-Q=1..M(U\Q[UC*&)XJ?!QR:U]HV8.A%%I[T_
MWJ9]M/K5)QS3*B51FBI1+4ET6Z&JK')S29II-85*FAK&*6P$TA-%&*XI7984
M48H-#T0"4AI:;6$V,6DHHK-C$-)2FDK"6XPHHHI %%%% !1110 4444 %%%%
M !2TE+30!2TE+6D1"BG4VE!KH@Q"XIP%(#2BNN"3)'=ZN6[_ "\U2J1)"OTK
MLIRMH1-71?,I'2@3FJGG CO2"0$UMS&/LRVTYQUJ SG/6C(I-H-*XU%(D20L
M>:G(4IG-42VPTOV@XP11<'![HCF^^:A-2,<G-,-<E;4WCHAAIM.-(:\Z:+0V
MBE-)7.QA1114W&)7K/[/'_)2)O\ L'2_^AI7DU>L_L\?\E(F_P"P=+_Z&E0!
M]34444 %%%% !1110!\.>-2&\=^(2.AU.Y/_ )%:L.MOQE_R/'B#_L)7'_HQ
MJQ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C)HHIW8"Y-&3244<S[@
M+N/K1N/K244^>7<!=[>M&X^M)13]I/N%AV]O6C>WK3:*?M9_S,5D.WMZT>8W
MK3:*/;5/YG]X60[>WK1O;UIM%'MJG\S^\+(=O;UI-[>M)12]I/NPL+O;UHWM
MZTE%'M)]V.PNX^M&3244N>3Z@&:***5V 4444@"BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>J?L^_\E-'
M_7E+_-:\KKU3]GW_ )*:/^O*7^:T ?5=%%% !1110 4444 ?#?C+_D>/$'_8
M2N/_ $8U8E;?C+_D>/$'_82N/_1C5B4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7JG[/O_)31
M_P!>4O\ -:\KKU3]GW_DIH_Z\I?YK0!]5T444 %%%% !1110!\-^,O\ D>/$
M'_82N/\ T8U8E;?C+_D>/$'_ &$KC_T8U8E !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9+I^KRH':TMK-K@6^>1O8'KCMQ^(YK6F\*>'- \8^ O$NBW<[:)JU[&Z179
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M"%2_!>UNSIWC6[56^QKHLL;MC@R$$J/K@-^= 'DU%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 :?A[^QQKUJ=?^T'2E8M<+;?ZQ@%)"CZG
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MFT1OD@J#D[@".O'TKCZ]7^.4%Q;7WA6"\S]IBT2))L]=X)#?KFO** "BBB@
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M"BDD$Y8\_,?3Z4GA#Q7=^#->36;"UM+BZCC9$%TC,J;A@L-K*<XR.O<UA44
M2W5S->7<UU<.7FFD:21SU9B<D_F:W_!WC;4_!-[=W&G16LZW<!@F@NT9XW4G
M/(# YZCKW-<W10!T-[XPO[WP79>%7M[5-/L[EKJ)T5O,W-NX)+$8^<]L].:S
M-&U>]T'6+75=/E,5W:R"2-O?T/J",@CN#5&B@#M[KXHZQ>>/;7QA/8:8VH6T
M7E1Q&*3R1PP#8WYS\Q[^E<GJFI7.L:M=ZE>,&N;N9II".FYCDX]N:J44 =!X
M.\8ZGX'ULZII:P/*T30O'<*61U.#@@$'J >O:HM"\47WASQ5'XATR*WBN(Y'
M=8=K>4 P(*8SG;@XZY]ZQ** -GQ3XFO_ !?K\^L:D(EGE55\N%2L:*H  4$D
M@<>O4FM'P5X^U/P+)?MIUI87(OHUCF2\C9UVC/ "LO7)SG-<K10!Z=_PN_5O
M^A6\)_\ @O?_ ..5C:K\2KS5];TG5+C0- 1],=GCAAM72*1CC!D ?+8*@CD>
M^:XJB@#8\4>)M2\7:]/K&JR*UQ+@!4!"1J.BJ"3@#Z^IZFK_ (2\=ZKX.COX
M+.*TNK._B\JXM+Q&>)QTS@,#G!(Z]#]*YBB@#T'P]\7M7\-^'(]"M-%T*:Q2
M1Y-MS;R2%BS%N?WF#C( XZ 5:F^-6JS021'PQX54.I4E;!@1D=OWE>:44 %3
MV=TUE?6]VBH[P2+(JN,J2IS@X[<5!10!M>*_%%_XQ\0W&M:BD"7$RHI2!2$4
M*H48!)/;/7J34/A_Q#J?A?6(=5TFY,%U%D XR&4]58'@@UET4 >CO\8]3A$\
MVE>'O#VE:C<*1+?V=EMFYZD$DXS[YKD/#WB6^\.>)K?7[=8KB]A=W'VH,ZNS
M*5);!!/WB>O6L>B@"YJVI3:SK-]JEPD:37D[W$BQ A0SL6( ))QD^M4Z** "
MBBB@ HHHH **** "NK\*^/\ 5/"UC<Z:EO9:CI5T=TUAJ$/FQ%N/F R,'@?D
M..!7*44 =9XJ^(&I^*;&VTPVUEINDVK;H;"PB\N(-_>(SR>3^9]:Y.BB@#?U
M#Q=?ZEX0TGPU-#;+9:8\CPNBL)&+DD[B6P?O'H!1%XNOXO \WA-8;8V$UV+Q
MI"K>:'P!@'=C'RCM^-8%% &]H_BV_P!$\.ZUHEM#;/;:NJ+</(K%U"$D;2&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M>J?L^_\ )31_UY2_S6O*Z]4_9]_Y*:/^O*7^:T ?5=%%% !1110 4444 ?#?
MC+_D>/$'_82N/_1C5B5M^,O^1X\0?]A*X_\ 1C5B4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7JG[/O\ R4T?]>4O\UKRNO5/V??^2FC_ *\I?YK0!]5T444 %%%% !1110!\
M-^,O^1X\0?\ 82N/_1C5B5M^,O\ D>/$'_82N/\ T8U8E !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/_@N_P#MM'_#,R_]#:?_  7?_;: /GZBOH'_ (9F7_H;3_X+O_MM'_#,R_\
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M .VT?\,S+_T-I_\ !=_]MH ^?J*^@?\ AF9?^AM/_@N_^VT?\,S+_P!#:?\
MP7?_ &V@#Y^HKZ!_X9F7_H;3_P""[_[;1_PS,O\ T-I_\%W_ -MH ^?J*^@?
M^&9E_P"AM/\ X+O_ +;1_P ,S+_T-I_\%W_VV@#Y^HKZ!_X9F7_H;3_X+O\
M[;1_PS,O_0VG_P %W_VV@#Y^HKZ!_P"&9E_Z&T_^"[_[;1_PS,O_ $-I_P#!
M=_\ ;: /GZBOH'_AF9?^AM/_ (+O_MM'_#,R_P#0VG_P7?\ VV@#Y^HKZ!_X
M9F7_ *&T_P#@N_\ MM'_  S,O_0VG_P7?_;: /GZBOH'_AF9?^AM/_@N_P#M
MM'_#,R_]#:?_  7?_;: /GZBOH'_ (9F7_H;3_X+O_MM'_#,R_\ 0VG_ ,%W
M_P!MH ^?J*^@?^&9E_Z&T_\ @N_^VT?\,S+_ -#:?_!=_P#;: /GZBOH'_AF
M9?\ H;3_ ."[_P"VT?\ #,R_]#:?_!=_]MH ^?J*^@?^&9E_Z&T_^"[_ .VT
M?\,S+_T-I_\ !=_]MH ^?J*^@?\ AF9?^AM/_@N_^VT?\,S+_P!#:?\ P7?_
M &V@#Y^HKZ!_X9F7_H;3_P""[_[;1_PS,O\ T-I_\%W_ -MH ^?J*^@?^&9E
M_P"AM/\ X+O_ +;1_P ,S+_T-I_\%W_VV@#Y^HKZ!_X9F7_H;3_X+O\ [;1_
MPS,O_0VG_P %W_VV@#Y^HKZ!_P"&9E_Z&T_^"[_[;1_PS,O_ $-I_P#!=_\
M;: /GZBOH'_AF9?^AM/_ (+O_MM'_#,R_P#0VG_P7?\ VV@#Y^HKZ!_X9F7_
M *&T_P#@N_\ MM'_  S,O_0VG_P7?_;: /GZBOH'_AF9?^AM/_@N_P#MM'_#
M,R_]#:?_  7?_;: /GZBOH'_ (9F7_H;3_X+O_MM'_#,R_\ 0VG_ ,%W_P!M
MH ^?J*^@?^&9E_Z&T_\ @N_^VT?\,S+_ -#:?_!=_P#;: /GZBOH'_AF9?\
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MKZ!_X9F7_H;3_P""[_[;1_PS,O\ T-I_\%W_ -MH ^?J*^@?^&9E_P"AM/\
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M_P"VT?\ #,R_]#:?_!=_]MH ^?J*^@?^&9E_Z&T_^"[_ .VT?\,S+_T-I_\
M!=_]MH ^?J*^@?\ AF9?^AM/_@N_^VT?\,S+_P!#:?\ P7?_ &V@#Y^HKZ!_
MX9F7_H;3_P""[_[;1_PS,O\ T-I_\%W_ -MH ^?J*^@?^&9E_P"AM/\ X+O_
M +;1_P ,S+_T-I_\%W_VV@#Y^HKZ!_X9F7_H;3_X+O\ [;1_PS,O_0VG_P %
MW_VV@#Y^HKZ!_P"&9E_Z&T_^"[_[;1_PS,O_ $-I_P#!=_\ ;: /GZBOH'_A
MF9?^AM/_ (+O_MM'_#,R_P#0VG_P7?\ VV@#Y^KU3]GW_DIH_P"O*7^:UUO_
M  S,O_0VG_P7?_;:Z[X=_!NW\!Z_+J[:R^H3- 88T^S^4$R023\S9/&/Q- '
MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUZ)0 445&]Q#&Q5Y5##J": )**A^UV__ #V3\Z/M=O\ \]D_.@":BH?M=O\
M\]D_.C[7;_\ /9/SH FHJ'[7;_\ /9/SH^UV_P#SV3\Z )J*A^UV_P#SV3\Z
M/M=O_P ]D_.@":BH?M=O_P ]D_.C[7;_ //9/SH FHJ'[7;_ //9/SH^UV__
M #V3\Z )J*A^UV__ #V3\Z/M=O\ \]D_.@":BH?M=O\ \]D_.C[7;_\ /9/S
MH FHJ'[7;_\ /9/SH^UV_P#SV3\Z )J*A^UV_P#SV3\Z/M=O_P ]D_.@":BH
M?M=O_P ]D_.C[7;_ //9/SH FHJ'[7;_ //9/SH^UV__ #V3\Z )J*A^UV__
M #V3\Z/M=O\ \]D_.@":BH?M=O\ \]D_.C[7;_\ /9/SH FHJ'[7;_\ /9/S
MH^UV_P#SV3\Z )J*A^UV_P#SV3\Z/M=O_P ]D_.@":BH?M=O_P ]D_.C[7;_
M //9/SH FHJ'[7;_ //9/SH^UV__ #V3\Z )J*A^UV__ #V3\Z/M=O\ \]D_
M.@":BH?M=O\ \]D_.C[7;_\ /9/SH FHJ'[7;_\ /9/SH^UV_P#SV3\Z )J*
MA^UV_P#SV3\Z/M=O_P ]D_.@":BH?M=O_P ]D_.C[7;_ //9/SH FHJ'[7;_
M //9/SH^UV__ #V3\Z )J*A^UV__ #V3\Z/M=O\ \]D_.@":BH?M=O\ \]D_
M.C[7;_\ /9/SH FHJ'[7;_\ /9/SH^UV_P#SV3\Z )J*A^UV_P#SV3\Z/M=O
M_P ]D_.@":BH?M=O_P ]D_.C[7;_ //9/SH FHJ'[7;_ //9/SH^UV__ #V3
M\Z )J*A^UV__ #V3\Z/M=O\ \]D_.@":BH?M=O\ \]D_.C[7;_\ /9/SH FH
MJ'[7;_\ /9/SH^UV_P#SV3\Z )J*A^UV_P#SV3\Z/M=O_P ]D_.@":BH?M=O
M_P ]D_.C[7;_ //9/SH FHJ'[7;_ //9/SH^UV__ #V3\Z )J*A^UV__ #V3
M\Z/M=O\ \]D_.@":BH?M=O\ \]D_.C[7;_\ /9/SH FHJ'[7;_\ /9/SH^UV
M_P#SV3\Z )J*A^UV_P#SV3\Z/M=O_P ]D_.@":BH?M=O_P ]D_.C[7;_ //9
M/SH FHJ'[7;_ //9/SH^UV__ #V3\Z )J*A^UV__ #V3\Z5;F%V"K*A)Z &@
M"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBL'Q!XIM?#VI:)93V\TKZM=BUC:/&$..IR1QTXZ^F: -Z
MBBB@ HHHH **** *&N?\B_J7_7K+_P"@&O/-#TN;6OV<HM.MD+W$^DN(D'\3
MC)4?B0*]0DC26-HY$5T8%65AD$'J"*CM+2VL+6.UL[>*WMXAMCBA0(B#T '
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M2T4 )M7^Z/RHVK_='Y4M% ";5_NC\J-J_P!T?E2T4 )M7^Z/RHVK_='Y4M%
M";5_NC\J-J_W1^5+10 FU?[H_*H(%7S;C@??]/858J"#_77'^_\ T% $VU?[
MH_*C:O\ ='Y4M% ";5_NC\J-J_W1^5+10 FU?[H_*C:O]T?E2T4 )M7^Z/RH
MVK_='Y4M% ";5_NC\J-J_P!T?E2T4 )M7^Z/RHVK_='Y4M% ";5_NC\J@@5?
M-N.!]_T]A5BH(/\ 77'^_P#T% $VU?[H_*C:O]T?E2T4 )M7^Z/RHVK_ '1^
M5+10 FU?[H_*C:O]T?E2T4 )M7^Z/RHVK_='Y4M% ";5_NC\J-J_W1^5+10
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MB:T0/#S:G_IY<XCW;#Y0?MMW=<\4 <7I\GAF[O(]/M?C/XA,S,$023NJDGH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M444 %%%% !4$'^NN/]_^@J>H(/\ 77'^_P#T% $]%%% !1110 4444 %%%%
M!1110 4444 %00?ZZX_W_P"@J>H(/]=<?[_]!0!/1110 4444 %%%% !1110
M 4444 %%%% !4%I_J6_WV_G4]06G^I;_ 'V_G0!/1110 4444 %%%% !1110
M 4444 %%%% !4%I_J6_WV_G4]06G^I;_ 'V_G0!/1110 4444 %%%% !1110
M 4444 %%%% "-]P_2HK3_CTB_P!T5*WW#]*BM/\ CTB_W10!-1110 4444 %
M%%% !1110 4444 %%%% #9/]6_T-,M?^/6+_ '!_*GR?ZM_H:9:_\>L7^X/Y
M4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %<%\2[?6E.A:MX=TJ6_U73KMI(PI78$9"KJX)'#
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M<?\ =D_[]F@">BH/M<?]V3_OV:/M<?\ =D_[]F@">BH/M<?]V3_OV:/M<?\
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M<?\ =D_[]F@">BH/M<?]V3_OV:/M<?\ =D_[]F@">BH/M<?]V3_OV:/M<?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7.>,?$Z>&M-@"6$FHW]],+:SL8R
M 9W(Z$G@*!DDFNCKCO'NCZM<MH^NZ%!'=:EHMRTZVDC[1<1LI1U#'@-@\$T
M<;I>LZE:0>(-1/@'0_[:T6YA$L-C&BR>6R;V(DYRP&.GOP:]4T/6+7Q!H=EJ
MUD6-M=Q+*FX8(SV/N#P?I7CVE^(_%\>M>*'T[P'K"7VM31M ;N/RX8"(@A+N
M0 <$9XZUZIX.T$^&/"&EZ*T@D>T@".Z]"YY;'MDF@#<HHHH **** "BBB@ H
MHHH **** "J=M_R$K[ZI_P"@U<JG;?\ (2OOJG_H- %RBBB@ HHHH **** "
MBBB@ HHHH **** "H(/]=<?[_P#05/4$'^NN/]_^@H GHHHH **** "BBB@
MHHHH **** "BBB@ KG?#G_(:\2?]?R_^BDKHJYWPY_R&O$G_ %_+_P"BDH Z
M*BBB@ HHHH ***CDN((O]9-&G^\P%)M+5C2;V)**I/K&FQ_>OK?\) ?Y5%_;
M^F?PW)?_ '(V;^0K)XFBMYK[T6J-1[1?W&E16;_;=N?]7;WDG^Y;/_A1_:Y/
MW=,U _\ ;$#^9I?6J/25_P 1^PJ=C2HK-_M.Z;[FDW1_WF0?UH^W:B>FCO\
M\"N$']:/K,//_P !E_D'L9>7WK_,TJ@M/]2W^^W\ZJ?;-5/324'UNA_A4-M<
M:KY1V:?!C>W6X]_]VE]9AV?_ (#+_(/8R[K[U_F;%%9OG:P?^7.T'UG/_P 3
M1YFM?\^UD/K,W_Q-/ZQ'L_N8>Q?=?>C2HK-WZU_SQL/^_K__ !-&[6_^>6G_
M /?Q_P#XFCZPOY7]S#V3[K[S2HK-W:W_ ,\M/_[^/_\ $T;];_YXV'_?U_\
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MXO9DN,ET)**0$'H0:6J)$;[A^E16G_'I%_NBI6^X?I45I_QZ1?[HH FHHHH
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M<@=:H_M/[R)+:WC_ -7!&O\ NH!4M%%;));&;;>X4444Q!1110 5!:?ZEO\
M?;^=3U!:?ZEO]]OYT 3T444 %%%% !1110 4444 %%%% !1110 5!:?ZEO\
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MQX>^(.M>$A>7-SIBVD5_9+<RF1X S%70,>2N>1GI^9J3X;?\A/QO_P!C#/\
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M)S2:KJ]M\2?$>@:=X?\ ,NM*TS4$U&_U 1LL(,8.R)2<;BQ/..@P?6M'7O\
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M0 5!:?ZEO]]OYU/4%I_J6_WV_G0!/1110 4444 %%%% !1110 4444 %%%%
M!4%I_J6_WV_G4]06G^I;_?;^= $]%%% !1110 4444 %%%% !1110 4444 (
MWW#]*BM/^/2+_=%2M]P_2HK3_CTB_P!T4 34444 %%%% !1110 4444 %%%%
M !1110!BZQ+KNZ:&PL+.6W:,CS);@HV2.> I_G5#PW'XAL-/TZPGL;'[+%&J
M-,MRQ;:!UV[>OXUT\G^K?Z&F6O\ QZQ?[@_E0!+1110 4444 %%%% !1110
M4444 %%%% !17F>G6<OQ)U[7+K4[^]BT'3;U].M;"UN&A65H\;Y)&0@MDG@9
MX%'V:Y^'GCC0K2RU"\N/#^MR/:O:7<YE^S3!<HT;-D@'H1G\^, 'IE%><W4,
M_COX@ZOHUS?7=OH6AQPK);VLQB-U/(I;+,N#M4<;<]>:Z'P]X.B\,:E-)IVI
MZ@=.EBV_V?<S&:.-\@AT9B67C((R<Y]J .EHKR[P_I ^)9U'7]>O+YM.-W+;
MZ=86]T\,4<49V[SL(+.2">3_ /6WKK0YO"_@'Q+!%K%_=PBSN)+7[5)ODMQY
M1^4/U(!&1GI0!V=%<_X$EDF^'_AV65VDD?3;=F=SDL3&O)/>L;X<7$]Q=>,A
M--)((_$5RB;V)VJ F ,]![4 =S17D'@GPY=>+X=8?7=7O9=)M]6NHH+""X>(
M.?,)+2.I#,!D *" ,>];/A\77A'XE/X4%]=7>CW]@;VR6ZE,KV\BMM= QY*D
M<^WYD@'HU%</KWA+P]-?SZAXHUZ\9)G)ABN-3:VA@ [(JLO3U.35+X::E_Q/
M/%/A^WUAM6TS3);>2QN7G$Y"2H6*;P3N"E2/SH ]%HKR?3=(U'Q/\0_&-E<Z
MU>6^B6UW"7MK:9HY)6,0PN\'*H,'(7&2?:M'2[5_!GQ/L]!L;R[DT75K&65+
M6YG:;[/-&1DHS$D J>F>OX4 >CT5YS=0S^._B#J^C7-]=V^A:''"LEO:S&(W
M4\BELLRX.U1QMSUYK<TCP-;Z'/>166J:E_9=U;M"VGS7#2K&Q_CC=B64XR,9
MYSGM0!U5%<-\+=0NW\/76AZE,TNI:'=R6,SN26D4',;\]BI 'TIOP_GGU[6/
M$GBB2>1[.[O/LFGH7)000_+O4=/F;)_"@#NZ*Q/&%QJ=IX.U>XT9&?48[5VM
MPJ[CNQU [D=0/6N.\&>'O"NMV6GZSI.NZG/JD7ERW-P-3D:5G&"R2QL2 "<@
MC:.#QZT =EJ_B2#2-<T32Y8)))-6EDBC=2,(43<2:VJ\E\?^$]-NOB-X3DD>
M]#:E=SK/MO) !MAXV8;Y.G\.*Z#Q9I,'ACX4^(;?3)KM MK+(KRW+R.&([,Q
M)'2@#NJ*SO#[M)X;TMW8L[6<19F.23L')KD/AQJ3Q^$M=O;R:65;;5;YB78L
M0BMG S0!Z!7&>']4OKGXG^,=.FN9'L[2.Q-O"3\L9>-BV/J:P/"WA1O'/A^+
MQ-XDU/5#?:CNGMX[6]>%+*,DA!&JD#.W!)(.<_C4?@/2KV#Q]X]TK5]1>_E\
MBRA-UC9(\9C<*3C^(*0">Y&: /5J*X;X6ZA=OX>NM#U*9I=2T.[DL9G<DM(H
M.8WY[%2 /I3?A_//KVL>)/%$D\CV=W>?9-/0N2@@A^7>HZ?,V3^% '=T5A^,
MM+GUKP;JVGVDLD5U+;MY#1L582#YEY'/W@*Y:Y\:27'P-_X2*%V-]<6 @4J?
MF^TL?*X]Q(2?PH ]%JCK/]I_V/=_V-]G_M+RS]G^TY\O?VW8YQ7&_##4KBS\
M(ZAI>MW)>\\/W4UM<S.Q)9%^=7R><;3Q["L2REU!_@;XDU^YN+A;S5DNM03,
MAS"C9"*I[#: 1CUH ]$O]5FT+PC/JVJ1I+/969GN4MONLZIE@F>V0<9J[IE\
MFIZ59ZA&C(EU DRJW4!E# '\Z\_\8Z1;:Q\&A>WDER9[313-&4N'0,QA!.\
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M,JNI5E#*>H(R#2@ # X% 'F$FJP?#[XEZ[=ZT'@T37U@F@OA&S1Q31J5:-R
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M,-Q[UW%-"(K,P50S=2!R: .#^&O_ "$/&_\ V,=Q_P"@I1<?\E[LO^Q=D_\
M1XKOL 48&<]Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KSGXLV=D8- U760LNA:=J >_MV/#JRE5;;_'M
M8CY1DD$\&O1J\P^,<NE62^&=2UORY]-M-1WSV3C=YZE2,A3PQ7@X/49H 8FO
M?!4H"(O#&,<9TY ?U2O0]$ETN?1K6711;C363-N+= D>W_9  P*\\3X@?!XH
MI6725&. =+88_P#(=>AZ+>:;J&C6MWHYC.G2IN@,4>Q=OLN!C\J +]>,>/?^
M%3-XSO#XHOKU-93R_-6,W&U/W:[<;1@?+M/%>SUR6M?$;P;H.K3:;JVKPV]]
M#M\R)H78KE0PY"D="* /*[#3_@CK.K6UI:WNHSWMS*L,66NLLS$*!N(XY/4U
MZ]X5\#Z+X,%W_8\<Z?:MGF^;.TF=N[&,]/O&N U[QEX<\3>*?"T?@Z7[7KB:
MG&TD]O;NFRUY$H=BHRI'4>WY^Q4 %%%% !1110 4444 %4[;_D)7WU3_ -!J
MY5.V_P"0E??5/_0: +E%%% !1110 4444 %%%% !1110 4$@ DG '>FR2)%&
MTDC!$499B< "LD++K9W.&BTWLO1I_<^B^W>LJE7E]V*O)]/\^R-(0YM7HASW
M,^K.8K)VBM <270ZOZA/_BJM:?;16BS0P($C5^!^ JVB+&BHBA548  P *A@
M_P!=<?[_ /04J=+E?/-WE_6B[+^F$ZEURQT7];D]%%%;&84444 %%%% !111
M0 4444 %%%% !4$'^NN/]_\ H*GJ"#_77'^__04 3T444 %%%% !1110 444
M4 %%%% !1110 5!:?ZEO]]OYU/4%I_J6_P!]OYT 3T444 %%%% !1110 444
M4 %%%% !1110 5!:?ZEO]]OYU/4%I_J6_P!]OYT 3T444 %%%% !1110 444
M4 %%%% !1110 C?</TJ*T_X](O\ =%2M]P_2HK3_ (](O]T4 34444 %%%%
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MB;2]/\6:M>37/B.YN)+G/VYP8@)&"H(PV-@51P1T- 'J]%%% !1110 4444
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MQ)9I;6S?\N=H-Y2/_>/WF]\#C%==?+]L^/VEPSC='8Z#)=0 ]%D>7RV(]]M
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M6Z<#VH NT5!ONO\ GE'_ -]G_"C?=?\ /*/_ +[/^% $]%0;[K_GE'_WV?\
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MX](O]T4UGN=I_=1]/[Y_PJ.V:X%M'MCC*[1@E_\ ZU %RBH-]U_SRC_[[/\
MA1ONO^>4?_?9_P * )Z*@WW7_/*/_OL_X4;[K_GE'_WV?\* )Z*@WW7_ #RC
M_P"^S_A1ONO^>4?_ 'V?\* )Z*@WW7_/*/\ [[/^%&^Z_P">4?\ WV?\* )Z
M*@WW7_/*/_OL_P"%&^Z_YY1_]]G_  H GHJ#?=?\\H_^^S_A1ONO^>4?_?9_
MPH ED_U;_0TRU_X]8O\ <'\JC=KGRVS%'C!_C_\ K4VW:X%O'MCC(VC!+_\
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MH\N:*(=7*2*Y ]\ X]ZO:!XI3Q+#<+'I&KV+11@O]OLVA&XY^5<_>(QSCU%
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M5I_QZ1?[HJ5ON'Z5%:?\>D7^Z* )J*** "BBB@ HHHH **** "BBB@ HHHH
M;)_JW^AIEK_QZQ?[@_E3Y/\ 5O\ 0TRU_P"/6+_<'\J ):*** "BBB@ HHHH
M **** "BBB@ HHHH *YG4?#EU>?$'1?$"2PBUL+6>&1&)WL7QC'&,<<\UTU%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'N: .Q\0ZQ#X?\.ZCJ\^#'9V[RX/\1 X7\3@?C7!ZMKOB?0O@,VNW6H$Z_\
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M0 4444 %%%% !4%I_J6_WV_G4]06G^I;_?;^= $]%%% !1110 4444 %%%%
M!1110 4444 (WW#]*BM/^/2+_=%2M]P_2HK3_CTB_P!T4 34444 %%%% !11
M10 4444 %%%% !1110 V3_5O]#3+7_CUB_W!_*GR?ZM_H:9:_P#'K%_N#^5
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MW,*R1KM"[0>Q Z$'(/TKR'2_$?B^/6O%#Z=X#UA+[6IHV@-W'Y<,!$00EW(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,>%OB5X2TO[%IT7@LEV,D]Q,]TTL[GJ[MCDUT>N>&M?O+K0O$>GSZ=%XET^
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M_G4]06G^I;_?;^= $]%%% !1110 4444 %%%% !1110 4444 (WW#]*BM/\
MCTB_W14K?</TJ*T_X](O]T4 34444 %%%% !1110 4444 %%%% !1110 V3_
M %;_ $-,M?\ CUB_W!_*GR?ZM_H:9:_\>L7^X/Y4 2T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $)"@DD
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MQ*,":Y'TF- %VBJ7]FQ_\][K_O\ -1_9L?\ SWNO^_S4 7:*I?V;'_SWNO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM:M:M:7NMW[WGV9_O0Q=$5O]K&2?K7;4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %8]SXK\.V<(FN=>TR&(R-$'>[0 NIPRYSU&>1V[
MUL5X_P#"OPGH>KVOB>^U33;:^FDUFYMP;F,2!(P0<*#]W)8DD=>/2@#TN^\3
MZ#ID$$]_K6GVT5P T+S7**)!ZJ2>1[BM%;B%[<7"S1M 4WB4,"I7&<YZ8QWK
MR#X/^#]#U+P1>MJ=A#?NUW-:J]T@D:.)3@(A/W1DD\8Y.:YVQOKF7X!^%-,>
MXE2WU+65TZYD5L$0-+(2N?3@#Z<4 >U0>,O#%REP\/B+2I$MQNF9;R/$8R!D
MG/ R0,^IK/\ B!K-YI?A91I,XCU/4+F"RLI  V))' SSP<+N/X5QWQD\'>';
M+X7W=W9Z9:64^G^5Y$D$00X,BH5)'+ ACU[\UN7W_$X^(WA72AS#I5B^JSKV
M+$"*+\02Y_"@"WH6NZE=?%'Q-H5Q<^986%M:O;H44%6= 6)(&3D^M=5::II]
M_/<06=_:W$ULVR>.&97:)O1@#\IX/!]*\*\9:EXFL/B-XZ_X1NU=F:QM7N[F
M-@'@A6-=Q3_:(/'< $CU'4:Y<Z7X<_9_N[[P:S1VTUNA2X4_O29'5'=VZ[^2
M#Z$8XQP =_'XM\-RWDUG'K^F-<PAFDB%VFY H)8D9[ '/IWK4MKF"\MH[FUF
MCG@E4/'+$P974]""."*\Y\2^ ?"]K\);Z"#3K6,V>FO<0W:1@2^8D98.7QDY
M(Y]0<5TGPX_Y)MX<_P"P?#_Z"* -^]O[/3;1[J_NX+6W3[TL\@1%^I/%5]*U
M[2-<C>32=4L[Y4X<VTZR;?K@\?C7 ^([2#Q'\;=&T/58Q/I=EI3ZA':R#,<L
MQD*98?Q8 S@^GN<P^,M,L?"_C[P7J^BVL-C<WFH#3[E+9 BSPO@'<HX./7Z>
M@P 0W?C&^\2?$V?0]'\:Z=I&F6D</EO&L,[7LK8RBECR><87N.E>M5Y9X:T;
M2U^-_BU%TVS"V]O9R0 0+B)R@)9>.#GG(KOO$NMP^&_#6HZS/@I:0-(%)^\V
M/E7\3@?C0!YKXC^(NM:?X[N+BTF3_A%='N[:QU-?+4[GE#;GW8R-AV@@$<@>
MM>B^+M0N-+\%ZWJ-E($N;:PFFA? ;:RH2#@\'D5XSH+ZHWPPU#1+SP1KUY<Z
MUYMU<7J1IM>60[DD&3GC"'ZBNCT3Q#+KO[/^N0WFY=1TS3KJPNT?[P:.,@9]
M]N,^^: -7X3>/[OQ7ICZ=KOR:[;1K,V4"?:(' 9) !QT(!Q[>M:<'B#4W^-%
MSX>:X!TM-$%VL.Q>)?-5=V[&>A/&<5QDV@7T?PZ\(>-?#Z?\3S1M-A9XQ_R]
M6^P;XSZ\$D?4XYQ5OPGX@L?%'QM_MC3WW6]SX7#8/5&\]05/N#D4 =%\2/$.
MLZ<-(T3PS,D6NZK<,(F9%?9'&I9SA@1Z#GWJ30_$.I^,/A4-3TJX%OKC6K)G
MRU.VZ3@@J00 2.F. U<4GB6\O?B]K'B"U\.ZGK5EI<9TJT:S52L;@@RL22.<
MDCCL?I5GX<:S/I?Q*UW0KO2KS2;;62=3L;:\4*P?_EH!CCG!/T2@#N_AYXE?
MQ9X'T[5)V!NRABNAC&)4.UN.V<9Q[UGS>(-4U#XN0>'M-N!'IFG61N=3Q&K%
MW?B./)!*]0W&,@FLCP]<0^!_B'XKT6Z<0Z9>0G7;4GA5'2<#\1G'HM7_ (36
M4TVB7_BF^0K?>(;MKP@]4A!(B3Z 9(]F% '.>$[CXB>-+74;^U\:06,-OJ$U
MHL+:7%(<)@@YP.S?I7:^'=$\9V&JB;7?%T.J66P@VZ:='"=W8[EYX]*\V^&W
MAKQ#J^E:Q<Z5XQN='MQJ]PAMXK1)06&TELL<\Y Q[5Z?X9\.Z_HU[--JWBVX
MUF%X]J0RVJ1!&R#NRIYXR/QH Q4\3ZOX:^)!T/Q'="XTC5SNTB\,:IY<G>!M
MH&3R ">?N^IQ*?$NJ^)OB!_8WAVY$&D:0V=6O1&K^;)V@3<"/J1R.>F!G.^+
MUQ#K-MI_@JQMDNM=U*9);?)(^QHIR9R1R, ,/?YO3!=\';^"RTB[\(75HEEK
MFD3-]KB!YN QR)@3RV<@9^G0$"@"W<7OC+Q/XJU73]&OD\/Z5IC+%]KFL1/)
M=2$9.T.0NP=,C]<\6?!?B/69_$.M^%?$+6\^HZ5Y<BWENFQ9XG&02O\ "PXS
MCCGVR;GC+QO#X:,&G6-L^I>(+WBSTZ+[S?[;G^%!SR?0^A(H^%_#NH>$M&UC
M7]35M7\3:@#<W:P?QE1\D,?L.@_P H [>4.T+B-@LA4A6(R >QKS+5[?XC:'
MI-UJFH>-](BM+:,R2.=-' '8>I/0#N36_P"'?&6L:UJZV=[X,U72H2C,;FY(
MV CH.G>L3XA@^*/&?AOP.A)MG?\ M/4@.A@C.%4^S,"/KMH 9H?B3QS!\+I=
M>U"P.J:S=NK:?:0V^"L;8"M(%[=6/M@9&>&ZOJOC?P'!8ZSK>MV.L6$US'!>
M6B68A:'><9B9>6P?4<_R](N[ZRTV&-[RZM[6-G$2--($!8]%&>Y["O+_ (E^
M'K_2BWC=M4DU2#2YUN1H]]_Q[ 9"@H%(PPSD$@_TH ]9HJMI]XFHZ;:WL:LJ
M7$*3*K=0& (!_.K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7S[LCK@]5C!/_ V]4J;P1X@L='^#=AJU[./LEA;.C.ISN$;M& /4G: /4D4
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MEF!8J%(7;N_BSD 'H-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR222<#TK>HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>avxl-20210630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 8KlZs7xRiXgen8uCandcSauPicPtxJFzyZkhv2pyfXl6vy0gr5Xl8irweyzmQYsE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:avxl="http://anavex.com/20210630" elementFormDefault="qualified" targetNamespace="http://anavex.com/20210630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://anavex.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" id="InterimCondensedConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" id="InterimCondensedConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" id="InterimCondensedConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" id="InterimCondensedConsolidatedStatementsOfCashFlows">
	  <link:definition>00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" id="InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity">
	  <link:definition>00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" id="BusinessDescriptionAndBasisOfPresentation">
	  <link:definition>00000007 - Disclosure - Business Description and Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements">
	  <link:definition>00000008 - Disclosure - Recent Accounting Pronouncements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
	  <link:definition>00000009 - Disclosure - Other Income</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferings" id="EquityOfferings">
	  <link:definition>00000010 - Disclosure - Equity Offerings</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000011 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationPolicies" id="BusinessDescriptionAndBasisOfPresentationPolicies">
	  <link:definition>00000012 - Disclosure - Business Description and Basis of Presentation (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000013 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" id="BusinessDescriptionAndBasisOfPresentationDetailsNarrative">
	  <link:definition>00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
	  <link:definition>00000015 - Disclosure - Other Income (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" id="EquityOfferingsDetailsNarrative">
	  <link:definition>00000016 - Disclosure - Equity Offerings (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000017 - Disclosure - Commitments and Contingencies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
	  <link:definition>00000018 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" id="CommitmentsAndContingenciesDetails2">
	  <link:definition>00000019 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" id="CommitmentsAndContingenciesDetails3">
	  <link:definition>00000020 - Disclosure - Commitments and Contingencies (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" id="CommitmentsAndContingenciesDetails4">
	  <link:definition>00000021 - Disclosure - Commitments and Contingencies (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000022 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="avxl_ParkinsonMember" name="ParkinsonMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingSalesAgreementMember" name="EquityOfferingSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreement1Member" name="PurchaseAgreement1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrantsMember" name="PurchaseWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants1Member" name="PurchaseWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants2Member" name="PurchaseWarrants2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionsMember" name="OptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2019Member" name="StockOptionPlan2019Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CapitalStockValue" name="CapitalStockValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_WeightedAverageNumberOfSharesOutstanding" name="WeightedAverageNumberOfSharesOutstanding" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" name="CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" name="SharesIssuedPursuantToCashlessExerciseOfOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsShares" name="SharesIssuedPursuantToCashlessExerciseOfOptionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" name="SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" name="CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" name="SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares" name="SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPusuantToExerciseOfWarrants" name="SharesIssuedPusuantToExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUponExerciseOfOptionsShares" name="SharesIssuedUponExerciseOfOptionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPusuantToExerciseOfWarrantsShares" name="SharesIssuedPusuantToExerciseOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureOtherIncomeAbstract" name="DisclosureOtherIncomeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureEquityOfferingsAbstract" name="DisclosureEquityOfferingsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingAgreementsTextBlock" name="EquityOfferingAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" name="ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GrossProceedsFromSaleOfCommonStock" name="GrossProceedsFromSaleOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PercentageOfGrossProceedsFromSales" name="PercentageOfGrossProceedsFromSales" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ValueOfSharesObligatedToPurchase" name="ValueOfSharesObligatedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" name="NumberOfSharesObligatedToPurchaseProrataBasic" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues4" name="StockIssuedDuringPeriodSharesNewIssues4" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues3" name="StockIssuedDuringPeriodValueNewIssues3" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues3" name="StockIssuedDuringPeriodSharesNewIssues3" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues4" name="StockIssuedDuringPeriodValueNewIssues4" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>avxl-20210630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20210630.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20210630.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20210630.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20210630.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20210630.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20210630.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20210630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20210630.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20210630.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20210630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationPolicies" xlink:href="avxl-20210630.xsd#BusinessDescriptionAndBasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20210630.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20210630.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20210630.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_CapitalStockValue" xlink:label="loc_avxlCapitalStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_avxlCapitalStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000010 - Disclosure - Equity Offerings" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationPolicies" xlink:title="00000012 - Disclosure - Business Description and Basis of Presentation (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000013 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000015 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000016 - Disclosure - Equity Offerings (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000017 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000018 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000019 - Disclosure - Commitments and Contingencies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>avxl-20210630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20210630.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20210630.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20210630.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20210630.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20210630.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20210630.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20210630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20210630.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20210630.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20210630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationPolicies" xlink:href="avxl-20210630.xsd#BusinessDescriptionAndBasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20210630.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20210630.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20210630.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptions_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptionsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptionsShares_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" xlink:label="loc_avxlSharesIssuedUnderSalesAgreementNetOfShareIssueCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreementNetOfShareIssueCosts_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" xlink:label="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares" xlink:label="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPusuantToExerciseOfWarrants" xlink:label="loc_avxlSharesIssuedPusuantToExerciseOfWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPusuantToExerciseOfWarrants_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedUponExerciseOfOptionsShares" xlink:label="loc_avxlSharesIssuedUponExerciseOfOptionsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUponExerciseOfOptionsShares_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPusuantToExerciseOfWarrantsShares" xlink:label="loc_avxlSharesIssuedPusuantToExerciseOfWarrantsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPusuantToExerciseOfWarrantsShares_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_50" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000010 - Disclosure - Equity Offerings" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationPolicies" xlink:title="00000012 - Disclosure - Business Description and Basis of Presentation (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000013 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems" xlink:label="loc_srtSupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtSupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExcessStockSharesAuthorized" xlink:label="loc_us-gaapExcessStockSharesAuthorized_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems" xlink:to="loc_us-gaapExcessStockSharesAuthorized_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_60" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000015 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:label="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ParkinsonMember" xlink:label="loc_avxlParkinsonMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlParkinsonMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AUD" xlink:label="loc_currencyAUD_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_110" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000016 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_GrossProceedsFromSaleOfCommonStock" xlink:label="loc_avxlGrossProceedsFromSaleOfCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlGrossProceedsFromSaleOfCommonStock_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4_70" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000017 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000018 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000019 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_OptionsMember" xlink:label="loc_avxlOptionsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlOptionsMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_120" xlink:type="arc" order="5" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>avxl-20210630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ParkinsonMember" xlink:label="avxl_ParkinsonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ParkinsonMember" xlink:to="avxl_ParkinsonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ParkinsonMember_lbl" xml:lang="en-US">Parkinson [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="avxl_EquityOfferingSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Series [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="avxl_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CantorFitzgeraldAndCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald &amp;amp;amp;amp; Co [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_PurchaseAgreement1Member" xlink:label="avxl_PurchaseAgreement1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement1Member_lbl" xml:lang="en-US">2019 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="avxl_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_PurchaseWarrantsMember" xlink:label="avxl_PurchaseWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrantsMember_lbl" xml:lang="en-US">Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_PurchaseWarrants1Member" xlink:label="avxl_PurchaseWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants1Member" xlink:to="avxl_PurchaseWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants1Member_lbl" xml:lang="en-US">Purchase Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_PurchaseWarrants2Member" xlink:label="avxl_PurchaseWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants2Member" xlink:to="avxl_PurchaseWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_PurchaseWarrants2Member_lbl" xml:lang="en-US">Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">2015 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_OptionsMember" xlink:label="avxl_OptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionsMember" xlink:to="avxl_OptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionsMember_lbl" xml:lang="en-US">Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockOptionPlan2019Member" xlink:label="avxl_StockOptionPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2019Member_lbl" xml:lang="en-US">2019 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - Note 5</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_CapitalStockValue" xlink:label="avxl_CapitalStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CapitalStockValue" xlink:to="avxl_CapitalStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CapitalStockValue_lbl" xml:lang="en-US">Capital Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">&#160;Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange gain (loss), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_WeightedAverageNumberOfSharesOutstanding" xlink:label="avxl_WeightedAverageNumberOfSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WeightedAverageNumberOfSharesOutstanding" xlink:to="avxl_WeightedAverageNumberOfSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_WeightedAverageNumberOfSharesOutstanding_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows used in Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in non-cash working capital balances related to operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Increase in cash and cash equivalents during the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance beginning, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">&#160;Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_lbl" xml:lang="en-US">&#160;Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfOptions_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsShares" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsShares" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsShares_lbl" xml:lang="en-US">Shares issued upon exercise of options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" xlink:label="avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" xlink:to="avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts_lbl" xml:lang="en-US">Shares issued under Sales Agreement, net of share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_lbl" xml:lang="en-US">Shares issued under 2019 purchase agreement Commitment shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued under Sales Agreement, net of share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued under 2019 purchase agreement Purchase shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" xlink:label="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" xlink:to="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts_lbl" xml:lang="en-US">Shares issued pursuant to registered direct offering, net of share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares" xlink:label="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares" xlink:to="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares_lbl" xml:lang="en-US">Shares issued pursuant to registered direct offering, net of share issue costs, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPusuantToExerciseOfWarrants" xlink:label="avxl_SharesIssuedPusuantToExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPusuantToExerciseOfWarrants" xlink:to="avxl_SharesIssuedPusuantToExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPusuantToExerciseOfWarrants_lbl" xml:lang="en-US">Shares issued pusuant to exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Shares issued upon exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedUponExerciseOfOptionsShares" xlink:label="avxl_SharesIssuedUponExerciseOfOptionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUponExerciseOfOptionsShares" xlink:to="avxl_SharesIssuedUponExerciseOfOptionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_SharesIssuedUponExerciseOfOptionsShares_lbl" xml:lang="en-US">Shares issued upon exercise of options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPusuantToExerciseOfWarrantsShares" xlink:label="avxl_SharesIssuedPusuantToExerciseOfWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPusuantToExerciseOfWarrantsShares" xlink:to="avxl_SharesIssuedPusuantToExerciseOfWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPusuantToExerciseOfWarrantsShares_lbl" xml:lang="en-US">Shares issued pusuant to exercise of warrants, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance ending, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Description and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="avxl_DisclosureOtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureOtherIncomeAbstract" xlink:to="avxl_DisclosureOtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureOtherIncomeAbstract_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="avxl_DisclosureEquityOfferingsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureEquityOfferingsAbstract" xlink:to="avxl_DisclosureEquityOfferingsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureEquityOfferingsAbstract_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="avxl_EquityOfferingAgreementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsTextBlock" xlink:to="avxl_EquityOfferingAgreementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_EquityOfferingAgreementsTextBlock_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_LiquidityPolicyTextBlock" xlink:label="avxl_LiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LiquidityPolicyTextBlock" xlink:to="avxl_LiquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of exercisable share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:to="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding stock purchase options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses and research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions for fair value of each option award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems" xlink:label="srt_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems" xlink:to="srt_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems_lbl" xml:lang="en-US">SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExcessStockSharesAuthorized" xlink:label="us-gaap_ExcessStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesAuthorized" xlink:to="us-gaap_ExcessStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesAuthorized_lbl" xml:lang="en-US">Excess Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Loss per share for potentially dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:label="srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems_lbl" xml:lang="en-US">Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Share issued for offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Common stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_GrossProceedsFromSaleOfCommonStock" xlink:label="avxl_GrossProceedsFromSaleOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GrossProceedsFromSaleOfCommonStock" xlink:to="avxl_GrossProceedsFromSaleOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GrossProceedsFromSaleOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceed from offering</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="avxl_PercentageOfGrossProceedsFromSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PercentageOfGrossProceedsFromSales_lbl" xml:lang="en-US">Percentage of gross proceeds from sales</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="avxl_ValueOfSharesObligatedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ValueOfSharesObligatedToPurchase_lbl" xml:lang="en-US">Total number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xml:lang="en-US">Pro rata basic number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price, value</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xml:lang="en-US">Number of shares issued for commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xml:lang="en-US">Amount of shares remain available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share Purchase Warrants Balance, at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Balance, at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xml:lang="en-US">Share Purchase Warrants Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xml:lang="en-US">Weighted Average Exercise Price warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xml:lang="en-US">Share Purchase Warrants Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_lbl" xml:lang="en-US">Weighted Average Exercise Price warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Option Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum number of common shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Description of grant option</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_doc" xml:lang="en-US">Commitment shares issued shares underterms of purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ValueOfSharesObligatedToPurchase_doc" xml:lang="en-US">Information related to value of shares obligated to purchase initially.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseAgreement1Member_doc" xml:lang="en-US">Represents the information pertaining to purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_LincolnParkCapitalFundLLCMember_doc" xml:lang="en-US">Information related to type of legal entity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xml:lang="en-US">Information related to number of shares obligated to purchase prorata basic.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PercentageOfGrossProceedsFromSales_doc" xml:lang="en-US">Represents information related to percentage of gross proceeds from sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EquityOfferingSalesAgreementMember_doc" xml:lang="en-US">Represents information related to equity offering sales agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CantorFitzgeraldAndCoMember_doc" xml:lang="en-US">Represents information related to cantor fitzgerald and co.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2015Member_doc" xml:lang="en-US">Information related to type of plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2019Member_doc" xml:lang="en-US">Represents the information pertaining to stock option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseWarrantsMember_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants2Member" xlink:to="avxl_PurchaseWarrants2Member_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants2Member_2_lbl" xml:lang="en-US">Equity Offering Sales Agreement [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WeightedAverageNumberOfSharesOutstanding" xlink:to="avxl_WeightedAverageNumberOfSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_WeightedAverageNumberOfSharesOutstanding_2_lbl" xml:lang="en-US">WeightedAverageNumberOfSharesOutstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUponExerciseOfOptionsShares" xlink:to="avxl_SharesIssuedUponExerciseOfOptionsShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUponExerciseOfOptionsShares_2_lbl" xml:lang="en-US">SharesIssuedUponExerciseOfOptionsShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xml:lang="en-US">OtherIncomeDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsTextBlock" xlink:to="avxl_EquityOfferingAgreementsTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingAgreementsTextBlock_2_lbl" xml:lang="en-US">EquityOfferingAgreementsTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>avxl-20210630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20210630.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20210630.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20210630.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20210630.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20210630.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20210630.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20210630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20210630.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20210630.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20210630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationPolicies" xlink:href="avxl-20210630.xsd#BusinessDescriptionAndBasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20210630.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20210630.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20210630.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20210630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_CapitalStockValue" xlink:label="loc_avxlCapitalStockValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_avxlCapitalStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_WeightedAverageNumberOfSharesOutstanding" xlink:label="loc_avxlWeightedAverageNumberOfSharesOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_avxlWeightedAverageNumberOfSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptionsShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptionsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" xlink:label="loc_avxlSharesIssuedUnderSalesAgreementNetOfShareIssueCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreementNetOfShareIssueCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" xlink:label="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares" xlink:label="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPusuantToExerciseOfWarrants" xlink:label="loc_avxlSharesIssuedPusuantToExerciseOfWarrants" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPusuantToExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedUponExerciseOfOptionsShares" xlink:label="loc_avxlSharesIssuedUponExerciseOfOptionsShares" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUponExerciseOfOptionsShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_SharesIssuedPusuantToExerciseOfWarrantsShares" xlink:label="loc_avxlSharesIssuedPusuantToExerciseOfWarrantsShares" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPusuantToExerciseOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000010 - Disclosure - Equity Offerings">
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="loc_avxlEquityOfferingAgreementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_avxlEquityOfferingAgreementsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationPolicies" xlink:title="00000012 - Disclosure - Business Description and Basis of Presentation (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_LiquidityPolicyTextBlock" xlink:label="loc_avxlLiquidityPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_avxlLiquidityPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000013 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems" xlink:label="loc_srtSupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtSupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExcessStockSharesAuthorized" xlink:label="loc_us-gaapExcessStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems" xlink:to="loc_us-gaapExcessStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000015 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:label="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ParkinsonMember" xlink:label="loc_avxlParkinsonMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlParkinsonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000016 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_GrossProceedsFromSaleOfCommonStock" xlink:label="loc_avxlGrossProceedsFromSaleOfCommonStock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlGrossProceedsFromSaleOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000017 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000018 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000019 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210630.xsd#avxl_OptionsMember" xlink:label="loc_avxlOptionsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>e3018_10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avxl="http://anavex.com/20210630"
  xmlns:currency="http://xbrl.sec.gov/currency/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avxl-20210630.xsd" xlink:type="simple"/>
    <context id="From2020-10-01to2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2021-05-25</instant>
        </period>
    </context>
    <context id="AsOf2021-05-25_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-25</instant>
        </period>
    </context>
    <context id="AsOf2021-05-25_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-25</instant>
        </period>
    </context>
    <context id="From2019-10-012020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_ParkinsonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:ParkinsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2016-10-012017-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-06-012021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-22</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-22</instant>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-06</startDate>
            <endDate>2019-06-07</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_PurchaseWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_PurchaseWarrants2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:OptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_StockOptionPlan2015Member_custom_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:OptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-10-01to2021-06-30">0001314052</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-10-01to2021-06-30">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2020-10-01to2021-06-30">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-10-01to2021-06-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-10-01to2021-06-30">--09-30</dei:CurrentFiscalYearEndDate>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPusuantToExerciseOfWarrants
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2020-10-01to2021-06-30"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPusuantToExerciseOfWarrants
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2019-10-012020-06-30"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2019-10-012020-06-30"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2020-10-01to2021-06-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2020-10-01to2021-06-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2020-10-01to2021-06-30">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2020-10-01to2021-06-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2020-10-01to2021-06-30">001-37606</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2020-10-01to2021-06-30">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-10-01to2021-06-30">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-10-01to2021-06-30">98-0608404</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-10-01to2021-06-30">51 West 52nd Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2020-10-01to2021-06-30">7th Floor,</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2020-10-01to2021-06-30">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-10-01to2021-06-30">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-10-01to2021-06-30">10019</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-10-01to2021-06-30">1-844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-10-01to2021-06-30">689-3939</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2020-10-01to2021-06-30">Common Stock Par Value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-10-01to2021-06-30">AVXL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-10-01to2021-06-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2020-10-01to2021-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-10-01to2021-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2020-10-01to2021-06-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2020-10-01to2021-06-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-10-01to2021-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2020-10-01to2021-06-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-08-12" decimals="INF" unitRef="Shares">75707382</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">157560045</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">29249018</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">8601258</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">4849340</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">258198</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">443839</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:Assets contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">166419501</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">34542197</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">4176707</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">3989054</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">4653234</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">3316574</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">443831</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">0</us-gaap:DeferredIncomeCurrent>
    <us-gaap:Liabilities contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">9273772</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">7305628</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-06-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-06-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">75149833</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">75149833</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">62045198</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">62045198</us-gaap:CommonStockSharesOutstanding>
    <avxl:CapitalStockValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">75151</avxl:CapitalStockValue>
    <avxl:CapitalStockValue contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">62047</avxl:CapitalStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">342938236</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">186851752</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">-185867658</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">-159677230</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">157145729</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">27236569</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">166419501</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">34542197</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">2434127</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1381477</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">6138528</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">4453654</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">8964528</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">6725002</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">23610888</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">19126717</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">11398655</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">8106479</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">29749416</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">23580371</us-gaap:OperatingExpenses>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">43280</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">54100</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">149888</avxl:NonOperatingIncomeFromGrant>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">1363661</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1319913</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">3593856</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">2980456</avxl:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">11453</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">56096</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">19110</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">172996</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-160880</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">248665</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">17191</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">-24182</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">1257514</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1624674</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">3684257</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">3279158</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-10141141</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-6481805</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">-26065159</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">-20301213</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">39000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">4817</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">125269</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">14031</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-10180141</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-6486622</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">-26190428</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">-20315244</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-10-01to2021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.39</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-10-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstanding
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="Shares">70589561</avxl:WeightedAverageNumberOfSharesOutstanding>
    <avxl:WeightedAverageNumberOfSharesOutstanding
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="Shares">59105399</avxl:WeightedAverageNumberOfSharesOutstanding>
    <avxl:WeightedAverageNumberOfSharesOutstanding
      contextRef="From2020-10-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">67810774</avxl:WeightedAverageNumberOfSharesOutstanding>
    <avxl:WeightedAverageNumberOfSharesOutstanding
      contextRef="From2019-10-012020-06-30"
      decimals="INF"
      unitRef="Shares">57401387</avxl:WeightedAverageNumberOfSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">-26190428</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">-20315244</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">5079395</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">4216306</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">3751918</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">905227</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">-185641</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">-62367</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">187653</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">456872</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">1336660</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">1452652</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">443831</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">-22709166</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">-15032274</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">153218758</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">20490297</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">5533473</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">24508</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">1466500</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">1868408</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">151020193</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">20465789</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">128311027</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">5433515</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">29249018</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">22185630</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">157560045</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">27619145</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">70030620</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">70032</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">251427781</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-175687517</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">75810296</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2082263</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2082</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">39979399</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">39981481</us-gaap:StockIssuedDuringPeriodValueOther>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2380953</avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2381</avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">46901681</avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">46904062</avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts>
    <avxl:SharesIssuedUponExerciseOfOptionsShares
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">305997</avxl:SharesIssuedUponExerciseOfOptionsShares>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">306</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">869300</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">869606</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <avxl:SharesIssuedPusuantToExerciseOfWarrantsShares
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">350000</avxl:SharesIssuedPusuantToExerciseOfWarrantsShares>
    <avxl:SharesIssuedPusuantToExerciseOfWarrants
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">350</avxl:SharesIssuedPusuantToExerciseOfWarrants>
    <avxl:SharesIssuedPusuantToExerciseOfWarrants
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1466150</avxl:SharesIssuedPusuantToExerciseOfWarrants>
    <avxl:SharesIssuedPusuantToExerciseOfWarrants
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">1466500</avxl:SharesIssuedPusuantToExerciseOfWarrants>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2293925</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">2293925</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-10180141</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-10180141</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75149833</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">75151</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">342938236</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-185867658</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">157145729</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">58664946</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">58666</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">171958462</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-147225382</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">24791746</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1400</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">5123405</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">5124805</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">16624</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">16</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-16</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsShares
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">721</avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsShares>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</avxl:SharesIssuedPursuantToCashlessExerciseOfOptions>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-1</avxl:SharesIssuedPursuantToCashlessExerciseOfOptions>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1251129</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1251129</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-6486622</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-6486622</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">60082291</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">60083</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">178332979</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-153712004</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">24681058</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">62045198</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">62047</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">186851752</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-159677230</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">27236569</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4007996</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">4008</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">24107190</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">24111198</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">78213</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">78</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-78</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:SharesIssuedUnderSalesAgreementNetOfShareIssueCosts
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5634576</avxl:SharesIssuedUnderSalesAgreementNetOfShareIssueCosts>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5634</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">76664391</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">76670025</us-gaap:StockIssuedDuringPeriodValueOther>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2380953</avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2381</avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">46901681</avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">46904062</avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsShares
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">652897</avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsShares>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">653</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1867755</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">1868408</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <avxl:SharesIssuedPusuantToExerciseOfWarrantsShares
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">350000</avxl:SharesIssuedPusuantToExerciseOfWarrantsShares>
    <avxl:SharesIssuedPusuantToExerciseOfWarrants
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">350</avxl:SharesIssuedPusuantToExerciseOfWarrants>
    <avxl:SharesIssuedPusuantToExerciseOfWarrants
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1466150</avxl:SharesIssuedPusuantToExerciseOfWarrants>
    <avxl:SharesIssuedPusuantToExerciseOfWarrants
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">1466500</avxl:SharesIssuedPusuantToExerciseOfWarrants>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">5079395</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">5079395</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-26190428</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">-26190428</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75149833</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">75151</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">342938236</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-185867658</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">157145729</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">52650521</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">52652</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">153633807</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-133396760</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">20289699</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">7364584</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">7365</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">20482932</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">20490297</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2
      contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">66465</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">65</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-65</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsShares
      contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">721</avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsShares>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</avxl:SharesIssuedPursuantToCashlessExerciseOfOptions>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-1</avxl:SharesIssuedPursuantToCashlessExerciseOfOptions>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4216306</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">4216306</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-20315244</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">-20315244</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">60082291</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">60083</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">178332979</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-153712004</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">24681058</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2020-10-01to2021-06-30">&lt;p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zhhjFNwEkW1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 42pt; text-align: left"&gt;Note 1&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82A_zUO5DzJkHDoa"&gt;Business Description
and Basis of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42pt; text-align: justify; text-indent: 0pt"&gt;Business&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;Anavex Life Sciences Corp. (&#x201c;Anavex&#x201d;
or the &#x201c;Company&#x201d;) &lt;span style="color: black"&gt;is a clinical stage biopharmaceutical company engaged in the development
of differentiated therapeutics by applying precision medicine to central nervous system (&#x201c;CNS&#x201d;) diseases with high
unmet need. Anavex analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will
receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. &lt;/span&gt;The Company&#x2019;s
lead compound ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 &lt;span style="color: black"&gt;is being developed to treat Alzheimer&#x2019;s disease, Parkinson&#x2019;s
disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological
monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&#x201c;MECP2&#x201d;)&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;On May 25, 2021, the Company filed
a Certificate of Amendment to its Articles of Incorporation with the Secretary of the State of Nevada effecting an amendment to
increase the number of authorized shares of the Company&#x2019;s common stock, par value $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210525_z8AbwXUUyDza" title="Common stock, par value"&gt;0.001 &lt;/span&gt;per share, from &lt;span id="xdx_908_eus-gaap--ExcessStockSharesAuthorized_iI_c20210525__srt--RangeAxis__srt--MinimumMember_zx1M2oZ5SxFk"&gt;100,000,000&lt;/span&gt; shares
to &lt;span id="xdx_905_eus-gaap--ExcessStockSharesAuthorized_iI_c20210525__srt--RangeAxis__srt--MaximumMember_zewSnWm0soxl"&gt;200,000,000&lt;/span&gt; shares. The Certificate of Amendment was approved by the Company&#x2019;s stockholders at an annual meeting of stockholders
on May 25, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxbVJpCHdrD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 42.55pt"&gt;&lt;span id="xdx_863_z4w2j1Gyuuce"&gt;Basis of
Presentation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;These unaudited interim condensed
consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission
(&#x201c;SEC&#x201d;) and accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for
interim reporting.&lt;span style="color: black"&gt; Accordingly, certain information and note disclosures normally included in the annual
financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the
opinion of management, the disclosures are adequate to make the information presented not misleading.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;These accompanying unaudited interim
condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion
of management are necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September
30, 2020 was derived from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The
accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto included in the Company&#x2019;s annual report on Form 10-K for the year ended September
30, 2020 filed with the SEC on December 28, 2020. The Company follows the same accounting policies in the preparation of interim
reports.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="color: black"&gt;Operating
results for the three and nine months ended &lt;/span&gt;June 30&lt;span style="color: black"&gt;, 2021 are not necessarily indicative of the
results that may be expected for the year ending September 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--LiquidityPolicyTextBlock_zgpITkUS9fIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span id="xdx_86C_zfo8cXMui8Uf"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;All of the Company&#x2019;s potential
drug compounds are in the clinical development stage and the Company cannot be certain that its research and development efforts
will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies
or generate commercial revenues. To date, we have not generated any revenues from our operations. The Company expects the business
to continue to experience negative cash flows for the foreseeable future and cannot predict when, if ever, our business might become
profitable.&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Management believes that the current
working capital position will be sufficient to meet the Company&#x2019;s working capital requirements beyond the next 12 months
after the date that these interim condensed consolidated financial statements are issued. The process of drug development can be
costly, and the timing and outcomes of clinical trials is uncertain.&#160;The assumptions upon which the Company has based its
estimates are routinely evaluated and may be subject to change.&#160;The actual amount of the Company&#x2019;s expenditures will
vary depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials,
the progress of the Company&#x2019;s research and development programs and the level of financial resources available. The Company
has the ability to adjust its operating plan spending levels based on the timing of future clinical trials.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Other than our rights related to
the Sales Agreement (as defined below in Note 4), there can be no assurance that additional financing will be available to us when
needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional
financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and
development activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;In December 2019, a novel strain
of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World Health Organization declared
COVID-19 to be a global pandemic as a result of the rapid spread of the virus beyond its point of origin.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The global outbreak of COVID-19
continues to rapidly evolve as of the date these interim condensed consolidated financial statements are issued. As such, it is
uncertain as to the full magnitude that the outbreak will have on the Company&#x2019;s financial condition and future results of
operations. Management is actively monitoring the global situation on its business, including on its clinical trials and operations
and financial condition. The effects of COVID-19 did not have a material impact on the Company&#x2019;s result of operations or
financial condition for the period ended June 30, 2021. However, given the daily evolution of the COVID-19 situation, and the global
responses to curb its spread, the Company is not able to estimate the effects COVID-19 may have on its future results of operations
or financial condition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;i style="font-style: normal; font-weight: normal"&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The preparation of financial statements
in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The
Company regularly evaluates estimates and assumptions related to accounting for research and development costs, valuation and recoverability
of deferred tax assets, incentive and tax receivables, asset impairment, stock-based compensation, and loss contingencies. The
Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes
to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of
assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#x2019;s estimates. To the extent there are material
differences between the estimates and the actual results, future results of operations will be affected.&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Principles of Consolidation&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;These consolidated financial statements
include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited., a company
incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex Canada
Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;i style="font-style: normal; font-weight: normal"&gt;Fair Value Measurements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The fair value hierarchy under
GAAP is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be
used to measure fair value which are the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;Level 1 -
	quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;Level 2 -
observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical
or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose
significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;Level 3 -
	assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The book value of cash and cash
equivalents and accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of those
instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;At June 30, 2021 and September
30, 2020, the Company did not have any Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;i style="font-style: normal; font-weight: normal"&gt;Basic and Diluted
Loss per Share&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Basic income/(loss) per common
share is computed by dividing net income/(loss) available to common stockholders by the weighted average number of common shares
outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common
stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive effect
of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially
dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are potentially dilutive
securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;As of June 30, 2021, loss per share
excludes &lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210630_pdd" title="Loss per share for potentially dilutive common shares"&gt;11,059,202&lt;/span&gt; (September 30, 2020 &#x2013; &lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20191001__20200930_pdd" title="Loss per share for potentially dilutive common shares"&gt;10,576,266&lt;/span&gt;) potentially dilutive common shares related to outstanding options and
warrants, as their effect was anti-dilutive.&lt;/p&gt;















</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-05-25"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ExcessStockSharesAuthorized
      contextRef="AsOf2021-05-25_srt_MinimumMember"
      decimals="INF"
      unitRef="Shares">100000000</us-gaap:ExcessStockSharesAuthorized>
    <us-gaap:ExcessStockSharesAuthorized
      contextRef="AsOf2021-05-25_srt_MaximumMember"
      decimals="INF"
      unitRef="Shares">200000000</us-gaap:ExcessStockSharesAuthorized>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2020-10-01to2021-06-30">&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxbVJpCHdrD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 42.55pt"&gt;&lt;span id="xdx_863_z4w2j1Gyuuce"&gt;Basis of
Presentation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;These unaudited interim condensed
consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission
(&#x201c;SEC&#x201d;) and accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for
interim reporting.&lt;span style="color: black"&gt; Accordingly, certain information and note disclosures normally included in the annual
financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the
opinion of management, the disclosures are adequate to make the information presented not misleading.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;These accompanying unaudited interim
condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion
of management are necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September
30, 2020 was derived from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The
accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto included in the Company&#x2019;s annual report on Form 10-K for the year ended September
30, 2020 filed with the SEC on December 28, 2020. The Company follows the same accounting policies in the preparation of interim
reports.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="color: black"&gt;Operating
results for the three and nine months ended &lt;/span&gt;June 30&lt;span style="color: black"&gt;, 2021 are not necessarily indicative of the
results that may be expected for the year ending September 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <avxl:LiquidityPolicyTextBlock contextRef="From2020-10-01to2021-06-30">&lt;p id="xdx_848_ecustom--LiquidityPolicyTextBlock_zgpITkUS9fIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span id="xdx_86C_zfo8cXMui8Uf"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;All of the Company&#x2019;s potential
drug compounds are in the clinical development stage and the Company cannot be certain that its research and development efforts
will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies
or generate commercial revenues. To date, we have not generated any revenues from our operations. The Company expects the business
to continue to experience negative cash flows for the foreseeable future and cannot predict when, if ever, our business might become
profitable.&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Management believes that the current
working capital position will be sufficient to meet the Company&#x2019;s working capital requirements beyond the next 12 months
after the date that these interim condensed consolidated financial statements are issued. The process of drug development can be
costly, and the timing and outcomes of clinical trials is uncertain.&#160;The assumptions upon which the Company has based its
estimates are routinely evaluated and may be subject to change.&#160;The actual amount of the Company&#x2019;s expenditures will
vary depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials,
the progress of the Company&#x2019;s research and development programs and the level of financial resources available. The Company
has the ability to adjust its operating plan spending levels based on the timing of future clinical trials.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Other than our rights related to
the Sales Agreement (as defined below in Note 4), there can be no assurance that additional financing will be available to us when
needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional
financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and
development activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;In December 2019, a novel strain
of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World Health Organization declared
COVID-19 to be a global pandemic as a result of the rapid spread of the virus beyond its point of origin.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The global outbreak of COVID-19
continues to rapidly evolve as of the date these interim condensed consolidated financial statements are issued. As such, it is
uncertain as to the full magnitude that the outbreak will have on the Company&#x2019;s financial condition and future results of
operations. Management is actively monitoring the global situation on its business, including on its clinical trials and operations
and financial condition. The effects of COVID-19 did not have a material impact on the Company&#x2019;s result of operations or
financial condition for the period ended June 30, 2021. However, given the daily evolution of the COVID-19 situation, and the global
responses to curb its spread, the Company is not able to estimate the effects COVID-19 may have on its future results of operations
or financial condition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;i style="font-style: normal; font-weight: normal"&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The preparation of financial statements
in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The
Company regularly evaluates estimates and assumptions related to accounting for research and development costs, valuation and recoverability
of deferred tax assets, incentive and tax receivables, asset impairment, stock-based compensation, and loss contingencies. The
Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes
to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of
assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#x2019;s estimates. To the extent there are material
differences between the estimates and the actual results, future results of operations will be affected.&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Principles of Consolidation&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;These consolidated financial statements
include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited., a company
incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex Canada
Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;i style="font-style: normal; font-weight: normal"&gt;Fair Value Measurements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The fair value hierarchy under
GAAP is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be
used to measure fair value which are the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;Level 1 -
	quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;Level 2 -
observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical
or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose
significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;Level 3 -
	assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The book value of cash and cash
equivalents and accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of those
instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;At June 30, 2021 and September
30, 2020, the Company did not have any Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;i style="font-style: normal; font-weight: normal"&gt;Basic and Diluted
Loss per Share&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Basic income/(loss) per common
share is computed by dividing net income/(loss) available to common stockholders by the weighted average number of common shares
outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common
stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive effect
of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially
dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are potentially dilutive
securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;As of June 30, 2021, loss per share
excludes &lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210630_pdd" title="Loss per share for potentially dilutive common shares"&gt;11,059,202&lt;/span&gt; (September 30, 2020 &#x2013; &lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20191001__20200930_pdd" title="Loss per share for potentially dilutive common shares"&gt;10,576,266&lt;/span&gt;) potentially dilutive common shares related to outstanding options and
warrants, as their effect was anti-dilutive.&lt;/p&gt;















</avxl:LiquidityPolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-10-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">11059202</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-10-012020-09-30"
      decimals="INF"
      unitRef="Shares">10576266</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2020-10-01to2021-06-30">&lt;p id="xdx_80E_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_z9betADO0Syk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 42pt; text-align: left"&gt;Note 2&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82E_z0ifvhz4vHZ6"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;i&gt;Recent Accounting Pronouncements
Not Yet Adopted&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The Company does not expect the
adoption of recently issued accounting pronouncements to have a significant impact on its results of operations, financial position
or cash flows.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2020-10-01to2021-06-30">&lt;p id="xdx_80D_ecustom--OtherIncomeDisclosureTextBlock_zbJZYOkloxza" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 42pt; text-align: left"&gt;Note 3&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_826_zTXy9RVvs1Ob"&gt;Other Income&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;Grant Income&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;During the
nine months ended June 30, 2021, the Company received $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ParkinsonMember_pp0p0" title="Research and development incentive income"&gt;497,931&lt;/span&gt; of a $995,862 research grant awarded by the Michael J. Fox Foundation
for Parkinson&#x2019;s Research. The grant will be used to fund a clinical trial in the Company&#x2019;s lead compound, ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73
for the treatment of Parkinson&#x2019;s disease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;The grant
income is being deferred when received and amortized to other income as the related research and development expenditures are incurred.
During the three and nine months ended June 30, 2021, the Company recognized $&lt;span id="xdx_904_ecustom--NonOperatingIncomeFromGrant_c20210401__20210630_pp0p0" title="Grant income"&gt;43,280&lt;/span&gt; and $&lt;span id="xdx_908_ecustom--NonOperatingIncomeFromGrant_c20201001__20210630_pp0p0" title="Grant income"&gt;54,100&lt;/span&gt;, respectively of this grant on
its statements of operations within grant income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;During the
year ended September 30, 2017, the Company was awarded grant funding in the amount of $&lt;span id="xdx_908_ecustom--NonOperatingIncomeFromGrant_c20161001__20170930_pp0p0" title="Grant income"&gt;597,886&lt;/span&gt;. The grant was received in equal
quarterly installments over a period of two years ending during the year ended September 30, 2020, in exchange for a commitment
to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;The grant
income was deferred when received and amortized to other income as the related research and development expenditures were incurred.
During the three and nine months ended June 30, 2020, the Company recognized $nil and $&lt;span id="xdx_901_ecustom--NonOperatingIncomeFromGrant_c20191001__20200630_pp0p0" title="Grant income"&gt;149,888&lt;/span&gt;, respectively of this grant on its
statements of operations within grant income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;Research
and Development Incentive Income&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;Research
and development incentive income represents income earned by the Company&#x2019;s Australian subsidiary, of the &lt;span style="color: black"&gt;Australian
research and development incentive credit, &lt;/span&gt;(the &#x201c;ATO R&amp;amp;D Credit&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;During the
three and nine months ended June 30, 2021, the Company recorded research and development incentive income of $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20210401__20210630_pp0p0" title="Research and development incentive income"&gt;1,363,661&lt;/span&gt; (AUD &lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20210401__20210630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"&gt;1,770,444&lt;/span&gt;)
and $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210630_pp0p0" title="Research and development incentive income"&gt;3,593,856 &lt;/span&gt;(AUD &lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"&gt;4,750,539&lt;/span&gt;) (2020: $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20200401__20200630_pp0p0" title="Research and development incentive income"&gt;1,319,913&lt;/span&gt; (AUD &lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20200401__20200630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"&gt;1,923,000&lt;/span&gt;) and $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20191001__20200630_pp0p0" title="Research and development incentive income"&gt;2,980,456&lt;/span&gt; (AUD &lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20191001__20200630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"&gt;4,471,000&lt;/span&gt;)), respectively, in respect of the
ATO R&amp;amp;D Credit for eligible research and development expenses incurred during the period.&lt;/p&gt;

</avxl:OtherIncomeDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-04-012021-06-30_custom_ParkinsonMember"
      decimals="0"
      unitRef="USD">497931</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">43280</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">54100</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2016-10-012017-09-30"
      decimals="0"
      unitRef="USD">597886</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">149888</avxl:NonOperatingIncomeFromGrant>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">1363661</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-04-012021-06-30_currency_AUD"
      decimals="0"
      unitRef="USD">1770444</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">3593856</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-012021-06-30_currency_AUD"
      decimals="0"
      unitRef="USD">4750539</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1319913</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-04-012020-06-30_currency_AUD"
      decimals="0"
      unitRef="USD">1923000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">2980456</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2019-10-012020-06-30_currency_AUD"
      decimals="0"
      unitRef="USD">4471000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <avxl:EquityOfferingAgreementsTextBlock contextRef="From2020-10-01to2021-06-30">&lt;p id="xdx_80B_ecustom--EquityOfferingAgreementsTextBlock_zJr0lD85aytc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 42pt; text-align: left"&gt;Note 4&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82A_zR1783jA5m2c"&gt;Equity Offerings&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Registered Direct Offering&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;On June 22, 2021, the Company and
Deep Track Capital entered into a securities purchase agreement pursuant to which the Company sold to Deep Track Capital an aggregate
of &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210601__20210622__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zR6mGDdDeuo5" title="Share issued for offering, shares"&gt;2,380,953&lt;/span&gt; shares of common stock at $&lt;span id="xdx_90D_eus-gaap--SharePrice_iI_pp0p0_c20210622__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zJjzmvmTiZE2" title="Common stock price"&gt;21&lt;/span&gt; per share in a registered direct offering, for gross proceeds of $&lt;span id="xdx_90E_ecustom--GrossProceedsFromSaleOfCommonStock_pp0p0_c20210601__20210622__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zttELwpFLcfi" title="Gross proceeds from sale of common stock"&gt;50,000,013&lt;/span&gt;. Net proceeds
of the offering were $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20210601__20210622__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z1CDELzc6tb4" title="Proceed from offering"&gt;46,904,062 &lt;/span&gt;after deducting offering fees and expenses.&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Sales Agreement&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The Company entered into a Controlled
Equity Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#x201c;Sales Agreement&#x201d;)
with Cantor Fitzgerald&#160;&amp;amp; Co. and SVB Leerink LLC (together the &#x201c;Sales Agents&#x201d;), pursuant to which the Company
may offer and sell shares of common stock registered under an effective registration statement from time to time through the Sales
Agents (the &#x201c;Offering&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Upon delivery of a placement notice
based on the Company&#x2019;s instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may
sell the Shares by methods deemed to be an &#x201c;at the market offering&#x201d; offering, in negotiated transactions at market
prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted by
law, including negotiated transactions, subject to the prior written consent of the Company. The Company is not obligated to make
any sales of Shares under the Sales Agreement. The Company or Sales Agents may suspend or terminate the offering of Shares upon
notice to the other party, subject to certain conditions. The Sales Agents will act as agent on a commercially reasonable efforts
basis consistent with their normal trading and sales practices and applicable state and federal law, rules&#160;and regulations
and the rules&#160;of Nasdaq.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The Company has agreed to pay the
Sales Agents commissions for their services of up to &lt;span id="xdx_901_ecustom--PercentageOfGrossProceedsFromSales_dp_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zngz6jyIzOG4" title="Percentage of gross proceeds from sales"&gt;3.0&lt;/span&gt;% of the gross proceeds from the sale of the Shares pursuant to the Sales
Agreement. The Company also agreed to provide the Sales Agents with customary indemnification and contribution rights. During the
nine months ended June 30, 2021, &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Share issued for offering, shares"&gt;5,634,576&lt;/span&gt; shares were sold pursuant to the Offering for gross proceeds of $&lt;span id="xdx_906_ecustom--GrossProceedsFromSaleOfCommonStock_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross proceeds from sale of common stock"&gt;79,107,547&lt;/span&gt; (net proceeds
of $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceed from offering"&gt;76,670,025&lt;/span&gt; after deducting offering expenses).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;2019 Purchase Agreement&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;On June 7, 2019, the Company entered
into a $&lt;span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Total number of shares obligated to purchase"&gt;50,000,000&lt;/span&gt; purchase agreement (the &#x201c;2019 Purchase Agreement&#x201d;) with Lincoln Park, as amended on July 1, 2020,
pursuant to which the Company had the right to sell and issue to Lincoln Park, and Lincoln Park was obligated to purchase, up to
$&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Proceeds from Issuance or Sale of Equity"&gt;50,000,000 &lt;/span&gt;in value of its shares of common stock from time to time over a three-year period until July 1, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;In consideration for entering into
the 2019 Purchase Agreement, the Company issued to Lincoln Park &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares"&gt;324,383&lt;/span&gt; shares of common stock as a commitment fee during the year
ended September 30, 2019 and agreed to issue up to &lt;span id="xdx_90A_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Pro rata basic number of shares obligated to purchase"&gt;162,191&lt;/span&gt; shares pro rata, when and if, Lincoln Park purchased, at the Company&#x2019;s
discretion, the $50,000,000 aggregate commitment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;During the nine months ended June
30, 2021, the Company issued to Lincoln Park an aggregate of &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares"&gt;4,086,209&lt;/span&gt; (2020 &#x2013; &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares"&gt;7,431,049&lt;/span&gt;) shares of common stock under the
2019 Purchase Agreement, including &lt;span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for aggregate purchase price"&gt;4,007,996&lt;/span&gt; (2020: &lt;span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for aggregate purchase price"&gt;7,364,584&lt;/span&gt;) shares of common stock for an aggregate purchase price of $&lt;span id="xdx_904_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value"&gt;24,111,198&lt;/span&gt;
(2020: $&lt;span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value"&gt;20,490,297&lt;/span&gt;) and &lt;span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for commitment"&gt;78,213 &lt;/span&gt;(2020: &lt;span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for commitment"&gt;66,465&lt;/span&gt;) commitment shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;At June 30, 2021, &lt;span id="xdx_901_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_do_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z1pZMS22sfic" title="Amount of shares remain available"&gt;no&lt;/span&gt; amount remained
available under the 2019 Purchase Agreement (September 30, 2020: $&lt;span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueNewIssues4_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Amount of shares remain available"&gt;24,111,198&lt;/span&gt;).&lt;/p&gt;













</avxl:EquityOfferingAgreementsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-06-012021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Shares">2380953</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USDPShares">21</us-gaap:SharePrice>
    <avxl:GrossProceedsFromSaleOfCommonStock
      contextRef="From2021-06-012021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">50000013</avxl:GrossProceedsFromSaleOfCommonStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-06-012021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">46904062</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <avxl:PercentageOfGrossProceedsFromSales
      contextRef="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Pure">0.030</avxl:PercentageOfGrossProceedsFromSales>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Shares">5634576</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:GrossProceedsFromSaleOfCommonStock
      contextRef="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">79107547</avxl:GrossProceedsFromSaleOfCommonStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">76670025</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <avxl:ValueOfSharesObligatedToPurchase
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">50000000</avxl:ValueOfSharesObligatedToPurchase>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">324383</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:NumberOfSharesObligatedToPurchaseProrataBasic
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">162191</avxl:NumberOfSharesObligatedToPurchaseProrataBasic>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-10-012021-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">4086209</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">7431049</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4
      contextRef="From2020-10-012021-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">4007996</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4
      contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">7364584</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2020-10-012021-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">24111198</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">20490297</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2020-10-012021-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">78213</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">66465</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues4
      contextRef="From2020-10-012021-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">0</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues4
      contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">24111198</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2020-10-01to2021-06-30">&lt;p id="xdx_807_eus-gaap--CommitmentsDisclosureTextBlock_zIkJvyhMG1I2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 42pt; text-align: left"&gt;Note 5&lt;/td&gt;&lt;td style="text-align: justify"&gt; &lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82C_zlOevWvPjd6g"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"&gt;&lt;span style="font-size: 11pt"&gt;a)&lt;/span&gt;&lt;span style="font: 7pt Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;&lt;i style="font-style: normal; font-weight: normal"&gt;Leases &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;During
the three and nine months ended June 30, 2021, the Company incurred office lease expense of $&lt;span id="xdx_908_eus-gaap--LeaseAndRentalExpense_c20210401__20210630_pp0p0" title="Lease expense"&gt;18,994&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--LeaseAndRentalExpense_c20201001__20210630_pp0p0" title="Lease expense"&gt;117,284&lt;/span&gt;, respectively
(2020: $&lt;span id="xdx_906_eus-gaap--LeaseAndRentalExpense_c20200401__20200630_pp0p0" title="Lease expense"&gt;58,554&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--LeaseAndRentalExpense_c20191001__20200630_pp0p0" title="Lease expense"&gt;169,469&lt;/span&gt;, respectively).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"&gt;&lt;span style="font-size: 11pt"&gt;b)&lt;/span&gt;&lt;span style="font: 7pt Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;&lt;i style="font-style: normal; font-weight: normal"&gt;Litigation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain,
and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution
of any such matter will not have a material adverse effect upon the Company&#x2019;s consolidated financial statements. The Company
does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"&gt;&lt;span style="font-size: 11pt"&gt;c)&lt;/span&gt;&lt;span style="font: 7pt Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;&lt;i style="font-style: normal; font-weight: normal"&gt;Share Purchase Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 58.5pt"&gt;A summary of the status of the Company&#x2019;s
outstanding share purchase warrants is presented below:&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 58.5pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zG3bATHydCJ6" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B3_zWem4hVgSjh7" style="display: none"&gt;Schedule of exercisable share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;Weighted Average Exercise Price ($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 26%; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Balance, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zZt7I7LCPgp2" style="width: 26%; color: black; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;350,000&lt;/td&gt;&lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgcydGQ8Rqha" style="width: 26%; color: black; text-align: right" title="Weighted Average Exercise Price warrants outstanding at beginning"&gt;4.19&lt;/td&gt;&lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Share Purchase Warrants Granted"&gt;150,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price warrants granted"&gt;3.17&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmCdkSLH3Dx9" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Share Purchase Warrants Balance, at ending"&gt;500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zqlxyNN9AmMg" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price Balance, at ending"&gt;3.88&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="color: black; text-align: right" title="Share Purchase Warrants Granted"&gt;60,000&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price warrants granted"&gt;12.00&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zIG3Y1h7hoLe" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Share Purchase Warrants Exercised"&gt;(350,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zAkki7I1YtZ4" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price warrants exercised"&gt;4.19&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Balance, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zY7gAfHgrpP" style="border-bottom: Black 1pt solid; color: black; text-align: right"&gt;210,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z214rzU2BAn9" style="border-bottom: Black 1pt solid; color: black; text-align: right"&gt;5.69&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AC_zlJXGQXwINx1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-indent: -0.8pt"&gt;At June 30, 2021, the Company had
share purchase warrants outstanding as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-indent: -0.8pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zDKAuYt6dEG" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="color: black; text-align: center"&gt;&lt;span id="xdx_8B0_zXQOBbmxKaSl" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="color: black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="color: black; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 12%; color: black; text-align: right; text-indent: -10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Number"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; color: black; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Exercise Price"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 30%; color: black; text-align: right; padding-left: 0.65pt"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zHM2VWOB4VFk" title="Warrants and Rights Outstanding, Maturity Date"&gt;May 6, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; color: black; text-align: right; text-indent: -10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Number"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: black; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Exercise Price"&gt;12.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: right; padding-bottom: 1pt; padding-left: 0.65pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zG4VWGu67Aa4" title="Warrants and Rights Outstanding, Maturity Date"&gt;April 21, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding: 0pt 0pt 0pt 10pt; color: black; text-align: right; text-indent: -10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210630_pdd" title="Number"&gt;210,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.65pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A4_zLtsZsKbyRy" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 99.25pt; text-indent: -0.8pt"&gt;&#160;&lt;/p&gt;















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; text-indent: -18pt; color: black"&gt;&lt;span style="font-size: 11pt"&gt;d)&lt;/span&gt;&lt;span style="font: 7pt Times New Roman, Times, Serif"&gt;&#160;&#160;
&lt;/span&gt;&lt;i style="font-style: normal; font-weight: normal"&gt;Stock&#x2013;based Compensation Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;2015 Stock Option Plan&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;On September 18, 2015, the Company&#x2019;s
Board of Directors (the &#x201c;Board&#x201d;) approved a 2015 Omnibus Incentive Plan (the &#x201c;2015 Plan&#x201d;), which provided
for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;The maximum number of our common shares
reserved for issue under the plan was &lt;span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Maximum number of common shares reserved for future issuance"&gt;6,050,553&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization.
At June 30, 2021, &lt;span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--OptionsMember_pdd" title="Maximum number of common shares reserved for future issuance"&gt;146,371&lt;/span&gt; (September 30, 2020: &lt;span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--OptionsMember_pdd" title="Maximum number of common shares reserved for future issuance"&gt;146,371&lt;/span&gt;) options remain available for issue under the 2015 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;2019 Stock Option Plan&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;On January 15, 2019, the Board approved
the 2019 Omnibus Incentive Plan (the &#x201c;2019 Plan&#x201d;), which provides for the grant of stock options and restricted stock
awards to directors, officers, employees, consultants and advisors of the Company. Under the terms of the 2019 Plan, &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Additional shares of common stock available for issuance"&gt;6,000,000&lt;/span&gt;
additional shares of Common Stock are available for issuance under the 2019 Plan, in addition to the shares available under the
2015 Plan. Any awards outstanding under the 2015 Plan or the Company&#x2019;s 2007 Stock Option Plan (the &#x201c;2007 Plan&#x201d;)
will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and any shares subject to outstanding awards
under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards (other than by reason of settlement of
the awards in shares) will automatically become available for issuance under the 2019 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member" title="Description of grant option"&gt;The 2019 Plan provides that it may
be administered by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined
by the Board at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder
on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#x2019;s shares of common
stock on the grant date. Stock options may be granted under the 2019 Plan for an exercise period of up to ten years from the date
of grant of the option or such lesser periods as may be determined by the Board, subject to earlier termination in accordance with
the terms of the 2019 Plan. At June 30, 2021, &lt;span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Maximum number of common shares reserved for future issuance"&gt;1,706,665&lt;/span&gt; (September 30, 2020: &lt;span id="xdx_907_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Maximum number of common shares reserved for future issuance"&gt;3,161,665&lt;/span&gt;) options remain available for issue under
the 2019 Plan.&lt;/span&gt;&lt;/p&gt;





















&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 2cm"&gt;A summary of the status of Company&#x2019;s outstanding
stock options is presented below:&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 2cm"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zcTlezsbyhr1" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_zp2UmFGfrnkc" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;Weighted Average Exercise Price ($)&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;Weighted Average Grant Date Fair Value ($)&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;Aggregate intrinsic value ($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 20%; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Outstanding, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zZi9dn5TUxF9" style="width: 19%; color: black; text-align: right" title="Options Outstanding at beginning"&gt;8,462,933&lt;/td&gt;&lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z3GmxeYlX9uf" style="width: 19%; color: black; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;3.58&lt;/td&gt;&lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; color: black"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zaIDX87OaK74" style="color: black; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;4,115,032&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Options Granted"&gt;1,695,000&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price Granted"&gt;2.96&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;2.27&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zWhXJEMOXRA9" style="color: black; text-align: right" title="Options Forfeited"&gt;(68,332&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;3.01&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Exercised&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z9tl9xthn3Ed" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Option Exercised"&gt;(13,335&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;3.15&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z0OqkVdTu2j1" style="border-bottom: Black 2.5pt double; color: black; text-align: right"&gt;10,076,266&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zrpkO0nJPtAl" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;3.48&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zAUOsn8yz2Ll" style="border-bottom: Black 2.5pt double; color: black; text-align: right"&gt;14,982,581&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Granted&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Options Granted"&gt;1,455,000&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price Granted"&gt;6.59&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;5.02&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCjQLOYsmJbc" style="color: black; text-align: right" title="Options Forfeited"&gt;(29,167&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;1.44&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Exercised&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOJJK2IZbjX1" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Option Exercised"&gt;(652,897&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;2.86&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Outstanding, June 30, 2021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zi0GXvSz7SV3" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Options Outstanding at ending"&gt;10,849,202&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zO24Gleu5ap3" style="border-bottom: Black 2.5pt double; color: black; text-align: right"&gt;3.94&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zDIb0TSEN4Bh" style="border-bottom: Black 2.5pt double; color: black; text-align: right"&gt;205,309,996&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Exercisable, June 30, 2021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Options Exercisable"&gt;7,930,452&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;3.64&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Aggregate intrinsic value Exercisable"&gt;152,413,269&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 58.5pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8A0_zKDIGJ8QmK2k" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 58.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 2cm"&gt;The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#x2019;s stock for the
options that were in-the-money at June 30, 2021.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 2cm"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;During the three and nine months ended
June 30, 2021, the Company recognized stock-based compensation expense of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_c20210401__20210630_pp0p0" title="Stock-based compensation expense"&gt;2,293,925&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_c20201001__20210630_pp0p0" title="Stock-based compensation expense"&gt;5,079,395&lt;/span&gt;, respectively (2020: $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_c20200401__20200630_pp0p0" title="Stock-based compensation expense"&gt;1,251,129
&lt;/span&gt;and $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20191001__20200630_pp0p0" title="Stock-based compensation expense"&gt;4,216,306&lt;/span&gt;, respectively) in connection with the issuance and vesting 	of stock options and warrants in exchange for services.
These amounts have been included in general and 	administrative expenses and research and development expenses on the Company&#x2019;s
statements of 	operations as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zFaM8Dq7r2Pa" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BE_z952apFZt7s" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="color: black; text-align: center"&gt;Three months ended June 30,&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="color: black; text-align: center"&gt;Nine months ended June 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; color: black; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,048,606&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;575,451&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;2,265,387&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,863,869&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;1,245,319&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;675,678&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,814,008&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,352,437&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;Total share based compensation&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Total share based compensation"&gt;2,293,925&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Total share based compensation"&gt;1,251,129&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Total share based compensation"&gt;5,079,395&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Total share based compensation"&gt;4,216,306&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AD_zx4xeshKWBng" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;An amount of approximately $&lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20210630_pp0p0" title="Remaining stock based compensation"&gt;6,664,000&lt;/span&gt;
in stock-based compensation is expected to be recorded over the remaining term 	of such options through fiscal 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;The fair
value of each option award granted during the nine months ended June 30, 2021 and 2020 is estimated on the date of grant using
the Black Scholes option pricing model based on the following weighted average assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zLVZvEpnKVF5" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_zOekhIMcCEVb" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_491_20201001__20210630_zhAydi1vKHU9" style="color: black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_492_20191001__20200630_zMMdh0NXUYMg" style="color: black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_zEzrkh4igtl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; color: black; text-align: left; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;0.71&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1.57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20210630_ztcQdR9VdBJh" title="Expected life of options (years)"&gt;5.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20200630_zsvOeZ87iyT8" title="Expected life of options (years)"&gt;5.53&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zr9dpGCdYKrg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95.87&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97.80&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zOWSvay9Y7I" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AA_zOv4f1JK5yae" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">18994</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">117284</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">58554</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">169469</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="From2020-10-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zG3bATHydCJ6" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B3_zWem4hVgSjh7" style="display: none"&gt;Schedule of exercisable share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;Weighted Average Exercise Price ($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 26%; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Balance, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zZt7I7LCPgp2" style="width: 26%; color: black; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;350,000&lt;/td&gt;&lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgcydGQ8Rqha" style="width: 26%; color: black; text-align: right" title="Weighted Average Exercise Price warrants outstanding at beginning"&gt;4.19&lt;/td&gt;&lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Share Purchase Warrants Granted"&gt;150,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price warrants granted"&gt;3.17&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmCdkSLH3Dx9" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Share Purchase Warrants Balance, at ending"&gt;500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zqlxyNN9AmMg" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price Balance, at ending"&gt;3.88&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="color: black; text-align: right" title="Share Purchase Warrants Granted"&gt;60,000&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price warrants granted"&gt;12.00&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zIG3Y1h7hoLe" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Share Purchase Warrants Exercised"&gt;(350,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zAkki7I1YtZ4" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price warrants exercised"&gt;4.19&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Balance, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zY7gAfHgrpP" style="border-bottom: Black 1pt solid; color: black; text-align: right"&gt;210,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z214rzU2BAn9" style="border-bottom: Black 1pt solid; color: black; text-align: right"&gt;5.69&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">4.19</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod
      contextRef="From2019-10-012020-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">150000</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice
      contextRef="From2019-10-012020-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.17</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.88</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod
      contextRef="From2020-10-012021-06-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">60000</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice
      contextRef="From2020-10-012021-06-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">12.00</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="From2020-10-012021-06-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">-350000</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice
      contextRef="From2020-10-012021-06-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">4.19</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-06-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">210000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">5.69</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock contextRef="From2020-10-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zDKAuYt6dEG" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="color: black; text-align: center"&gt;&lt;span id="xdx_8B0_zXQOBbmxKaSl" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="color: black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="color: black; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 12%; color: black; text-align: right; text-indent: -10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Number"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; color: black; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Exercise Price"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 30%; color: black; text-align: right; padding-left: 0.65pt"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zHM2VWOB4VFk" title="Warrants and Rights Outstanding, Maturity Date"&gt;May 6, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; color: black; text-align: right; text-indent: -10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Number"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: black; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Exercise Price"&gt;12.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: right; padding-bottom: 1pt; padding-left: 0.65pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zG4VWGu67Aa4" title="Warrants and Rights Outstanding, Maturity Date"&gt;April 21, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding: 0pt 0pt 0pt 10pt; color: black; text-align: right; text-indent: -10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210630_pdd" title="Number"&gt;210,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.65pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2021-06-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="USDPShares">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2021-06-30_custom_PurchaseWarrants1Member">2024-05-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2021-06-30_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="Shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="USDPShares">12.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2021-06-30_custom_PurchaseWarrants2Member">2026-04-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">210000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_OptionsMember"
      decimals="INF"
      unitRef="Shares">146371</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member_custom_OptionsMember"
      decimals="INF"
      unitRef="Shares">146371</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2019Member"
      decimals="INF"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2019Member">The 2019 Plan provides that it may
be administered by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined
by the Board at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder
on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#x2019;s shares of common
stock on the grant date. Stock options may be granted under the 2019 Plan for an exercise period of up to ten years from the date
of grant of the option or such lesser periods as may be determined by the Board, subject to earlier termination in accordance with
the terms of the 2019 Plan. At June 30, 2021, 1,706,665 (September 30, 2020: 3,161,665) options remain available for issue under
the 2019 Plan.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2019Member"
      decimals="INF"
      unitRef="Shares">1706665</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2019Member"
      decimals="INF"
      unitRef="Shares">3161665</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2020-10-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zcTlezsbyhr1" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_zp2UmFGfrnkc" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;Weighted Average Exercise Price ($)&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;Weighted Average Grant Date Fair Value ($)&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;Aggregate intrinsic value ($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 20%; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Outstanding, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zZi9dn5TUxF9" style="width: 19%; color: black; text-align: right" title="Options Outstanding at beginning"&gt;8,462,933&lt;/td&gt;&lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z3GmxeYlX9uf" style="width: 19%; color: black; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;3.58&lt;/td&gt;&lt;td style="width: 1%; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; color: black"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zaIDX87OaK74" style="color: black; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;4,115,032&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Options Granted"&gt;1,695,000&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price Granted"&gt;2.96&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;2.27&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zWhXJEMOXRA9" style="color: black; text-align: right" title="Options Forfeited"&gt;(68,332&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;3.01&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Exercised&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z9tl9xthn3Ed" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Option Exercised"&gt;(13,335&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;3.15&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z0OqkVdTu2j1" style="border-bottom: Black 2.5pt double; color: black; text-align: right"&gt;10,076,266&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zrpkO0nJPtAl" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;3.48&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zAUOsn8yz2Ll" style="border-bottom: Black 2.5pt double; color: black; text-align: right"&gt;14,982,581&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Granted&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Options Granted"&gt;1,455,000&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price Granted"&gt;6.59&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;5.02&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCjQLOYsmJbc" style="color: black; text-align: right" title="Options Forfeited"&gt;(29,167&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;1.44&lt;/td&gt;&lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Exercised&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOJJK2IZbjX1" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Option Exercised"&gt;(652,897&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;2.86&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Outstanding, June 30, 2021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zi0GXvSz7SV3" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Options Outstanding at ending"&gt;10,849,202&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zO24Gleu5ap3" style="border-bottom: Black 2.5pt double; color: black; text-align: right"&gt;3.94&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zDIb0TSEN4Bh" style="border-bottom: Black 2.5pt double; color: black; text-align: right"&gt;205,309,996&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: black"&gt;Exercisable, June 30, 2021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Options Exercisable"&gt;7,930,452&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;3.64&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Aggregate intrinsic value Exercisable"&gt;152,413,269&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 58.5pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">8462933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">4115032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">1695000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">68332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">13335</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">10076266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">14982581</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">1455000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">6.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">5.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">29167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">1.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">652897</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-10-012021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">10849202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">205309996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">7930452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">152413269</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">2293925</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">5079395</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1251129</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">4216306</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2020-10-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zFaM8Dq7r2Pa" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BE_z952apFZt7s" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="color: black; text-align: center"&gt;Three months ended June 30,&lt;/td&gt;&lt;td style="color: black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="color: black; text-align: center"&gt;Nine months ended June 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; color: black; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,048,606&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;575,451&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;2,265,387&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,863,869&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;1,245,319&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;675,678&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,814,008&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,352,437&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;Total share based compensation&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Total share based compensation"&gt;2,293,925&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Total share based compensation"&gt;1,251,129&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Total share based compensation"&gt;5,079,395&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Total share based compensation"&gt;4,216,306&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-04-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">1048606</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-04-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">575451</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">2265387</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">1863869</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">1245319</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-04-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">675678</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">2814008</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">2352437</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">2293925</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1251129</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-01to2021-06-30"
      decimals="0"
      unitRef="USD">5079395</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-012020-06-30"
      decimals="0"
      unitRef="USD">4216306</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">6664000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2020-10-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zLVZvEpnKVF5" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_zOekhIMcCEVb" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_491_20201001__20210630_zhAydi1vKHU9" style="color: black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_492_20191001__20200630_zMMdh0NXUYMg" style="color: black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="color: black; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center"&gt;2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_zEzrkh4igtl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; color: black; text-align: left; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;0.71&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1.57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20210630_ztcQdR9VdBJh" title="Expected life of options (years)"&gt;5.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20200630_zsvOeZ87iyT8" title="Expected life of options (years)"&gt;5.53&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zr9dpGCdYKrg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95.87&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97.80&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zOWSvay9Y7I" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-10-01to2021-06-30"
      decimals="INF"
      unitRef="Pure">0.0071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-10-012020-06-30"
      decimals="INF"
      unitRef="Pure">0.0157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-10-01to2021-06-30">P5Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-10-012020-06-30">P5Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-10-01to2021-06-30"
      decimals="INF"
      unitRef="Pure">0.9587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-10-012020-06-30"
      decimals="INF"
      unitRef="Pure">0.9780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-10-01to2021-06-30"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-10-012020-06-30"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979626937656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0608404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">51 West 52nd Street,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">7th Floor,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">1-844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">689-3939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock Par Value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVXL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,707,382<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979630381544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 157,560,045<span></span>
</td>
<td class="nump">$ 29,249,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">8,601,258<span></span>
</td>
<td class="nump">4,849,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and deposits</a></td>
<td class="nump">258,198<span></span>
</td>
<td class="nump">443,839<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">166,419,501<span></span>
</td>
<td class="nump">34,542,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,176,707<span></span>
</td>
<td class="nump">3,989,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">4,653,234<span></span>
</td>
<td class="nump">3,316,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred grant income</a></td>
<td class="nump">443,831<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">9,273,772<span></span>
</td>
<td class="nump">7,305,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CapitalStockValue', window );">Capital Stock</a></td>
<td class="nump">75,151<span></span>
</td>
<td class="nump">62,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">342,938,236<span></span>
</td>
<td class="nump">186,851,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(185,867,658)<span></span>
</td>
<td class="num">(159,677,230)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">157,145,729<span></span>
</td>
<td class="nump">27,236,569<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">&#160;Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 166,419,501<span></span>
</td>
<td class="nump">$ 34,542,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CapitalStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CapitalStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979632961624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">75,149,833<span></span>
</td>
<td class="nump">62,045,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">75,149,833<span></span>
</td>
<td class="nump">62,045,198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979623907688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 2,434,127<span></span>
</td>
<td class="nump">$ 1,381,477<span></span>
</td>
<td class="nump">$ 6,138,528<span></span>
</td>
<td class="nump">$ 4,453,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">8,964,528<span></span>
</td>
<td class="nump">6,725,002<span></span>
</td>
<td class="nump">23,610,888<span></span>
</td>
<td class="nump">19,126,717<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(11,398,655)<span></span>
</td>
<td class="num">(8,106,479)<span></span>
</td>
<td class="num">(29,749,416)<span></span>
</td>
<td class="num">(23,580,371)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">43,280<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,100<span></span>
</td>
<td class="nump">149,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">1,363,661<span></span>
</td>
<td class="nump">1,319,913<span></span>
</td>
<td class="nump">3,593,856<span></span>
</td>
<td class="nump">2,980,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">11,453<span></span>
</td>
<td class="nump">56,096<span></span>
</td>
<td class="nump">19,110<span></span>
</td>
<td class="nump">172,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss), net</a></td>
<td class="num">(160,880)<span></span>
</td>
<td class="nump">248,665<span></span>
</td>
<td class="nump">17,191<span></span>
</td>
<td class="num">(24,182)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,257,514<span></span>
</td>
<td class="nump">1,624,674<span></span>
</td>
<td class="nump">3,684,257<span></span>
</td>
<td class="nump">3,279,158<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before provision for income taxes</a></td>
<td class="num">(10,141,141)<span></span>
</td>
<td class="num">(6,481,805)<span></span>
</td>
<td class="num">(26,065,159)<span></span>
</td>
<td class="num">(20,301,213)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense, current</a></td>
<td class="num">(39,000)<span></span>
</td>
<td class="num">(4,817)<span></span>
</td>
<td class="num">(125,269)<span></span>
</td>
<td class="num">(14,031)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (10,180,141)<span></span>
</td>
<td class="num">$ (6,486,622)<span></span>
</td>
<td class="num">$ (26,190,428)<span></span>
</td>
<td class="num">$ (20,315,244)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_WeightedAverageNumberOfSharesOutstanding', window );">Basic and diluted</a></td>
<td class="nump">70,589,561<span></span>
</td>
<td class="nump">59,105,399<span></span>
</td>
<td class="nump">67,810,774<span></span>
</td>
<td class="nump">57,401,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_WeightedAverageNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_WeightedAverageNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979626924360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows used in Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,190,428)<span></span>
</td>
<td class="num">$ (20,315,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,079,395<span></span>
</td>
<td class="nump">4,216,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in non-cash working capital balances related to operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="num">(3,751,918)<span></span>
</td>
<td class="num">(905,227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="nump">185,641<span></span>
</td>
<td class="nump">62,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">187,653<span></span>
</td>
<td class="nump">456,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">1,336,660<span></span>
</td>
<td class="nump">1,452,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred grant income</a></td>
<td class="nump">443,831<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(22,709,166)<span></span>
</td>
<td class="num">(15,032,274)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows provided by Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares</a></td>
<td class="nump">153,218,758<span></span>
</td>
<td class="nump">20,490,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Share issue costs</a></td>
<td class="num">(5,533,473)<span></span>
</td>
<td class="num">(24,508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">1,466,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">1,868,408<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">151,020,193<span></span>
</td>
<td class="nump">20,465,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase in cash and cash equivalents during the period</a></td>
<td class="nump">128,311,027<span></span>
</td>
<td class="nump">5,433,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">29,249,018<span></span>
</td>
<td class="nump">22,185,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 157,560,045<span></span>
</td>
<td class="nump">$ 27,619,145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979624560952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2019</a></td>
<td class="nump">$ 52,652<span></span>
</td>
<td class="nump">$ 153,633,807<span></span>
</td>
<td class="num">$ (133,396,760)<span></span>
</td>
<td class="nump">$ 20,289,699<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning, shares at Sep. 30, 2019</a></td>
<td class="nump">52,650,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">&#160;Purchase shares</a></td>
<td class="nump">$ 7,365<span></span>
</td>
<td class="nump">20,482,932<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,490,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2', window );">&#160;Commitment shares</a></td>
<td class="nump">65<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptions', window );">Shares issued pursuant to cashless exercise of options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsShares', window );">Shares issued upon exercise of options, shares</a></td>
<td class="nump">721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2', window );">Shares issued under 2019 purchase agreement Commitment shares, shares</a></td>
<td class="nump">66,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued under 2019 purchase agreement Purchase shares, shares</a></td>
<td class="nump">7,364,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,216,306<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,216,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20,315,244)<span></span>
</td>
<td class="num">(20,315,244)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2020</a></td>
<td class="nump">$ 60,083<span></span>
</td>
<td class="nump">178,332,979<span></span>
</td>
<td class="num">(153,712,004)<span></span>
</td>
<td class="nump">24,681,058<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending, shares at Jun. 30, 2020</a></td>
<td class="nump">60,082,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 58,666<span></span>
</td>
<td class="nump">171,958,462<span></span>
</td>
<td class="num">(147,225,382)<span></span>
</td>
<td class="nump">24,791,746<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning, shares at Mar. 31, 2020</a></td>
<td class="nump">58,664,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">&#160;Purchase shares</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">5,123,405<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,124,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2', window );">&#160;Commitment shares</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptions', window );">Shares issued pursuant to cashless exercise of options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsShares', window );">Shares issued upon exercise of options, shares</a></td>
<td class="nump">721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2', window );">Shares issued under 2019 purchase agreement Commitment shares, shares</a></td>
<td class="nump">16,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued under 2019 purchase agreement Purchase shares, shares</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,251,129<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,251,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,486,622)<span></span>
</td>
<td class="num">(6,486,622)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2020</a></td>
<td class="nump">$ 60,083<span></span>
</td>
<td class="nump">178,332,979<span></span>
</td>
<td class="num">(153,712,004)<span></span>
</td>
<td class="nump">24,681,058<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending, shares at Jun. 30, 2020</a></td>
<td class="nump">60,082,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 62,047<span></span>
</td>
<td class="nump">186,851,752<span></span>
</td>
<td class="num">(159,677,230)<span></span>
</td>
<td class="nump">27,236,569<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning, shares at Sep. 30, 2020</a></td>
<td class="nump">62,045,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">&#160;Purchase shares</a></td>
<td class="nump">$ 4,008<span></span>
</td>
<td class="nump">24,107,190<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,111,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2', window );">&#160;Commitment shares</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsShares', window );">Shares issued upon exercise of options, shares</a></td>
<td class="nump">652,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts', window );">Shares issued under Sales Agreement, net of share issue costs</a></td>
<td class="nump">5,634,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2', window );">Shares issued under 2019 purchase agreement Commitment shares, shares</a></td>
<td class="nump">78,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued under Sales Agreement, net of share issue costs</a></td>
<td class="nump">$ 5,634<span></span>
</td>
<td class="nump">76,664,391<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">76,670,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued under 2019 purchase agreement Purchase shares, shares</a></td>
<td class="nump">4,007,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts', window );">Shares issued pursuant to registered direct offering, net of share issue costs</a></td>
<td class="nump">$ 2,381<span></span>
</td>
<td class="nump">46,901,681<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">46,904,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares', window );">Shares issued pursuant to registered direct offering, net of share issue costs, Shares</a></td>
<td class="nump">2,380,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPusuantToExerciseOfWarrants', window );">Shares issued pusuant to exercise of warrants</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">1,466,150<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,466,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued upon exercise of stock options</a></td>
<td class="nump">$ 653<span></span>
</td>
<td class="nump">1,867,755<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,868,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPusuantToExerciseOfWarrantsShares', window );">Shares issued pusuant to exercise of warrants, Shares</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,079,395<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,079,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(26,190,428)<span></span>
</td>
<td class="num">(26,190,428)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 75,151<span></span>
</td>
<td class="nump">342,938,236<span></span>
</td>
<td class="num">(185,867,658)<span></span>
</td>
<td class="nump">157,145,729<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending, shares at Jun. 30, 2021</a></td>
<td class="nump">75,149,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 70,032<span></span>
</td>
<td class="nump">251,427,781<span></span>
</td>
<td class="num">(175,687,517)<span></span>
</td>
<td class="nump">75,810,296<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning, shares at Mar. 31, 2021</a></td>
<td class="nump">70,030,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued under Sales Agreement, net of share issue costs</a></td>
<td class="nump">$ 2,082<span></span>
</td>
<td class="nump">39,979,399<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">39,981,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued under 2019 purchase agreement Purchase shares, shares</a></td>
<td class="nump">2,082,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts', window );">Shares issued pursuant to registered direct offering, net of share issue costs</a></td>
<td class="nump">$ 2,381<span></span>
</td>
<td class="nump">46,901,681<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">46,904,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares', window );">Shares issued pursuant to registered direct offering, net of share issue costs, Shares</a></td>
<td class="nump">2,380,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPusuantToExerciseOfWarrants', window );">Shares issued pusuant to exercise of warrants</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">1,466,150<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,466,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued upon exercise of stock options</a></td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">869,300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">869,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedUponExerciseOfOptionsShares', window );">Shares issued upon exercise of options, shares</a></td>
<td class="nump">305,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPusuantToExerciseOfWarrantsShares', window );">Shares issued pusuant to exercise of warrants, Shares</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,293,925<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,293,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,180,141)<span></span>
</td>
<td class="num">(10,180,141)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 75,151<span></span>
</td>
<td class="nump">$ 342,938,236<span></span>
</td>
<td class="num">$ (185,867,658)<span></span>
</td>
<td class="nump">$ 157,145,729<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending, shares at Jun. 30, 2021</a></td>
<td class="nump">75,149,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment shares issued shares underterms of purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPusuantToExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPusuantToExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPusuantToExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPusuantToExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUponExerciseOfOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUponExerciseOfOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979628242488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Description and Basis of Presentation</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zhhjFNwEkW1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 42pt; text-align: left">Note 1</td><td style="text-align: justify"><span style="text-decoration: underline"><span id="xdx_82A_zUO5DzJkHDoa">Business Description
and Basis of Presentation</span></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42pt; text-align: justify; text-indent: 0pt">Business</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221;
or the &#8220;Company&#8221;) <span style="color: black">is a clinical stage biopharmaceutical company engaged in the development
of differentiated therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high
unmet need. Anavex analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will
receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. </span>The Company&#8217;s
lead compound ANAVEX<sup>&#174;</sup>2-73 <span style="color: black">is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s
disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological
monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">On May 25, 2021, the Company filed
a Certificate of Amendment to its Articles of Incorporation with the Secretary of the State of Nevada effecting an amendment to
increase the number of authorized shares of the Company&#8217;s common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210525_z8AbwXUUyDza" title="Common stock, par value">0.001 </span>per share, from <span id="xdx_908_eus-gaap--ExcessStockSharesAuthorized_iI_c20210525__srt--RangeAxis__srt--MinimumMember_zx1M2oZ5SxFk">100,000,000</span> shares
to <span id="xdx_905_eus-gaap--ExcessStockSharesAuthorized_iI_c20210525__srt--RangeAxis__srt--MaximumMember_zewSnWm0soxl">200,000,000</span> shares. The Certificate of Amendment was approved by the Company&#8217;s stockholders at an annual meeting of stockholders
on May 25, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxbVJpCHdrD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 42.55pt"><span id="xdx_863_z4w2j1Gyuuce">Basis of
Presentation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">These unaudited interim condensed
consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission
(&#8220;SEC&#8221;) and accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for
interim reporting.<span style="color: black"> Accordingly, certain information and note disclosures normally included in the annual
financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the
opinion of management, the disclosures are adequate to make the information presented not misleading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">These accompanying unaudited interim
condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion
of management are necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September
30, 2020 was derived from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The
accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K for the year ended September
30, 2020 filed with the SEC on December 28, 2020. The Company follows the same accounting policies in the preparation of interim
reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="color: black">Operating
results for the three and nine months ended </span>June 30<span style="color: black">, 2021 are not necessarily indicative of the
results that may be expected for the year ending September 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;&#160;</p>

<p id="xdx_848_ecustom--LiquidityPolicyTextBlock_zgpITkUS9fIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span id="xdx_86C_zfo8cXMui8Uf">Liquidity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">All of the Company&#8217;s potential
drug compounds are in the clinical development stage and the Company cannot be certain that its research and development efforts
will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies
or generate commercial revenues. To date, we have not generated any revenues from our operations. The Company expects the business
to continue to experience negative cash flows for the foreseeable future and cannot predict when, if ever, our business might become
profitable.</p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Management believes that the current
working capital position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months
after the date that these interim condensed consolidated financial statements are issued. The process of drug development can be
costly, and the timing and outcomes of clinical trials is uncertain.&#160;The assumptions upon which the Company has based its
estimates are routinely evaluated and may be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will
vary depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials,
the progress of the Company&#8217;s research and development programs and the level of financial resources available. The Company
has the ability to adjust its operating plan spending levels based on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Other than our rights related to
the Sales Agreement (as defined below in Note 4), there can be no assurance that additional financing will be available to us when
needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional
financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and
development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">In December 2019, a novel strain
of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World Health Organization declared
COVID-19 to be a global pandemic as a result of the rapid spread of the virus beyond its point of origin.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The global outbreak of COVID-19
continues to rapidly evolve as of the date these interim condensed consolidated financial statements are issued. As such, it is
uncertain as to the full magnitude that the outbreak will have on the Company&#8217;s financial condition and future results of
operations. Management is actively monitoring the global situation on its business, including on its clinical trials and operations
and financial condition. The effects of COVID-19 did not have a material impact on the Company&#8217;s result of operations or
financial condition for the period ended June 30, 2021. However, given the daily evolution of the COVID-19 situation, and the global
responses to curb its spread, the Company is not able to estimate the effects COVID-19 may have on its future results of operations
or financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><i style="font-style: normal; font-weight: normal">Use of Estimates</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The preparation of financial statements
in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The
Company regularly evaluates estimates and assumptions related to accounting for research and development costs, valuation and recoverability
of deferred tax assets, incentive and tax receivables, asset impairment, stock-based compensation, and loss contingencies. The
Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes
to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of
assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent there are material
differences between the estimates and the actual results, future results of operations will be affected.</p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Principles of Consolidation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">These consolidated financial statements
include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited., a company
incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex Canada
Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><i style="font-style: normal; font-weight: normal">Fair Value Measurements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The fair value hierarchy under
GAAP is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be
used to measure fair value which are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 1 -
	quoted prices (unadjusted) in active markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 2 -
observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical
or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose
significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 3 -
	assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The book value of cash and cash
equivalents and accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of those
instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">At June 30, 2021 and September
30, 2020, the Company did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><i style="font-style: normal; font-weight: normal">Basic and Diluted
Loss per Share</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Basic income/(loss) per common
share is computed by dividing net income/(loss) available to common stockholders by the weighted average number of common shares
outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common
stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive effect
of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially
dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are potentially dilutive
securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">As of June 30, 2021, loss per share
excludes <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210630_pdd" title="Loss per share for potentially dilutive common shares">11,059,202</span> (September 30, 2020 &#8211; <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20191001__20200930_pdd" title="Loss per share for potentially dilutive common shares">10,576,266</span>) potentially dilutive common shares related to outstanding options and
warrants, as their effect was anti-dilutive.</p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979628312696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_z9betADO0Syk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 130.6pt 0 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 42pt; text-align: left">Note 2</td><td style="text-align: justify"><span style="text-decoration: underline"><span id="xdx_82E_z0ifvhz4vHZ6">Recent Accounting Pronouncements</span></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><i>Recent Accounting Pronouncements
Not Yet Adopted</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company does not expect the
adoption of recently issued accounting pronouncements to have a significant impact on its results of operations, financial position
or cash flows.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979628425480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DisclosureOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income</a></td>
<td class="text"><p id="xdx_80D_ecustom--OtherIncomeDisclosureTextBlock_zbJZYOkloxza" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 42pt; text-align: left">Note 3</td><td style="text-align: justify"><span style="text-decoration: underline"><span id="xdx_826_zTXy9RVvs1Ob">Other Income</span></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">Grant Income</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">During the
nine months ended June 30, 2021, the Company received $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ParkinsonMember_pp0p0" title="Research and development incentive income">497,931</span> of a $995,862 research grant awarded by the Michael J. Fox Foundation
for Parkinson&#8217;s Research. The grant will be used to fund a clinical trial in the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73
for the treatment of Parkinson&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">The grant
income is being deferred when received and amortized to other income as the related research and development expenditures are incurred.
During the three and nine months ended June 30, 2021, the Company recognized $<span id="xdx_904_ecustom--NonOperatingIncomeFromGrant_c20210401__20210630_pp0p0" title="Grant income">43,280</span> and $<span id="xdx_908_ecustom--NonOperatingIncomeFromGrant_c20201001__20210630_pp0p0" title="Grant income">54,100</span>, respectively of this grant on
its statements of operations within grant income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">During the
year ended September 30, 2017, the Company was awarded grant funding in the amount of $<span id="xdx_908_ecustom--NonOperatingIncomeFromGrant_c20161001__20170930_pp0p0" title="Grant income">597,886</span>. The grant was received in equal
quarterly installments over a period of two years ending during the year ended September 30, 2020, in exchange for a commitment
to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">The grant
income was deferred when received and amortized to other income as the related research and development expenditures were incurred.
During the three and nine months ended June 30, 2020, the Company recognized $nil and $<span id="xdx_901_ecustom--NonOperatingIncomeFromGrant_c20191001__20200630_pp0p0" title="Grant income">149,888</span>, respectively of this grant on its
statements of operations within grant income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">Research
and Development Incentive Income</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">Research
and development incentive income represents income earned by the Company&#8217;s Australian subsidiary, of the <span style="color: black">Australian
research and development incentive credit, </span>(the &#8220;ATO R&amp;D Credit&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">During the
three and nine months ended June 30, 2021, the Company recorded research and development incentive income of $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20210401__20210630_pp0p0" title="Research and development incentive income">1,363,661</span> (AUD <span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20210401__20210630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income">1,770,444</span>)
and $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210630_pp0p0" title="Research and development incentive income">3,593,856 </span>(AUD <span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income">4,750,539</span>) (2020: $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20200401__20200630_pp0p0" title="Research and development incentive income">1,319,913</span> (AUD <span id="xdx_906_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20200401__20200630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income">1,923,000</span>) and $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20191001__20200630_pp0p0" title="Research and development incentive income">2,980,456</span> (AUD <span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20191001__20200630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income">4,471,000</span>)), respectively, in respect of the
ATO R&amp;D Credit for eligible research and development expenses incurred during the period.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979628195912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DisclosureEquityOfferingsAbstract', window );"><strong>Equity Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_EquityOfferingAgreementsTextBlock', window );">Equity Offerings</a></td>
<td class="text"><p id="xdx_80B_ecustom--EquityOfferingAgreementsTextBlock_zJr0lD85aytc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 42pt; text-align: left">Note 4</td><td style="text-align: justify"><span style="text-decoration: underline"><span id="xdx_82A_zR1783jA5m2c">Equity Offerings</span></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Registered Direct Offering</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">On June 22, 2021, the Company and
Deep Track Capital entered into a securities purchase agreement pursuant to which the Company sold to Deep Track Capital an aggregate
of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210601__20210622__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zR6mGDdDeuo5" title="Share issued for offering, shares">2,380,953</span> shares of common stock at $<span id="xdx_90D_eus-gaap--SharePrice_iI_pp0p0_c20210622__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zJjzmvmTiZE2" title="Common stock price">21</span> per share in a registered direct offering, for gross proceeds of $<span id="xdx_90E_ecustom--GrossProceedsFromSaleOfCommonStock_pp0p0_c20210601__20210622__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zttELwpFLcfi" title="Gross proceeds from sale of common stock">50,000,013</span>. Net proceeds
of the offering were $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20210601__20210622__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z1CDELzc6tb4" title="Proceed from offering">46,904,062 </span>after deducting offering fees and expenses.</p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Sales Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company entered into a Controlled
Equity Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;Sales Agreement&#8221;)
with Cantor Fitzgerald&#160;&amp; Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company
may offer and sell shares of common stock registered under an effective registration statement from time to time through the Sales
Agents (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Upon delivery of a placement notice
based on the Company&#8217;s instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may
sell the Shares by methods deemed to be an &#8220;at the market offering&#8221; offering, in negotiated transactions at market
prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted by
law, including negotiated transactions, subject to the prior written consent of the Company. The Company is not obligated to make
any sales of Shares under the Sales Agreement. The Company or Sales Agents may suspend or terminate the offering of Shares upon
notice to the other party, subject to certain conditions. The Sales Agents will act as agent on a commercially reasonable efforts
basis consistent with their normal trading and sales practices and applicable state and federal law, rules&#160;and regulations
and the rules&#160;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company has agreed to pay the
Sales Agents commissions for their services of up to <span id="xdx_901_ecustom--PercentageOfGrossProceedsFromSales_dp_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zngz6jyIzOG4" title="Percentage of gross proceeds from sales">3.0</span>% of the gross proceeds from the sale of the Shares pursuant to the Sales
Agreement. The Company also agreed to provide the Sales Agents with customary indemnification and contribution rights. During the
nine months ended June 30, 2021, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Share issued for offering, shares">5,634,576</span> shares were sold pursuant to the Offering for gross proceeds of $<span id="xdx_906_ecustom--GrossProceedsFromSaleOfCommonStock_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross proceeds from sale of common stock">79,107,547</span> (net proceeds
of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceed from offering">76,670,025</span> after deducting offering expenses).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">2019 Purchase Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">On June 7, 2019, the Company entered
into a $<span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Total number of shares obligated to purchase">50,000,000</span> purchase agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln Park, as amended on July 1, 2020,
pursuant to which the Company had the right to sell and issue to Lincoln Park, and Lincoln Park was obligated to purchase, up to
$<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Proceeds from Issuance or Sale of Equity">50,000,000 </span>in value of its shares of common stock from time to time over a three-year period until July 1, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">In consideration for entering into
the 2019 Purchase Agreement, the Company issued to Lincoln Park <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares">324,383</span> shares of common stock as a commitment fee during the year
ended September 30, 2019 and agreed to issue up to <span id="xdx_90A_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Pro rata basic number of shares obligated to purchase">162,191</span> shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s
discretion, the $50,000,000 aggregate commitment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">During the nine months ended June
30, 2021, the Company issued to Lincoln Park an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares">4,086,209</span> (2020 &#8211; <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares">7,431,049</span>) shares of common stock under the
2019 Purchase Agreement, including <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for aggregate purchase price">4,007,996</span> (2020: <span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for aggregate purchase price">7,364,584</span>) shares of common stock for an aggregate purchase price of $<span id="xdx_904_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value">24,111,198</span>
(2020: $<span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value">20,490,297</span>) and <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for commitment">78,213 </span>(2020: <span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for commitment">66,465</span>) commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">At June 30, 2021, <span id="xdx_901_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_do_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z1pZMS22sfic" title="Amount of shares remain available">no</span> amount remained
available under the 2019 Purchase Agreement (September 30, 2020: $<span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueNewIssues4_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Amount of shares remain available">24,111,198</span>).</p>













<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureEquityOfferingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureEquityOfferingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979630200936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_807_eus-gaap--CommitmentsDisclosureTextBlock_zIkJvyhMG1I2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 42pt; text-align: left">Note 5</td><td style="text-align: justify"> <span style="text-decoration: underline"><span id="xdx_82C_zlOevWvPjd6g">Commitments and Contingencies</span></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"><span style="font-size: 11pt">a)</span><span style="font: 7pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;
</span><span style="font-size: 10pt"><i style="font-style: normal; font-weight: normal">Leases </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">During
the three and nine months ended June 30, 2021, the Company incurred office lease expense of $<span id="xdx_908_eus-gaap--LeaseAndRentalExpense_c20210401__20210630_pp0p0" title="Lease expense">18,994</span> and $<span id="xdx_904_eus-gaap--LeaseAndRentalExpense_c20201001__20210630_pp0p0" title="Lease expense">117,284</span>, respectively
(2020: $<span id="xdx_906_eus-gaap--LeaseAndRentalExpense_c20200401__20200630_pp0p0" title="Lease expense">58,554</span> and $<span id="xdx_90B_eus-gaap--LeaseAndRentalExpense_c20191001__20200630_pp0p0" title="Lease expense">169,469</span>, respectively).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"><span style="font-size: 11pt">b)</span><span style="font: 7pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;
</span><span style="font-size: 10pt"><i style="font-style: normal; font-weight: normal">Litigation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain,
and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution
of any such matter will not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company
does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its consolidated
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"><span style="font-size: 11pt">c)</span><span style="font: 7pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;
</span><span style="font-size: 10pt"><i style="font-style: normal; font-weight: normal">Share Purchase Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">A summary of the status of the Company&#8217;s
outstanding share purchase warrants is presented below:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zG3bATHydCJ6" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span id="xdx_8B3_zWem4hVgSjh7" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Number of Shares</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Weighted Average Exercise Price ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; width: 26%; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Balance, September 30, 2019</span></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 8%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zZt7I7LCPgp2" style="width: 26%; color: black; text-align: right" title="Share Purchase Warrants Balance, at beginning">350,000</td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 8%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgcydGQ8Rqha" style="width: 26%; color: black; text-align: right" title="Weighted Average Exercise Price warrants outstanding at beginning">4.19</td><td style="width: 1%; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Granted</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Share Purchase Warrants Granted">150,000</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price warrants granted">3.17</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Balance, September 30, 2020</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmCdkSLH3Dx9" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Share Purchase Warrants Balance, at ending">500,000</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zqlxyNN9AmMg" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price Balance, at ending">3.88</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Granted</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="color: black; text-align: right" title="Share Purchase Warrants Granted">60,000</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price warrants granted">12.00</td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Exercised</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zIG3Y1h7hoLe" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Share Purchase Warrants Exercised">(350,000</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zAkki7I1YtZ4" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price warrants exercised">4.19</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Balance, June 30, 2021</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zY7gAfHgrpP" style="border-bottom: Black 1pt solid; color: black; text-align: right">210,000</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z214rzU2BAn9" style="border-bottom: Black 1pt solid; color: black; text-align: right">5.69</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AC_zlJXGQXwINx1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-indent: -0.8pt">At June 30, 2021, the Company had
share purchase warrants outstanding as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-indent: -0.8pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zDKAuYt6dEG" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="color: black; text-align: center"><span id="xdx_8B0_zXQOBbmxKaSl" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="color: black; text-align: center">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="color: black; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="color: black; text-align: center">Number</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Exercise Price</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; width: 12%; color: black; text-align: right; text-indent: -10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Number">150,000</span></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 8%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 12%; color: black; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Exercise Price">3.17</span></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 8%; color: black">&#160;</td>
    <td style="width: 30%; color: black; text-align: right; padding-left: 0.65pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zHM2VWOB4VFk" title="Warrants and Rights Outstanding, Maturity Date">May 6, 2024</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; color: black; text-align: right; text-indent: -10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Number">60,000</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Exercise Price">12.00</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="color: black; text-align: right; padding-bottom: 1pt; padding-left: 0.65pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zG4VWGu67Aa4" title="Warrants and Rights Outstanding, Maturity Date">April 21, 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; padding: 0pt 0pt 0pt 10pt; color: black; text-align: right; text-indent: -10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210630_pdd" title="Number">210,000</span></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 0.65pt">&#160;</td></tr>
  </table>


<p id="xdx_8A4_zLtsZsKbyRy" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 99.25pt; text-indent: -0.8pt">&#160;</p>















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; text-indent: -18pt; color: black"><span style="font-size: 11pt">d)</span><span style="font: 7pt Times New Roman, Times, Serif">&#160;&#160;
</span><i style="font-style: normal; font-weight: normal">Stock&#8211;based Compensation Plan</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">2015 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">On September 18, 2015, the Company&#8217;s
Board of Directors (the &#8220;Board&#8221;) approved a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided
for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">The maximum number of our common shares
reserved for issue under the plan was <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Maximum number of common shares reserved for future issuance">6,050,553</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.
At June 30, 2021, <span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--OptionsMember_pdd" title="Maximum number of common shares reserved for future issuance">146,371</span> (September 30, 2020: <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--OptionsMember_pdd" title="Maximum number of common shares reserved for future issuance">146,371</span>) options remain available for issue under the 2015 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">2019 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">On January 15, 2019, the Board approved
the 2019 Omnibus Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock
awards to directors, officers, employees, consultants and advisors of the Company. Under the terms of the 2019 Plan, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Additional shares of common stock available for issuance">6,000,000</span>
additional shares of Common Stock are available for issuance under the 2019 Plan, in addition to the shares available under the
2015 Plan. Any awards outstanding under the 2015 Plan or the Company&#8217;s 2007 Stock Option Plan (the &#8220;2007 Plan&#8221;)
will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and any shares subject to outstanding awards
under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards (other than by reason of settlement of
the awards in shares) will automatically become available for issuance under the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member" title="Description of grant option">The 2019 Plan provides that it may
be administered by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined
by the Board at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder
on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common
stock on the grant date. Stock options may be granted under the 2019 Plan for an exercise period of up to ten years from the date
of grant of the option or such lesser periods as may be determined by the Board, subject to earlier termination in accordance with
the terms of the 2019 Plan. At June 30, 2021, <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Maximum number of common shares reserved for future issuance">1,706,665</span> (September 30, 2020: <span id="xdx_907_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Maximum number of common shares reserved for future issuance">3,161,665</span>) options remain available for issue under
the 2019 Plan.</span></p>





















<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 2cm">A summary of the status of Company&#8217;s outstanding
stock options is presented below:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 2cm">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zcTlezsbyhr1" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span id="xdx_8B6_zp2UmFGfrnkc" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#160;</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#160;</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#160;</td><td style="color: black; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Number of Shares</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Weighted Average Exercise Price ($)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Weighted Average Grant Date Fair Value ($)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: center">Aggregate intrinsic value ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; width: 20%; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Outstanding, September 30, 2019</span></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 5%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zZi9dn5TUxF9" style="width: 19%; color: black; text-align: right" title="Options Outstanding at beginning">8,462,933</td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 5%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z3GmxeYlX9uf" style="width: 19%; color: black; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">3.58</td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; color: black">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zaIDX87OaK74" style="color: black; text-align: right" title="Aggregate intrinsic value Outstanding at beginning">4,115,032</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Granted</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Options Granted">1,695,000</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price Granted">2.96</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Grant Date Fair Value Granted">2.27</td><td style="color: black; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Forfeited</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zWhXJEMOXRA9" style="color: black; text-align: right" title="Options Forfeited">(68,332</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price Forfeited">3.01</td><td style="color: black; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Exercised&#160;</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z9tl9xthn3Ed" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Option Exercised">(13,335</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price Exercised">3.15</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Outstanding, September 30, 2020</span></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z0OqkVdTu2j1" style="border-bottom: Black 2.5pt double; color: black; text-align: right">10,076,266</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zrpkO0nJPtAl" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Weighted Average Exercise Price Outstanding at ending">3.48</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zAUOsn8yz2Ll" style="border-bottom: Black 2.5pt double; color: black; text-align: right">14,982,581</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Granted&#160;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Options Granted">1,455,000</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price Granted">6.59</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Grant Date Fair Value Granted">5.02</td><td style="color: black; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Forfeited</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCjQLOYsmJbc" style="color: black; text-align: right" title="Options Forfeited">(29,167</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price Forfeited">1.44</td><td style="color: black; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Exercised&#160;</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOJJK2IZbjX1" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Option Exercised">(652,897</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price Exercised">2.86</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Outstanding, June 30, 2021&#160;</span></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zi0GXvSz7SV3" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Options Outstanding at ending">10,849,202</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zO24Gleu5ap3" style="border-bottom: Black 2.5pt double; color: black; text-align: right">3.94</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zDIb0TSEN4Bh" style="border-bottom: Black 2.5pt double; color: black; text-align: right">205,309,996</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Exercisable, June 30, 2021&#160;</span></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Options Exercisable">7,930,452</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Weighted Average Exercise Price, Exercisable">3.64</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Aggregate intrinsic value Exercisable">152,413,269</td></tr>
  </table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">&#160;</p>

<p id="xdx_8A0_zKDIGJ8QmK2k" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 2cm">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the
options that were in-the-money at June 30, 2021.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 2cm">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">During the three and nine months ended
June 30, 2021, the Company recognized stock-based compensation expense of $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20210401__20210630_pp0p0" title="Stock-based compensation expense">2,293,925</span> and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20201001__20210630_pp0p0" title="Stock-based compensation expense">5,079,395</span>, respectively (2020: $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20200401__20200630_pp0p0" title="Stock-based compensation expense">1,251,129
</span>and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20191001__20200630_pp0p0" title="Stock-based compensation expense">4,216,306</span>, respectively) in connection with the issuance and vesting 	of stock options and warrants in exchange for services.
These amounts have been included in general and 	administrative expenses and research and development expenses on the Company&#8217;s
statements of 	operations as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zFaM8Dq7r2Pa" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span id="xdx_8BE_z952apFZt7s" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black">&#160;</td>
    <td colspan="7" style="color: black; text-align: center">Three months ended June 30,</td><td style="color: black">&#160;</td>
    <td colspan="7" style="color: black; text-align: center">Nine months ended June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2021</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2020</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2021</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; color: black; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation">1,048,606</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation">575,451</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation">2,265,387</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation">1,863,869</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">1,245,319</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">675,678</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,814,008</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,352,437</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Total share based compensation</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Total share based compensation">2,293,925</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Total share based compensation">1,251,129</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Total share based compensation">5,079,395</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Total share based compensation">4,216,306</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AD_zx4xeshKWBng" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">An amount of approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20210630_pp0p0" title="Remaining stock based compensation">6,664,000</span>
in stock-based compensation is expected to be recorded over the remaining term 	of such options through fiscal 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">The fair
value of each option award granted during the nine months ended June 30, 2021 and 2020 is estimated on the date of grant using
the Black Scholes option pricing model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zLVZvEpnKVF5" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B7_zOekhIMcCEVb" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_491_20201001__20210630_zhAydi1vKHU9" style="color: black; text-align: center">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_492_20191001__20200630_zMMdh0NXUYMg" style="color: black; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2021</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2020</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_zEzrkh4igtl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; color: black; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">0.71</td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1.57</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20210630_ztcQdR9VdBJh" title="Expected life of options (years)">5.66</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20200630_zsvOeZ87iyT8" title="Expected life of options (years)">5.53</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zr9dpGCdYKrg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95.87</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97.80</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zOWSvay9Y7I" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  </table>


<p id="xdx_8AA_zOv4f1JK5yae" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979628299976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxbVJpCHdrD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 42.55pt"><span id="xdx_863_z4w2j1Gyuuce">Basis of
Presentation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">These unaudited interim condensed
consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission
(&#8220;SEC&#8221;) and accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for
interim reporting.<span style="color: black"> Accordingly, certain information and note disclosures normally included in the annual
financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the
opinion of management, the disclosures are adequate to make the information presented not misleading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">These accompanying unaudited interim
condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion
of management are necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September
30, 2020 was derived from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The
accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K for the year ended September
30, 2020 filed with the SEC on December 28, 2020. The Company follows the same accounting policies in the preparation of interim
reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="color: black">Operating
results for the three and nine months ended </span>June 30<span style="color: black">, 2021 are not necessarily indicative of the
results that may be expected for the year ending September 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_848_ecustom--LiquidityPolicyTextBlock_zgpITkUS9fIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span id="xdx_86C_zfo8cXMui8Uf">Liquidity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">All of the Company&#8217;s potential
drug compounds are in the clinical development stage and the Company cannot be certain that its research and development efforts
will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies
or generate commercial revenues. To date, we have not generated any revenues from our operations. The Company expects the business
to continue to experience negative cash flows for the foreseeable future and cannot predict when, if ever, our business might become
profitable.</p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Management believes that the current
working capital position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months
after the date that these interim condensed consolidated financial statements are issued. The process of drug development can be
costly, and the timing and outcomes of clinical trials is uncertain.&#160;The assumptions upon which the Company has based its
estimates are routinely evaluated and may be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will
vary depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials,
the progress of the Company&#8217;s research and development programs and the level of financial resources available. The Company
has the ability to adjust its operating plan spending levels based on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Other than our rights related to
the Sales Agreement (as defined below in Note 4), there can be no assurance that additional financing will be available to us when
needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional
financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and
development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">In December 2019, a novel strain
of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World Health Organization declared
COVID-19 to be a global pandemic as a result of the rapid spread of the virus beyond its point of origin.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The global outbreak of COVID-19
continues to rapidly evolve as of the date these interim condensed consolidated financial statements are issued. As such, it is
uncertain as to the full magnitude that the outbreak will have on the Company&#8217;s financial condition and future results of
operations. Management is actively monitoring the global situation on its business, including on its clinical trials and operations
and financial condition. The effects of COVID-19 did not have a material impact on the Company&#8217;s result of operations or
financial condition for the period ended June 30, 2021. However, given the daily evolution of the COVID-19 situation, and the global
responses to curb its spread, the Company is not able to estimate the effects COVID-19 may have on its future results of operations
or financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><i style="font-style: normal; font-weight: normal">Use of Estimates</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The preparation of financial statements
in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The
Company regularly evaluates estimates and assumptions related to accounting for research and development costs, valuation and recoverability
of deferred tax assets, incentive and tax receivables, asset impairment, stock-based compensation, and loss contingencies. The
Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes
to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of
assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent there are material
differences between the estimates and the actual results, future results of operations will be affected.</p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Principles of Consolidation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">These consolidated financial statements
include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited., a company
incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex Canada
Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><i style="font-style: normal; font-weight: normal">Fair Value Measurements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The fair value hierarchy under
GAAP is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be
used to measure fair value which are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 1 -
	quoted prices (unadjusted) in active markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 2 -
observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical
or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose
significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 3 -
	assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The book value of cash and cash
equivalents and accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of those
instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">At June 30, 2021 and September
30, 2020, the Company did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><i style="font-style: normal; font-weight: normal">Basic and Diluted
Loss per Share</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Basic income/(loss) per common
share is computed by dividing net income/(loss) available to common stockholders by the weighted average number of common shares
outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common
stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive effect
of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially
dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are potentially dilutive
securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">As of June 30, 2021, loss per share
excludes <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210630_pdd" title="Loss per share for potentially dilutive common shares">11,059,202</span> (September 30, 2020 &#8211; <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20191001__20200930_pdd" title="Loss per share for potentially dilutive common shares">10,576,266</span>) potentially dilutive common shares related to outstanding options and
warrants, as their effect was anti-dilutive.</p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979641541688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Schedule of exercisable share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zG3bATHydCJ6" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span id="xdx_8B3_zWem4hVgSjh7" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Number of Shares</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Weighted Average Exercise Price ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; width: 26%; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Balance, September 30, 2019</span></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 8%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zZt7I7LCPgp2" style="width: 26%; color: black; text-align: right" title="Share Purchase Warrants Balance, at beginning">350,000</td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 8%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgcydGQ8Rqha" style="width: 26%; color: black; text-align: right" title="Weighted Average Exercise Price warrants outstanding at beginning">4.19</td><td style="width: 1%; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Granted</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Share Purchase Warrants Granted">150,000</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price warrants granted">3.17</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Balance, September 30, 2020</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmCdkSLH3Dx9" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Share Purchase Warrants Balance, at ending">500,000</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zqlxyNN9AmMg" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price Balance, at ending">3.88</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Granted</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="color: black; text-align: right" title="Share Purchase Warrants Granted">60,000</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price warrants granted">12.00</td><td style="color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Exercised</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zIG3Y1h7hoLe" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Share Purchase Warrants Exercised">(350,000</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zAkki7I1YtZ4" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price warrants exercised">4.19</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Balance, June 30, 2021</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zY7gAfHgrpP" style="border-bottom: Black 1pt solid; color: black; text-align: right">210,000</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20201001__20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z214rzU2BAn9" style="border-bottom: Black 1pt solid; color: black; text-align: right">5.69</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock', window );">Schedule of share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zDKAuYt6dEG" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="color: black; text-align: center"><span id="xdx_8B0_zXQOBbmxKaSl" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="color: black; text-align: center">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="color: black; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="color: black; text-align: center">Number</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Exercise Price</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; width: 12%; color: black; text-align: right; text-indent: -10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Number">150,000</span></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 8%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 12%; color: black; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Exercise Price">3.17</span></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 8%; color: black">&#160;</td>
    <td style="width: 30%; color: black; text-align: right; padding-left: 0.65pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zHM2VWOB4VFk" title="Warrants and Rights Outstanding, Maturity Date">May 6, 2024</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; color: black; text-align: right; text-indent: -10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Number">60,000</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Exercise Price">12.00</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="color: black; text-align: right; padding-bottom: 1pt; padding-left: 0.65pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zG4VWGu67Aa4" title="Warrants and Rights Outstanding, Maturity Date">April 21, 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; padding: 0pt 0pt 0pt 10pt; color: black; text-align: right; text-indent: -10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210630_pdd" title="Number">210,000</span></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 0.65pt">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of outstanding stock purchase options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zcTlezsbyhr1" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span id="xdx_8B6_zp2UmFGfrnkc" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#160;</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#160;</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#160;</td><td style="color: black; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Number of Shares</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Weighted Average Exercise Price ($)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">Weighted Average Grant Date Fair Value ($)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: center">Aggregate intrinsic value ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; width: 20%; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Outstanding, September 30, 2019</span></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 5%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zZi9dn5TUxF9" style="width: 19%; color: black; text-align: right" title="Options Outstanding at beginning">8,462,933</td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 5%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z3GmxeYlX9uf" style="width: 19%; color: black; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">3.58</td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; color: black">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zaIDX87OaK74" style="color: black; text-align: right" title="Aggregate intrinsic value Outstanding at beginning">4,115,032</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Granted</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Options Granted">1,695,000</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price Granted">2.96</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Grant Date Fair Value Granted">2.27</td><td style="color: black; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Forfeited</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zWhXJEMOXRA9" style="color: black; text-align: right" title="Options Forfeited">(68,332</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price Forfeited">3.01</td><td style="color: black; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Exercised&#160;</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z9tl9xthn3Ed" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Option Exercised">(13,335</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price Exercised">3.15</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Outstanding, September 30, 2020</span></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z0OqkVdTu2j1" style="border-bottom: Black 2.5pt double; color: black; text-align: right">10,076,266</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zrpkO0nJPtAl" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Weighted Average Exercise Price Outstanding at ending">3.48</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zAUOsn8yz2Ll" style="border-bottom: Black 2.5pt double; color: black; text-align: right">14,982,581</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Granted&#160;</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Options Granted">1,455,000</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price Granted">6.59</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Grant Date Fair Value Granted">5.02</td><td style="color: black; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Forfeited</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCjQLOYsmJbc" style="color: black; text-align: right" title="Options Forfeited">(29,167</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="color: black; text-align: right" title="Weighted Average Exercise Price Forfeited">1.44</td><td style="color: black; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Exercised&#160;</span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOJJK2IZbjX1" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Option Exercised">(652,897</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 1pt solid; color: black; text-align: right" title="Weighted Average Exercise Price Exercised">2.86</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Outstanding, June 30, 2021&#160;</span></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zi0GXvSz7SV3" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Options Outstanding at ending">10,849,202</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zO24Gleu5ap3" style="border-bottom: Black 2.5pt double; color: black; text-align: right">3.94</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20201001__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zDIb0TSEN4Bh" style="border-bottom: Black 2.5pt double; color: black; text-align: right">205,309,996</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Exercisable, June 30, 2021&#160;</span></td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Options Exercisable">7,930,452</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Weighted Average Exercise Price, Exercisable">3.64</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Aggregate intrinsic value Exercisable">152,413,269</td></tr>
  </table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of general and administrative expenses and research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zFaM8Dq7r2Pa" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span id="xdx_8BE_z952apFZt7s" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black">&#160;</td>
    <td colspan="7" style="color: black; text-align: center">Three months ended June 30,</td><td style="color: black">&#160;</td>
    <td colspan="7" style="color: black; text-align: center">Nine months ended June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2021</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2020</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2021</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; color: black; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation">1,048,606</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation">575,451</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation">2,265,387</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation">1,863,869</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">1,245,319</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">675,678</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,814,008</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,352,437</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Total share based compensation</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Total share based compensation">2,293,925</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Total share based compensation">1,251,129</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Total share based compensation">5,079,395</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630_pp0p0" style="border-bottom: Black 2.5pt double; color: black; text-align: right" title="Total share based compensation">4,216,306</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for fair value of each option award</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zLVZvEpnKVF5" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B7_zOekhIMcCEVb" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_491_20201001__20210630_zhAydi1vKHU9" style="color: black; text-align: center">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_492_20191001__20200630_zMMdh0NXUYMg" style="color: black; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2021</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; text-align: center">2020</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_zEzrkh4igtl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; color: black; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">0.71</td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1.57</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20210630_ztcQdR9VdBJh" title="Expected life of options (years)">5.66</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20200630_zsvOeZ87iyT8" title="Expected life of options (years)">5.53</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zr9dpGCdYKrg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95.87</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97.80</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zOWSvay9Y7I" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979658103608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>May 25, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems', window );"><strong>SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Loss per share for potentially dilutive common shares</a></td>
<td class="nump">11,059,202<span></span>
</td>
<td class="nump">10,576,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems', window );"><strong>SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessStockSharesAuthorized', window );">Excess Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems', window );"><strong>SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessStockSharesAuthorized', window );">Excess Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of excess stock shares permitted to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979658104904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems', window );"><strong>Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 1,363,661<span></span>
</td>
<td class="nump">$ 1,319,913<span></span>
</td>
<td class="nump">$ 3,593,856<span></span>
</td>
<td class="nump">$ 2,980,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">43,280<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,100<span></span>
</td>
<td class="nump">149,888<span></span>
</td>
<td class="nump">$ 597,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems', window );"><strong>Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">1,770,444<span></span>
</td>
<td class="nump">$ 1,923,000<span></span>
</td>
<td class="nump">$ 4,750,539<span></span>
</td>
<td class="nump">$ 4,471,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_ParkinsonMember', window );">Parkinson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems', window );"><strong>Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 497,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_ParkinsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_ParkinsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979625738984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Jun. 22, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember', window );">Equity Offering Sales Agreement [Member] | Cantor Fitzgerald &amp;amp;amp;amp; Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued for offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,380,953<span></span>
</td>
<td class="nump">5,634,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_GrossProceedsFromSaleOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,013<span></span>
</td>
<td class="nump">$ 79,107,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceed from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,904,062<span></span>
</td>
<td class="nump">$ 76,670,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member', window );">2019 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued for offering, shares</a></td>
<td class="nump">324,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,086,209<span></span>
</td>
<td class="nump">7,431,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Total number of shares obligated to purchase</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic', window );">Pro rata basic number of shares obligated to purchase</a></td>
<td class="nump">162,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues4', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,007,996<span></span>
</td>
<td class="nump">7,364,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues3', window );">Number of shares issued for aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,111,198<span></span>
</td>
<td class="nump">$ 20,490,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues3', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,213<span></span>
</td>
<td class="nump">66,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues4', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 24,111,198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to number of shares obligated to purchase prorata basic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfSharesObligatedToPurchaseProrataBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PercentageOfGrossProceedsFromSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to percentage of gross proceeds from sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PercentageOfGrossProceedsFromSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ValueOfSharesObligatedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to value of shares obligated to purchase initially.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ValueOfSharesObligatedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979633417976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Purchase Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Purchase Warrants Balance, at ending</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Balance, at ending</a></td>
<td class="nump">$ 3.88<span></span>
</td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod', window );">Share Purchase Warrants Granted</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice', window );">Weighted Average Exercise Price warrants granted</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Share Purchase Warrants Exercised</a></td>
<td class="num">(350,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice', window );">Weighted Average Exercise Price warrants exercised</a></td>
<td class="nump">$ 4.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance</a></td>
<td class="nump">210,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</a></td>
<td class="nump">$ 5.69<span></span>
</td>
<td class="nump">$ 3.88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979636581528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">210,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member', window );">Purchase Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">May  06,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member', window );">Equity Offering Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">Apr. 21,  2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979623794216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2) - 2015 Omnibus Incentive Plan [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at beginning</a></td>
<td class="nump">10,076,266<span></span>
</td>
<td class="nump">8,462,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at ending</a></td>
<td class="nump">$ 3.48<span></span>
</td>
<td class="nump">$ 3.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at beginning</a></td>
<td class="nump">$ 14,982,581<span></span>
</td>
<td class="nump">$ 4,115,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">1,455,000<span></span>
</td>
<td class="nump">1,695,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">$ 6.59<span></span>
</td>
<td class="nump">$ 2.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Granted</a></td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="nump">$ 2.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited</a></td>
<td class="num">(29,167)<span></span>
</td>
<td class="num">(68,332)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option Exercised</a></td>
<td class="num">(652,897)<span></span>
</td>
<td class="num">(13,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at ending</a></td>
<td class="nump">10,849,202<span></span>
</td>
<td class="nump">10,076,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="nump">$ 3.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="nump">$ 205,309,996<span></span>
</td>
<td class="nump">$ 14,982,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">7,930,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 3.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value Exercisable</a></td>
<td class="nump">$ 152,413,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979633359560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 2,293,925<span></span>
</td>
<td class="nump">$ 1,251,129<span></span>
</td>
<td class="nump">$ 5,079,395<span></span>
</td>
<td class="nump">$ 4,216,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">1,048,606<span></span>
</td>
<td class="nump">575,451<span></span>
</td>
<td class="nump">2,265,387<span></span>
</td>
<td class="nump">1,863,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 1,245,319<span></span>
</td>
<td class="nump">$ 675,678<span></span>
</td>
<td class="nump">$ 2,814,008<span></span>
</td>
<td class="nump">$ 2,352,437<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979633382632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 4)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.71%<span></span>
</td>
<td class="nump">1.57%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 7 months 28 days<span></span>
</td>
<td class="text">5 years 6 months 10 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">95.87%<span></span>
</td>
<td class="nump">97.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139979624441944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Lease expense</a></td>
<td class="nump">$ 18,994<span></span>
</td>
<td class="nump">$ 58,554<span></span>
</td>
<td class="nump">$ 117,284<span></span>
</td>
<td class="nump">$ 169,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,293,925<span></span>
</td>
<td class="nump">$ 1,251,129<span></span>
</td>
<td class="nump">5,079,395<span></span>
</td>
<td class="nump">$ 4,216,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Remaining stock based compensation</a></td>
<td class="nump">$ 6,664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">2015 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">2015 Omnibus Incentive Plan [Member] | Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">146,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member', window );">2019 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">1,706,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,706,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,161,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of grant option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 2019 Plan provides that it may
be administered by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined
by the Board at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder
on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common
stock on the grant date. Stock options may be granted under the 2019 Plan for an exercise period of up to ten years from the date
of grant of the option or such lesser periods as may be determined by the Board, subject to earlier termination in accordance with
the terms of the 2019 Plan. At June 30, 2021, 1,706,665 (September 30, 2020: 3,161,665) options remain available for issue under
the 2019 Plan.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>35
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<H4$BTWAKLA"P80@0A)'))!4R*WPR@<>5Y^]8)!%0;!P%\\@QYX':Z3XZGA
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M[%:"JLYS*E\O62:V8P<Z;P_N^--:F0?N9%32)[9DZJ&\E7KFME92GK.BXJ(
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M/TZ8- +Z_4H(]38Q[6_[N3/Y#U!+ P04    " "CB0Q3_(N4"+X"   1"
M&    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)666V_:,!3'OXH5[:&5.G+C
MUBI$HD UII:BTFX/TQY,<B!6$SNS'>CVZ6<[:03E4N"!^'+^Q[_SMXD)UHR_
MB@1 HK<LI:)G)5+F-[8MH@0R+!HL!ZIF%HQG6*HN7]HBYX!C(\I2VW.<MIUA
M0JTP,&-3'@:LD"FA,.5(%%F&^=];2-FZ9[G6^\ 36292#]AAD.,ES$"^Y%.N
M>G:=)2894$$811P6/:OOW@RZ.MX$_""P%AMMI"N9,_:J.^.X9SD:"%*(I,Z
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M9\>M3LMM7G=]_P/L;F#;<YHM][J[G[=;\W;/YU6WFY"8QH0N]T%W3X7>#3P
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M7#BPP>ZN7##(-BI:%KB #'L=ZRLY]E>DO\%J,L.L$6 %;)\W9E\+:X-Y[/2
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M3H!8O;^O[Q^LVE17WH6R<(&NAFO.<JZ= ?R^5,J^/K@%ZG]-)O\#4$L#!!0
M   ( *.)#%,#JE#@>0D  '0Z   8    >&PO=V]R:W-H965T<R]S:&5E=#8N
M>&ULM9MK<Z-&%H;_"J5-[295UJCOP,1VE4<H&6<SMM?R9&MK:S]@J6U3(PD%
MD#W[[],@62WZ9D!X/HR%=/KTX>W;<[KA]"7-ON5/G!?>]^5BE9\-GHIB_7$T
MRF=/?!GG'](U7XE?'M)L&1?B,GL<Y>N,Q_.JT'(Q0@"PT3).5H/ST^J[F^S\
M--T4BV3%;S(OWRR7<?;_3WR1OIP-X.#UB]OD\:DHOQB=GZ[C1S[EQ=?U32:N
M1GLO\V3)5WF2KKR,/YP-+N#'"?7+ I7%'PE_R0\^>^6MW*?IM_+B<GXV &5$
M?,%G1>DB%G^>^9@O%J4G$<>?.Z>#?9UEP<//K]Y_J6Y>W,Q]G/-QNOAW,B^>
MS@;!P)OSAWBS*&[3E\]\=T.T]#=+%WGUO_>RLP4#;[;)BW2Y*RPB6":K[=_X
M^TZ(@P((60J@70&D%,#,4@#O"F"U!M]2@.P*$*4 ))8"=%>@NO71]MXKX:*X
MB,]/L_3%RTIKX:W\4*E?E19Z):NRHTR+3/R:B'+%^>75W>3V\HLWOKZ*)E?3
M251^FE[_?AE=W(F+Z9WX\V5R=>==_^*-/U]<_3J9>I=7XOOK\3\_7_\>36ZG
M__ F__IZ>?<?[\>OJW@S3PH^_\D;>E^GD??C#S^=C@H19EG9:+8+Z=,V)&0)
M:9PNEZ(+38MT]LW[[Q>^O.?9_PQNQFXW%W,1BNB+\<*[B9/Y,%EYXWB=%.+:
MX31R.[WEA1A\?.Y-XFR5K!YSEZ^)V]==*F*I%QN)UMLW(=HW(:K\$(N?3_PQ
M697!B!&SB%<S?N(]QXL-]^+"F_+U!P^#$P\!&)J:8NN:5:[+2>7YG")&T>GH
M^5!IW0I2S# .@%^WC'3+(<08A\QGH&XZT4T10$'(PG!O6-,#[_7 ;CVV*GCW
MK[J<>/E3G/&\D2!;WU01!% $S5&1?53$%54YX7_,U_&,GPW$C)[S[)D/SO_^
M-\C SS>;;/8D)KM=F*:HB*:5CQE56HEHH2-  A1BI3FC#I%ZIOYMK# $*/3-
M6M&]5K2K5N7DD!1BI2H<:E$M+DTKW62HVD0=@C3*=+R?FHILKR)SCH/IMM,G
M>;X1$]9ZD^6;6,A6I-XLSI\6/,\]_IUGLT3TO/3!2]?E;&G4D^G#7Y&3Z7(J
M)I$SV!9J'N^GIJ:_5]-OH>9F+58H@WHGCE[I:QKYMDDEV <5M EJ->=9-;&5
MK;V=4N+'C/-JN&@CQQ5KH(\@1@X&2"W:<!]MV%NTRISHBC74=<6,T("8HX5
MHA%X.]X*0^?>+%T*-L_CLI6-2.-TU;Q[CW>.#F^'(,@P8,IXZJO&28,:ZP(>
ML"5T"G@E$IU%FAM;S5VTC6 ].8IVCFJ3& (84D2(@BZ-3.NB29J#;IR;K.9F
MEOMMLWI%%P2,DNI$Q0 (L#)7[\P.@X=^@+%8MD.UC^FF0T%^/A1YJ*:);HL(
M"R"@@442"72P&='Q2II#G'M;$YWG2DT0"BU3+Y1 !YV<Y.3N+W$FXH*.N'2B
MHP%C3&TK';&@#T,QN3$5Z@RF0TA\A"@.D-I6!G(C?@A]8AOS$MV@$V?<]/VV
M+#J7E;*0T!J8I"'8@0P: S@T,! !0&TNG8,H1)@ %2V[Q&J>O(TUD@!8UFHH
M>0<Z@>=H"(<Z[T"M>^LV0]4HZA*G6:OC'=6UE)@&VW#:,2B^J\C%XE"'-PW&
MW?&VT?1X1W5-)4S"5C39 <BA@1QM1(XD-:(&U/@>3(YT3H.,(0MP($EIR$UI
M[X3E2&>D<L8$!Y-F/>"#_2XW(;7A<K>K%IB)#-2$*(1(9::^:IPTJ+$NH.0I
MY.8I%Y>[B[81K"='$=(1;LB(H *D8DT3R[ID$O:0&_:Z4SG22<]$Y<A$>F8J
M-YA:J=Q@ZZ9R)$D/-2.]#E2.##MT3BI'$O.0>]>KX6ZX)2Z=\A@"Q%?;2H<N
M&+" 0E_=.8\,IJ*M0N;["&L;XKHM$F:,,MN(ES"'W+M73??$+;+HF%;*0F%H
MZT22C% '0&A,Y4BG(;'$!&ISZ4"$" 0BCP)J:_6%1>8JQ3^K8I)[D)-[CN;R
MG?O:68*FF$Y&0]4HZA*G6:SC'=4/BB2KX5:LUH$AL0YEC*+ =@*")97A]E0V
MC46JX%V\TMB)MQ(+N8BS"F]K*H H+\R1ZCQ&&2;4MV366/(8;L!C[T&\6"<@
M/T 06P(^."!T\T__VF)]-T=HJXPJK..)SQ@C.%33,W?\+8:6N4H? &39'\"2
MB+";B-XI;< ZL(@IW0]#6S>5O(+=O&)/PC.Q*N8%S\37\R3CL[+A'WA6+9.M
MN@'5C[1QH.;G6(<?PD( F6H9N6^H33<P5TD LX QEKR%NYXR=E'UQ)O:>X8!
MCW  0FJ;#R0=X39G>^O-_A8.%X.7.,O$U^;0?*WA,54W![%A0XPP!E7#R!UM
MFV8WUTAM*3B6V(9;'3RJ"V=>/;OCV,;".K@QJJ9$6(<H@=F^3]7=5'>P;00S
MUA@08*$V+*D-M]FM>J.+.4>!CF:BJUEW58AD(=+?::?;58M- J+C$Q63/0[5
M)NZKQDF#&NL"2F(CW4\[W47;"-;7:2<Q'6$RD1(1I(#^I)%I733)CJ2'TTYH
ME%0_[?0II.IJ2W2&Q 2%.!")M=K'3*>= 153#J.:)H;-.>I#@=.V[3DB\93T
M<=QI%L7 >Q22,,"619(</+_6SW&G.2[# VP J ^FC8EAMTJ$CWQ?8R.#Z1#Z
ME 7B?GVUL71;GP80(!M4$@F5I*?C3K,L.I>5L@@LLTWGDLM(&R[K(<<A^MX8
M NK)\ICHD(;#L)Q?U5U,=_QM9G1CE0$D@>V130F&I-5#7WWE.$3GLE)*Q&R#
M5'(9Z7K0V%>.0W1R,^0X1 <I2X[COJ$VW<!<I3W'(1+>2#MX>[\<A^ATY\QQ
MJ,0[VF:KJT..L_/OSG&HX8S2F..XHVWS<*VY1FN.0R7/T58[<*USG)W[FF#J
M4WQCJK-5P$*L/ED2N6-MHY>Q0F9[V(]*DJ.M=@$[[*52 ZH!&EJ?)I= 1=OL
M]QV1?%$=KUS)%Y5P11MLIC5,OMRN6N02U$!;@HQ#I#T(W]<+ PUJK MX\,:
MF\-<R9>[:!O!>G(44</K!Q#  $"BK(^31J9UT20C4C<C=D^^J Z#IN3+8&9+
MO@RFUN3+8/M&\D4E\M%F)Z4=DB]J>,+?G'R-#E[8*]_'%(F"2!]R;\$?1%'P
MP1<^LNTKCMN+(EU7[_#=IT61+JN/3SP6.%H:B-\?TK1XO2A?"]R_:'K^%U!+
M P04    " "CB0Q36M;-%PL0   0*@  &    'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;+5::6\;.;;]7K^"\'L8)(!LRT[26Q; <=++3-(QVKT,,)@/5!4E
ML5-55),LR^I?/^?>2[)*CNR\-YCYT!U+Q>4NYYZ[E%YLG?\8UL9$==NU?7AY
MM(YQ\\WI::C7IM/AQ&U,CR=+YSL=\=&O3L/&&]WPIJX]/9_/OSCMM.V/7KW@
M[Z[\JQ=NB*WMS9578>@Z[7>O3>NV+X_.CO(7/]G5.M(7IZ]>;/3*7)OXR^;*
MX]-I.:6QG>F#=;WR9OGRZ.+LF]=/:3TO^-6:;9C\K4B3A7,?Z<,/S<NC.0ED
M6E-'.D'CGQMS:=J6#H(8?Z0SC\J5M''Z=S[]6]8=NBQT,)>N_<TV<?WRZ*LC
MU9BE'MKXD]M^;Y(^S^B\VK6!_Z^V:>W\2-5#B*Y+FR%!9WOY5]\F._Q?-IRG
M#><LMUS$4K[14;]ZX=U6>5J-T^@/5I5W0SC;DU.NH\=3BWWQU>LAX)L0U!L3
M:F\W8JJ^4:]UL$&YI;KR)I@^:GKRXC3B3MIY6J?S7\OYY_><_[5Z[_JX#NIM
MWYAF?_\I9"T"GV>!7Y\_>.!?A_Y$/9G/U/G\_.R!\YX4 SSA\Y[<<]X'O]*]
M_9/5FZE+UP?7VD87.TS5)W-\:WO=UU:WZAI?&N S!O6/BT6('@C[YP,2/2T2
M/66)GO[77/+P^3^Z:-29.G1-=>\UX_*+7M^86_7.+HVZKJWI:Q-@-[\Y48_^
M\C]?G9_/G\L2_G#VO')>Q;51Z=FEZS:ZWZ6'CQ6NTJJ&C+:&34,$$ZB%=9NU
M1LS59HC\?2V[E.E76- HV_.9C;D!K6S("14$;NQR:3P^6'BFH15>;_B(H!8[
MI3>;=F?[E0)]U99II3.-K:&7BD[5V.AQ5V_\C1N""KL _Q:E+G^\+D(W-AA0
M04"PQK5:(_*KH>] H;TQS4DVD>YUN_L3JU:F=YVM%6"EU=*[;JKPT%@LP?VV
M(<F7.U(?!/G1^#!3V[6MUTI[HX9 *CDEC*8V< MC+ZYUA!QM6T$K XICRTQT
M5PO3FZ6-:ID\$<'>D6Q&3N[-X%UC("(V$$,RU-*WQ;J0-.M\ D^>??GT.7EN
M8<B<:9V(QX>KB_;/M0%Y>S+9V9?/0]X^4U=0S2+*^ORH2H_XX@W 2?YKVYUR
MI,1];LGBS("%NH41(8@G.XT/PD"F"^HG$R.V]0TL#P&TK N0&O^PIJU;D3>J
MSO4.EB!7V>!\0]=K-CS@TPT2"B&C[^_'\.)'/"3CS8"EN-ZUQY>;[XX7MF\$
M:% 'J\\+BMZ_O;PZ+SCZT*OW>J?.GPF=S?C8%"%J:5O35%I=&@]80#Z$+1QV
M 7\T[#W"# !P@<=U:SAD?^AK1*+S$K.,3CKRVM3>1"1=6L-?Q'3:C^9&-UH9
M! [R(T36X)K)#16LZ]D[M*T?N@5L@GUZB&OG[9_0/B!4Y?:)],7OB%Q8%3AW
M]<<94.O5C6X'H_Y7S4_F\S-U-I_/YO(?;##^G5FHVF.AG]?XH(9>P^&1>2 :
M;Q%/#NFEAZ.JNC X'B\+68>1K-<(3B#7],0#$ CK-H,/@Q:3DA)^('L2'KU9
M#6UR>[:=J0=OHTTKWM[6:]VO6//.!J*5*GO[^NUE\36MU77MACX*-&!9NVF%
M'A![A'@\-YLX\MLO/6O)W@K)^1Y(*'#ZY>3Z1'UW<7%5KD&05]DJ4,]YN@V4
MA)L]8;+=S1!2/J)>PRU2U>4$TU-F /+KUH6!?-K38Q),8FP43/?]@'@Y:%_;
MLYZ^P2,C&"QB3HQ?7*9 2Z#'&.\X@L/WH"=.@',2HW(;T*CDY0YLNV())(JF
M:E"XZ\;\,1#H<7*G/PJ>IP;8",X,FP&E5FA1X[+M!'2D$T.;O/<) JM1G<\C
M$(4G<SA,"[E^1Y7'W\]XJPV,#Z)FMCY6 V^>8W.Z5C)#\D<R1+5G"-:[1U((
M@4*?Z'^IK<^:EI+FKB4@!<$#TH-_05]L@7VU%KIE[TKCH!F;UP1=XH<JE6=S
MM<43D"BR2B-YC[&3+"<8.FRAQ1!5XQB!,8./S35UJX='K1=R+@AC8:N'G:7^
M/\X*:S>TN .L $"0P;'G]Z&O]RDV7S$]\'!\Y$@+G*0-L?B=Z+K+H<E2$LX*
MMU)# N8\_EO)Z3L#9C548Q_R Z>223IX>TFGO $TF,_/OY)UXNB2?UR+EHVE
M5 $Y88^]H&)-#)@D%B8MB,I!(1(C7C]LN+KH5_@JH&$*8S&R]B;5'%2'==(M
MB":2%07&+A8H6R:DAC(BU2N"X'(PUT,=LBH\9FXWB#/R[!TSD0[%3J6=.$%5
M"TC!D3M4,.U]*:W4*%7CAQ77IK!+(SR3#%(*O$D1E:I;TG6:YVNX%]I!W,S+
MK()EHD MXZF*P9[I2<C79-B*ZC[:":XDVRP'".U1$BTGW\S&\XKDZH[D? X5
M1'08ZF3O;I+5@FZE/#U8D0,"5-^GZM%PMC>>$>]Q7#]0O?BSH\H7%=+6"/^3
MNGD+\<"N+!:6< ,R@B"&V7Z*2G&IH'*1>I**JG='R!R8WVF-Y\X$F%D)2FH=
MUFK)@,Y@P+^PK]&+%G\/<?#BF^0/0!H00VF]-CU;E,PS8]GRO<@2Z/EA,JAM
M*A@-53:==H*JKI#PPK066Q,P&1N@<^I8:%Y!0*SUQE*%O7'!)E+)7ETN*<PD
M'W9$M8?P>/><Q(N)2<W.)<#UYC:JL_,48Y5>(D@E5W)>3.(%\V_1)&,_A('Z
MGY^9$1SACV*(L39%+RP,N9 R0Z1R) =$M)U4H"@)AD@VY>TEE*+'G8'Z#K"O
MA(K<I7%OMY$B;=B0 3DW3H-LC4Q$TYN&XJ RR+$=UU0DML=M\"=8Q5!MFD#9
M9!()P^)WRM8$,J[TTJ5U)%+6'7'B?51!2 3;1,Y7W*3=4"INS":1$(NK)X7U
M$N<Z'R9=#>5" F0+\\349''O&^P*R)Q8K1E&"DZ OF.\625L[58^.>>0U/?2
M#F_472@N:^DA7U<P@<V($1H*Z!MM6XF'2017Y K.F O;$M-"'RELF*)<SA1J
M@Q)#A6PHOBG[T/53P-RK+?(.MY" =L^!ZRE>2;]6!@2.S7'-%'<!DTC$/N*J
M9<D5T(+&ED3J/#5Y^G@F23M!&'YA\'DNACB"=--P$(^5#23, 5TL0DJCER5N
MJ6AFP%4PLTQ94F@[W^46J2KC$BWS;$ODJ=%.R['&=U0>[_F5(H8 E"^6@\0'
M1=IJE)81"=M21"RH#1/!X'*2ER2B UGJ&7W*VH%/:\%G P/OJ*X/< :@ZK;P
M).*9OM*26.^FMVJ*,Y[5<HO%I?Y8J,S/OJ8&OG<$.QJY6:YYT6U AQOK!\AZ
M^>'7']X<TT(J/Z4$$;$X^<!;B#$IMGX;@ SL6$-WOND]BT.UD'01OSF/VN][
MHUN43M-1(52L6^H=JWP=74 N5JO6+8C-H92AJ8^F"9=4)SG@/)@:C3./T?-W
M+'VF:TG65H@%??8J4UTZ'(RUP.:/]#@+4.44R.F:KV!*<RT-=4JP)[+_3_#\
M1> F;2:0J HKTVV)I5!_M"#2%1I9*N%+#BP*,'C8,>YP\3M*06+:TJRFD,]E
MGUM6TY)ADH!IPLBS?U@#J<^"7@GE<;0FTNZ0B+-GT^<$/QTNI4=WLQ%GJW(Q
M#U /2"S.DRE+F#H-#8TTG&P"K2@KT<'*P@IUO,\H(YS&NX&3ZI"Q<KE#-9%K
M4FG]UP'%]ECW?N^V4MZL8*<T6]4VP6>8-HI%\&*T,8&+.:D21U8+@D,4.PLV
MG*!]]A QY;3,:[*QRH64CC-0Z,!/ ##U _6ZA]SP2^"&X6TI '[^M'LYA/OJ
MP:E&JKC"M/G.<X9)K4$3H$FI(OF"U116R%0E-06KA/5&>L:JM9(Q>? 4QUA.
MCKFWU[SOZ%1S\QJN4\+8SY7)44*-=-79;3**\9."*3R@YIAMIQTDH?+>.H,J
M0P2?')X#WJ/,!D93V<#S?K,TG@8 4=\F2W'$4H^3!MGT1.;B!#(\YF4<7=;+
MM(A'D\=26%!7 T-,<-VZ$%)S@9:EYI0TM<6"WP,0'N^W "5LJ?FYO(,4:QN(
MAHA'QF9%+D2!:&G.+=/O7 [F6B!W$Y5DFTGJ1Q^7ROG:^GKH@ )Z-3-+_BQ!
M(K4Q37NDA^(Y*WD#:"7'_#XTJP2>!5A:3M3>\RB%9[=,MB,PU1XP$^#@:4_E
M,2?GD!86E GR4UM/M$!4@[93BXVX!V3U4RFY5W$G7:K1<#P!FO(*486\#"J$
M2A>06QI *% J*/.H3VKV[$?N7)F*;B-'-%=^)'8^M,IOG*C<79BX-8D\][$0
M/Q%^]B![C?4BDP.EVJMQ7$S98^\UI<PG/YNZJSQ'2_XI1/# &SV=:I'MVL&"
MQZCC:. _+()M+'!*\$J[+P8JQP %=86:_IWT*B=4K*5)'%V?WDW@C!&MK=Z*
M%/F <N1W*&;)F]]UB^\G!ZG/')2V232EHR[!RXVNWL4]D3YW$OU]Y=T-40I]
M_M!'"LY9.NZ$AT1<1!WG$Z$"Z*,6-Y( :5(JKQTJGGP;ZN1ZS7[]E@:RO_(;
MD?>(Y2&W[81W'M;*VY*U!3; E#N1LN*L8_?:(1JCI2:))W";@6!6 EY2A$>7
M%;>.0<S#9AQ&!RR"\<R08V>GL73HQR>SZ62MRF\C.Q%Z*NOXRE*&+#1%!'=\
MH]YQLWBFCJL_!L?3?C @+/-HZ*4!-,UC>7O ],WO0-.D4-Z-$ETFWL%W$]IY
MGLX^Q]D37<0(B4JX"4PBS-2^!#SH@E.0U Y?\*E8AXXH4E:?GG>7*'%@5G"/
M#>46 6_GT$@=YP%ZN@BA&(IJM&NB,*[EQQ6-!OB=(6A+O-+0(?[NCN=\CUCE
M"8QWC[!RY\.'3K%"?(RM443J75(U]W6[A+*D]N3<*K<-(YQ2'!YTB^0%^LW/
MN)@'?3+'"^N*"C,\*L50X;V-WA6\<[(R=Q(9#4%O2SEJ_42FH!H9-/)H?(U*
MZ9@:;TH+]&8PO64E/]@>I#9P2(,MXG[9S7=_.JW?+Y'W^P-\D9UUCT'HO6G-
M)[^QJ-S1H+ZC"@:Y15W3B]JT@)BO,Z>/J+QYS$_E16W%;W.)6HC1ABBYM8'7
MN GJ3;RS=6^D,7W9BXS1$#92:M[R[Z.H J4:;C5]EYQW\7OD"C4'E2Y\73.4
M5BW7H4FK>Q50_P$%JD,*H)PC81^=/=[3Y_@S^J@']9FI1^>/T_M*ZK-N<M]3
MC; '?*ATHG&/-"]N,Z:7+2HS37BFCG55?MX!3MZ)&_AG"4X&FH^>'+R+SV2.
MG/SZHBJ+0GG??4(OGN@=[<:%\8U_DSQ"IFTSUL0+H,(ZO;2='1:;5DU_\Y%O
MK<+^6W9:9V[3:[)2NDW.YT'S_9(L#/^0(X5RTGN;W^Q!%'N<K^:Y!D[;B]79
MG0.K)$Q09V>S^;.O9UBDSN:S9U]^,3O_XHM#/P,[G?Q*KS-^Q;]%))B"C^0'
M>^7;\G/'"_F5W[A<?BOY7OL5J 7Y?HFM\Y,OGQW);#-_B&[#O_E;N!A=QW^N
M468;3POP?.E@\_2!+B@_ GWU+U!+ P04    " "CB0Q3O/3[,6\"  !_!0
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M!];5YD[V[W',9VGY"EEK]PO]X!LE'A2=-K(9P:2@X6*XLX>Q#C- %CX#B$=
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M'YL/&F]G(Y=2UJ)II6J8%LN+R57X_'I&^^V&/Z78MGO/C"Q9*/6%7MZ4%Y.
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M965T,3(N>&ULK5IM<]LV$O[.7X'QS=PX,_)K7MKF;<9QVJ:]Y.*IF_;#S7V
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MRTUTAL%/0Y$^5@\4Q:=#47SZ8%%\;X%*8&&[KQ#^R:WJ E!/F7D;#!V@@R"
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M/\7_MQ*-QW,ID@M2A&<W9X'ZX%\@AHYF)6U]B;:C[2OGUM_MX3?S^HFT9?K
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M:5X>+D9P]'SA"]MLE;G@SZ8[LJ'W5'W=W0E]YM=15JR@7+*2 T'7%Z,Y_+B
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MYA-GI:BHW?N3 \YG9.OGK:1B]R8:=,K2&*CRO3NJ-%ON6WXI4M_0M=YVT[K
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MZL[!H_,HV)Y3P>[?#_/?4$L#!!0    ( *.)#%.7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ HXD,4P/+&!>& @
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MV;A8V4]H6V^OI^Q)$??H?38:NR54MG4]MW5K\2AI<;IAGF['=W\ 4$L#!!0
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M<F]P<R]A<' N>&UL4$L! A0#%     @ HXD,4U)3FI3N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ HXD,
M4YE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " "CB0Q37M\:84D%  #\%0  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ HXD,
M4TH03 <2!   ^@P  !@              ("!C T  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( *.)#%/\BY0(O@(  !$(   8
M      " @=01  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" "CB0Q3 $%JS6<%  #1$P  &               @('(%   >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ HXD,4[CX"WLP!0  01$  !@
M             ("!91H  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( *.)#%,#JE#@>0D  '0Z   8              " @<L?  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "CB0Q36M;-%PL0   0
M*@  &               @(%Z*0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ HXD,4[ST^S%O @  ?P4  !@              ("!NSD
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( *.)#%-*?#U3
M60,  ($(   8              " @6 \  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " "CB0Q34?%1B*H%  #@#   &0
M@('O/P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( *.)
M#%/6EKW-; D  'D7   9              " @=!%  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ HXD,4Q*WSKL\#@  [R4  !D
M         ("!<T\  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " "CB0Q3VXAW3AT%   -#@  &0              @('F70  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( *.)#%/SFAI5-P,   <*
M   9              " @3IC  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ HXD,4^BN[Y]Q P  $@P  !D              ("!J&8
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "CB0Q3]CP7
MJ6 $  !_#P  &0              @(%0:@  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( *.)#%-.#X+<?0,  !D+   9
M  " @>=N  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
MHXD,4_5U%-[H @  - D  !D              ("!FW(  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " "CB0Q3,PQ'/5D$  !Q$   &0
M            @(&Z=0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( *.)#%.WK54:(0,  $0*   9              " @4IZ  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ HXD,4[?&&0"G @
MM0<  !D              ("!HGT  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " "CB0Q3(=24F)@%   J$P  &0              @(&
M@   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( *.)#%/Y
M\BYS"P,  (L0   -              "  4^&  !X;"]S='EL97,N>&UL4$L!
M A0#%     @ HXD,4Y>*NQS     $P(   L              ( !A8D  %]R
M96QS+RYR96QS4$L! A0#%     @ HXD,4P/+&!>& @  H0\   \
M     ( !;HH  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *.)#%/@%T=8
M+0$  /D-   :              "  2&-  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( *.)#%.O$6DP: $   0/   3
M  "  8:.  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     > !X "0@  !^0
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>82</ContextCount>
  <ElementCount>216</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>19</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Business Description and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation</Role>
      <ShortName>Business Description and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Equity Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferings</Role>
      <ShortName>Equity Offerings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Business Description and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationPolicies</Role>
      <ShortName>Business Description and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://anavex.com/role/RecentAccountingPronouncements</ParentRole>
      <Position>12</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>Business Description and Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Equity Offerings (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingsDetailsNarrative</Role>
      <ShortName>Equity Offerings (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferings</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Commitments and Contingencies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails3</Role>
      <ShortName>Commitments and Contingencies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments and Contingencies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails4</Role>
      <ShortName>Commitments and Contingencies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="e3018_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="e3018_10-q.htm">e3018_10-q.htm</File>
    <File>avxl-20210630.xsd</File>
    <File>avxl-20210630_cal.xml</File>
    <File>avxl-20210630_def.xml</File>
    <File>avxl-20210630_lab.xml</File>
    <File>avxl-20210630_pre.xml</File>
    <File>e3018_ex31-1.htm</File>
    <File>e3018_ex31-2.htm</File>
    <File>e3018_ex32-1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2021</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>40
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "e3018_10-q.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "contextCount": 82,
   "dts": {
    "calculationLink": {
     "local": [
      "avxl-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avxl-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "e3018_10-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "avxl-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avxl-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "avxl-20210630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd"
     ]
    }
   },
   "elementCount": 249,
   "entityCount": 1,
   "hidden": {
    "http://anavex.com/20210630": 14,
    "http://fasb.org/us-gaap/2021-01-31": 23,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 42
   },
   "keyCustom": 31,
   "keyStandard": 185,
   "memberCustom": 11,
   "memberStandard": 8,
   "nsprefix": "avxl",
   "nsuri": "http://anavex.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://anavex.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Equity Offerings",
     "role": "http://anavex.com/role/EquityOfferings",
     "shortName": "Equity Offerings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Commitments and Contingencies",
     "role": "http://anavex.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Business Description and Basis of Presentation (Policies)",
     "role": "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationPolicies",
     "shortName": "Business Description and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)",
     "role": "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative",
     "shortName": "Business Description and Basis of Presentation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "AsOf2021-05-25",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Other Income (Details Narrative)",
     "role": "http://anavex.com/role/OtherIncomeDetailsNarrative",
     "shortName": "Other Income (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2021-06-012021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Equity Offerings (Details Narrative)",
     "role": "http://anavex.com/role/EquityOfferingsDetailsNarrative",
     "shortName": "Equity Offerings (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2021-06-012021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "AsOf2020-09-30_custom_PurchaseWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "AsOf2019-09-30_custom_PurchaseWarrantsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Commitments and Contingencies (Details 1)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
     "shortName": "Commitments and Contingencies (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "AsOf2020-09-30_custom_StockOptionPlan2015Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Commitments and Contingencies (Details 2)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
     "shortName": "Commitments and Contingencies (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "AsOf2019-09-30_custom_StockOptionPlan2015Member",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets",
     "shortName": "INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:IncomeTaxesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Commitments and Contingencies (Details 3)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
     "shortName": "Commitments and Contingencies (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Commitments and Contingencies (Details 4)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
     "shortName": "Commitments and Contingencies (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations",
     "shortName": "INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInIncomeTaxesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "AsOf2019-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
     "shortName": "INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "AsOf2019-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Business Description and Basis of Presentation",
     "role": "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation",
     "shortName": "Business Description and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Recent Accounting Pronouncements",
     "role": "http://anavex.com/role/RecentAccountingPronouncements",
     "shortName": "Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Other Income",
     "role": "http://anavex.com/role/OtherIncome",
     "shortName": "Other Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3018_10-q.htm",
      "contextRef": "From2020-10-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 19,
   "tag": {
    "avxl_CantorFitzgeraldAndCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to cantor fitzgerald and co.",
        "label": "Cantor Fitzgerald &amp;amp;amp;amp; Co [Member]"
       }
      }
     },
     "localname": "CantorFitzgeraldAndCoMember",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_CapitalStockValue": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock"
       }
      }
     },
     "localname": "CapitalStockValue",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment shares issued shares underterms of purchase agreement.",
        "label": "Commitment shares"
       }
      }
     },
     "localname": "CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under 2019 purchase agreement Commitment shares, shares"
       }
      }
     },
     "localname": "CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_DisclosureEquityOfferingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offerings"
       }
      }
     },
     "localname": "DisclosureEquityOfferingsAbstract",
     "nsuri": "http://anavex.com/20210630",
     "xbrltype": "stringItemType"
    },
    "avxl_DisclosureOtherIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income"
       }
      }
     },
     "localname": "DisclosureOtherIncomeAbstract",
     "nsuri": "http://anavex.com/20210630",
     "xbrltype": "stringItemType"
    },
    "avxl_EquityOfferingAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityOfferingAgreementsTextBlock",
        "verboseLabel": "Equity Offerings"
       }
      }
     },
     "localname": "EquityOfferingAgreementsTextBlock",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/EquityOfferings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_EquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to equity offering sales agreement.",
        "label": "Equity Offering Sales Agreement [Member]"
       }
      }
     },
     "localname": "EquityOfferingSalesAgreementMember",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_GrossProceedsFromSaleOfCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from sale of common stock"
       }
      }
     },
     "localname": "GrossProceedsFromSaleOfCommonStock",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_LincolnParkCapitalFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to type of legal entity.",
        "label": "Lincoln Park Capital Fund, LLC [Member]"
       }
      }
     },
     "localname": "LincolnParkCapitalFundLLCMember",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_NonOperatingIncomeFromGrant": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income"
       }
      }
     },
     "localname": "NonOperatingIncomeFromGrant",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NumberOfSharesObligatedToPurchaseProrataBasic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to number of shares obligated to purchase prorata basic.",
        "label": "Pro rata basic number of shares obligated to purchase"
       }
      }
     },
     "localname": "NumberOfSharesObligatedToPurchaseProrataBasic",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_OptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options [Member]"
       }
      }
     },
     "localname": "OptionsMember",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OtherIncomeDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherIncomeDisclosureTextBlock",
        "verboseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeDisclosureTextBlock",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/OtherIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_ParkinsonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parkinson [Member]"
       }
      }
     },
     "localname": "ParkinsonMember",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PercentageOfGrossProceedsFromSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to percentage of gross proceeds from sales.",
        "label": "Percentage of gross proceeds from sales"
       }
      }
     },
     "localname": "PercentageOfGrossProceedsFromSales",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "avxl_PurchaseAgreement1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to purchase agreement.",
        "label": "2019 Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreement1Member",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 1 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants1Member",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offering Sales Agreement [Member] [Default Label]",
        "verboseLabel": "Equity Offering Sales Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants2Member",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Purchase Warrants [Member]"
       }
      }
     },
     "localname": "PurchaseWarrantsMember",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ResearchAndDevelopmentIncentiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveIncome",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share purchase warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Purchase Warrants Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Purchase Warrants Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
        "periodStartLabel": "Weighted Average Exercise Price Balance, at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price warrants exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price warrants granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_SharesIssuedPursuantToCashlessExerciseOfOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to cashless exercise of options"
       }
      }
     },
     "localname": "SharesIssuedPursuantToCashlessExerciseOfOptions",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued upon exercise of options, shares"
       }
      }
     },
     "localname": "SharesIssuedPursuantToCashlessExerciseOfOptionsShares",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to registered direct offering, net of share issue costs"
       }
      }
     },
     "localname": "SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to registered direct offering, net of share issue costs, Shares"
       }
      }
     },
     "localname": "SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueShares",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedPusuantToExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pusuant to exercise of warrants"
       }
      }
     },
     "localname": "SharesIssuedPusuantToExerciseOfWarrants",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedPusuantToExerciseOfWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pusuant to exercise of warrants, Shares"
       }
      }
     },
     "localname": "SharesIssuedPusuantToExerciseOfWarrantsShares",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Sales Agreement, net of share issue costs"
       }
      }
     },
     "localname": "SharesIssuedUnderSalesAgreementNetOfShareIssueCosts",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedUponExerciseOfOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SharesIssuedUponExerciseOfOptionsShares",
        "verboseLabel": "Shares issued upon exercise of options, shares"
       }
      }
     },
     "localname": "SharesIssuedUponExerciseOfOptionsShares",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesNewIssues3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares issued for commitment"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues3",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesNewIssues4": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares issued for aggregate purchase price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues4",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues3": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Number of shares issued for aggregate purchase price, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues3",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues4": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Amount of shares remain available"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues4",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockOptionPlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to type of plan.",
        "label": "2015 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2015Member",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_StockOptionPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to stock option.",
        "label": "2019 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2019Member",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ValueOfSharesObligatedToPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to value of shares obligated to purchase initially.",
        "label": "Total number of shares obligated to purchase"
       }
      }
     },
     "localname": "ValueOfSharesObligatedToPurchase",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_WeightedAverageNumberOfSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageNumberOfSharesOutstanding",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstanding",
     "nsuri": "http://anavex.com/20210630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "currency_AUD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia, Dollars"
       }
      }
     },
     "localname": "AUD",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r265",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Series [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]"
       }
      }
     },
     "localname": "DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r106",
      "r108",
      "r122",
      "r123",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r243",
      "r244",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r106",
      "r108",
      "r122",
      "r123",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r243",
      "r244",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r106",
      "r108",
      "r115",
      "r122",
      "r123",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r243",
      "r244",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r106",
      "r108",
      "r115",
      "r122",
      "r123",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r243",
      "r244",
      "r253",
      "r254"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r15",
      "r202"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r148",
      "r149",
      "r150",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r125",
      "r144",
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Total share based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Loss per share for potentially dilutive common shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r40",
      "r65",
      "r67",
      "r71",
      "r76",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r168",
      "r172",
      "r181",
      "r200",
      "r202",
      "r228",
      "r236"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r126",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r14",
      "r39"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r35",
      "r189"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Increase in cash and cash equivalents during the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r18",
      "r85",
      "r231",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies - Note 5"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Maximum number of common shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r42",
      "r43",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative",
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r41",
      "r158",
      "r164",
      "r165"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense, current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeCurrent": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred grant income"
       }
      }
     },
     "localname": "DeferredIncomeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Share based compensation"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Remaining stock based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r24",
      "r25",
      "r26",
      "r42",
      "r43",
      "r44",
      "r48",
      "r55",
      "r57",
      "r64",
      "r77",
      "r109",
      "r110",
      "r148",
      "r149",
      "r150",
      "r159",
      "r160",
      "r178",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r245",
      "r246",
      "r247",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of excess stock shares permitted to be issued.",
        "label": "Excess Stock, Shares Authorized"
       }
      }
     },
     "localname": "ExcessStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign exchange gain (loss), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r27",
      "r65",
      "r66",
      "r69",
      "r70",
      "r72",
      "r227",
      "r232",
      "r235",
      "r242"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r82",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r21",
      "r230",
      "r240"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "verboseLabel": "Deferred grant income"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in non-cash working capital balances related to operations:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Lease expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r40",
      "r68",
      "r76",
      "r95",
      "r96",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r169",
      "r172",
      "r173",
      "r181",
      "r200",
      "r201"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r40",
      "r76",
      "r181",
      "r202",
      "r229",
      "r238"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r35",
      "r36",
      "r38"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows used in Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r22",
      "r23",
      "r26",
      "r28",
      "r38",
      "r40",
      "r47",
      "r51",
      "r52",
      "r53",
      "r54",
      "r56",
      "r57",
      "r61",
      "r65",
      "r66",
      "r69",
      "r70",
      "r72",
      "r76",
      "r95",
      "r96",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r179",
      "r181",
      "r233",
      "r241"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r1",
      "r45",
      "r46",
      "r49",
      "r50",
      "r58",
      "r59",
      "r60",
      "r74",
      "r75",
      "r78",
      "r79",
      "r111",
      "r112",
      "r113",
      "r114",
      "r151",
      "r161",
      "r162",
      "r163",
      "r177",
      "r182",
      "r183",
      "r184",
      "r196",
      "r212",
      "r213",
      "r214",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/RecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expenses)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Business Description and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Share issue costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r126",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r80",
      "r81"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceed from offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Issuance of common shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r32",
      "r147"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r22",
      "r23",
      "r26",
      "r34",
      "r40",
      "r47",
      "r56",
      "r57",
      "r65",
      "r66",
      "r69",
      "r70",
      "r72",
      "r76",
      "r95",
      "r96",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r167",
      "r170",
      "r171",
      "r174",
      "r175",
      "r179",
      "r181",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r116",
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r116",
      "r197",
      "r199",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r156",
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "verboseLabel": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r155",
      "r210",
      "r255"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r110",
      "r152",
      "r202",
      "r237",
      "r248",
      "r252"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r42",
      "r43",
      "r44",
      "r48",
      "r55",
      "r57",
      "r77",
      "r148",
      "r149",
      "r150",
      "r159",
      "r160",
      "r178",
      "r245",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r125",
      "r143",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of general and administrative expenses and research and development expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.",
        "label": "Schedule of exercisable share purchase warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r126",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of weighted average assumptions for fair value of each option award"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of outstanding stock purchase options"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r124",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Description of grant option"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance",
        "periodStartLabel": "Share Purchase Warrants Balance, at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Annualized volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Additional shares of common stock available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Options Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted Average Exercise Price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted Average Grant Date Fair Value Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodStartLabel": "Aggregate intrinsic value Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r130",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options Outstanding at ending",
        "periodStartLabel": "Options Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r124",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted Average Exercise Price Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Common stock price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r139",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate intrinsic value Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance ending, shares",
        "periodStartLabel": "Balance beginning, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r20",
      "r24",
      "r25",
      "r26",
      "r42",
      "r43",
      "r44",
      "r48",
      "r55",
      "r57",
      "r64",
      "r77",
      "r109",
      "r110",
      "r148",
      "r149",
      "r150",
      "r159",
      "r160",
      "r178",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r245",
      "r246",
      "r247",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r64",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Shares issued under 2019 purchase agreement Purchase shares, shares",
        "verboseLabel": "Share issued for offering, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r109",
      "r110",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Option Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r109",
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Purchase shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "verboseLabel": "Shares issued under Sales Agreement, net of share issue costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r109",
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Shares issued upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r40",
      "r73",
      "r76",
      "r181",
      "r202"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Warrants and Rights Outstanding, Maturity Date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r256": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r257": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r258": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r259": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r260": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r261": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r262": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r263": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r264": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r265": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r266": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r267": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r268": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r269": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r270": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r271": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r272": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r273": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r274": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>41
<FILENAME>0001731122-21-001347-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-21-001347-xbrl.zip
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MW \EI,<8W=L9LL@C2\:HD2N7C!>NT.<(2.;L:&.)B"WZB*L' DN<,[DB[,D
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M5U+FN.U=\6/>3W'KZ\5]W)#?<>Q'S'W:Z,^ISM>._ZN*6Y8)E_\ 4$L#!!0
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M_=3N$3!<X)-WFGMX^O$$/3PY0/NL<_KN_)11_B[1R']>@@%3F]G?B=$N->K
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M_I_8O\4FF;EL5HQ76HHMHY;A#\_0:E2;T*W*SRH)OV?_L+('^.;_4$L#!!0
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M90^A^.ZJVI6PRJIO? 11_2I$;0H4,A#:^,_XV5SIS>_.*ET%JZKT^D<8E:Y
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M":^B>)&$/V'^ "ZAC\3H]T^5L"NO?]J"*'W^:5+UWD(F-Z7=;':)(YDZXI=
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MV_P1BHPX4A/QTD(9ELN&08U;0'J6NHF\L^0;JQ=)Q)?JK[?W<124YU\U[6F
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M?E7W/^BR55=S'QS'3F9VDYVY+466,ZYU+*^ES-S>EQ1-PC(W%*$#*3_FKS^
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MTD!^/:2V(!1A% -/P5K/()?HJ(=WJP@46!3+KI8=I#EA_.0FZ2SDT0OU):$
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M;^$$3;%' -3%2V#<@9,<C(TEPKP1+P*&Q!L[+!2GT7SCLUJL G%4Q==8D0E
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M]F*#$C4)P!MV+'&$B%T<)T*\?7M&'DA ETD@A CBFR?6OPBR$/8$W_\1)MP
MYY0EYD94C,01]KG*(]9Q-X@>TFZMDLHB;D :%N89O*+A9$E8 E9JM@J/SR<1
M.2K93BAK8+I4S>A#(\N6.+ZVKN3"G%\_-5W>[L\!9L>%[LX=82,:<-)I"EUA
M^A!1<URM7,G71<,#["WKKB^K7&K R^8&X;#EX>D..%)YX]9'@UWV8IL1U/6
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M70IV@;($5<8.RFLC20U4+)'C,$A:)UZ]P961+A<EM#[R];KF_==VJD<M7/;
MY-N\\UXR^4Y:FGSO#B;??KA&U\&YPRA:+5(?QHT??3MG1#@P"%?!^$:9E*B'
MKI%GATZRE?0E($L6CM9^M#I^U]F_"%N8\'@"^L3>.':F@T9E8I/R=378<D9_
MHP%O)O#CYQ[G0UGGV/=9K9L2U5)ZR7IYYC_X'M\*(FAEN6OL"ZK6ZF2=A/;
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M2?"CI**HJS":\8![33*(+/U[ ;+(RT0"63X#ZQVHLC4HB#?8:>-2E<%&F_H
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MY>"&\RBJ([8^N_DVF"A2EO?8&2HVW0<WW1%GH=DRF=B$'=J$[;GR)[9 $;=
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M"W/.DP4(XS3]5C;'':R+BI17I8)V&A% ?=3'E7:>W+;5H2MW.?OK$;2>X_S
M0NZNO\<=42E2W+D@6('X0[M"PG8&D.?#879W9Y*8Q6,6WX;%YWNH3'EU3S6S
M,=?&7'N:D0FIU@"+(4Q^RDPRBO/7JW&S+'XOJRU-44GBS=XFOAVHTOU]X?39
M?!EJPF;N-2@_L)M-^6BS=)S-<GM/PL0,'C/XA@P>90V^F%&(&3QF\ T9/(*)
MDKERWSFV=J[B/@UNS0]%72(LZ\&ELRL]7/2U_]+>F.Z'HWO$*R+FCCC'3'+H
MU,QACC/'=#^X<HB@:SS7#SMFDD,KAWUV/U]";>[MD-MW-'/*].;?#KWYMTAO
M>M:MTB=UH8^*J(*3FCX-BI/5E,6>F^!+UQJ3?":E97UW(H8]6#[85>?,H/;$
MV6XNJ(S9+F:[@T:WB_C/O2%>R\4A[@X6,N:4-V>=8I*?C&7PW@*+0Y\WO \6
M$S_>#-LQ;HDYY?@MP^8Q0TS\MQXSK+UQ_#-62=ET7I7R4D]69</415-^P<77
M/I !GP8#E=26UL.31D;W6DLDG#/;P,@7)@[*7A$^]KSL*JN8O8Z'O:)Z@G9%
M(^F8O8Z)O:)I'%<T](O9ZVC8*X+%S&M]KRHVL*BWNH#5&_R"%:U/D/+VF,L'
M'F*_:],K1&/6.@;6.D*?*V:M8V&MH_.W8M8Z"M:*B*\U4&6+KYYJBVV4>E@T
M!CJ^D@TMQ7.92WC&&<SY:G8*,MJ2\6M=4<?&TBEL)-"'MIX#X'M<,H\DOP _
M+N*6O%L>], O-S6/ IP-<# /H]>HKDEOL*I!$+!NVO5XF9_7:V#G^QDL^$#H
M(TRSAF1]^-$GP3Y]D%\O81W:0&]A@WQ$/^EB4:)"]^D#P ?_DC^?^L@P1PHH
MG)ZH=V3U$K$75Y\^].G7G_XGD4"W,E:D2U0=*#CQ*'8P2B2N/L$ SGN$UQ.B
M(G?@706WS8_(&BEA:OU+Q/']Z2=-S32UWB5*]LV+F3&:F@Z@66]<*V+K&<%K
MR- 46?J(["^=EZWON>GW;9"WA"&/\27Y]",:RI+9A9]9]K\75__W'TY@/UHK
MMO_K6M2'F54MQ8<S2'_Y(XM?$K N 7A% E  VCKH5P.5\1!5M9ZH,M8'#*J!
M#FD[*(*Q/B(W1EN@^8@A^63T175V:"ZU;M2+JZ=RJ5Z\.3^KU?/U8LU9!QEK
M*<2' _93\ZI6+#Q52_52L79^EB_?H.+/PEV^_+F("I6'AU*M5JJ4/WUH7NUA
M"622YKZ1Q/M"T@_1Z,IJQ]14YOSLYGWA/>+9="JW'\0LDX50\9+UA9?;2O4!
M0*+O$ZWZ*KTV<FRV@24L)Q(W6FM ? M2P=EH$1L/&H)K-(@CR0K@V(WYYUZO
M_]<4?O_MP'B@,55-I=9%;B';J%=Q>S[J,+6I*WJ!5)$X;^2(O7N^BRMX]!O5
MPM,QI\3:$T,[I N6K665^)^6$IPG7:(M]F1E=+F.>.\>1/WY_*RBXG]"P(0#
M89)[GZ:69ULP#ZD__:F&>>8OSC'_MP%XOUA71E7<UW336PY^5_]VOW^7GLMW
MTM9RT-;TGFC^>R&_FI=-35.PJ)KZ 'L)R!Q,!,VY3$KXN$1<SL^^/>6K]6+U
M_A>J%A\KU3IZ?*K6GO+E.JI7$%B0.E@)Q"51I8JX]#OI'U2Y1?6[(IH:EXE=
ML2B:+]2M'^!!+I=,[4DBMV7#.5&.+)RWFGY^9G8Q^NM0&%D!$X)X"H/[-6%8
MMRLIX9:FTSCS$@W@.7!M57RQP-G<'&<_TI&+5J#FS==WP[98S=]+E=_I0/A:
M(G$QO->5Q-$(8F"L>K'W#& 75U\&*D9)ED%DU*4689^&X5C9<&NEF)GW",@5
M#O1FL55:L:GTOOZ1;OZRGYM!:L6VJ!B>:G$>*ELOII;I18L6]6J^7"L1#7A^
M%FO'*,,YT8[FA-".>FP#"Z$&^9^I6?]&>!T'<XK\ DCNGI0-DMD\/[N5%8Q
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M8/"!+U'V(Z+59C A2B0<:93DE]6B,XU0+1@2IM:'(7C"8O8GSAL"$?A/E(,
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M><R!2A;]J(/1'8 #2V/61XAP6R/KOTL"Y)2[&_.F0X&T-[]_Z1?N)/TFM5,
M3/_XBT;LL&$AM!.2C7%JR/_A/H\&@Q8F%1%6 '=^YAG!'6L8LVHVD"JPP0,G
M;P.^E97^:3G9H?.SECL]U)ZDA8Q)H@-UP9D'=Q2K)'  >SAW(I<(HSX@K@3Q
M,77<&2BV)^>X#;@UT&53MI\ W=0EBLYJ]&$8-,!V/+A:L3"),LC#XH3]8')P
M*N2^8L43X*L3-Q:^QWUS&A(]J72=U/@:MA(!P1(G+N+3^]I[]#F??YQ, PJ.
M^"L68F"!FDZF>[_".Z?[!#KQ0941 SZT3G;A  )+51)M3",(DKV0)EDB SZ
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MBB--CM?<A!6+NT (,2 )[ZS;U+UV=J%X89?L2@I+3NR@X3LDM,M5I$J):F_
MW1?W&/T[$XGS"-VU)&VKC9S#$DJRHNN9CH8S@$T<[N[ 8;":7:?G!'!'8K/2
M860@F/)8L;D GP<]BLV'!S8?&SS%<!D[=<=%I!)J KIKG,' MKG3L>25@=<3
MWXQJVHQ7LM-#XT-_I2'Z- \<;OK,2P\GC+\&?W7A4 X,.-6@AX72;%F.CR)Y
M9P^,>TQ'8Z]C&B F<0Z,\U9DCMCH!\ P\[G?^#[L>"Z<PMT=T="97XC?(TM)
M..GQ2?!PN&LSC"<(6&/D\9DPYH3A)+OTXQ?T[HXPE,:'<B TM;2@<"?J<D+-
M)#U"B@;^)QHY<>'@N\(^K1M,#1%?8*V!T-*7\4W4%5O9;=2!6QP#GU<4IPLO
MX\<%6!8M!A/MZ)@,:;H6WN<Z.%3Z),?+\1)L-#R_22KQP1ET6+\FFVQP]4T-
M>Y2?+>R19)"MOZ?Z) 96WCS,5<Q*I?RXH,7ALP4M-G-OIT8AEK&W13-?R6?M
M[>PA!\T5%>90"HQT"H2J>CMJ%_^]__[U_LW-J/AHH,4LMM1<*) ?O;OFC]K5
M5_?86N'@'@?N*L\ [BK>CJ[SP>7@T\^34>@\-[CK]'94['K7M8?+ZLG7H^4C
MBTYN1W?.C]-<];#^KIV?'5FT$.RKL!S85P'&_,_7HO\Y_R/X5'E&V-?9[>@B
M*'[X)WQ[>-&OKV1SWG\I?3LJYBZ<:FFM8%^5VY%G?0E/OOSS^<>;QR&8EJ^-
MX-"4NE;G)->I5S^ZZP'Y O5]9;VUW_UST?DGW_P%(%\Y$-Y/-^^O/H5_#>_6
M'_$%9ZUX;O_KM+^X]NGB-]@6\34'XBOC_+[]U/G[[+Q_\^FD_;CSNRIYJ=V.
MG-Z5]:-X>CKH))EC,R*B-(D8DZ%)"9K 1&4*4)JL$.;J52H7P)$$ILTB-0MB
MS?934&;)HN0DF@<SP <W")2VT%#AUH0+2I*'R<A" +H]E*'\6'1&"SVKP(SP
M8IS Z*-O1]&7NNUZ#YFD<(L/=V4<<"K0&!&R1:YA<.6Y+OB7E)1_+/M;3@_Y
MSO>VVU'CQK5'07W8\?/+H'TK/!GMV]&C:-\VE(,YHID#@[=?^*=[]K;E]^XB
M!'L&S9R>Z.'#IBCGQ*G;C#9,LU4SS_^U[60V9C)JH%-_N33*P-4S(JZ$)/"3
MBIMR*'&M!SNME<+>?Y;6">-IQD]]F8A>P#C#E!4%^Y8YC:4-O=9N^YQV='H#
MW^D%8/W<QT?[ O@;"]D47RON@! CGQA/Q6"'BI5RHI5711BXVN;)DQSCL2;)
M&9WCY\7*CKX[U6:O?///S[.H3;)XO4X<@BGRN@UF9T]OTRH7K#H32^)*Z1QF
MXFW(5V=$SSXJ;W5DEBH%LUI,@O"_%#$OK4;,9^A9O$SA+[[M_K2_N5^K86OF
MUD8;>BCFI95:[5&)<V66I_<D7MY)F?ELS/EDVN^9[?[%WS/C68^.:GDU1_5<
MFDQDW^'A[/=S_=RRCZAU?O+UZ/#">G\8D5REVVU3#^?Z',CX^CW%$<S!*H#=
M:M-/^E%\]6?)S.?+9JY82#F(VS9?F4;NAG;T7DI9@MZ--Y#-\=[Z7A L617H
M""EIH2ZI8?>RCG?"(B15(<#!EDC>6<NY'@F2JU3+F]VE^\T\HIK:Y3%QFZ:1
MC:Y(A*?9F4\MVLM;M.<4>=VP+!Q4*YLK\<LD9,S<._HCANLP6L?&W!-*?7*T
M<*WU^M3U6Y\#4$CJ0K!6&8A?OC?]F>>W;&<#K<=E4H*+10A!;%7K>.?3;=-9
MMCOYI?/UW>G'BZ]7M<EPI]J)V=5.2DOX9>F=A&59!WNR<F064UW%V24K,R&T
M(J'-+=..3-B>-34F%Q#M%9N3<Z[=NERIQ8-<$@/&8U3VT[(NK\4%__(C0E)X
MFV/@PW5MD["R=M:QYCIX++&NS&Z>A#Z,C\\]GRT=NJ=6;S5&0'7@5G\..KWB
MZ7A$2>G-YA(0$C/:"',ORCJ8 /DBF !)A7E+$/#U 8I,D>W",HT)N;WK;DJL
MX(2LV-28:V77Q]#(K^AXS=9.X=&G:M87S_.<N?I)Y*=VD]C&,YX:\%7(/45W
MD^S[8H9&(<MO]+.:L$D:0&P)W#7*6,I=_'OWN7D3%G[DI]1AS[@^ZP,'>R)3
M*6?F#BMFH3(]&?'KG()EMDB>#S^VS+/A]^\N<KUWEX.:NRA^S*:?-O-DS=VJ
M\ FMI])T3-ES=]2:8:\?942E/VJ5?;D65SN1=CA^<LC:,K5"[9^+H'<T'!4^
MN)MYKJ=#TY9]DC.@:?F2"9ZV63Y*B[MN(Y&S8-,RXY!KFV.LK!ZAML23_W(0
M:O-P32X'H58J;SA";:Z*B.4BU%8DPK\60NVI1%XW4RL'Y>KF2OQ<N?3E(]2>
M2NI_%83:<QR \D'N\3B2;41WBU!;>9 I$Z&V3._Q^,??'RZ^!=UW]<;+0:@]
MM3U9J)KYRN.QK\^!4%MJI<,""+5G,B9?)$+M.:[4_$&IM$6H;>-"6X3:(E60
MCT"H+=,(N'CW[GWA_'O]Q]?\2T&H/;4)4"D7S*/J=!O@94/4YBK^7SI$[9EL
MB5\0HO8<ED;AX&A^2,,6HK:%J#VWZ1.#J,48U^>RA5XN.F?%)&:GRS:7G-S;
MK_?7H\/KS\5I)&:;C+?)0+(]398N9QZ5JF9AAICMKW-6G@7)MO03=%$HO77M
ML&SUIW"#KNO9F!N+]F1F4O&@.CT@L\6BK2L6;9DD21E8M-/58-%.SNNYF^O3
M3Z4WG<T\US-@T99\DC.P:(5<V2SFJF8UE5AF&W2<)>B([1BVEO>J*=FTQ1:6
M]V.:D&:!W+0W;9"6F5B?Y[.L#\TJ'(12>6M8KX9B6-OJJ3'+)XQ4FIM_<M;9
M[JYL[>[-M;LGBNOKT^6U/EU>X_9D?CDG'BWW&=B)G_&PKV3QGMD:SY<+9BE?
M- N5-!"MLL9%PSKL=K;$7FKEH[@DBW9JX[VEHZZ*1S5LR'ER_O;=T=_=]X6D
MCIS+',A2>\;==&S#2A5M)S!@EQJA2[U.K0";X.WN-)U6R_:IOW#='CS8=H^:
MX]GR$NQ3NDZTS./^ED.*TZ+X<<LU_,N_H8=/A4'=V8/XE\:[ZW&/+^S^30.0
MG?4&'6M@/-C8)[VW#W_9[WH]>XCQX)@3<O D[?82GKVL1KV<GZ>5&71\VZ8E
M[#DP19CPH!-@^-MNCK69-?65-'R[X;5[SLAN\F**-I$-O4VD_1-_IDWX3[Q'
M6S5W.-5L$SJW%(MQQ'7H]90W+V;@)"9.05^58HG3)80)S$*U:%8+J8WK:5LF
M5JXXV\J-1X>>;>42NT(^=NW*9NZP:A:KJ6MG@H0&?1M^=V^[0V,/!_+[Y&).
M!S[P8BHQS#WW8DHQS"UK*?-FH9PW\X7)VQ$O*5K,1#F<CD"=H!]ZSJ6+L_,L
M9^E*9B%?,8NYI#!?@A2^AFL%1]:S>2H/SJ!#2M4)@M#"ZP\7^MX.L'NH\7__
M3_4/T)SQWJ_X ;CUJ(P#GV;_;'300*.[++#]>[CT@H/=';B&0?%:72_$#W:L
M>[Q:X5YU>M2&MXG?;=L]<,9<>B:^S&IVG9X3#+"3]+TM=X#?B?UF+;_1H7\T
M;9B-UT<+,/J4UTNZ:;%WK6Q?CO< 3:IO<[/J "V EN>ZWD.0V<)V^0WJ5][0
M]K3;=[VA;5_SGJ2XTC#U!OUTT;I2%RI#>XZ]8!#<V(NWOBTFMKY=\KAN1V?6
MQZ.3?P_]PJ6UC":YQ1?8)'?%[6Y/;T?5<L'JGWT?' :S=+O5#_ZC#OWL:.#L
M\,;2P>'S(ZBVP]\.?_'A+]1)=[IVT%_*W4B3-<+"I7,-V>KU<(9Z&MD/]89<
M1MU35.[Q4PWAT[BO.C:"M=^/9^_'BQ;-N@\PM^X#W)057#7F=WIWX=*BW87?
MIMHJXVLOWE1\3.O&_R0D&'4F1F$8V\UDN_F4[:+$R%64-SCO@:=K7TN_Z(,P
MM3F-H#XE)E[K-6NQ:8MW).84;KP!+%6 8S,F?>J)UJ.YY%:4V1[W;$LP6PQ-
MSO9VILDN(]21*QV9E41_/5&8%FB\N73Y.UE,_L9#5EOYFPR>/;7\E0_+9JD\
MO3/$&DG?FP6E+Q6;^ M+WWCIU1-+7\$L5,IF\6AZL>,:R5]A(?F;B#IOY6\R
M_OWTM^]1I0C_F<YE-;/\K01'N^1PW55*%.T9ZA:3#ECQ><Q;N2H@="?1FBSA
M>"U0A?D,!N\,TU]*9J\$"C\__< ];<1N.8);?AZ[^)<0W'1+^4D$MP)V<N5P
M?FKN31#;P^<QJ'\1L4TSL9]$; OF4;YDYG(O4W!/G\<2_Q4$-\,V?R+!+2)(
MMK@@#<X*;?3'!9\7,=>SI6<=2V.2#FME.5;]\@[64K'JRS3)5XOC?.%564FB
M=[0<N_SEB=Z38C=_2=&K+<>V?HFB]\08[%]0^!:+1TS!1[\ X7MJX/7212^E
M/"RK?NOD=O2S]-,..N^_O-%HI)X"T6S_)(2W/IY"L7H[.A^U[BI7WZS3J\(*
MQX,CH961PY@8UO^SOV^<.;;;_-VXM-H@F-?VOR'6?L% *G]PVP3XT=C?ER>W
MZ=QK4SF\'=4;U\T/YX./7RK3"B0C;TX ?0=>'QY>0!$0OY'?J!"T=CZ0=:$(
M&WW_U3^J_O"^GU>.%EA8E0W*_8:O]V-*I5!\<SNROG]YL"IW?GT0$54F ='B
M3]*662[P'\;-L ]K6_.MNM/XP\#:5=Z$3QXN=[ZH?^N_\FOXI^@@R$/P/_^%
M;4G>H<+MZ+)0J?T]"B^[A\ZKZ"2V[?VZ;UMW^W4;% "\VW(?K&$0WYQ*PM[@
MALV\.<O>@LKMR/]\<?3UO-X=N)W9MV!<A22NG+[@N!.\V%GG1S_6I=O1U\%=
M[L.'[Z<_RT^C9B8'M\)ZC5I/E+ @:MWJ]WWO)]P- RSHRBR+FZG(X9/7PU(;
MNTE5S '=M/K?L=#ADS?X9@^B$@B=QEBK"8_?V5=VUW)Z6,+#M3L)]_:4R_9)
MQI]5EKV$$+Y9J9126G51T<#NCM-++QUU BHR:&!![\ SZC85G/J(]/7N;2K;
MA=_(=8;#UU7U4F&C8T0%O;X7MCM&R\%Q8AEK*;-X=T77\@K?A/76+<OQ=W>X
MPAI6P+;4"G")M-'F+D1&,ZK[G:CVC9<X4[(:+3;:"7A7ERJV19%7$VN[L9"$
M>AZ% 3QT=P?_P-?N=:/CN5@2QF/ 2FQ\;==KVJXX#>)!7/R%?WR0%"B6H$"Q
M@B#L\C:^M-JP9-(4_6RB%<3!\&@5;O#V>$Q!6#ZQ(&P9@[D=??C\_?ZTWWO_
M^:R\C"JPTI-5@1T^J@IL->4#XP5>8/)>V'>=\X^-X]//]5DJO+).$Y6*HLHP
MTC7&3"V<%H.WRVF50!X38B^C3FW8=/+W[__ZISI'0<CJ*BZB\19N$]SUT<>/
MS4[NT]=_OGUL+SC>;;'*"RVU4**36PI?GVK+I^GA*R>X._-MI-RQ?;BGK^!F
MOFWV;T>G(_^N4W+: S>:YQ/7?)0K"]9\X*3V6UADYHAI&3[,*P4E>/08R&DF
MF#5?6 2BN?+]77*$EZC1A!F_7]#L^$NXLE_]F3LX?"1@_;?MQJ5OW,+1T2G;
MEC\H/Q+G_=OF0&Q/I:OH.BTR:*3_MS>T+3]0;7A654<\'HLX6P8I79)4R8G>
M@,.;OVT.OB7FKT:#QM_-J^KGYIMW'165F+9&ZG3,Z_-HTKH?V(W?P<G$)TZX
M/RM;!^P/6ZE,Q..33=AIN_Q4(E)[4A&9-%N#^PO[^]&A,[PY6J:(3%%GSR<@
MY>)2!"39O%L*!VW6-#Y[+CS&=09#9>#YU6;_[7'SVWN__>0&WB(ZNM;KA? A
M)(R[5[-9^:E[N@L_>:N>UE:KE@]FJ.[*L-!^J7U8E>E5/3PX2@I[S[@+R2IF
MK@Y]BZS7B7/OP(%M*@5S\>7ZWAI6OQV>+Z!?GLCPDX..^8<O2(CU37EJMR\Q
M=?,K:I)IF[ J/?*X+5@ M5*#0W]?:N7?O2\/+?O1Z>1*\>!H/!"9EF[)&%;^
MS>VH]6_KV[O.N]+G=F.UPU(#RH*I'*;"5)X#C+(<O,-*@26EQP!+-A(^LG*0
MR'+2H?,<T;&7U3VW.=\;Q6L&H(P#U(^_&V&_;_L-*[#33J-RFJW;7*[X2OIL
MYP.[:Q0.C(]6SV*]'O&-8KHQ# )*98%A4.M9[C!PB'STS.E9O89CN9AV;#H#
M^9DK.PA=YB>]4-RDJ3B!IYAX]M([ _A\8_&!C+_MS//Q#MS_X'EWF(M7)5G!
M4XU@B7B)5)P$R,#?H>4/D#T>MKSO^0.$(<#DN_"&_;\E-R[(4$LLB"L6).*P
M/3!JKFOHG+:##L%1J.F5SG0+[QMX/EK+1@ON[H ,!\OI,??N(&LXNSLX'E,,
M*#X  YGU??JE%_H@OF"0.WT"9[3" 2;9&Z[3H]<RA6<;R?8]?VAT'=>&(?5L
MP[[')YGR"RUU+/I>0*?"W-VI(ZK##I J'VWK]I >UW<M04+LU7\PK3%-MJL.
M(F>7^<$1T:]I(( Y:UD1Q_+@(9T_'N5"[H^Z[3HP4)/^F?]C=T?\OFL-Y>_D
M1R4^9?SW#0(7A!._CQ9M_"^8;^HU)YY/AN#X0(*.%[H3G\6;"0[V8'(L"1\.
MPG;;GOPLKK+\%:YUX,#>63XBHGR;5%L .\3=$Y")'[LI($HJ%.O,LV#D%%JN
M> (R%_\:,5/I'Y GPR3&:B\<&"Z,:& )44D2SN5 =F;3%JN_U^,F1F["P,BA
MIYN1((&O\2?&,R^%W$&EO'#;O&@EHDAFTEOR1X]Z1;5R6$U_1\;%/?>[HL @
MZDC4;XR@A$- <$&$C'%[CT C,(^W V2_9Z;-6/*J;\(*TYU1YR4&[1"$C09H
ME%;HNL/='="7S; QB-\@H'+4OP<^W!(,(,(']7V//X\].!$3&&RW8N&M\"UL
M=8,*#-6JY<)V6'VTL] J:%GWGD]J#J&N4<L;IPL:CM#1!'O%&,$]?)_I^-7Y
MZ8"99OO\+3Y0U!QGNUFSORN^V-3HX.+S^<E^OKJ[ Q<B^:6TO@ZH)KO5LAMD
MS87;$['XB6#U/L"N&*"<?+1:$:[HX]^D:8<=)"RC[:'! K]KV'YON^(+K[C]
MTVZ$".T.?5SP%/9_-$\)P V/8E^@9]3#9ML>;)=^OJ47%VB@[T'3[H)]3T[7
M[@YH$EBPQA"E'EYBP6W=9W,WL%HV? &>T'(8\[N]D9=\&KPZ^NND[(.PCPXZ
MZ/J6\2^FL5L.-CYK..1<$1+"=:TZW-'@:F_7?+$U!_>R8U,XQ7*]'K;E\[E%
M4L/K=K$5($8H+'\ MP)\?\QZU3[DC.C*2#\3W.>O:PVQKHC*RNXQ?((=E"QW
M:Q8M?F)4L($<-G%^(I-VJYX>O=B^[3K4*8P*J!R_22?"P: E+'7/Z^W'G#?U
MCV 0-IWM<C]"MIMV"X$&5AMD.H";0,HR[(?X4,.UG.YVB1\1C0";IAUBP:):
MY0 ,4A__C!Y6H[.5X,?;,Z@7L' 6_P$+'**)B78,A8U=%SS7D%5U']:2+,R!
MZ%>XC?NL8%>P[!G,%S1T,)3@IVR#ZS3L7D!=C]N^S>'V[:HO39NS[D:3,7GY
MG5X+2Z=IW;?+OAQAYV@^):O(I/'M?T/'CS*H^/<V5OOW..P B@;^QQ+%PMM=
M6'@7A$KG,$^RO!/:3O$G8,IOP E:M[E=^-G?19P6 W)_MLLV7[1=1S8$ W!R
MB'4"$]_-4+4/[C%MB&N3?<+.O7#[O1Y'A?$SX\B(K3?TZ"UIV@$\%U>;K9;M
M$B\YQ]2R E"Z/B)'>:U)YF&Q>TB%8SM])D5BO7UV4A.!K&TZ?.Z+<1)"%:&F
MT$&J=QT&W7"R8RQMBWMQKW]%;43 AB8E3H37A="%%!=*AWM1]-+O(ZBLZ8=M
M^'EW)UD> D8(;;?\L5O>L (P224 [B!Q1>-(^D>#;XM'!/YY-DCD%]OH6/>2
M5Q2T3Y %T=O=<>%Y2+TFH 6-T/=E,_#&0+N10;9_<,0 $UMH.XHUEKC#2-"9
MQBOH>]1S_,$6#S-:OM>E/_YS<'U@G'E>DT/*)W@:]"95'LQZ3\#F0 D*U-QK
MDX\J)1/TDQD..I[/  FR"Q3R<0!3:8K$  Q#@ \I1V");#X:R]$7&A)!;.($
M)'Q81SQ.("C-&)8F%IYE8(TY-JB>;3<9&CFY,S'8'8+^0$_AJJ/.L8Q>B(T!
M<$2^$]S!@T-,C6/$1\U=9P2*-F02X,=[A$]!O=/PG3HA6!4,$HD.C#.XASP_
MD*!%IV=<HL5V;AH$U<[7I%7&5: )\-OW!N8QFYSPP5=><^1/#O?T9Z.#13S,
M($7ZF.["$]"_--?"$3&7Y>1Z\9!Q97H>"FG'0KF_MP^,"Q*+0(HH>9JS@H/U
M;$:+)[V[\]!Q&IBE"EWL40O:-L!C(J]RF+42A?C^@K!0G1#LS8'QT?-M='9-
ME#^6(T1RPF;"+X>&\B3N.>?N6WVGB6DO7!62![MW[_@>^<H'I!1P!>0@#9 4
M.+WB8&'B'N1$)?"= =*\X3J! @P<S"_+6)^&["7/T6XZ,"G+=6./-^'+/B*6
M>CAZ$"V<;-R>P:_(P0@-HI;%8T(_4%+B/;RB> WR5TS\""Q!W>%KCPTD\6H\
MI W877MW1YA#\D3B_>O \<5IP-;"FL.*"=WB@8S$(-GTM@R0[#<O-!CS2ROE
MXQZ'?0Z+II_,0*Z9E+68+CPPON#5T\,'XH&$/PSA-:2&:$7N%5-:P_$;81<>
M#=*"0-N6R[7ZCF322Q_$@P-KCZG.1@>U6A,7TVLTZ")L&F-KQF*<N6Q"P:>^
M7%^VW1TXN78?IR<#/$VC3D:2"ZH/1<VU'H*Q.R&(#C_]542#_NDY^%:J3PA,
M(6IA%X^XX=7A>A,:RX.-88Y"'PTX>)7"IJ>-\PGQRBMXPTQE:T?;LK7YRM;*
MV[*UM2M;>[8C5@N,,)BA>(?,!9.CVPS6%8;2PT2U21B,_P9N15.O_!"_KO7
M3O\I_]"UX9KE7QD?D*GE&O-W>"L<@]-X@,:>"[<J#T&4*X.I:5LX6*&#1>'2
M@Q/8SZCZEEU&=@%7VK%P2]X(X^+EE+"E;SE:;Y8>>X/3MKM3=[Q^QP+[LF&'
MY/^3$8EFCMUKPR?4]:V#.^&FY;L?D3SD(*.<6'UZ1"!O[B'>GNC-.%1HV44+
M!PF%,<4#7_3)>?'OO1"D,!@&Z -(+^WXT[7TTN!-@6V1YX=6?\=I=T!VN_:
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MD0I[C&U[Z-@]7B4T>@Z,\Y[!6AUNJGO8' HG4!)4Y'Y$0%/M!IC;GGH %@G
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M1T+V.>9ILBRBRP]ZKAEA?LXQQ,VUZCB(^$Z<(6!8V%D2V (?D"\_\/RV*OM
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M]L""4%E;RXX,2*L+.HY2F[&EWG %<JP4*"V;1L^DH,B<L9#*7]KPMNC)*SI
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MME2<)T&#*^E4C -]9IB%\,*;1L?I][T&N"YXRU$J:A^,".J*2)H!KF""C;;
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MDK,G'*].(BDG-;_2T;EL]J71=$Y;=67'B]YMXZ!GY/@@WK?$'1;6,<4Z231
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M*&)]BU1/7*JIE92\U"4_;-WW+/@*2COH>Y&4D"T?9<V@GM([B/!+&]Z"[%@
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M;AU^Z1=;--TC=6NY;<<BD%9"D5:@5881X&^@-PO1>&W(AZ+^L:+,597@2GI
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M4[(2B;BBH,2C /L0A+3M! JJJI&_*18$CO8+2+W1A*7JVR-'D!^2W9LZ4^[
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M/?PZ**9!ZOG(5_?SI=(?>'WN.>D/YX^!53Q-.&5=O5BP0<>>7&[P"+@IQ/X
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M,0<,!5RI[,+@&L0$@*95"AZ"]0+!74!U%7K4@9E9,P!7F<6JM:EN\XM,UW5
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M8LIWG@@JNF06 OS[>\PELY@3U49>$*QA1@XBV?:2(Q82_8S0L%'SKQSX0K:
MG_&GNAKF?RTD2SQ?/[@BV6CSM H_Z!_*P\*>K*PA7.N$>9<]PRK_$;Q@]4'Z
M9?8-#OJY\;YRWX0R=<+[9K5KT7_WDF\QF)F*8H)2[_DLEUR/07\C=4#*CH=%
MQ I02.N*9F_FB5SR0%*H'9G[&P,>2.YZQ"H:1#)P- [+[E X#8V")'U/IJ.Y
M0!$Q0E>1=0#FH6!&>P!/WX,#X&_Y@ K/#Y.1>%BWQH-5L(NIR<^L/[J>WTH
MGAC1AH5+;^;[H4F.9;X GR.1Z(5O6+:8)_1J]$_GYXK)?SNJC;4O?N]LSB=>
M?<YPVS,1E#X(Q>SOH4,#[1BD6EB>%.$'B"O#%UDCM0R%Y$^J,ZIP] X0A^3!
M2T@KNP >5JT6A!^L+?:U_3WX'F\!#VEY2!U<)H/+%2,,NF#D6K#G$(V))A2&
MW@6;4'=8:N&(]](=H9&4B@>,)%8/0'?M_A[&B:) %<[,%O)23_UI4TUQ.=K2
M$UN7D83CO'(8/"F1C$A9*1"9\E_+HE- 618:!8:9NAK-"(7<1CHL?$5P7$^T
M^:R:H7A)F@*U16:'")"'!8H=9W,FIB'Q1.1O(GI9(/:>3 ;8UQB.3C>\ KQS
M:H2C@  @D:51O![H4'@=?)P+?Y#OF)OY&_?EMY]%WS!_IK R0@.J7FXME26R
M(&$Y"4X?D8)D))Y-1Q+QW"_$03U$LOT]8.S*1'*Y]+KFN@@]%>B#)YEXV%'D
MDF2@:@($)I.-)$0I*-*T]:B0AS<\<?SM[RT$D@WSJ2U@:4,$>QK+^@ /<F0<
MY#TDED5H+I^=FB]2]];Y60 @,W, >$^E1Q?2AL^Y$;E@=KXW\=0'8(@90DV>
M[>]YYP=1S.'SS@!*.=R ()Q-#?DH5=JS12L\> XN_"U\_A7("66"Y>3,>U"D
M0Q3K_Y.'H[_)AH[B>UI71T)5@TE_H"?BBI;!J>8?BLL'WT1#$$BTS2DU$J0H
MK-ZJ^WN!.P,5=2BY)X]2O$'Z5T;@@5- X>[1TB4SCIGZ^/\5:1)8>!H<0=XY
M)+\=UJCARZ6+C^5=,^]#ZN-95?_N&_IR!/X8;4#FF#*_R\*(*#,ZNX;I@);L
M8($9&"$43(&L@\M8"7%5W<X]7/J8MP+P8SGK@:$RS@-FEBSEK2RM$@C,DV*"
M$(T49E2%5O#0Z4 %!5_<,!VB&5Y<BBVE]<C(:(%'H&9,0-32X%T(H+IEQ*(4
M:*ODU ,A@T0>H,:%X\7[<J!F!,$3 P^'6D4,(^ R(><F+6)B7&4C,G/4-B1_
M'<B3P%D7Z#+ .P7KW +33S$DH#!O8D%#6)-C(Q\1P,%:%"O#,Z:0ST-^T+ G
M-JZ"GZ'D'S<+BQ;=W[O&D:]>.]<>(9*:A8* !#RT7&;EEB-6G&EP.6,"Y//^
MSD*CX^"(OE@Q^J!0)Y"V$^IKP$;M<88F)"49:A;@Y6&A(3@1\<PE*L8$AF$B
MY#IR<]B@A3@%BH-DGQ2' 62% G>#T#."3E@&16/@G('Z2,H:C)R8FHIED+B@
MEDL>HYM;1H*4'D?6]8J1 U\AJU&7;55^W/9RQ$TRKL1=QM7+,JZRNXRK3Y=Q
M]3LAIA$,"1%[J7-!GBVK:,6#1[6]$EFBX&S-&N,91C2.%(W_P<]K8IO8MN^D
M]?R*]/#K>G#'H H#YM^J4T/P>@BHY+2;>)OG&.%+?:60_&2 9#XL*-]4M:&A
M=X-PRPAY#'Y0A*VE6-+;K2I?= -/1=)0>Y/Q[K]8NVJ#FW-Q.=8<OR ""XL,
M=^),$';CQY*C/A- !B$GWX*C/B!C%.><OXQ[\-_7P/Z0*VK3OZP4:<B#3^D'
M<"\'L:#>]69**323W)L1=/CXH9Q@OCGGBO/7G/S %05[U ,SL?O:H+ON8L>Q
MGUN'TA+T<ZG@N5TEZB=>J'MGWJA$1,K&([F4M!SZ^)X0HT#V[F&(KMD((4_@
M\D8(1JP6 U80<^&[3&,AXL^P ]XZ&/(L>AG9&8='P,P!<:A67R.3F+<L*+P?
MTK2<#PT9;0'@'<_MI#UB];D+O01X1(9^"'OLL$,G&#85H&0$YI>R<>!WX;J*
MX ;L]C-#>'KR/X>Q%,E>3H0/[TY],+#C*&(V1QWWKF'D(*(X"BQ^N?P%'Y,1
M2=7I'D F&@[>:7K@G0"2R- "(H+"(C/X#/G(M6@;_'.+0PB -YKQR0QE8 >%
MZYK)4&-,Y0'HXX&A]+,OZ]O[?:A'M5EI5PKYJI O%,XOZ^U*_5AHG%<KA4JI
M]6;GR$<$#D/)?W%EB(;OR-(@8<8C_;#T(0H?B)E*V3O@AH@N#U\\O;,&Q59&
M3A4?T1-^=QE)F\>?P"&-( -# 4A1FER%>!^&#K^UH%'*X#G4D'&(<4&!FP4P
MRH?X=W06D$-J. J2(;&-AH#E4&L%ARO"W6"#E/T%MH=7C.QMK-#A$O%="9R$
MR:?<8!XU'!GL\T!K:*)WL+H.B!Z\S@+&/CFB30LA6WQ,F0")S=)8)J0E;:!K
M8W0[@7/7<[CPY"O=4MPA6032$G+:((,&5PG@2E)U=!SS2X<=F,!WC;\MR]CO
MD.LVEN&A5NYHFH&A)/(,WG\ ZB^@<G$Z@0R#0NKX@DND7N'@6/YZ^N5^#%?K
M*=8-YN?C# D@XKS&<G_/ASRRUQAI'TG \<XKA_\0L]'/#/*2D.FG]&)0*I3J
M[9">;9[7R<^%4HW\X>VT[6;=^4?WI@ 0P-[SQK!J^AL#S(:T--C(Y#RNFPZY
M4'@D,9J"J)5Y7V0;EFF8+D,H])AC$+H-1)<=Z16FY M<R<-/OH[WF5%:01V/
MU!6J5]G*A?SB4XGDJ^U<# H A\]?@CLB*EJ1H2+M"=-$5__W3?XW'D]^XY#"
M2,8C1:'FEZP&T'>-&<HR^63 /B#W7?\LD3NFZPC,J0"</^LU\T<,[/VO_G73
M"7CY?]\E[N/%)!46DR2F(D&8GL4^&G O5D$J/K$(O*5]W_GI[P1O+H3P5) >
M/*%SW[8W'^,5NH8+EHX$]@$B-^J(Y>,?!<;O7<N(U4%:8JYIYO(-6(5@05IH
M?C/R2':)"_.2(6@^C_BRU_MV#$V.)S-*S6=FDP"*/P]E>C1AQ-P4$)<:K'Y(
M!>.\?BJ$'(>09CW'##$,TC%C'(P;3E^D>XC7M@!\JL0N\R\#Q/CQO%P8SJ-;
M!$;"XGR;S $&D8/C!TABA1C-+HTS4P<X9R"DTP+30%95[K'X.N8<]76M"V"0
MF",XQF1I76$I&2QDS(HK_-L1^TX$L5@'4 8 0T:P"(7Q#_HT<=["?!EJOXTB
MEHE=Q/)E$<O<+F*YBU@&3A)%MBQ0FV!$0K87$-;*U&/HZVS;'4%TTJ:Q)B-P
MQX04$<K?$LB7#FH_/WTFK.96J\(GU2"-81 MRC/2D">713;HV4;U*7=D\OX\
M?TAB/KFJD9?2$Z1)3@Q!E&1!3/W0_A263R^X,5','_9^1EV(<T)KV11 T-48
MW^P*&)_@+?\B*ARQ#"_ZY> ZK)DX#&YL,G,P:';QPD-MLRFA@4P_^X\.-13^
MW/8#!N_F!=^)4Z$P_ -N2E(,9.\JN[]'%PXCC.]]E?_@0#=':UZ)Q07^1>"
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MM*BFXEJ;24G9D)+H81O]FAERZVO:>)%"LU1:2#T5M?:V)N&\]%2!QNQ'"8V
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MG4/VQ?])W_M0Z%/:IF\ELJ\IZ-N,/P!02P,$%     @ HXD,4S9+#=QAY0$
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M)L&%8=<\+J2,1UL-M%MW-G=T*1^1>7U/IS&_XLYM8J<[,.#A!1F2_C1X,?[
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MU@B:L+FA>7_'V+22%S"@)4CH1O6'%%CRCU-@HYZ%EEJL,>EZ6M[4M%:O:)=
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M.6IDK5E! SU_1C7*0!EN%- Y]7^Q]]9!<:U9WV@G)"% D"00W((%#^XT$CQ
M<)<$"-*X>Y,0-+@F6 =W=R>X!/?&W=T::)K;G#,S[YEY9\YYZ[MU[W>K[O='
M4T777NM9^EMK[=W/?D@5Q)ED'\/MU"68Z1[/GV.;,VJON>U:[B<)=60\JR'
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M6&_N,_TN!U03JIG/G%GP8KN+B3*$@FX!CXOW72I>'E+!](\N<"HHZ\V]TUO
M;V*H)WC%^M\"2J=G9@XZ#VAIY*>VDK#<$TKH)6C^5E/+A2HP"6?+S;F?( <4
MRR_1EZKG"29^7\NUIF9TRI^P^=.(234]U$(*3C]'6=N3S_TN6FQX/78M7K;4
MC?0K1V7=L_8SZI5H%>TM;:>0+!TY#!TW]#W6)PQ?PM]^&OVDGFNV&NQ2XM"3
MKYO.'90Q^W94,7-:CC&IO+&.X_F^=/:,.9%)4BM(CW\$3:03]D/-TDLD/Z:B
MELICRO.XLD@9(C%2M&&^[]C'EV5I'26-]VW1T#AR2\XF;4L]NN <:I+$P>+<
M0X)>P/[:5N0T/RU&J8=X_N<@LMH*))._;?S6[Y2MK4A/L,"$WA^>BSO%*?02
M:I* R=!)_VY-CWE82['T?C&Z;6HK3Z-OBGIE;[RV0B+X5=R)8D5-!,O0B5B1
MR&D/*1\7B?:CT">Y3-KRGZ5#"/6L(O"H4E%)B(9P*VI?SNUR\=& 8JU/&X'O
MG#QF,'3BE/PXD'3GW3D:;74OV>LVK]S+DCXSO\,!,PQGIK:RJG]2D-%B3TG-
MV+JJ$-:[2>(!W,?M]HD9U,O.$<1*B<T_7-"<J&#6!Z)MWY?;HXQ(%K[Y9NV#
M?6E"ZW[%PK<WNC^)FU;2_OZ]%BA]WR:@0^'KJ-K4.0-C)YQCI5^J-:%[1%#+
M@V8^UHV>V[VBBQFC=#">_O14J GB,GWOP7TLT4T)3_C2*YE.'8@X6J>=<MA/
M"5S5%_\[MYW]W]@!C66S_"CBZL+'J9&;AI6IJL!(:3S9VP1E6Q7]I%"!U*C+
MX)Z@$&AI1MR-@X"R/O!M9$2$O_I:(+D;_DF_A_Q'LR:RD0:!A[^(Y-.@'0ZV
M%\II]3C&EO<E95H6;5\_XL6]MW[5&;[2'&BG;9;0&0!:FL.DE;%.MHYR,U';
M#*I8]!:>/?*U\GR>OZU/!?-U<;*L\E4ME\/D_A@I6^9F(D,IP\">FQ2VWB@6
M##AD5I2$I>=[\E0>QN@3?N[$D!YA],>/Y)A_^+Y2(^G5YB^' 5ZJ6*&QIN=C
MBAW83V:EK$)1Q$<2>-=8:DX"Z:NM'2Z<4[ZM%+J3(F5*81N&RQL=,<H>A?EF
M2!5(X7W54C0SU=3S_DCIRW,]]VG3=8-+O",!-0QNM.@<==[:B:FPH!9V-?A6
M1OP#M7(]Z3%N*9-.SM4IRD3.#VS2NA%!MQ4@.0RD-''Z9N14 "-<4(<&*FOD
M>,^WEH!)RP<%Q0<;)<K=!M5,N[$X7-"TV&)"#*\IA;<@\9<ZNS@! _%GV\=H
MDZC0^MY7*+\$*9<&GVZ1/Q&4K%8W$93([7&Q+PEZ5Q(Y:1':LK?-,=GXP<(
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M8*7Q3_K=$E;J(W+_LT>-8=QU93/4#@\!BQM4I\#L3/DT?2V9S 7H]'1@[Y2
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M.@?TE:4%/],4F<R1/ADJ?&>>9\<R/4#WXDWM1XE+;NN);_SE^&C?17$Z=+L
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M09>@\7YNR!9\[RR'\[QNJ$&HR$VQ;'E^"9=[R.-3$OD[L/9*))1'0Y*AUYZ
M!,?+PHWU@%9+7:YV]JUH!.>7@ZZW5RLHQQF;CHKRP'MY-]J3!NV;3M,&>H<W
M626H!X9&#UN+G(M3S_<NPV5G)U:KQE@GQ1OO<S QTB 'V#EO2>$ \HW@D[.:
M9(JH!]\G"!^S$AA5EHY2-3Z?T]63I:E)D3%&N9=AWXZ=FSYE5319XN%U.C_)
M;_6RUP.3I]UYDBTFDKF%XN)Z-MS"^()#"Z8B6N<3&T6?8>AUP8/W^2H6[J]\
M4?W$Y%W91_&33U-788H;2ESM!P]L!4<XV:*4V=OS[FSFW5/MLG!:TI@GVU>]
MXU W_K"RZPOK&8;"BZ.TR-'KXII'-Q;^D:A!G/FP K+QM?*/;9TKGN]E-E!_
M;"N><O4RC[?.<)4-4GP*6P_D@RKFD@I@]V;):[P+PZ9A+5*G>(TC:XN:K1TK
M)LO"#U1.=JVEMVC$JK3:*TJ?/!7BB^"0+FM)K/GP6DMJ*,2;*_[')OY.?IN=
M$\J,S@QOG PML4B7T-5ID3,?&?T+Z;G(L57VI*>P\: S@>L<>.T!"XWB?L.7
M\-[\:7G:Z%D(Z-$HR"BCNE9GAQQ/5RHJ"M=D!68_=<.HTWK!MGW4YD %SIZ6
M'*K=W_3>N@%""FV?SBKB*DN0C%#;^U"K?4 QRI)R9]XO8B9IK#@66[5B)HZE
M=K=3$02RFP.W)Q@(PM03#<;WWSQ28"P9H3BBC07C^4(;JBRG7&=M0N@%%T])
M91#^-5=5"46I)&2R!KH%(H84,8O8"I6%FGR,C(3*";[UM=R-F)5-]2YX*8)^
MX!@LGY4(X8"75:P%+ <-K&E?==QH&:CG2AW"0''Y=A8)?@URN#R3;)V-3VD-
M41<QZ<740U,65GD'>&(G;@'KUG/M4+HOQ(IU#-7QT6B"/^R5'O$! V^\0K6/
M:/QN#@)]M[8[S9B-HM>\"O@$P]U75B/7[(\%!%(*NJC']G+T&UMGN6;7G8C?
M^(O78+\]RSU75KA QFTQZ$7!1((WJ@9;0^-AY<[.Q#6UK\UT5B2W=/_6Z19"
M0M[+H>AGUA9&)E,GAPFA5^2C#;.S1S4SB=?U_6GKV^:?3Y_Q67H[O;2XBE$J
ML-O&-PL&J&E] P@!^A5+O/63T<]W!B=SAS>5^HR<<G?<*^SS6_AZWW]MMN5W
M(;\8E\_JR]AVYH$*!<_E#_BK78OJVI"R^4YF+S)&Q;]K2":EK4]YX_RD]_@9
MP2<?Q28 /(_7- YJDH"F3X^?GHXCM4Q?QSQ777R)IB[;PPS\M>DX)2B?7D$[
M,J_A;TLB%7I493=YW=C(Z#Z"X6%#HEL8E<=6QK29_$),BKSOI.BED(Z2GVP7
MV-XG2OI9M<K8V<Z[#B>[!YUFIG%\"O:;JVR#^A+/TNGUZL%Z743#H5'-9U/0
ML>PCKO&OF7 7VFEIEU^4(EVY /=Q@R?(8M/S_A:@!\Y4C5<;HPM*2T"L2\\<
M4/6VD[<D%)*$/_E*K="];5^0_8#<2/N5L!0I?FIBPH;R^%4RWF  %^,M &=N
M>7KET[Y>R,#K5#DRMYT.*ZC%_8M._J0)2_*^,N/0&%.[A^[N)Y>3>-S98#O"
M,(^=[^_.-&(#@9^X\!K'.S+\Y<S7_+I_FLWF=F5)?-SLE9OW8M(N)&AV<JHM
MSQM<%DA\QO5J7_A7"$G<EU>H/U;O[>@4NU<E3$3CMG%/JJ,]\#FEV" O/N'J
MZL^SP'_*J;*@VT?L)!7[C>P&+<>D-L7>WSPCHC,5I_QYI92(4&X=C[JSSBZ-
M]L#V@=5 ZS;G,-V((Z^!@Q!440![^;)%Z1)[2/5<\LU14]6PZ:\7 QHH@O!O
MRS7Q]35QJ[H]@H6\%$%:/892XBD-*D@?R\77RM5.N!"8OQ C#*C=F5*]1K4Z
M*]6?,[!B 5F4P\+6VT-E!<++J5!I4M'O;?(!W"?B,G.;HO/-)N6B(!\D(L$-
MV7QX_?+_76[:FH05TV3&GE(QEG,ZBS ?#[5K1NB6CE[@>56]_(+\0%>'<XDV
MS**#F=BI7&%$4DJ^, [EK* 2%8&#?]YT"YB6>-_XZU@DX@XS5S-,@M0&?^S)
MG <U]9^#N>"?9^"-7=8'NNXCH;1IT5[6?&H*\IDC7:+9]SVQ\WW8WP[; N>U
MA\>,1QS[,$C);JRATCBR"Z:,/GO;,CN3AUS=4DYV3YAQ';HC:Y]T%XA0VZ/A
M3F_$K7],<-/7(LZO?Z9HG14@4:O7R&JK%A4:-3$!5PCO^(IYJJX]GF/#L"98
M/?M:G+6XV:"W-CAF=L#*KS1!D8+[B&RE@J=(R()A),F-JM=46?=X7<#@OKA@
M%5'7],DZ:Y0D<-%IREP[+)?_<75K2!(YYUD!\$M?;:5G"M"AJWBA6"SZ;54B
M]9NGC2(=GMY68LJ="G)]QU*3)FKI)"0OX;< ;E-3K6C*C"KI6T!#QC!9U&C5
M%FN6C5YQAQE++)DHA[0JUO?EV(),(+5E$'G>61&>F!2HD#3R[;2Y\X;E*"/O
M3L.)4IFY3;L+F<%U:/!0N&2%TG7'B:*SMTQN9[)Q(W/Z+:#)HO$KC:K^1X&?
M-O02.N.SZ:M,L]$RU.Y?CC+S?Y@PGPCS=EC>?![R;)T7/+]T?U>52.R:\!;L
M2,;@7:1<I/ !\UDJ8/%>_QNK;I7CXD8MTE="?$79#P:<N$."B!A!L5\!'$]"
M5!Y,% LKC+0LKE=\+ UVBU,GR6G)RT]O+3MXL,%7Y*;L,K09*C'F/^\A\(G2
MYXVLU\J6#.E:U@(GP106!H]%N56FCO9E&DWG+:!1'M%5P8UXIY>CH"!D=LYU
M;RS;JSMAO5LZ</FE062PQ:RV343NVYPVHY$L1'LE4^B JIV86=SP=_3G\=?C
MPKV977OT.O:L%5J!OY@9;CCDSK_:/C$%45NB"E=2;3J'K86)VRGP<]*!Z=8-
MS>N<WF2_+;IXT<[Q0K1FCS?WO<='I9=Y> HA] M353/<5=+,"2FDPA@>'S])
M];8G#1,YL3Q+8DZ]+_\@9_\^^RW@*9X6B^4OG<,"CHJ/Q3I;0]KM1UG2WK5Y
M;6)5FN?W87,)ULGOU%Y*TE3*H+7&JZV,XA+NH6/XE(;96CBDZUQ^6;O410ZK
M1C.7P@:\.RJ[>4T='M)X4-"K5;T=0B:&-PD+!VE9X\2J83ZJH6DS?,HS9?1M
MLM4H9A]5@:T,L0PI8DX44MC3^SHXWZ9%?F+LJ NW%KP>SEY3J"RM+J?KT?U8
MZ*#=&7Y"T%M8)=BVO+RGAPN>M+G)UC?13SX"(PP7SA=N >:3WR8GUO*F-(L-
M^B%TW^J738[A=^_5A=K]91/*]S0CTD@T[@. +&/4[ ?6H.:8XPW=+E2PSF+>
M*XJFCU#V?6#/"KDX;.PD9NR,&4/7CQO-!*>W=F#BP<K.PC%>ZUDZW40MHBA*
MW?T6\'WXS'^F;A0>E@=%$'C*YVU=?/$*/G:CBJ;SL^K"W$-X,5KLSZ&&%#D1
M^F\R,;\I1)QCH9X _=SF"--46?8A<@_L7JB#"@<&98Y>0!P*W*1D-+7/0NQ[
M-E[,U8\9U2*<%"44=R&XNN8\?,?6*#JO!8W)Z\!DP(.\]5<':KLO<BU[S@\D
M+Z3$E[-UW/8XOX49E7YAQ.&O!43#F[5GQAUO[(\LJ4?6OAN^B/0M\_)U$2K?
M"E[<3)^J9Q1J\)UAK"^$#^3+C2S(I)RHC4?3]I3DZ/)\IP>$N0V^ Y,;R8\=
M+3,_L3C*N;8J[G',$SX^MSDYV-)M,DN?%K;^>(9M4>NF/!1I32L=(L?YF7O[
M4QCVD@X9T1"XJF@N@[?*]Y%(]KKE!L#+UJV GU%&HF),+V2%.L%>0TICF9'9
M</D<)+U46M':\6*-$I_B2=CE"M=WCV7Z RN::I  P<1;D[2 )Z\=?@Y6&@VK
M$,E00\36U*J@VXYYP-(&,H/,B9P9J9Q )_C)+2!<30A?;JQH*6%#KN[I0,#[
M4-II*OJ-XZU+=2Y A#T6)EE_QN[9A_.@2J<T 69UN4163)V._ 85"T9;ZD\D
M083OG.:V>84;I99"798)#Q9!+N6E07J?F'$%- TW?!,ZJ:.C[,TRT>FM^29L
MC,J.U!OSM"Q.M&;F"%*G&AB*)*6*V!FJ_:S6&D:<^EQ%S(V#[G^VBS[18%)P
M'Y:;RE2,=/-&.>\?V_ &!TV:)]@=UO?D6D2UEQ58ELSDK\V%CU;29"4[Y</H
M*2M%J=-.Z^^WV%7< @*+9(-):<^:?N1E9E;PIQ/!0&*-U0FND'>-T)2WIBYQ
MZ;DVOQ I9ZJN10XOK4M+)+ *WMJ^]R<@XSLO\@ZV"'&)*U"HJ H+W#T#8BOF
M@]J4*ETABC4S5/+K3R@ ID(G/_.Q/5 #J2=.9]PB.&>(9DN[OJD0=MV<7!(M
MV=N%)+DKJWJ@FKA4=5P[N9@T;:A71<%<VK0_S\>$;5]8VK42L+4,*)+6 K,+
M%9<:,92"1\Y-?1[4E[U\WN#9X2_ES1B&-)B,\&FL0DR"Q54S*XPZKU1>P*SA
M%K#XPF:7A7,FW<KQ$PW@&0K*Y)9:3EJ51E46R^30JW\Y)_2WLT(U1,OK:YJU
MK*8Z2R$I"E.G%_U2&5L<%M7$&HSH-Y=LHU,>DTXV(,SDNI_W'TK<>/4;:><%
MK^DD#F>L7J:TC&.H]K^KM*?*C:A\,\ZH*J\>:(RIQ"4[_EP]L#^B4FR<0Y49
M^17SN\JWXQAJZ=QBOU]O%FALT*&(.[B<'9PF\U!0Y:&@:DBDA:A2H30];D!P
MA.J'##PJ:MRCM[A'TL9?E=%#+42E,P15/Z?C4>02OASG93FS4FEGVVS"-^0B
MZ(Y:/_,W*E4\X,DGZUEHQDM/TY9:UE,^D:YL/,ZJ#N1JCPRIH"S#)UQQL<7\
MO]A[SZ@FMRU<.(J*=%&JE*B - 'IG0A*$^F=4 1$! 2D=R(@57IO@DCO13J!
M2.\@O?=>0N^$Y ON<^[=>Y^S]7QCW'O/'>/N'_GQ)NN=ZUG/FFNN.3/F7,L9
MY(U@RSB1D9 5E)-H<>@6\N60O[^^Y1*! @P7LE%]5-3MH3@4UL8G;#^7AG\?
MTZF7F,<Q#+]QP^3-%ZCA^+\]//C_Y&?OD]Y<=!DD7V]:W.XE365EN H>S>(-
M PEW.>A(KB+X>Y.<EP75"^:Y%!TZ$=]@2$/F"&1E6Q8%@(6@ $V** !VL@X*
MD%S+BT2"+BLH6L7_F:>ZA.QL/((X+23O9!_.G)X/0+874(!=HC])4"_NDSQ*
MHJD^]SIG(QB[6/E/>@"..P9O;!%L0D'&QTG\?VX@B6!R<T"Z'\R<GZ  "'$7
M*J+?\A)!)3L7R=..*W_\&?@'=,2;MHH7F7Y;=;-_@_\;_/^;X!?+D_&%U%]J
MCYD>#4_LUK171?$:9KR#'G*;(6\54D&^=X!^R],0"XB)5;6 LU66Q2@^;X=!
M]U" $S%7FT!(@Q0["J!WF0S"17#=<=5V]Q[PZ.(RMT(W19RM<&BS;O;,FW5[
M6Z@1>0MVF7N" D3\: QI(%V G9%#]MPOQ8L$B,"42\Y]#[%U9J:=?!'WW2^3
M-E" Q<M#!"\3D!TWD#YZB*3+5(="^2\A?Q:, OR0O/_O):N7G'NM$]7 H/L$
M)V((!Q3@*=MOZ1R7^?=ZP;!5(Q2@?>TR$>/@C.'L0JYSB^ RJ6@?+7(.>W?D
M C?U=YD;S)<Y."&_95T4*OP&9<Y-+,;A.$G_S^+D3\1^9(^@N_N1+9*E*#FR
M?J3W[K?F>NCFZI?-@;]E"<G\>!T%^/'^Z?^ H_M/.%V@.9Q+-+!3X<OFDI<L
MH0 I,2@ _8^LHH'5U(U#%[9*B$+ZU,5*+*2!^#)3!;+GC.8AY(\#'\GL^ST2
M_7_I^;*KF?_1E6ZR.% O=\RM_G?S\[N>34!HFH9M4 "L>RC MQ\C/\3^)W+E
M?X]<\!_OK_P>N4B*3,UY[T/HB<U\MZ3QA-U'LT]Q8RN3'><V(^2Z @0=.2C
MORPNM:],:YK@K?M+D10UL/]4^^<@1G/G(.AN[XG*V3;B8@UVO(M&'0":4]Z
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M-^T)P)^O$+;/)L6FU4UJ$35I;\F*7V!\.\ZVY'IJ-,]0ND85R-'A04NE2;9
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MJJVY 0Z>TM**I MSE&T4)CUF9N;IP_2BX;<2GQY&98,[N:/W=@0(ER4@,2A
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MA%O0B6O%(W7H2_7KJ7U11CJ1NKC>_7Q!QH,W\+(@X4,,8N@>6P1;9'<4IC
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MM4HYQFH_Z;9X:F23WXP R+Q#\6X%G,!/X&::$_[HH(*0QN;MDI^;0T;XF^_
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M#, LDR;MW_E,]/;5W':W4SY*HV^)%,^-<+2_<L+?WC*A%5@<H.4 \R[JP+]
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M/NXP&^Q%B6P.*$/RM]5R(_*UJ[J&:R(EH#'8X\63=VH6I,Y">M2?BDMG%Y*
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M',A6'Y8.Y&XO9>1/K4G<2-9Y2"['R.?BBYS(6U<;$NR,N=*4MT;O'&TTR27
MLTWZ3'P9K!OC"L4@@C>,$)VXK=81EJ$?UP;<E;E-.<_3&NJ&2>:".+[*3Y\:
MB3LZ7$KG71[&<A?T%+P3&1OS"PL$[C,7MLVB!THVSE84Z:P,P\^WFSTKX,I:
M(#46EE)3:UO5L*N6SAT.[._N,^G?I*R:NK'XE;',=?]]NM3@(>[L(&ZI$J?*
M$WZK>/[E?[AP#TB>F^_A[>C;#PM0I9Y>[)G:TY+.#,7&")0\W 8]Q_9PZ@S?
M0(O:^5J!?/M>^_B0[7B5D5EL('QWMEQK> ^FQWQYH7;,.;*4VM] JO_T<\+_
M\,C'H6W#H!]=ENW(CN'TJ#?\RKPONI_'"6 \>RJ+:NQ%LSR9>H=!-)<'LTZX
M+?F6?X!5SYYV#0%HK-DNP9TD #NF1GB.&)1VP/%&BQ'^H3(QK6D7XF#R95CP
MMQT"\,GNT"@&S4R1[I9U1?SO"-5_IP/_"Y6L+P++B3B^B\I+ &ZR$8"YXT_-
M><X:'9TA  O-"*PF:'S0%]R$;<+<1+BC"$#<+%T7U?$N8C&6DP#<16!?IQ"
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MC;LX*<X;XW.LVU*#8&O9].FS%%M-%,$+E^L12;+O)]1\WR6$*\**"( ,D\:
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MBND(7LK/ $\ \-W[;[X3 #1]$>([Y.B45F;J01D\S#[S8!Q47G_#F_6$WE+
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M;<="T1BCN:",W 2*9"[ZC:"!V80?VJY6E"7*P&?J7M1]"D_TW,II0]=( U.
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M>3$"8Z =4)(&3@XV$YCQHQ\OB7_(9M84*LWX"B=.^U[4D/WQ$3,IQ]B_)/*
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MJ,#V:=S^=;@'?5ORUQ-59:DK;%MNU9-PP2:U1^-')4*:_H]L-#M>+=T6/D)
M[K%+=R2M# ;6[+>_!O(&:+3(*_$('P\ZP3=UG#9&-S:X."U>[28_[5UJX14E
M&,5D#PAVPSI,!>>G@09\SMFF#^[- 77XS=KLCKDAB&0Q4>:?)LMCQ/TI*UJ9
MX<F/T/GUNG-9;T[GRB'FP8Z8ONGLJ)#R+EZ%WA)A<=5B P,Y!^+5'UE&A>)5
MP@SJ? 8JO'8"PWUW@I4E<U/V>W//%+]#5Q0-#8W.BV@<^[+J&1+6E$I;LNP6
M&QMG)2QFK^:>RLR0DM'Y%B77-=4WUEW*= QQ0.;,DNI:[DW<02F--UJDO23K
M40O$>1\5JNW7IS O!UDR11;KUQ0YM*T.PH,,]B>ZBB2BIXU;'T0(\E1;]N(<
MKAW13LQZZ]6/Y56$T[#KC<-D+W,^EN.G\:6EZ'#FVWJ%YP<GN'.LY]T'$/!M
MO=?.@EO6T@*IYQ;4GH5V!+T_T[RD M8:<>G4A#<>0;LB LF%#=2@8"J[T<=F
MVK?WP[LK(E2$3XO8'?+F/4SW5,HAMO5VO?6AXA;RW2_Y)B&+MLE-F/MX1D^3
M'+9^X%DL^#Z^2XQ$90(W,,,U=P:9.6K"I9SC_.XM27FAB_D>^]:9M6()F?6T
M:K=)8GV>C7Y\DNEH-;'$KIUAJ,$@Q0 ?<@8-X%[1CW>+7$?=AYI5OQSIMC0R
M WVY>07F*W=4ZL5 NO7X25G.!BR+L)XT4C);RT#9&-6U:U#D':BW<DVLC,B
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M3P7[OO42 #]3N1X1URUM^1M7RS#H@[T/(4V2?[*YF&QC3VZL\F7HY ,.7\-
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M+MT,J0#K_WI#-GIFBJ3:\&,:5ZNT1:73V@ ]R$:&UDM5@ M]W)&OSSD:(."
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MBIFT6J\7(:#+P  Q=:]Q/?%RVLXAPWEU:7CEK37)_#G$2U\1#Y92:N-P<:Q
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M!#996S?$'T9E9V-CFMX[:<MX[=9UYC*]<1NAV=XD2RU.B*=J'9S'<+.A*"P
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M;<V"4"2R'&)C7&&7J*?"AHV'*>=:>[596PV1S4[Y\LLWQ45U*;F)>^D4 %@
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MY&;-&J9UAF+Z@HV)\] -K:7]_??4$:NY[&UZNE0IF68I+N+5&<L16K3J6FC
M'^!-K<U[M90?IT57=LZ?%^1.*[P>4<RR:A/I7YU.37A7KS;.$+TKU778T^=Q
M?,GVIGIT[Y@J3534G?G%G;=W!W"M,F'9#4R)8M3QX\5JBVQXM1>B*69WO3[2
M3?+'> Q9N,DYVQA9^.?M,T10WQ:^:,E[SY?8\2W4H\TP&44WNN^L*&K0G';=
M9B^KBDZ>JPTKS#2J4TH+EM-1*Z W%S["%]V<W!,DW'YK92%]2-,;KX. K'.,
MNN.41,](8E7VWO-O_BG$*3 >J,@'CB-O/-F6,.46SXN^CH/:,RER/I#'*1JP
MXUQ@L9VVU\E4G.3!%@5/.9R<W7(E/Q2SGYF6WB3:;3>-F'5;U)B_-_:RHG'H
M.'^<J3&I4S<L5WJYU9.N51 H%[B\(PDGRPF?#LQBC%AK>DP5%&O\174HW'D;
M*AZOK#7&MVMG4!LTZ GBF2?&<:R@N,LB)"HCED*80ZS/5-/\2=DU[:3<K)."
MUQ#A]*BN+B8[0>K=N^0"8;TUMHJOP/8)#\;X)*O7S>&.UIU%*%@*D?#62-UT
M@Z?.0%FG?68HFR3/_+N"N<WSU]KCO'SJ'8Z4;L<X;G@C+;ZPH+!=,>V\?<5R
MHPZ\=+NT]%U"37".UW;A0)L&^7-[ !7#1(V7*(Q^,[2A)9O2\O8]XO;TXP?>
MWCKGKN<3Z5$1XDH6=D-'CEL:&VM1[6-'#U@RFTQF_N6GOOPSX^P09;EPV0T]
M:?;&,Q:']F-X7-T^:J(423AS)/:M_9M'NL2P%-E'CQ_."S+2AG,OPCG#FP07
M"UYH5)J)1&;*?B1F>EP@OF%_'E^F4?9@U(<Z+P2IOZSHUG7^O47CJE3>8]LG
M,U=NX%[.F,34^@](K"0!TA=16?<A=AJPYMDBQGE_)\:Z9Y\A.K'AA/9*WSRQ
MC&Q@>^O0*WJ;/NRS"Y,>Q5'/"F\YD 2)&^2EM<^\M]TUBLI#X$+QO!1JFF$M
MR97MI^.<=C[IYH-Q=WNTVFN4GJAV.1QZC*'P8*!V+_JX3_-,%1>B R^UHSSJ
M%6HTVW#"_?V$05<!F@BKAPZ(G66%@>URCO>1 \H ']@&_X8VKZ(+V41G?BX:
MH!BFKWNOE@?0U0-U"W?9"!#_F#0UU'1]99 0PMF59&DQ[XW*ALWH?Z[E1IW<
M:S8\>_;J@R^O_Z'SXH0#7AL0)S>"-GO:Z"(#$+$7T/$^<<9OT;;;R"'<4^4J
M9R@/>TEKH/B]K=>]#2\Z[.B[H^;U^L,/]Z/Q+M83N_:!X3YW(?*?AKB2/H$1
M*4;1@FS2K=MM)V)1",H2PFL0$^UZA+K3$IA4WYTGL]^,Y!VY(MPE4L+/P<\>
M:V.51@O:A@;@6B51G 06+'M"F=5CA:S?2SL[)L#O8E^5I13"!GXS:P8\DRV%
M/D>:PC$<^/5+-,#P4&MFM:KFT*OXCZ9TA8VS";O\S7%C(A_J/CNW'-E,*O\>
M4FW5:_/C&B_Q5QU>=7E_;=[!]03?@7@NFX7PEP _%15.;3^^&BD)):6_3NW?
M3G/\>?56/#AXL(.0'*$&HD2X.%O8[?4W?_MTPOJ'P%LU_4"<O=EV;+%[*-C[
M6\9++_H7.NQ(VXL@@7MW F%S#9)6@-6F//I!ZV,PI[%A7KA3 !RXE!?*!.??
MK![-:QDMM>/@W-UC5Q$-8;I^47LU< C_EOOBZ2:(1 ?&OA_@LD^X,X\WZK5>
M%6%M]RWVC_!9_97]VYT2MB+'S!;?K,;,L;]4$5Z["5SJ/$3D_1&EUI!PKOCB
MJ/%)4QM-ME]Y5_W&'8?PF!X@UTYO%)'D,F>$#P7OIA/DA<UM9=:R1?.73;U+
M)MBVN+?LKW>S#SS!&_?2!X?8.+_=@%6GIJYM*^7J>^9-,H3AV:M'8YM9K*X
MCK<,:.?C5H!TB-KV";W!()LJ6D'I>@I%>H/L0[F/_M5R1SB%&WFE2H#WMZ:-
M@\6) \^*L^$W_6:+6^2E7U 1-MH2KNBB <3\M+R??&Z,\4M]J+HP\2?[P%7
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MHYSFS$\$B;:F$^(8)M1F@Y'MO$Q?HNL>< ^MU_*]9:]J-NDD9KBS^[0&.IL
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M(BV[5 ">,:,!,RSGNX3K2$KOWX)_"_XM^/],P5MP*8:#;%5ZL<@V35+3<A"
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M?W];L#KAOET]4;+L81![S^R'DY+8A0SU5?"<MF,&_ /D[/'?MR;T72V*LR(
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M#!\,!YAG=U+3^:/JHL_)KPDRL)G(-3D8ZQ'4C@>JB!_'@A3BHUI-(KR8#Q$
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M_E!-*/,II.E8FV)(>7# NBU*GWHYN$[VD")'^:^ 1P&#O/6[P:FC% *"+HK
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M%DZ8GQBT<GG(WC>]JZF^(TNR$%B9YP?&UE ]Y05C/UUZ)<5:[/1!B.YA:;F
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MFGCU9Q\1_U<M2C].K]4%KK>GC$\>I7-UW+V_DBY^/QM[4#J4T[$T$/PC!:J
M_XI<I8H$8V"83\)O9+.V*[(9,C,D/=P83%-_!Q]@W1C>+SS*'O"F*[$X/Q3
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MBU4\>*R1V9OK;-V0^3=@/G6_>?;42P[H$4)I;./ZR-#OENYNQE_]B-Z1JQO
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MPL>HT^@NJ"ATP"-"%%1"%&0_0// $QWE[PWX7PWE$2H:.@;F8RQLG(<'&IX
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M\.URPJVX_YLW-MFYV<I;O9UTSUX:-+:3SXBA\J]:ISHG3)%6><%W#-<DYWD
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MJ^&V5T/DT3&BG_#HN_93?R:GAZ;BG'B'-.$4POW;*_=^:>^L:AZ-RO^>__X
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M=5T,%KSGL%B-YS!9S?1$<>9H?:WT^V5A]Y>SKS]]5I4&/]L?2"+O@>WN61X
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MY+34O1*987;4$50B7"SVDYA?'KOQ8W]VA*60Z?/>O2R4KWL[RM+CBT#0C[G
M*EUE6Z+L4W%,9 ,O^S/R^_C^/4C\2'F1SIY:.'#KR CR@<_*(#;*RBR' &G,
MY7T/7YKO166AJ3GRP#CG.[*.!'$E?S\DM'RT,K.P#S#P53"_"D6(0U_)6EVD
M^/_%WGN'195L>\.;($$4%$$DHZ @07+.*#EGH0541$(+2,XT07(& 25+D$Q+
MSCE)EMCDG',3F]3]]9Q[SLR<\\W<>\^]<]]SW^^;/^IY8/>JJE6UUE[KMZI6
MU78( +M(<-!]Y4ZN$MA*=6U+]^)SUUP$H\'GUN$61620::RV>Y56@5D>@"')
MX-T)U0#+-AN*C5P2/+PP'XLC>W#.^RME[>JW>U%(@K$QMU][;'U.6L>( GQ.
M4<!2;%C>I4+=Z'$]HU;5#QYL#\Z))7]*7;E,XU!RP+WBNH\@S5D1<S P#I<-
M*F<G P]O410$PXCGKTE(R62DYS#,$T%S-RU0P(<ZISR$D#""=;&LIK0QI+NJ
MK$[&.<F^'PLKB5CH2%QA%:TQDONG[3M&K9Y4$5)E@_:/"S1D8RS[ZJ+OLK97
M7ZT2<@%+::06UF'Z!3_D;^]W^FD)Q3Y\=^]VU-1I[.I'-0S-B1G>V./Z26;A
MY@??\Y:8%9+FERI)KY%@E"\VDA@A.MOX*<;2(Q^V=0=K7+M/PNQW#SMF2M0U
M1@T!:1-*]3L.=#!XM-SL<%="X+N)J+;WO*^>O1IN1F.'J,IMD4G=@#K1+ O^
MZ\\J3QQ!;]=RL6-"+U:KB8B<XRY:4QY5PG;&6$+&#:8]<KCS2Q]K@+#OG 9M
MC16OIQ$D5&3QE1;,6<3C4RB["$_+%6.2<!>_!AB2WIR/"OW#]F1-XW4$"M#:
M+P_K3X@[T0^/M7=2?I7S=+4-%/'I1B@-[K+ O.YC:< AA1GAG8OXVC&EQ#>F
M;Q5C,?7EV[>0GD#^T\ !QIBS5/WE]70O_F,B,J--PUM#[KP\?#TF7T4B"-*_
M185$JRR"</=HO-3)0J"+Z"#PSG/+L ^PU_!,YEDS=PPO)V-:IAW$&'K.ZC,0
M%2C@V?YN>3KHZ;N3R9KT:9'@]I'[#);WO:A5U<!U^[S0T+)&3+[B!=.*L8(B
M4S-HF3S;Y1Y;@,SC%%O,H^;E]S:=T:,S_,]'CLQ#)PTSG$Q8;I!5?,Y@<"7.
M?.LE.F1IVN9H=-U=W6VQYSE/(/05B)I=,7P:Y,?H>$"_R5TK<N@G-GIX;#!2
M[J&JEZ2<N\GO5)+3Y/8Y00HWC559(^UFGUT;C&(V/GUC %L-9,[7@1?'Y?E:
M1:_?+2:B.Y4H!+JP+X(D_FETIW\='5.3<''$1\=+,&8PL&&?2F6AK^K'RW[3
MY6Y\@L'9]. ,/:<?"F@DO\%AB[$FDG,ZD+8>Z;PFL?_H,U^ M>EB(<Z9R+#)
MP\_5=Z/1?G<;5]PY)>G-'>\4][=E]@.WP$*/4,!VH?YYF_@3MB(:CCF#G\88
MT3%940G>-]BITQF<VJPI/^<M2@FDOQ"MN=8T+K;>C7ZU6D5@?J,A.U*GFM7@
MQ(OJW5W*@M+O;XP1,0G0_S#8HSQ/#8$>&UW?H*%.H30I'0KUQY5^16\M*!ST
MFLBP2><:B1K.540(] @%X&RFD 53OBT>R0K7RW0P?O#1Y%79;A.Y^@B%B.CB
M%@JX^1S,Y_A^2IX&:C86\SDV2(O.1_<&AZ<Q3%RA":U)E_<7IU# M2U3[>%7
M%7%V!$\K5O3B;X;N%Q Z'Q>E+EBE+NH8Z.KLQV41;SJJ%UUQPA[MTL-\FSL/
M.^EYUWA%LU9&_;I?3$SW60K9EK2LD'M^L&7"6F_$VC)D]U6O':U3S)A$@%LG
M[8F5;:.>7WU\T17*CALO$K.1Y-3N_/;+8G[BWO5)9\@V7-KRVG1E^*;*QAM/
MKIDJJNO9N8B(%V,9SX^5C=4:G@EJ5U>[ &)IG+R?)2B1U' '%.#_SB%1D<DR
M,T*G#"S8V]V6QT$7VWJ#]M/QP%#F?D"8@^JU60/E[*PRN$'+RZJ*&BFX0O9%
M-][&@.?:6'4W$]9H'8;EXA3DQB8ZBOWPL+Q.MHIC=OT1/=.DR\WB((:7\W9)
M6%W-19TJ8Y>J)O-&)!8-S-\J?]@OO7J8Y9]("IUX.D!'_S[TLNV(7+1T'=QT
M=*6I-F0E-OAU[L7$0*A+W$&99812+D[FR'$?2#_JS:B#<,^::HV5J3G?%?^=
M8.#+?V9['G3B^:2Q>/]MQH+9EPH^_L/,@^_=LV8FS#+#M??.9-5^4O3&#+!0
M0, QV$-3L1KL]IW2WI9]61+7!V_>UZ -!9 [V)&.)'@&?3%/B)V,354O*9L0
MQAKQ9YA/-719K5L,!C04.=\RQ'0QUEL[B[?#D-=A,M"OK99L34'I4[8%7?X=
MSCJX(JX_F8OLA1W;M5;]JY124RJN%_IBB+&7"G=\! '?N;&@XZG\"!+%1=SP
MVTX/-^J9, Y.X^="387M]I*<"M#S7#.T5ZX:V$A*WR@46Q&6/RM4Q]U&;JQW
M&U#C:O.16LKM$D- I4OK$(601>>RK0C"R>?39>G"R5:B(O2?O%MIA7>O?KC:
M#9#.TT5*XF+;/ZAX!'<*LF(-0T<@HR;E].9^>PQ,LE_Q.T1SL&H0?DNCJM3.
M7?:Q/LX. O3#?6/RS(%Y# 3A>*_QSJ\ON+,L@@;P$.&P%\.+/J#$EPO$"XKW
MI_U4).B.C&>+<])N%M*W"\4%+&;"24,RG?*YE71QC:T8;:.28@7IR2_!Y?M:
MLP_0H(JWD=C9=K-5 ?8Z9(=>U1M/L<GSW.^MJ)R&Y!(KT3TH1Z[EKFE9E6*(
M>::_6;^&W'C^XV/LGUX)*+9%BD!\6R,85J8H?M-,1^&4(K3+^$3]O12'0:^+
ME<JNP-*&D3B8/S\77.-W@'EW=57>2_1]K^IQ[C'M'?!Y>U7ER'&]S,GM[^&+
M&\LOSN>3=+3_<ZEYB*QH_&BSY(QHOAOAV=?DEF^Y49B@<0 !/$;S8[-=KK-;
M:TU<+J8W#=J&?ZY:E\>^$3[>P1(,JWN:YQRO%Z\S:I7@UL5Y>'0=5R+M/7#R
MDTP'=QJX+!:%]7BIR:1&'2BE":QS9B>MDSE_Q&&_B3 4=841%8+U P(=W,(T
M-:O,T6;/KGII'! &!#!SU"7N3!B(AAW73TLJ12J4Y+QJ9K;EWFDW0V2W.:6P
MP:EGJR%4MV<,WLU&/L;C2T]K8D@)%AX3)<%H7!P@,T)T((<.U?PG'[-9$@]>
MJRGQ"7[N8]N9^@D%^(GKP@WV H_JL60;0&9L]H&]MWJ(^78**Q\>=#)84G/.
M5D\R8<VR#[0-$,J:9+5F3CB7= N,;)PGFJ\NIT?BM9J&NE8X=_+2MEF3SB(L
MUIJZ<NLHX@-YRJ-/S@4IF4L:KF-5?B5\CWLJ^YKE>X&(]B+U$]AVC6=M[B0(
M!0PP/5F6IO42**@VB78QU,MT8;"+<Q)D]9#GP6!;689-AK4?[=2XK)AGBA5T
M,A[S0A?GR#;%..'X8WM+E3[KZ71W\[HSK*6XVM;@!=>9L,I&1#0A\#MM%"04
M=15WR6S>E2-'GIG8<O&5!3@*B"QCA"8<N5VDACCJMYC+2I2.0%^+*5?4V,_O
MDJ5!>"[S8>(<?<X/W[4N[A%/31 PN4OF=5J0F?FQ,^#A?N4.=5/#M80/:(1O
M==R]2^!8:;=18Z\#X\;I?]MS=PT6E>H.^Z01+<\0_9=[-/_,[/R_H/RQF9U_
MT$6!_W\O?W ^U[\\V?[_*^6_<VA =\@5'0' K0L0 6JC]^$,<5TN[P_/V-XR
MC+^(HW>$1T7;M+]% :W<[%<WL]%@>NZJPDO,,[W!&PU3WQJ=4ZHB"1HO+&GW
M>WM0P%-S%-#LA (LTXA2<Z!ID(7/\4C_870POH><DKWD1HO_QR1DWP %3)EA
MK6VRK-,BWIJ@@"]E*&"^%@54H(WPC=[&([[42S+(R21P=AY\CHLD_PQ9MQ1'
M/$$!.V60/[GXDXL_N?B3BS^Y^).+/[GXDXL_N?B3BW^:B[\+6F"@OV-AJX'Z
MDK)RGZ;Q2=%DS^8='IQ[P]M(-:5(>7'N-_"(MA^X.?]JJ/]G^;/\6?XO+2^<
M(MA%M%A3>EH=!Z6@E@SQ%)E#+T%,N!_4>P37<-,*&F]L'9K-8;(Y3.AE5U4,
MT[PT>=T^;345 RMBPAHT@]*FMKH6!K2F(I0RX'<+W!5)/XVL1.U^:D$![)\&
M[S7L-E4#QN5F%OKMG>'NL@MA.),'FZTJ#4/^I1XG>DJV790O&5YUTEF)+!4"
MKGZD:Z[WJ_;CVXH77D%<G#(M^'!V!ZU6N>KK<L;?W)C>8>G'GX>E_W20DG+Z
M*26IBQ;')GX:/E..)\P:!8C&'&;L.** PPEQ(2 A..!O?XO]]<<T_)P_"?\D
M_)/POTB8!?IDX%.0([^.D89O]@==(?;'E6_NDHN)1D06^@\_GAPJG)>/EX=E
M=-Q:RNVBLE^"?C7#<OU59LAUBK7+D//X*U<T2DNC..PC4DS4OTI*'RZ,K&\[
M5PR,A-P)C:4-PJR7DAMZ/BEXV^ >J<FK2,E-O)P=-K8"-N/RTLK@V=G[%0)?
M) )]?V TI1%QC+B#,Z;=;S@&GY/5U0PU-%7DS7>;FEV6) HM$[O9D^>P[N@V
MBPGNFW04;%A;\P>0R;C,>#U+X8*61TBF2!Q#98P(G#UXK7=,!GE61IRL+]0J
M)!_M[5EUV.V-%<UMC D59NA;\#F>.@Z<IJ=P;'H(B*CA O$<SB%+?@63]EUV
MX/0-E<H[;<U1)K'?[M W"%[>=)76&.8)XY<NOW@2_\K2!,?IWLXB'OXQG8/8
ML:/7]2PKC!%H"<:*^!%%K=9.X_)#CV/5*QPOMAVCW8CNL/RKP3.-00G\<DB-
M.#,?]%1V15$:>#2*7+_,F6R<H8UE(P$2=2\R#C(L4("]IU:9&J;E?U O#X_4
M?2H<=^[HA/1UFN^50^<%&ONJ84_]<ZW\$[W[7#/B6_(^O1+U>YY#AP(,;) H
MX(@$@^^_,XA_MUY:F38G/]9>I;5KL9H^)-?Z=.KLQ__D^ :UVJ:)&F;J-]LE
MS9%9C7/6:Q)W_L#V_U:/-]:1]J/]44ZAMG+F"Z(:8:V^4Z*A='2<%"'7.$."
M\>1_8#ZQ&+0/IE:HB2Q,2J 3K^<]FJ<F,V.N0%<WN6!(T=<HX#V$&8CY-V)+
M]?&?:OS+]Y_^L;P(:%.]\=PY4>+9*&\N3SZ+O,C9(XU@#&I\MF'<+U0P(T,[
MN.:V_UY+4.$M$9')U',7N\#3=V)JGE-.#@,D&.T;!\YO=P]$Q6!+XH%*O<VW
MY(7SHEV!;> */&4?@L]3_VBR&S05,G%?N=#N_51FS$Q$H9TG4]F^P'[8X.BK
M(4VE THP<P=G)XVA>,BPM6"^."'-N6J $);%?>3(NV''RUV62X:UAIDRC)'?
M H/:PM9G^$8>FBA ,C]690HII3NGA7Y9S3!7?F]+5!+W?"OB%&U(<S?QQ&$O
M((U7UP#5WYL:-4EDS=(5"EAG=O4A.H;1[J'[D;@S^#O(5.MNZB;HZ@3I(/J+
MEO\1M&&_TF)2%H]6M(*++PVQGTH#RK_#.-8;%*"##NF5RM&UGC=.TW:G,IY7
MGE.80"]=VY'S2"T,MG_UUO1O%1?Q8#$.9Y'9]B^SK2?Y\HS.O )%A0Q7W]5<
M'QM]V@5LA@M=VVT-!<=8[;6&BBCE/73UP#$TL6#R5O+@2!579K]^^8T$X"#G
MV,@[P1WJ89Q5=AI(T$H2.5W#[=TTN0PUTC^!7K?0K>GT*YN152N]ZZ3+$40S
MC8EIFM:\]I4E(KYMCK@L)U5M5(3^Z\"K>W.L?/QO!BB(ZB08"26VA6!.&9MC
M";L1YGG/Y5?U9V0>A@4V-V_+OA:B &I_2PJ_.*JB7REI&L''W[L="YMVJTA\
M#NF3_6L7(/K'J/%?;?S(\;7L\S@4X-&8_,<08_)/BRL$#R-%'Z MG%;AWUG;
MWSNQ=O,?S*-[ZN;<NGE<(WR+[,+W3 V[['_!567_+^$TNRM6CGU<UZ\,L,^U
M/C80VLD,?6S@37Z]IHKA?=,2W3+%'C@"/EN>K\\7D6[&U6Z=N\7/ANVD\77!
M*CAKIN6(%9BG -;*V2DO):N&3/P[%_I&R$KNJ[/&!VZ0TQ=Q\'L(9#OC:L$?
M1;S*<+8RPIB=?-[D\YC=I%Z&8"2>F:QZ@.8X-5//N49.Q#A3#U&R:ZFJ6.M=
M6+3[D0,R8_VX;#^O;:G>E<R7=PTN[EM6:"'79CLC0?',T+OY?O%.I(T$Y2]3
MJLW[K#9&KEY9M,6PC)!M_(C84EAU+1CX]&(JT=>*,;071\FM8]M#:'CV61#Y
MLL,S]>C>]]?<AVM;PN9K/?@Z*/T0T4^TL3 7EW8\7TYW:![L=+@MP5?KV=OX
M"A<C@ER)_'A]US9.:D 6\7&;<N&+!K/ZNU@Y-Z-QZP'7%[:=/& &E:)0+G(5
MR4OST=4:@]A&7[$GG>D;G%>I<F/V:U5\@:KQU&V6/4SK7'6W6(9R@#S'N0/B
MAO-LI*\NB]CC.#:%(P[CY&22U(6TF]>9B<H[KR;$]R8R=FQ0@*/JQ8D9INO_
ML8<_>P/9R27D=NKI]@C'='H/Y_TS]_V 'VK7)O_D[M_A;OA*$=(PUQ_QU]]R
M+(O47],%7&P[2[G]^).YWW_X]B)@0UT?TIEIM!L,-NC0NBRQ1R[D[!2I6V9H
ME+QA6O?W>J*NYE$DOMN% CS[:,$1%R60N5(TKO@_])"X"UF(]/\,1@$TQ9 J
M\5B94_5/XY8Q7Y!8RI4UTI5A"EV1:>_]O=A^59=Y.N.;&BWC*!XZ<O^7Q^3_
M\(69<$14]@9,C"9$K6[,/\CF:W_EW80@\H/,C;#&-CP&RSV#,)>U=H$O?I?\
M^9LZ4*<O&Y/>,6I!QH>8N5)W90PW"V'A1QAMAAL-K(/$NQ<@^->@K^8-CU(8
M$I"S^!2RO<\I)=7N,&4GA;H&GQ02*94,EK%0\ZNL]D^2AM/7.JY@%;FM%7EL
MA<%QVU(#3FDH:OTM=0;4_,WT[O;?KE]A>,GTXKT'=ZC.6FLMP0[WPFZ :2XN
MJ*I02TA\5G+D\3DF[H($]<\.^"5B;$!M1.1.P:2Y4LLY6/XN=39VDCUNL:@X
MQ6RZEXC"6CL-015"'@7@C=RM'D6VGYB5^95;ESU<G<:J))^F79VY<BY4C'&:
M'R!&*+;-WF=?IKYMGZRRH57EHU[>*D@^7R'C 1X]8?S<^'JO@]\X23,0^Y:,
MY(X$C7FFD>22:HA\T8;2\/JD3-)8R_YC?+:VL.ZOLG3L&L)(T@W[X+Q@4A+F
M<*\;&(H2US0K4$!D[.DH.LZO_E6<_^3W5H*U;D&*JE  Y/QZRJ_"]*/_"&#E
M6;P'$W>1#[-;6OX@2E+%B(S9\;]7Y*84WTY6.9F$GVO^W=(*6ZEC,'SI&U5$
M:G@9QL2@7*T/T':WDX'PJ.Q_.?+'H2E/TS?"WWN8 ']XFPJO*)G,NQ-8+'6G
M_P(2"\NRB+!Q/V6[+N=D\%TK6KPVR7BRQFT.L5^- HJ4+\-,$.+(9SOTR'K-
M,S6<F7]U,/!;Q2Z%$R[D#%;V>O@A(>SJJ&6ROX,+(_G[NOP\$SE#POI6.'PW
M(O]%1431NIJL0ZY9)9O0I-R%=-N[+.JG-%@O]Y4!FQK#TEQ]R<6;SQ"X3Y&3
M@U:OB%N-*5A30(].'JC8-AEG-^+4:SX=8W.7_#)A,28=5CZMR&QUCUXTHDJ$
M-LOY)'Y1G*RST/G+T1[&%KY'H3*EA-72P8)7H _QK@0NMFEX^68*X0]5?Y'[
M6>N%=%$[='B[]00I()J)1U[\OV5BF),K+S] &W+1,'ZT.]L2!=QGV<N#K/-@
MV/[>Q\Y_UG.MX[^ILQ?C[QU'+W)J33V@@#->0=B1P0KK^<G[:Y?^=>CWW*@'
M!:1'>PG]\CW/G.4J'_;C&)G4/0Z21$4=GL3QZ.#,\XY$VMF&RDL&W#,MHZES
MT_WI>!1@RV>]S,(8E%Z9<#%H$29;9C1MKJ[7..6X=F50OYRZ"Q)'J%\5J<X,
M\V*A@'<2R+?Q8SE'L2C@]L7UY#!F%OX+E8V&U1A[R.P;VK&(2@O&K^$H8)_E
M _J?@M8!%( 1?X9;'!\_V]@[E,,F/E)YL7.YF3W%JSDL+WE<0[N@-O7"HD%]
M(KLY;&=L:>YJTD@OP!0%>/5<^H[WU%S SA))=*R3"VC/[,IH]="MW9']7 @9
M*(\\[YV[5!8OD"V]^.1&-N.Q/I1>ZK1E=-C1BD0VHJED=JR1+N8HX!2. A )
M8M\:8Z]Z16-V&PX5@OMF"E'  )LX$BG^$^&5-=)Y'#('0P&+YAZO("SH]AAG
M/%9C21-7P4:'>V\@._D0.(_+Y'<4$*_X]"@)!<!YD,6T*Q [HM<7T'H*+1WK
M25ZT/W]R=VWC/03=%RR?Z,ROS3/^*0H(RMCBV$9/!CDDTHW<R<@5!7"C^[^P
MRIV3I_7K1@%^M%8CM>M[B!>,B*'S7F'Q2QRC99H. ]C?S]5)V/K%I'3GP@/:
M+;4I"SN&-]1/]B]WNOU$4<!L]G&")\0.!="=<!_\=;).:IV&>3'0DO)&RD3L
MQ.Z]RB&Z<&0\TS@??;*PS>S(DU,PMU-K<YI69U18^A,+4V-8>SP]QY60_>SC
M/-K^AOT34DAL GI8)\C/LVNTS\<A"NI0<UFD4?JE"M/Y*-&:D2O1*]TSHVFS
M02V9TJ_\BA>0#HG'2UK#4UG'Q><*C4M:^4-N\AZ+]E\;>M"X@&!*9L,!_USN
M\:(S*#/',Y1Y9/'D3567/4-ZY"W76^860;<;%LZU=%+A&V07Z5G659ZQI-F7
MKM+(]=^'#SZG2)$GD*T8"+V>)Q$*B!*60P%0+:36C)MAQ;=P1>6O>C-XS-D8
MML()7Q9$+2:IQ7KD8AZS<A;(K65$78;9BGB2:Y\\ 2>>;Q7_^%:>))H>'J G
M3:*KU_^;H:)N*@IHD5X<( $+%5;ZZ2J4#I?UQ)5&'UP9RB8X=,P'9P(9 EW]
M;F[V*12);=!K;8:/RKZ%+S)B/MY^\TAP)+P6M*HA[(M0PUDAC4V#6%W%+5U
MML7-+A3/:(UG*KN0-Z<:0XH@UT?_\5I;@K:&1ZI$G=8D^AZS&3DS<2"0L%:/
MG"XY:^<']:@X4>Y9+WZS(O8%M(Z50V]U026+)B=!+S9@<Z:W0<1286GSQ>*<
MY)N<!EF_'?_JL/NYR^,&'_&.LJ5%WYO4>S!QG[Q;4,/Y7&?T;U%E.64;>J2U
M&Z3);%]</NOF7L^,%&<&2J5-S83J])'>K_);[[23+A-P92PQWS/%)<WX>ZM.
M&@)9E&,5T<XT(\(.X\NF&I)]$%4N\@U_P-,.I/5/[0UW9<G119L*R(V4>@!]
MSKT4C6U]3JW<SFNJH]N6K%KR-M89O#55SK>2_-U-;:Z[(>EYMQ(Z+[W94<#6
MI.H5-BS(&;0X\*$,ZE<Q>7-F>0M"'1I90N!(;S/CG61<E79S#+X6Y'F_$R=U
M7E'=Y(Z4/PK0K:9]6%KB,]C9V=N39$H;/PM5_,%3S6. ,Z"2< *:>!D!GNX[
M7;'*BF#,%?M:Y[NPU]YXS1G<Y*H3X^3 PZ\FX[ZB^);>Y;7\=ZICJ/%@N9NR
MFVSY*"MURM@*?UMOECSMTR$O=ETR*&/$T96%QU.I&*51^\Y)F<^V(I^-6[RD
MY 0$Z5(3O]H89+TWI"^&^T,798;GX=+^OAE]?A6WZ,!3272F'4L=A+NZD3AR
M:=CE"&@6:+K39#%,# 6TZD);"B]-N^SFWF3XB/9?<^*#Z9Q6;-B 132;Z;H5
M[_CKT*2%WWP_R=[:B/U\L_2I>'PAV,Q[S4/#QDYL>#"8'["#62_IB]W9-]__
M6@M5-&6U,8/MD<15W%ZSK+W6]@&K:=J-2')#@MKRUX+^GP)XRM'/%Z0.:M()
M"SH!#:O);^6=ZGK9^CY2.MV/H91?7QE]]'@^KP%I6UQ#>FQ'HH I7=KO$*'6
M+0X(;OT&TLWS44.'XN(P[+*2R3D5E*CR?*=092+3H!=QD3\<X5G^?6(35L&O
M\>(IYQR+=;S3@Z?#J88":*]P>UW7A'CG4<+.B&7,>W*L"H!:",9M;6[CP.&/
MER*/WP%L'!]!8WNW7B/+1QV-]COK?;(#3JAI[7ZPE1_55(;+O2M:>6LH)7O@
M.VTE0,H^66X.&=V /]T3.;LBH4A4*!'R_'PMEZZ$O5<V5U \-S_VZ"AW[..#
M3>5L2TOK ],@P6$-B]O#_:O6406*IWN67TZ"B>?R*<1+OGJ^'65_C@*^]=R[
MNF:NKGML)KJ+M+[<EJV(5V2/YH9\*P!=F248;['NSHUE1L@,TU]4\*& T)<H
M0*A>FM<_O5S-R!97/^-"=>^!(M@9!8PV4Z" &B^M,G400UR'96456BYM?X'3
M/Z\.JOZRA?2[V/O?)?:3W,0X'QJ4N)WH#"K@3,T+#AV?Y <])QKCU&'*?1\R
M0Y+UL)29FEW5JN)N-G(<BM D#/E*4W$7!7QXJ;W)3'U=U1E:39(W8F1^M6K^
M@R<#[5[5/<E)("_-DPL#S^5:S\=B2<6UOUR&[#X].89\OEHU-M/!4!G][+PC
MC +"9"TS0.5E[QAK-;0\I@)HQ\H3=VFSI-%H@"8*4L-T7DBT;/3>S;6QMQLR
MWC6) M1H3PY&(&]H)E/2Q'>^B??JQ))XZ,2_/#D6_MPXH4E4FS?GR9J- DPR
M+OBV[4=W&TF?7K$H!(L5J@[L059I)CV-;%$ /?\VA==&@2*BE1SYT2-  PW_
M:CWY-O2U-,[+A!LOKQNA"0W_2NB:?74M'EYA!,_83H!>73-& 4WJ** =W2VR
MD' /!6#&GP54Q)N<LA]P>_;D0WZHT%[BH(#MG L^* J0O">^3XD"2@J9F7YI
MV2!^NO%[WX783[\30"YQ?Y.ZSJWQ$A\%?'(S=_P+([V\@6L1NC6@N)DG!XK&
MY$<"Y]H@^ZC=UW)VJV08G%LI+(.\A8^&D&/R7T//BCL4:I)H<&QV681;*"QS
M!]\Y/*6QRO9[42SRF#XYH]Q]12FXK/AFKEOA[!5D8>"U8!:O0I_;V-E/\:J1
MEK/D;P0UN(D&9DC&?;'&/ LD16F$WN#QX[Z9V3BCGI3'$7/.B1FF142B /56
MWCXTE*>1;$)1U#OA\<Y<3TU9E7(,J/'4 (*UTWS$&YQZ]_+QC5*0!8R?0G2;
M54<1=.$D>T]4$O A>D>1,>]@Z=0Y>Q_NEY4Y-BF]?&L*)#+XJ6_"L&1'9"D-
MMW%-XL;^VV(7TWG:NYMNF=4I/6HC;X+>O)Z8B-,^MQG*,4_!^08G:EUWE\P#
MZR?5M*]$3-&JDPTQ>7_F?TEW'Q.J9%QIX>1W<^B2"YY;DB+L]B7'PE!KZ)NV
MS#'#/N>F,VGW^GMG3Z.;>JPI%(@/"2\B,Y3-K8;D3?BQ[%Z**12O5=@->:&5
MU5_-#Z%KG>-K_\2:+4$O%$;TF#6M:&5:97H'%VOL&Y(&(65T%T&DU CG*\XQ
MH&_1&9LDR+TOI\6)\2GWVO)W1D:Z]YSM3@EBI1G@%*(XRVNP;;66D\7[Y*%-
MZC8KL2*Y5#9'!0,?( <*/WTA^P5:%9Y: "ON]],WD<R6FK)PPGH7FXQUW8-Q
M61*-,MM94L&;/,&2=(\!0%;45>?TP[7.@ :Z+4-BLGA^H=>3TI WE5R?:8!>
M[1^<RT4NY!MG"3$+Z&CGTAH%&-]  >?7-?0A7<XCD&VC$!0@2P$D&N['!WQM
M3%6#R]0[=W''W-"E2 0]!:BCM..S<[ORC&[RLB-2G+-;3\Y;+2;??F:KB^-G
M%TCZ$$M ,HL_39)+FVSG^C9K092_W?,1))"S^:K* ?]FJ<7=/N9$%9$OA%JA
M#O-V^BC@QM?*:C3*#RMZ=U0YS/9($<=G9N$V=2(#1@51;2UE,2S%#*O$FMI9
M^D6&<[8T(>'U1$0)T=6QP3536J+UK)[D!TW%@@,3,8*7>0V-B_5$+8/-CRIS
MVM^61A>3W7"Z'7J$.Z*&R[F_A911I48!X^:-1QB&WH:<\]:!GG>&CU$ F:)3
MH22QD44'^*V)]>Q]-2Z!XV.H:1H1+R+.(<@=-%]+3:8&I@RI+DHWMY73Y@3Z
M*K^\S I>:V"16E(8%KN',-:'%;QIJ/[,YB106^ORK(2H1F6IF55&KEUVB?WL
M<2I1X];B*0IXIH,>8-EC$<7Y>I#LAYR$U>D"4(TU51'D%A/6 ,^6.(Z%JQ9_
M SW"*V:K\G;0PZH(PUM7R>-O"LR*2*6.EFE2_2P1PAW#D)8&V-X>E'YD>?\2
MQD%0]E)Z\5EMU(' F3>6>)CZCTOC>28>-S>CVWKCYA3M98K4,UD[@;J$:9BR
M/8=8([?'82JOANI,]E& =MF/EW?'XG\H8[..?;UFRN*U((<=NI1D%PRT_!#!
M27FT?YQ2N6BIJ54]NK<(@G)13MP'62[9%IAE,C71YXBL%B ZM4=$;L\;"#4[
ME#[ZXN)"DTJ3[U9V3WLB(N%L?D<R-"4[1NN2'2XL.23":9J%B%XY*C15\68K
M>K?F=QHG0<+E13@_CFT\]A5>QF_X9%\E"CIN!F/G2\V1S2E*=KC[,(7AK4:M
MX$6WDW&1P);$O1K_U/E$Y0?@0OI%VGAHZ^UHEC586QAK,!?6%]N"S'T9X;&
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MLY/RR-I0!]1Q0W2ENBTXB-PVS^W.%4M=D6DG!5]$@9F"@X?<AB*8:P GK;2
MS9INGL.XT]VX$4:"L1*'Q!H]%I5M_RG7MTXFP3^*%?+VT/IS]//E4"%K+%P&
M?W)<FFG=/'>QFO*Z?9P@&],U%Z)WF?B9LPO5TP1.9Z5]+B@@2+>EIB+'@8U^
MT:\HPD4T;])(1#,C)-,0@_Y]JS&]^/*YJ1]K6;UP2XUE2HC0M/F/EKOXL:WX
MN([?YY>7X1*4O)V&"!?[1O(7SI%@M8F-A ]2;#K]RTSRW5^T'&P]-7 PJ)N*
M.NH:E D4X4;M!K:P=I>:BQOOJ9E;S*^WO7[3\ST_JFX7^\X4K1+P=MT09VR/
M5F%HN-W5  7X'B6.UE;>[?1HW7G=11G)Z:7Z @4HN9&ZJ 9>\F8@A-M2*.OW
M,Y^JCNX>WRO,+*NTJ]@<CUFU4CI2XZZE\GQ^;/'')?Y%G@Z5S[07^N!;\5_V
MS]G>]^X2'2@WU<@TS^]!4N5(]DV063O@O8M]NNMB%+@H&6>WS9S^7-5ST5(I
MS&N%C62%[&KI4O8HGT_?WC%TJ)8'QGZZYID]_E.:%LM#!6V'_$KKP[TSUUWS
M_B]9HN@.XZU[)0  PTL(0U&:=.CU?_?8TO\:X,.G>FQ]Q--CA#@.N6J^S/W/
M8AJ,%5>:6M/]*4-8F1$Q]\1SPTTNHPU8'^6]-WH<2FY> B9B#<B)%&4%VL!9
M@1]O!G7TRD2)=6NK&LTFC.,LJ^26^OEO1\MWB$._<N7GZJAUN_IPW60";A!>
M UP^)!30$C4\W*IT_>',H^SQ,H%@@9+'1IDBUFS:Z[VJ.@K8*H)*PAMB%CUT
MP,ID.V2.^VV&BL>!A57OO.AOV%1_DU\*)2P?+/'7*,# ]2%R)=4F8<[1I@;N
M87J)9+30/!SVI):%+*C>Z;5?LG3BJ> G[IC5[B5L]]8!0GU49%& 8<TZ;X@U
M#<)(/T#)?X7MK;_B\R=%#SBS.I;I;4VCTY+>>,_6!(0Q&)0\*#ENO3&<@]7C
M3@NG?#981YYM=IXQ+5EDOE_X,>%YI6.5RRU+#"U"IY<OC]9B=,5N*]O9X(:8
MUI7QQ7,A?!:6*Y_<:VNG?RA/165*NEZKZWF5X<B99!?\ D."AG.>B'JC@0(Y
M50R+!A'(.R165HQ0$SQEL3Z+C"0<NS<@*GEY?A-SV7EX$8Q([Q 4_W8TA64*
MMF,PD>XMFG!4.BS#"%TJ?.>,*U$_:!^F,Z55H04.TU]=Y64MHN!_ESN?TI ,
MAJ81W1WF9<??:&"!<U]*AA/MM.;(62:J59AK3=JLX-EF&D.Q$F ($][Z@8A+
M2SO3K(;/YES/>>[NX05N3]#=_.8Q,SX37G=HF/8]M%M/DMD6G_KQ^!H/1A."
M'JF &X&6T<D<"G@V"$4!7:;[D"L70Q2PSF)P\I>U . 0G_>Y&*V[(LSJ.&W?
M+.&\F8>LA<]L,8&7>; :F$_)0 $P T/?)0_&MO."L03VR2<["X%U\5NW0>\G
M )E[2W8O8SKO48,S3&YD/<<DPJ8Y8LYCTE;+$P(XT-J#VR9<NW<-4;&E/K3@
M),8TC&Q*%X/E2;6M(3$1M I' S?7OR'L6ET=(W"NZTL46V'M<=!R>S(RP@M$
MK:5&RAL#76\<2N'X97:<NO5$S,[0QN),KZW0<@AT\HZKX7A6%X#6*9Z=)T_;
MU==1*OG@A89BO.2WI(KDCMF^Z<(??&R$C_ _5:G;%QGL6SRM#4I+5 V*JK"B
M>97JQ6?9[P1AA94-:S ML:J3*E(E9Y#S8*S-$:]1J%3/HX!;+_)O"JN.4%ME
M79?S>Z/\)9&Z=&Y#?[)]-"+"DV8K$N&Y*]PL6C<&KWG#HEA)]R;<A3ZJW2$3
M$X^>;@@]>JV_C;[!&RXNY=LRZ1%SE76\SC8T<?3!NZ\Y6>NQ<M7\&P>!>UM*
M" /PD]SYF[9#!^RE/0XY<](\+W</)L+OF3;@B\>Z&H[.-9I-RW"'VRB&VJ<1
ML>RKAI>E$C@;SK5Z,B67S1C+:UJ='#Q;[L[SE(D ]J[9#*>VDHJW;ETD:R[J
MAEGOVI]MWX _+WNO&L$A6]P21]LB1][Y;K&>(R_NAA9Q/5I'WG.G'&$LH8>[
MNU='MCA5**OH-XW(4+W #+PPS"6XDXH@F/=@&1;A3V]=&+BY,2ER[[$Y9GL5
M45V3>Q\B*;7CVW$]@<88\OXZ=Q\>Q=T8RIF])^)N]IY:E':I']V;EJA@KR2N
M.5N69\(O950#D)H>_M3OMW+&SZ0;XU>9/;"S:?5/F95NK%&=_\ -=I>^L(I8
M4E94'!X,N'Q4H:9/C]'27X(WG6K]N%_9*46D-$ 5H5PX 7HRSG94&<Q[I*V$
M<79]FP,?.SR9B9X>QTM@:HO\F-W7=D*_XTU5JM0$!6%!!R%PGL),&Y#"_>,X
M&5=VB VJ7?Z<E1X4HAQ*0T^15_4NG&/:#6:CC!?<VZS%[4!G:X;EBP"C?1X1
M)0H8[[1!.\$L,MH#P^W&;8,8%" ;O/?MW]Z7_]*IG7Y/UHF)>SPW=?4(GOAE
M6V#L[8SO;W9K@ZSA.Z_%U*,E12B.+ Z)0FTW=!07DA5!!VO#EKS4AQ,",VNY
M&EPD^^W. J(R9AA!4'=2)KR0UGN=Y,.1M*,L/X[D[:N/P'KVZE8\8TI3(?;X
M-',G$EB8=7 Q.G<:IBR3(2UC+_N*>RC@N\.Z*]MJ8H[96*6K8.C&T-?U&^K;
M!@T]WA'=7NRP4.=3)"FW<_\^(OW\F/?CP>5HZ+2EZDS1M.4]VB?#[6ZBMOJP
M-FN<=:&R2:O"_%9K#\(YKD=^XT5:',N/J?'0FOEM&(FW)51>GE6XFR&ZTYM_
M0P]<4,IY'6=18/F8=VN6=%\L9+[9Z2J":N.D,,4Z45@^N;8X].BBH^JF6X<A
M%9P_V)V-UC?KPK J(<F2X>1D-Y'-A3C@=0:SK/K.V07IW[OV7\[36ZS\*G43
MJ/XM "E)ARG?1+U1(A<E,R37?%M&+Z@)LT2JIS"YGX*-O^3(_&H@_<*I($][
MY?0UE''X\H)>[FFB;CK5*?=F_^L2Q^ ?5/+V0HTYJDCF0O.307W6'TW>]+KS
MGIB%Z:QF.<&D6B\!#B#GY<\((W=HQ?W0*?XX?;OQZYU<AQYJLN-J-#@ D?O]
M>5CZ+T6+7S>N0MVETHFCF5;YH$K]+$&[VKOWE6E8:'X-!Q7UTHAKN#2@*,VA
M?/M3"\-3YIS7B?[SHC8;3_M(E$(8 OVF+'!>\M-*;IIA'&D^C!-X8/XVBCY,
M1F_&"W"+4=<WTIO[XB9<]>36>WUR+.\SM6O!C_W-QK2#,B7I?;0);D0*S6N]
MG]-_T<.@9B#)&K6_'HW#<HR5A9X8.S%!^&N$>&O))E-DW_N29_G8T9:L%!*9
MY_OXXG[@KGSSOCMY%G&!*W(ZAQ]WQ*KZ */T;T=OJP8OV3#&'*H<A#^-ALS=
M*F;M9/ "!.9?NBWF(5C:?R"@K12.V2P@T,Q,!F>YO"_I_<#S(_(TPH3@0J<<
MO>?7^./C3A;"R?IC-<65$CZ_#?IR&/>,T]AQO]5*U&Y#@BB]6IFR8ZPF-4A$
M\JOBPTR.C6BIR+ZUB#E<Y38D;CCS=I\H.BJQ[PD3;]/9,,;L.2D4):6:CJ[2
MK!4TR$YAPG(-?F,GS6E#DK-""?9[Z5CYY8A'9/#9]Q*YP"'J''(O5@_<0D L
MV']U<[:?GFT$+GEO\R_2<->4%E%DY6*(JI21P:9M4\-:3Z\;7(7K!C;0(U+E
MAR^U'T699#W,CJ5RY.BK[8NPZ;))R8#5 ZX&I&N3.K6+XD3.BSTMLX_J?;4"
MM(+E67GOS=\2=.[0H\;M&:XZ.5Y(>5 +I\F"RQ#=-!>[[T$S8C9G]591[BLK
MTD;)?6F8-A9P?4C:;4Y##9<.S[W9\67)+4QF%/^0#:3BP\F(3?191H:0B"8V
M:%&4LB-!)2#?XL>E1-6#H4GPQP\;C@AADF\OEJ;(TXADTNNF6EW%PQQ2B<R%
MZAIO/;FS$U?\HHP>[:FMU=KM(MS?UO\_[+UE6%W+DC"\\"0XP3U  D&#NP</
MFN": ,&"VT8WD*!! @1(<'=W)\$EN"4;9^.Z-[KQC]SY[LFY=\YYYKTS]YVY
MS_/.C_JS5J_N6M5=U575U56/_.XQ8Q;-*)%V)B2HS60(8//X8ZQ9ZZQ$6D[)
MIQB2FNNJ2%)W^U'):-5/%-N^EK?CL%V*N]Y28"[B'[D_J//Z7LXGOW2S&! A
M4*VI;ZC8?O;9EL.VE,P7%J3I)%;/*Q(K<^<Y:TC2)[H]$ZZ>=.HCX)P9Q<>2
MO2NCT<\@.HWQ&P7\>E\OU>\>4V&'>@4_V)PD?FW]&G16U'8P9(D\2$34]8WX
MP^?2A_)9-)T_$Y8,^%)8"6F'5K>(=R76K$R+T3?4QZR+VSF\0I:]%_#D^W<B
M.507'J2M/XMR_D/O=]>E+)RM)\AEX.YNM0!OJ!V[3*-^'ZTV:X??^P"=- DA
M;2L#BZCJ%",/%T,OZ3JE@4'BU3P^E0O?48H'6O<\T7N>W0#'(1B,A:"R;B&^
MN$<Y7K#20;97A@=<1C(/9/84"V.CC 3V]:])$6]=70LVSV4;EG)'*=1"^O*4
MB=H-]&>!IG(J=*297IIE;FEUA'^9C18)N4KL(I6OJ.PR7[#/)3(+Z#TR/PDC
M*DX]E&<2-E29F!<@(DB51'6KWE#-317JWSM@YCJSQ&5DN'[JJ8:1/XT#^9;8
MT_GY2)@-O7^Y1U5&J.2J/:!_F,QR%,/YU,D#2A_)/:N=8E,K]@"V'L$X)?($
M8@NU42QRS#%Z]L"#(?0)]:-A1LL5+XL-)&?-:?M+^N5MTKRQ-R0=B<GP'UVN
M;_@&L78$#C&DL@/0A=Q%BQK*6 )%GD.C[NOH@B*I6&2KQDKIVQ*4 ^ 6#9^G
M/YW:,J .B;5>M6C\G&+/T@*+3"MMH=2,)T%C$&Z&2"^DR[X-#"=+Y-2:91]&
MB>9QUF/,E 2AE/89O<Y"W90^%!$7(#IV[[&W].WK]I/H6>NZ1YS<(4L1^-DQ
MVM=;A0$*90^G7;9GYI3:C3BF,BUKJ)0ZXZULWRP<K%OR?XRZ@IXF+:"$:QMZ
MM[U!7.5T",Q11;Y]. $<Z5(;LX6<SDA0R04WZV8A4MC%J^PH!]]\M6-;"\V,
MI_.@B/:CWQZKW1[FN-U:6T4V<3'Z[8\\,NM1$.U\JXP+M38C&W^;^H">::+,
MNUJ+YI$[GWB0'P]3/O\<>)CI!MBONB:T;[P!4F^MPP6+2R9D3V;L4^/#?O&+
MG1L@D&*O;?TC^/3'#7#OY[FLS_3E0=3UA?B2[$79V2K-U0FX_><Q[H+KSU"(
M&Z!U&*'>NGWM<6L*^J3!TN]N":Z'03 2+>Z28U513QHM;^GK4%M-,42@*["#
MV_-EL-=R>-P3')C;VWCX=KY_O3YT[#O9U9DH'%\)J@0')UW7\+R[;S V<SY*
M((?:V/S>T2U(F%<P;*ZQ+4O\B*A,[?=8_PZ#YSD*TH8S<Z>$:ZL;JK\EW_E]
MBQ=/:GJ2^.BEW _C-[^<E,BSC_Y97VJH1R]^1X+?D0Q)E C]-QI$_"+8S^/_
M7R3(^HU@/Z,%_A.#_*9U_.I)K7V:^LWWB+L+0_IY*!"_?V7D_W_GRZ_%DE%K
MXX\_0X[?TEC7-O:_J/_?0)W[=S>\>5/7K:XF?,1;P>U9M^C;4G^'LE2;)-P
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MAGWYH,9#Y:D:'WWY9OZG5@[M\R_NMZ?C:=;&14<]C NEST5G&6%"^=P 'TI
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M*I,*;+6K!G[Q_2@>N?C_30!02P$"% ,4    " "CB0Q3-_GO /T)   C6@
M$0              @ $     879X;"TR,#(Q,#8S,"YX<V102P$"% ,4
M" "CB0Q3IGJ-X%H)   J9   %0              @ $L"@  879X;"TR,#(Q
M,#8S,%]C86PN>&UL4$L! A0#%     @ HXD,4PI67Y04$P  7RT! !4
M         ( !N1,  &%V>&PM,C R,3 V,S!?9&5F+GAM;%!+ 0(4 Q0    (
M *.)#%- CJHI5#0  #KK @ 5              "  0 G  !A=GAL+3(P,C$P
M-C,P7VQA8BYX;6Q02P$"% ,4    " "CB0Q3"Q9+NOD@   2+ ( %0
M        @ &'6P  879X;"TR,#(Q,#8S,%]P<F4N>&UL4$L! A0#%     @
MHXD,4PW.-Z1# 0$ SQH)  X              ( !LWP  &4S,#$X7S$P+7$N
M:'1M4$L! A0#%     @ HXD,4U9H//ZR!@  1AP  !               ( !
M(GX! &4S,#$X7V5X,S$M,2YH=&U02P$"% ,4    " "CB0Q3B1+("-<&   ;
M'P  $               @ $"A0$ 93,P,3A?97@S,2TR+FAT;5!+ 0(4 Q0
M   ( *.)#%/;3F5:$@8  -08   0              "  0>, 0!E,S Q.%]E
M>#,R+3$N:'1M4$L! A0#%     @ HXD,4S9+#=QAY0$ K!@#  T
M     ( !1Y(! &EM86=E7S P,2YJ<&=02P$"% ,4    " "CB0Q30NK&>T$*
M 0!P<@$ #0              @ '3=P, :6UA9V5?,# R+FIP9U!+!08
.."P + +<"   _@@0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
